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SUMMARY 
Dengue virus (DENV) is one of the most important human pathogens among the genus flavivirus, 
with 3.9 billion people at risk of infection through mosquitoes, such as the widely spread ‘Asian 
tiger’ mosquitoes, and the four serotypes of DENV are endemic in over 100 countries in tropical 
and subtropical regions. Clinical manifestations of infection with DENV range from flu-like 
symptoms to the life-threatening dengue haemorrhagic fever. The dramatic increase in the 
incidence of the DENV infection, the rapid spread of DENV to new areas and the recent re-
emergence of another member of the genus flavivirus, Zika virus (ZIKV), have highlighted the 
urgent need for specific antiviral therapies against infections with DENV and related viruses, which 
are not currently available. DENV RNA-dependent RNA polymerase (RdRp), the enzyme 
responsible for the synthesis of the viral genome, is one of the most attractive targets for the 
development of direct acting antiviral agents but its molecular mechanisms are poorly 
understood. Thefore, the aims of this PhD project were i) to build a model of the de novo initiation 
complex of DENV RdRp, of which there is currently no crystal structure available, ii) in silico design 
and synthesis of novel nucleoside and nucleotide analogues as potential inhibitors of DENV 
replication, iii) and finally to investigate the mechanism of the RNA synthesis by DENV RdRp. 
Molecular modelling techniques allowed for the creation of a model of the de novo initiation 
complex. The application of in silico drug design approaches resulted in the identification of three 
families of promising adenosine analogues: ribose-modified, nucleobase-modified and acyclic 
adenosine analogues. Strategies for the preparation of these nucleosides were investigated and 
ten adenosine analogues and eight nucleotide prodrugs, which are phosphoramidate ProTides, of 
specific nucleosides were synthesised and sent for biological evaluation in vitro. Innovative 
microwave irradiation conditions for the preparation of phosphoramidate ProTides were 
developed and successfully applied to synthesised nucleoside analogues. Finally, the application of 
molecular dynamics simulation methods on different complexes of DENV RdRp provided insights 
on the conformational changes of DENV RdRp during the synthesis of the viral genome. These 
results contributed to the understanding of DENV RdRp activity and will aid the design of inhibitors 
of the viral replication. 
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1.1 DENGUE VIRUS 
1.1.1 GENUS FLAVIVIRUS 
Dengue virus (DENV) is a small, enveloped virus belonging to the family Flaviviridae, genus 
flavivirus. The family comprises three genera: flavivirus, pestivirus and hepacivirus.[1] More than 70 
viruses belong to the genus flavivirus that have originated from a common ancestor.[2] The 
majority of flaviviruses are arboviruses (arthropod-borne viruses) as their transmission between 
vertebrate hosts occurs by arthropod vectors (mosquitoes or ticks).[1] 
Most flaviviruses are not relevant from a medical point of view. In fact, many flaviviruses circulate 
between birds and small mammals, which are their natural hosts. Humans may become infected 
when in close proximity with the cycle and infection may remain asymptomatic or cause mild 
febrile syndromes. In such cases, a low level of viraemia is often induced in humans and does not 
enable further transmission of the infection.[1] However, a small group of flaviviruses including 
DENV[1, 3], yellow fever virus (YFV), Japanese encephalitis virus (JEV), West Nile virus (WNV)[1] and 
the recently emerged Zika virus (ZIKV),[4, 5, 6] represent important exceptions. Besides non-human 
primates and some other animals, humans represent the natural hosts of these viruses and 
infection may lead to a variety of diseases. 
Being responsible for 390 million infections every year, DENV is one of the most significant human 
pathogens. Infection with any of the four existing DENV serotypes can be associated with a wide 
spectrum of clinical features, from a non-specific viral fever, referred to as dengue fever (DF), to a 
life-threatening condition, known as dengue haemorrhagic fever (DHF)[1, 3] (see section 1.1.3 for a 
description of the clinical manifestations of the infection). 
ZIKV has recently become a threat to human health in a global context.[4, 5, 6] The current outbreak 
in the Americas and the Caribbean has caused over 2 million infections in over 30 countries since 
2015.[6] Due to the potential spread to temperature climate aereas and to the association of ZIKV 
infection with severe neurological complications and foetal malformations, ZIKV was declared a 
Public Health Emergency of International Concern in February 2016.[7] 
To date, there is no specific treatment for any flavivirus infection and vaccines are available only 
for a limited number of viruses, such as YFV and JEV.[8] Recently, one DENV vaccine has been 
licensed for use in endemic countries.[9] However, the vaccination only provides partial protection 
against the four serotypes of DENV and will only be beneficial for a restricted population (refer to 
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section 1.1.6).[10, 11] Therefore, the development of new agents against flaviviral infections remains 
of high priority. 
 
1.1.2 EPIDEMIOLOGY 
Today DENV is the most widely distributed mosquito-borne human pathogen, being endemic in 
over 100 countries throughout South East Asia, the Western Pacific, the Americas and Africa[12] 
(Figure 1). 
 
 
Figure 1. Geographical distribution of dengue-endemic areas in 2013. Lines of the January 
isotherm and July isotherm define areas of year-round survival of Aedes Aegypti mosquitoes. 
Figure reproduced under permission by WHO.[13] 
 
DENV has been circulating since antiquity (10 000 years) and the earliest description of a 
syndrome compatible with DF has been found in a Chinese medical encyclopaedia dating back to 
the Chin Dynasty (265 – 420 A.D.). First epidemics occurred in the 17th century in the West Indies 
and Central America.The first accurate clinical description of dengue fever was by Benjamin Rush, 
regarding the epidemic that occurred in Philadelphia in 1780.[1, 14, 15] 
Expansion of DENV has been linked to the spreading of its primary mosquito vector, Aedes 
aegypti. Since World War II, rapid urbanisation and increased transportation and human travel 
allowed for a worldwide resurgence of the mosquito and for the following spread of dengue.[14, 15] 
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In the 1950s and 1980s the first epidemics of DHF were observed in South East Asia and the 
Americas, respectively.[14, 15] Today, DHF represents a leading cause of paediatric morbidity and 
mortality in many countries of the Asian region.[14] 
Recently, a dramatic rise in the number of dengue cases has been reported worldwide, with an 
estimated 30-fold increase of reported DENV infections in the last few decades.[3, 16] The World 
Health Organization (WHO) estimated that the incidence falls in the range of 50 million to 100 
million and around 40% of the World’s population is at risk of infection, accounting for 2.5 billion 
people.[3, 12, 17] The worldwide estimated cases of DHF are 500 000 per year, resulting in over 20 
000 deaths.[18] However, the true burden caused by DENV is likely to be even higher: recent 
estimates reported that up to 3.9 billion people may be at risk of infection in 128 countries[19] and 
the real incidence may be more than three times the estimate of the WHO, with 390 million cases 
annually.[20] 
Factors involved in the continuous increase in the incidence of DENV infections include the 
intensification of the disease in endemic areas and the geographical expansion of DENV to 
previously unaffected areas. Many countries in South East Asia and Western Pacific, which were 
hypoendemic (circulation of only one serotype) until ten years ago, are now hyperendemic 
(circulation of numerous serotypes) with epidemics occurring regularly every 3 to 5 years.[14, 15] 
Hyperendemicity occurs in the majority of countries in the Americas too, although DENV 
transmission was efficiently controlled in the region by the middle of the 20th century.[1, 14, 15] In 
Africa the number of cases is likely to be underestimated due to the fact that dengue is not 
officially reported to the WHO and to the common misdiagnosis of dengue infections as malaria, a 
disease that is significantly spread throughout the region.[19] Dengue epidemics caused by all four 
serotypes occur frequently in the African region, however severe manifestations are observed in 
sporadic cases.[14, 15] 
Dengue infection of international travellers to dengue-endemic countries (imported cases) occurs 
frequently.[21] The virus represents the leading cause of febrile illnesses in returned travellers from 
every region except Sub-Saharan Africa and Central America, being confirmed or suspected more 
frequently than malaria.[21, 22] Although severe dengue manifestations are rare in travellers,[21] the 
incidence of infections in international travellers is relevant as it contributes to the significant 
spread of DENV to new areas. Indeed, the threat of dengue epidemics is now real in Europe and in 
the US.[12, 15, 23, 24] Intercontinental trade of used car tires containing eggs of Aedes albopictus 
caused the establishment of this mosquito, a secondary vector of DENV, in Europe by the 20th 
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century.[1, 14, 24] Imported cases in travellers are frequent and local transmission, made possible by 
the presence of the mosquito, has been observed in France and Croatia in 2010.[3] Moreover, an 
important outbreak occurred in the Madeira Islands of Portugal in 2012 and resulted in over 2 000 
local cases and several imported cases in other European countries.[3] Similarly, both imported and 
locally acquired cases have been reported with increasing frequency in the US, especially in 
Florida, Texas, Puerto Rico and Hawaii.[3, 23, 24] 
 
1.1.3 CLINICAL FEATURES 
There are four different serotypes of DENV, named DENV-1, DENV-2, DENV-3 and DENV-4.[14] In 
the enzootic, or sylvatic, transmission cycle, DENV circulates between non-human primates and 
mosquito vectors in Asian and African rain forests and rarely infect humans in small rural centres 
(rural transmission cycle).[14] The urban transmission cycle of DENV is the most important one 
from a public health point of view. The vectors involved are the Aedes aegypti mosquito and the 
Aedes albopictus mosquito, which is commonly known as ‘Asian tiger’ mosquito. The Aedes 
aegypti mosquito is the primary vector and is highly domesticated: adult female mosquitoes feed 
on humans (anthrophilic), rest indoors and breeds in collections of water in and around homes, for 
instance storage jars, containers, flower vases etc.[14] 
After biting an infected person in the viremic phase of the illness, a period that may vary from 2 to 
10 days, the mosquito becomes infected and, following an incubation period in the vector of 8 to 
12 days, is capable of transmitting the virus by feeding or just probing on another person. 
Infection in humans may become apparent after a variable incubation period (from 3 to 14 days), 
and clinical manifestations vary in severity.[1, 14, 25] As mentioned before, two distinctive illnesses, 
DF and DHF, are caused by DENV infection. 
 
1.1.3.1 Dengue fever 
In young children the manifestation of dengue infection is often a febrile illness, which can not be 
differentiated from other viral diseases.[1, 14] In older children and adults DF is characterised by a 
classical fever-arthralgia-rash syndrome with a sudden onset of high fever and various symptoms, 
including headache, weakness, skin rash, and muscles and joints pain, the latter of which might be 
severe (bacause of this common symptom, dengue fever is also known as ‘breakbone fever’).[14] 
DF is generally self-limiting; although it resolves in few days (the fever may last from 2 to 7 days), 
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many adult patients experience a prolonged phase of convalescence associated with weakness 
and depression, which may last for weeks after the acute phase of the illness.[1, 14] Haemorrhagic 
manifestations are common and include skin haemorrhages, gum and nose bleeding as well as 
gastrointestinal haemorrhages. Other frequently occurring features are low blood platelet and 
leukocyte counts and high blood transaminase levels.[1, 14] Given the non-specificity of symptoms, 
only laboratory tests by virus isolation or antibody detection can confirm DENV infection.[1] 
 
1.1.3.2 Dengue haemorrhagic fever 
DHF or severe dengue occurs primarily in young children under the age of 15 years, but cases are 
observed also in the adult population.[1, 14] The onset of DHF does not allow to distinguish this life-
threatening disease from either DF or other febrile illnesses, being characterised by an abrupt 
onset of fever. This initial febrile phase usually lasts for 2 to 7 days and is accompanied by non-
specific symptoms.[1, 14] The critical stage in DHF is the defervescence, when initial fever subsides, 
on day 3 to 7 of illness. The characteristic manifestation is plasma leakage from the blood vessels 
into the interstitial space due to increased vascular permeability, which may be very severe. 
Patients also present reduced platelet and leukocyte counts and clotting abnormalities. 
Haemorrhagic manifestations are mild and usually include scattered petechiae, whereas bleeding 
and gastrointestinal haemorrhages occur less commonly.[1, 14] Four grades of DHF (I – IV) of 
increasing severity have been classified by the WHO.[14, 25] The symptoms described above 
corresponds to the mildest form, DHF-I, which differs from DHF-II by the absence of bleeding. In 
contrast, in DHF-II additional gum, nose and gastrointestinal bleeding is present. DHF-III is 
characterised by circulatory collapse and hypovolemic shock due to plasma leakage (rather than 
blood loss). In DHF-IV the patient is moribund due to severe plasma leakage and undetectable 
pressure. Grades III and IV are also referred to as dengue shock syndrome (DSS) and are life-
threatening conditions: if untreated, DSS causes death of the patient in shock within 8 to 24 hours. 
Appropriate fluid replacement therapy usually allows for rapid recovery, which is followed by a 
short period of convalescence (2 to 3 days) for patients with any grade of DHF.[1, 14, 25] 
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1.1.4 CLINICAL MANAGEMENT 
No antiviral agents are available against DENV infection, therefore treatment is symptomatic 
according to clinical manifestations. Most cases present a self-limiting illness and do not need 
hospitalisation. The patient should drink and avoid aspirin, because of its anti-platelet effect, as 
well as other non-steroidal anti-inflammatory agents (NSAIDs), which may worsen gastrointestinal 
bleeding. Paracetamol may be administered to provide symptomatic relief.[1] Patients with DF or 
mild DHF (grades I and II) may recover spontaneously and do not require intravenous 
administration of fluids, whereas patients with DSS (DHF-III and DHF-IV) need hospital admission 
to ensure an accurate management of the illness.[1, 26] Intravenous administration of electrolyte 
and colloid solutions is essential to stabilise the plasma volume and restore blood pressure, but 
requires careful regulation to avoid fluid overload once fluids will be reabsorbed.[1, 12, 26] 
 
1.1.5 PATHOGENESIS OF DHF 
Increased risk for DHF appears to be associated with secondary dengue infection (infection with a 
heterologous virus serotype following a primary infection) and with particularly virulent viral 
strains.[1, 8, 25, 27, 28] Therefore, both a host immunologic factor and a viral factor may be involved in 
the pathogenesis of DHF.[1, 8, 25] However, the lack of a suitable animal model for DENV presents an 
obstacle in the study of DHF pathogenesis, which still remains largely unclear.[25] 
An increased likelihood for patients, especially children, for developing DHF has been shown in 
epidemiological studies for those who are experiencing secondary infections with DENV.[27] After 
infection with one serotype the patient develops life-long immunity for the specific serotype 
thanks to virus-specific memory T-lymphocytes. Prior circulating antibodies derived from a primary 
infection, as well as acquired maternal IgG, although responsible for immunity for the specific 
serotype, are a risk factor for DHF. The so called ‘antibody-dependent enhancement (ADE) of 
infection’ theory has been proposed to explain the pathogenesis of DHF (figure 2).[25, 28]  
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Figure 2. ‘Antibody-dependent enhancement’ of DENV infection. DENV: dengue virus; Ab: cross-
reactive antibodies; FcR: Crystallisable fragment receptor. Figure adapted from Virology Blog 
by V. Racaniello under the license Creative Commons BY 3.0.[29] 
 
Antibodies to the first virus serotype are not able to neutralise the heterologous virus serotype, 
but are cross-reactive. The resulting complexes bind immunoglobulin crystallisable fragment 
receptors (FcRs) expressed on the cell surface of leucocytes, especially monocytes. The formation 
of these non-neutralising antibody-virus complexes facilitates the entry of the new virus into 
monocytes and leads to an increased intracellular viral replication, and thus viraemia, which 
appears to be directly correlated to the increased severity of illness.[28] Infected cells expose viral 
antigens (major histocompatibility complex, MHC), leading to the stimulation of T-lymphocytes 
and the production of cytokines, in particular interferon-γ (INF-γ). The increased level of cytokines 
results in the activation of other macrophages that will upregulate the expression of FcRs and 
MHC on their cell-surface, making them more susceptible to viral infection and thus initiating a 
chain reaction. The higher levels of cytokines produced by macrophages, lymphocytes and 
endothelial cells might also have a direct effect in the severity of the disease, as they might result 
in increased capillary permeability and thus facilitate the potentially fatal plasma leakage 
associated with DHF.[1, 25] 
Additionally, the combination of specific serotypes may be correlated to the severity of the 
developed illness: indeed, primary infections with DENV-1 or DENV-3 followed by a secondary 
infection with DENV-2 appear to be the most pathogenic sequences of infections.[30] 
Despite many cases of dengue haemorrhagic fever occurring in patients experiencing a secondary 
infection, the illness is also reported in infants during primary infection with DENV.[31, 32] This 
Monocyte 
FcR 
DENV 
Ab 
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observation suggests the involvement of alternative or contributing factors playing a role in the 
pathogenesis of DHF. Like other animal viruses, DENV exists in different virus strains, which are 
genetic variants of the same serotype.[1, 14, 30] Some virus strains present a mostly sylvatic 
transmission cycle, hence they only infect humans sporadically.[1, 14, 30] Other virus strains in their 
urban transmission cycle infect humans and cause a mild syndrome, whereas other genetically 
different viruses are characterised by higher virulence.[30] Infections with a virulent viral strain of 
DENV may be associated with an increased virus replication and thus an increased severity of the 
clinical manifestation.[30] 
 
1.1.6 PREVENTION 
To date, a specific anti-DENV therapy is not available. Until the recent approval of the dengue 
vaccine by Sanofi Pasteur (CYD-TDV, DengVaxia®),[33] dengue prevention and control relied 
exclusively on vector control methods. The WHO presented many strategies for reducing Aedes 
mosquitoes populations, mainly by limiting the breeding of Aedes mosquitoes in urban areas and 
by the use of insecticides and larvicides.[12] However, effective preventative programs have proven 
not to be sustainable in dengue-endemic areas as a long-term approach and both health 
education as well as community participation would be essential for effective and long-lasting 
mosquito control.[1, 3] Simple preventative measures, such as the use of insect repellents and 
mosquito nets, should be adopted by travellers to tropical areas, especially during the rainy 
season, to decrease exposure to mosquito bites, and thus reduce the risk of infection and limit 
DENV geographical expansion.[1, 21] 
The approval of DengVaxia in 2015 is the result of a challenging development process that lasted 
20 years. The difficulties associated with the development of a dengue vaccine were mainly due to 
the presence of four dengue serotypes.[34, 10] Infection with one serotype allows for the 
development of a life-long immunity to the specific serotype involved in the primary infection. A 
cross-protective immunity against the other serotypes is observed over a short period of time 
following convalescence.[34, 10] However, on the long term the pre-existence of antibodies against 
one serotype increases the risk of severe dengue during a secondary infection.[25, 28] Therefore, the 
administration of a non-tetravalent vaccine may actually predispose for severe dengue, rather 
than eliciting protection.[8, 16] In order to be safe, a dengue vaccine therefore needs to be capable 
of inducing a balanced protective immunity against all four virus serotypes. Furthermore, the ideal 
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dengue vaccine should be safe and effective for use in both children and adults.[8, 16] Moreover, 
the cost should be affordable to most people living in dengue-endemic areas, which include many 
developing or poor countries.[8, 16] 
CYD-TDV by Sanofi Pasteur is an attenuated chimeric vaccine, constructed by replacement of pre-
membrane (prM) and envelope (E) genes from each DENV serotypes into the licensed yellow fever 
virus vaccine (YFV-17D) backbone. The four distinct recombinant viruses are combined in the final 
formulation.[34, 10] Previous evaluations (preclinical, clinical Phase I and Phase II trials) 
demonstrated CYT-TDV to be safe and immunogenic, capable of inducing neutralising antibodies 
against each of the four serotypes, following a three-dose schedule over a 12-month period.[35] 
Nevertheless, the induction of broadly neutralising antibodies did not correlate with protection 
against dengue in humans, demonstrating that more reliable markers of immunity to evaluate 
dengue vaccine candidates are required.[8, 16] In fact, CYD-TDV was found to be ineffective against 
DENV-2 in a Phase IIb efficacy study in Thailand[35] and this result was confirmed in two clinical 
Phase III trials, which involved larger populations.[36, 37] Although the overall vaccine efficacy was 
56.5% and 60.8% in these large-scale Phase III studies conducted in Asia and in Latin America 
respectively, the vaccine failed to elicit a high level of protection against DENV-2 (efficacy against 
DENV-2 was 35.0% and 42.3% in the two Phase III studies).[36, 37] However, a significant reduction 
of the risk of hospitalisation due to DHF was observed (88.5% and 80.3%, respectively) among 
participants over nine years of age.[36, 37] CYT-TDV was partially effective against DENV serotypes 
and the response to vaccination was variable depending on the age as well as on the previous 
exposure to DENV of the participants. In fact, vaccine efficacy was higher in DENV seropositive 
individuals among all ages, suggesting that the vaccine may be beneficial in endemic countries 
where most of the people have already encountered the virus.[10, 11, 38, 39] Given the complex 
efficacy profile of the dengue vaccine by Sanofi Pasteur, the level of dengue burden and the 
population target of vaccination need to be carefully considered before introducing DengVaxia® 
(CYT-TDV) in a national immunisation programme.[10, 11] Follow-up studies will be of crucial 
importance to monitor the long-term effects of the vaccination in endemic countries, including the 
occurrence of severe dengue as well as the duration of the protection,[10] as the immunity seems 
to wane in few years.[40] 
Besides CYD-TDV, several other dengue vaccine candidates have been developed, including 
classical live attenuated vaccines (LAV), chimeric attenuated vaccines, recombinant live attenuated 
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vaccines, purified inactivated viruses (PIV), protein subunit vaccines and DNA vaccines.[8, 16, 34, 41, 42, 
43] Vaccines in tetravalent formulation that entered clinical trials are summarised in table 1. 
 
Table 1. Tetravalent DENV vaccine candidates in clinical trials. 
Developer Type Method Clinical trial Status 
MUa, Sanofi 
Pasteur 
classical LAV  sequential passages through 
cell cultures 
Phase II discontinued 
WRAIRb, 
GlaxoSmithKline 
classical LAV  sequential passages through 
cell cultures 
Phase II discontinued 
Sanofi Pasteur chimeric 
attenuated vaccine 
prM/E proteins in Yellow 
Fever 17D vaccine backbone 
Phase III 
completed 
marketed as 
DengVaxia® 
CDCc, Takeda chimeric 
attenuated vaccine 
prM/E proteins in attenuated 
DENV-2 strain backbone 
Phase III ongoing 
NIAIDd, NIHe chimeric 
attenuated vaccine 
prM/E protein in viral strains 
attenuated by nucleotide 
deletion at 3’-untranslated 
region (UTR) 
Phase III ongoing 
WRAIRb, 
GlaxoSmithKline 
PIV non-replicating viruses in the 
presence of adjuvants 
Phase I ongoing 
WRAIRb combination of PIV 
and classical LAV 
synergy between two 
previously developed vaccines 
Phase I ongoing 
NMRCf DNA vaccine plasmid encoding prM/E 
genes from each DENV 
serotypes 
Phase I ongoing 
Merck subunit protein 
vaccine 
truncated E proteins from 
each serotype 
Phase I ongoing 
aMahidol University, Thailand. bWalter Reed Army Institute of Research, USA. cCenter for Disease Control 
(Inviragen, USA and Takeda, Japan). dNational Institute of Allergy and Infectious Disease, USA. eNational 
Institute of Health, Laboratory of Infectious Diseases, USA. fNaval Medical Research Centre, USA. 
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1.1.7 REPLICATION CYCLE 
Flaviviruses are small enveloped viruses, spherical in shape with a diameter of approximately 50 
nm. The viral genome is a single-stranded, positive-sense RNA, approximately 11 kb in length. The 
nucleocapsid is enveloped by an inner lipid bilayer, which is acquired from host cells, and an outer 
glycoprotein shell.[44] Figure 3 illustrates the replication cycle of DENV in the host cell from the 
entry of the viral particle to the exocytosis of mature virions.[45] 
 
 
Figure 3. DENV replication cycle. The red frame shows the putative organisation of the viral 
polyprotein through the ER membrane. ER: endoplasmic reticulum; TGN: trans-Golgi network; 
C: capsid; prM: pre-membrane; NS1 to 5: non-structural proteins 1 to 5. Figure adapted from  
Kato et al. under the license Creative Commons BY 4.0.[45] 
Polyprotein 
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The interaction between the virus particle and multiple receptors on the surface of host cells is 
responsible for the internalisation of the virus via clathrin-mediated endocytosis.[46] Lowering of 
the pH inside the endosome causes an irreversible conformation change in the E protein, from 
dimer to trimer, that facilitates the fusion of the viral and endosomal membranes. The 
nucleocapsid is released into the cytoplasm and disassembles. The viral genome is then translated 
into a single polyprotein that undergoes post-translational cleavage by host and viral proteases, 
thus generating the viral proteins. The synthesis of this polyprotein is induced by the viral genome 
itself, which acts as mRNA, and occurs at the membrane of the endoplasmic reticulum (ER). In the 
early phase of the infection, the synthesis of new antiviral genomes (amplification) occurs in the 
cytoplasm whereas, at a later stage of the infection, this process is translocated to a structure 
referred to as replication complex (RC).[44, 45] The RC consists of viral genomes and membranous 
organelles derived from the ER and the trans-Golgi network (TGN), whose formation is induced by 
DENV infection.[44, 45, 46] The viral RNA presents a single open reading frame (ORF) between two 
highly structured and conserved 3' and 5' untranslated regions (UTRs). The ORF of the viral 
genome codes for the aforementioned polyprotein, which includes ten viral proteins required for 
the viral life cycle: three structural proteins and seven non-structural proteins (Figure 4).[34, 46] 
 
 
Figure 4. DENV genome codes for ten viral proteins. C: capside; M: membrane precursor or prM; 
E: envelope; NS1 to 5: non-structural proteins 1 to 5; UTR: untranslated region. Figure reproduced 
from Simmons et al. under the license Creative Commons BY-NC 3.0.[34] 
 
The structural proteins capsid (C), E and prM form the virion. The non-structural proteins are NS1, 
NS2A and NS2B, NS3, NS4A and NS4B, NS5 and are involved in RNA genome replication, virion 
assembly as well as evasion of the host immune response.[46] The non-structural protein 5 (NS5) 
comprises a RNA-dependent RNA polymerase (RdRp) responsible for the synthesis of the viral 
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genome. RdRp synthesises a negative-sense intermediate RNA strand, which is the template for 
the synthesis of double stranded RNA (dsRNA). Capping of the 5’ end of the positive-sense RNA 
genome is catalysed by the viral methyltransferase (MTase) domain located at the N-terminus of 
NS5. The processed dsRNA is unwound by non-structural protein 3 (NS3), which contains a RNA 
helicase at its C-terminal. The viral genome is encapsulated by the C protein in the cytoplasm to 
form the nucleocapsid that acquires the viral envelope by budding through the ER membrane 
containing the E and prM proteins. The immature viral particles traffic through the TGN. The 
extracellular release of the virion occurs via exocytosis after accumulation in intracytoplasmic 
vesicles, where the prM protein undergoes cleavage by an host protease (furin) into the 
membrane (M) protein in the late stage of maturation of the virion into an infectious virus.[25, 46, 47, 
48] 
 
1.1.8 DRUG DEVELOPMENT 
As previously described in this thesis, hospital admission of DENV-infected patients is required for 
the clinical management of the potentially fatal DHF. This is the major cause of the huge economic 
burden posed by DENV infections in dengue endemic countries, many of which are resource-
poor.[49] Vector control has proved itself not to be an efficient strategy for prevention of the 
disease in these countries and vaccination with the recently licensed dengue vaccine by Sanofi 
Pasteur does not provide complete protection against all four serotypes of DENV (see section 1.1.6 
for further details). Furthermore, a dengue vaccine will not reach the majority of the population 
that is at risk of infection, because of limited vaccine production capability and transport as well as 
high cost of the new vaccine.[49] A safe and effective antiviral drug for the treatment of DENV 
infection, which as of yet is not available, would be highly beneficial not only for DENV-infected 
patients but also to reduce the expenditures that are due to DENV infections in endemic countries. 
Even if a true tetravalent dengue vaccine will be available, an antiviral agent would still be needed 
in countries with a low vaccination or for parts of the population who cannot receive the vaccine 
for safety reasons (e.g. young children, pregnant women). In addition, the administration of an 
anti-DENV drug would rapidly reduce viraemia in DENV-infected patients, thus decreasing the risk 
of progression of the disease to severe manifestations as well as preventing spread of the virus to 
others through mosquitoes.[50] For these reasons, an anti-DENV therapy is an urgent unmet 
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medical need. Large efforts have thus been undertaken in this field and are described in this 
section. 
The development of an anti-DENV drug can be based on two general strategies: the inhibition of 
viral targets by direct-acting antiviral (DAA) agents and the inhibition of host targets that are either 
essential for viral replication or involved in the development of severe clinical manifestations.[48, 50] 
The viral target-based approach has been successfully applied to the development of DAA agents 
effective against other viruses, such as human immunodeficiency virus (HIV) and hepatitis 
viruses.[51, 52, 53] Advanced studies have been undertaken on hepatitis C virus (HCV) in the past[52] 
and the similarity of DENV to HCV, viruses belonging to the same family of Flaviviridae, make it 
plausible to repurpose anti-HCV drugs or drug candidates for DENV.[34, 50] 
 
1.1.8.1 Host target-based approach 
Despite the advantage of a high barrier for the emergence of resistance, the host target-based 
approach is challenging as it lacks selectivity, and thus is often associated with toxicity.[48, 50] 
However, it has been proven to be a valid antiviral approach as exemplified by the marketed anti-
HIV drug, Maraviroc (1, figure 5), an inhibitor of a host co-receptor for virus entry.[54] 
 
 
Figure 5. Structure of the anti-HIV drug Maraviroc (1). 
 
In the case of DENV, multiple receptors on different cell types mediate viral entry and this 
represents an important obstacle for the identification of host target antagonists as inhibitors of 
the viral entry.[48, 50] In addition to proteins, lipids are also involved in different stages of the DENV 
replication cycle.[55] As inhibitors of cholesterol biosynthesis, statins were evaluated for their 
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potential antiviral activity in vitro and were found to exert an effect on both the viral entry as well 
as the maturation and release of viral particles.[56] However, clinical trials demonstrated that the 
administration of Lovastatin (2, figure 6) was not beneficial in dengue patients.[57] 
 
 
Figure 6. Structure of Lovastatin (2). 
 
The inhibition of human enzymatic activities, which are essential for viral replication, seems to be 
a more promising approach for the identification of broadly active anti-DENV agents. Besides 
virus-encoded proteins, the DENV replication cycle requires host proteases and glucosidases. Host 
signal peptidases are responsible for the cleavage of a number of junctions in the single 
polyprotein derived from the translation of the viral genome, while furin activity is essential in the 
late maturation of virions as this host protease cleaves the prM protein into the mature 
membrane (M) protein.[48] However, inhibition of host proteases is likely to be associated with 
severe side effects.[48] Host glucosidases that are located in the ER lumen are essential for the 
correct folding and the glycosylation of both structural and non-structural viral proteins. The host 
α-glucosidase inhibitor Celgosivir (3, figure 7) was safe and well tolerated in a Phase Ib trial[58] and 
will be further evaluated for its efficacy in dengue patients.[59, 55] 
 
 
Figure 7. Structure of the anti-DENV drug candidate Celgosivir (3). 
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Cellular purine[60] and pyrimidine[50] biosynthetic pathways represent potential host targets for 
developing broadly active antiviral agents. The nucleoside analogue 1-β-D-ribofuranosyl-3-ethynyl-
[1,2,4]triazole (ETAR, 4, figure 8), which is structurally related to the anti-HCV drug ribavirin (RBV), 
was found to inhibit the replication of all four serotypes of DENV in vitro and is a promising drug 
candidate for the treatment of flaviviral infections.[60] The fact that the antiviral activity was 
suppressed by supplementary guanosine suggests that ETAR inhibits the host enzyme inosine 
monophosphate dehydrogenase (IMPDH), resulting in the depletion of guanosine triphosphate 
(GTP).[60] 
 
 
Figure 8. Structure of the IMPDH inhibitor ETAR (4). 
 
Similarly, inhibitors of the dihydroorotate dehydrogenase (DHODH), a host enzyme involved in de 
novo pyrimidine biosynthesis, were active against a variety of virus families in vitro.[50] Figure 9 
shows the structure of NITD982 (5) as an example of this class of compounds. However, no 
efficacy was observed in vivo suggesting that inhibiting DHODH actually may not represent an 
effective antiviral strategy.[50] 
 
 
Figure 9. Structure of the DHODH inhibitor NITD982 (5). 
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Finally, targeting the pathological pathway that leads to plasma leakage and other DHF symptoms 
is an alternative strategy.[50, 61] In particular, the modulation of the cytokine response against DENV 
may prevent the progression to severe dengue.[56] The anti-inflammatory agents prednisolone 
(6, figure 10) and chloroquine (7, figure 10) were evaluated in clinical trials.[62, 63] The latter also 
acts by interfering with both early and late phases of the viral replication cycle.[56, 64] Although 
both agents were safe, no beneficial effects were observed in dengue patients,[62, 63] suggesting 
that the approach remains of poor feasibility due to the incomplete understanding of the 
illness.[50, 61] 
 
 
Figure 10. Structures of the anti-inflammatory agents prednisolone (6) and chloroquine (7). 
 
1.1.8.2 Viral target-based approach 
Antiviral agents have been directed to target both structural and non-structural viral proteins, 
principally the E, NS3 and NS5 proteins, in order to inhibit viral entry into cells and replication, 
respectively.[50, 65] 
The E protein is the largest structural protein (500 amino acids) and is embedded in the lipid 
membrane of the virus. The role of the E protein in the attachment to the host cell surface and the 
fusion to the endosomial membrane allows for the design of viral entry inhibitors based on 
targeting this viral protein. Indeed, targeting viral entry is a known strategy for antiviral 
therapeutics as, in a similar way, HIV-gp41, which is a subunit of HIV envelope protein, is inhibited 
by Enfuvirtide, an approved anti-HIV drug that acts by blocking the fusion of viral and host cell 
membranes.[50] DENV E protein consists of three domains (I, II and III). A hydrophobic pocket 
interacting with the detergent molecule β-N-octylglucoside has been identified between domains I 
and II. Both small-molecules occupying this pocket, such as compound 8 in figure 11, or peptides 
interacting with the E protein inhibit the conformational changes (from dimer to trimer) of this 
structural protein, which are essential for the fusion of viral and host membrane.[66, 67] 
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Furthermore, the polysaccharide curdlan sulfate (CRDS, 9, figure 11), was also reported to inhibit 
the E protein of all four DENV serotypes in vitro by binding in a newly discovered pocket at the 
interface between domains I and II.[65, 68] Recently developed strategies involve the use of 
monoclonal antibodies directed against epitopes within the E protein, either to prevent host cell 
binding or to block the rearrangement of the viral protein required for the fusion step.[65, 69] 
 
 
Figure 11. Structures of a small molecule inhibitor targeting the β-N-octylglucoside pocket (8) and 
the polysaccharide curdlan sulfate (9). 
 
The DENV C protein is a highly basic protein that interacts with the viral RNA genome to form the 
nucleocapsid, and is involved in both the uncoating and assembly of the virions. In the cytoplasm, 
C proteins are arranged in concave-shaped homodimers that are attached to ER membranes at the 
‘top’, whereas the RNA is believed to bind the ‘floor’ of this concave structure.[70, 71] ST-148 
(10, figure 12) has been recently reported as a potent DENV replication inhibitor both in vitro and 
in vivo,[70, 71] through stabilisation of capsid self-interaction and formation of rigid oligomers, 
altering both release of viral genome from nucleocapsids and late-stage assembly of viral 
particles.[71] 
 
 
Figure 12. Structure of the C inhibitor ST-148 (10). 
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Among the ten non-structural proteins encoded by the viral genome, only NS3 and NS5 are known 
enzymes. Although activities of the other non-structural proteins remain to be clearly understood, 
they appear to be essential for RNA replication. In particular, NS2A, NS2B, NS4A and NS4B are 
transmembrane proteins involved in the formation of the viral replication complex and represent 
valid antiviral targets.[48, 65] 
The DENV protease consists of the N-terminal domain of NS3 (170 amino acids) and an 
approximately 40 amino acid region of NS2B.[48] The enzyme is a serine protease containing the 
catalytic triad of His51, Asp75 and Ser135.[48] As already mentioned, the translation product of the 
viral genome is a long polyprotein that needs to be cleaved into the individual proteins. The viral 
protease NS2B-NS3 is responsible for the cleavage of specific junctions (precisely, between C-prM, 
NS2A-NS2B, NS2B-NS3, NS3-NS4A, NS4A-2K peptide and NS4B-NS5), whereas host proteases 
(signal proteases) cleave the other sites of this polyprotein.[61] The NS2B-NS3 activity is essential 
for viral replication, therefore the enzyme represents a valid antiviral target.[48, 65] Protease 
inhibitors (PIs) have also been successfully developed for the treatment of other antiviral 
infections, in particular there are ten HIV-1 PIs and two HCV PIs (telaprevir and boceprevir) 
currently in clinical use.[50, 53] However, treatment with PIs is generally associated with the rapid 
emergence of drug-resistant viral strains, hence PIs need to be administered in combination with 
other antiviral agents, especially for long-term therapy (both HIV-1 and HCV cause chronic 
diseases).[50] Furthermore, telaprevir and boceprevir do not exhibit a pan-genotypic effect, being 
active only against HCV genotype-1.[50] Although dengue is an acute illness, the identification of 
NS2B-NS3 inhibitors effective against all four DENV serotypes might be a significant challenge and 
combination with another DAA agent would be required.[50] To date, there are no PIs against DENV 
which have advanced to preclinical trials. The main challenge in the development of PIs is related 
to the properties of the active site of NS2B-NS3, which is relatively flat and negatively charged. The 
positively charged scaffold required to interact with the active site would cause poor permeability 
through membranes and antiviral activity would be compromised by pharmacokinetic aspects.[48, 
50, 65] However, the design of peptidomimetics as well as the identification of small-molecule 
inhibitors through high-throughput screening (HTS) of libraries[48, 50, 65] remain valid approaches for 
developing potential DENV PIs. Recent in silico design efforts enabled the identification of 
effective and more membrane permeable peptidomimetics (figure 13) that represent a promising 
starting point for further development.[72] 
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Figure 13. General structure of peptidomimetics inhibitors of the NS2B-NS3 protease. 
 
A further antiviral target is the DENV RNA helicase, which is located at the C-terminus of NS3 
(approximately 440 amino acids).[50] The main role of the RNA helicase is to unwind the dsRNA, 
separating the positive sense single stranded RNA (ssRNA) that constitutes the viral genome, from 
the negative sense RNA template. Although helicases share high structural similarity, the presence 
of an additional domain in the viral helicase compared to host ones may allow for developing 
selective inhibitors. Additionally, an adenosine triphosphate (ATP)-binding site is present in the 
NS3 domain and is endowed with both ATP-hydrolysis and nucleotide triphosphatase activities.[48, 
73] Unfortunately, the DENV helicase domain does not show any significant pocket and the ATP-
binding pocket is shallow and polar, and thus challenging to target with a small-molecule 
inhibitor.[48] As of yet, there are no marketed helicase inhibitors for the treatment of HCV 
infections and only few compounds are undergoing studies as potential DENV helicase inhibitors, 
including ivermectin (11, figure 14) and ST-610 (12, figure 14).[50] Recently, the inhibition of the 
ATP-hydrolysis was demonstrated to be sufficient to confer antiviral activity.[73] This discovery may 
facilitate future advances towards novel DENV NS3 inhibitors.[65] 
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Figure 14. Structures of the DENV helicase inhibitors ivermectin (11) and ST-610 (12). 
 
NS5 is the largest DENV protein, being approximately 900 amino acids long with a mass of 104 
kDa. NS5 contains a methyltransferase (MTase) at its N-terminus (approximately 270 amino acids) 
and an RdRp at its C-terminus (approximately 600 amino acids).[74] DENV MTase has a dual activity 
as it catalyses both the methylation of the N-7 position of guanine at the 5’-end of the RNA 
genome and the methylation of the hydroxyl group at the 2’-position of the first adenosine 
nucleotide, and thus is involved in the viral RNA capping synthesis.[65, 75] S-adenosyl methionine 
(SAM) is the methyl donor for both methylation reactions with S-adenosyl homocysteine (SAH) 
being generated as a by-product.[61] The two distinct reactions occur in one single active site and 
are sequential. Therefore, repositioning of the RNA substrate is required after the first 
methylation of the N-7 position of guanine to allow the second methylation at the 2’-OH of the 
ribose of the internal adenosine.[75, 76] The N-7 methylated cap then binds to DENV MTase in a 
second pocket, referred to as the GTP pocket, so that the second methylation reaction can 
occur.[75, 76] Although the activity of the MTase is essential for viral replication and the enzyme 
constitutes a valid antiviral target, the highly conserved domain of the enzyme makes it 
challenging to design selective viral MTase inhibitors that do not interfere with the activity of host 
MTases.[65] Nevertheless, the SAM-binding site as well as the GTP pocket have been investigated 
as potential targets for drug development. Indeed, both SAM analogues interacting with the active 
site, such as compound 13 in figure 15, and molecules binding to the GTP pocket, including BG-323 
(14, figure 15), have been identified, proving the druggability of the viral MTase.[50, 65, 76] 
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Figure 15. Structures of DENV MTase inhibitors targeting the active site (13) and the GTP pocket 
(14). 
 
The RdRp domain of DENV NS5 is likely to be the most attractive target for the development of 
specific antiviral agents. Firstly, NS5 is the most conserved protein among the four serotypes of 
DENV, which share a minimum of 67% identity of their respective amino acid sequences,[74] as well 
as other RNA viruses of the Flaviviridae family. Secondly, the activity of the polymerase is essential 
for viral RNA synthesis, and therefore for viral replication.[48, 65] Finally, host cells lack RdRp 
activity, leading to fewer inhibiting effect on host enzymes.[48, 65] Structural and functional 
properties of DENV RdRp will be described in section 1.2.1. Inhibition of the viral polymerase can 
be achieved by two different classes of compounds: nucleoside inhibitors (NIs) and non-nucleoside 
inhibitors (NNIs). NNIs are small molecules that act as non-competitive inhibitors by interacting 
with the polymerase in allosteric sites. Commonly, NNIs stabilise an inactive conformation of the 
enzyme or interfere with the conformational changes required for RNA synthesis.[48, 50] The first 
allosteric inhibitors of DENV RdRp were N-sulfonylanthranilic acid derivatives, such as NITD2 
(15, figure 16), possibly acting by sterically blocking the tunnel for the access of the RNA template 
to the polymerase active site. However, development of these compounds did not advance due to 
their poor pharmacokinetic properties.[77] Recently, a number of DENV RdRp inhibitors targeting 
allosteric pockets have been identified by in silico drug design methods.[78, 79, 80] Specific NNIs are 
described in paragraph 2.1.3.4 of this work. 
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Figure 16. Structure of the DENV RdRp allosteric inhibitor NITD2 (15). 
 
The main drawbacks of NNIs are associated with the fact that allosteric sites are generally less 
conserved than the active site of the polymerase. Drug-resistant virus strains may circulate and 
rapidly emerge upon treatment with a NNI, hence combination with a second antiviral agent may 
be required. For the same reason, NNIs might not be active against all four DENV serotypes.[48, 50] 
A novel strategy for the inhibition of DENV replication is the disruption of the interaction of DENV 
RdRp with its partner proteins, such as the viral protein NS3 and the cellular α,β1-importins.
[76] The 
structural elements involved in the NS5-NS3 as well as the NS5-importin interactions have been 
identified in the DENV RdRp crystal structure, as described in detail in section 1.2.1. Although an 
exact role remains to be clarified, the binding of NS5 with its partner proteins appears to be crucial 
for viral replication.[50] The anti-helminthic drug ivermectin (11), previously identified as inhibitor 
of both the DENV helicase and protease,[50] was recently reported to disrupt the interaction 
between NS5 and the α,β1-importins.
[76] N-4-hydroxyphenyl retinamide (4-HPR), also called 
fenretinide (16, figure 17), inhibits DENV replication in vitro and in vivo and acts by blocking the 
NS5-importins interaction.[76] 
 
 
Figure 17. Structure of 4-HPR (16). 
 
NIs, in their triphosphate active form, are competitive inhibitors and act by incorporation into the 
nascent RNA strand. Being directed to the highly conserved active site of the viral polymerase, NIs 
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overcome the disadvantages of NNIs such as the emergence of resistance and the lack of activity 
against all four serotypes of DENV.[48, 50, 65] On the other hand, drawbacks of this class of DAAs 
include complexity of prediction of the structure-activity relationship (SAR) and in vivo toxicity, 
which is often not observed in previous in vitro studies (see section 1.2.2 for further details).[48, 50, 
65] In this respect, the adenosine analogue NITD008 (17, figure 18) is a noteworthy example. 
NITD008, a potent inhibitor of DENV RdRp in vitro and in vivo, did not show any cytotoxicity in 
over 100 biochemical assays; however, its further development as an anti-DENV agent had to be 
terminated due to severe side-effects observed in animals.[81, 82] The cytidine analogue prodrug 
balapiravir (18, figure 18), which was originally evaluated for the treatment of HCV infections, was 
repurposed as an anti-DENV candidate.[50, 56, 65] Although a potent inhibiting effect was observed in 
vitro,[50, 56, 65] balapiravir was found not to be beneficial in a clinical Phase II trial.[83] Nevertheless, 
the fact that balapiravir is the only DAA that reached clinical trials in humans so far demonstrates 
the high potential of NIs as anti-DENV agents.[65] 
Properties of NIs and anti-DENV NIs will be further described in paragraph 1.2.2.2. 
 
 
Figure 18. Structures of NITD008 (17) and balapiravir (18). 
 
Extensive efforts were undertaken to develop an anti-DENV therapy, as exemplified in this section. 
To date, a restricted number of drugs, including two non-specific drugs, one host-targeting 
antiviral agent and one DAA, have reached clinical evaluation, none of which showed encouraging 
results.[55, 56, 58, 62, 63, 64, 83] An effective agent for the treatment of DENV infection remains an urgent 
unmet medical need. 
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1.2 DENV POLYMERASE AS A DRUG TARGET 
1.2.1 DENV POLYMERASE 
DENV polymerase is a RdRp, capable of de novo RNA synthesis, hence in the absence of a peptide 
or RNA primer. DENV polymerase synthesises a transient dsRNA intermediate, composed of viral 
positive and negative sense RNA strands. The negative sense RNA acts as a template for the 
synthesis of the new positive sense RNA, which displaces the old one in the dsRNA.[84] The dsRNA 
is then unwound and the positive sense ssRNA, which is the viral genome, is available for 
translation to the viral polyprotein, synthesis of complementary negative sense RNA strands or 
assembly of viral particles. 
Complementary sequences are present at the 5’ and 3’-ends of the viral genome, named 
cyclisation sequences (CS) and ‘upstream of AUG regions’ (UAR). The interactions between these 
regions (long-range RNA-RNA interactions) cause the viral RNA to circularise (figure 19).[84, 85, 86]  
 
 
Figure 19. Schematic representation of circular DENV genome. 5’-3’CS and 5’-3’UAR are long-range 
RNA-RNA interactions causing genome cyclisation. DENV RdRP recognises the 5’-end and initiates 
RNA synthesis at the 3’-end of the negative sense ssRNA. CS: cyclisation sequence; UAR: upstream 
of AUG regions. RdRp: RNA-dependent RNA polymerase. Figure adapted from Gebhard et al. 
under the license Creative Commons BY-NC-SA 3.0.[86] 
 
Cyclisation of the viral genome represents a crucial feature for the de novo synthesis of the 
negative sense RNA strand, as DENV RdRp specifically recognises a promoter element, called stem-
loop A (SLA), at the 5’-end before starting the de novo RNA synthesis from the 3’-end of the ssRNA 
template.[84, 85, 86] In contrast, the presence of the 3’-end of the negative sense RNA template in 
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the dsRNA replicative intermediate seems to be sufficient for the synthesis of the complementary 
positive sense ssRNA. This may be explained by the fact that in the dsRNA replicative intermediate 
the SLA at the 5’-end of the old positive positive sense RNA is positioned near the 3’-end of the 
negative sense RNA template, and thus it may promote binding to the RdRp domain.[84, 85, 86] 
However, the exact mechanism of the de novo initiation of RNA synthesis by flavivirus 
polymerases is not yet fully understood. 
The DENV RdRp domain is located at the C-terminus of NS5 and consists of around 600 amino 
acids.[74, 84] Three crystal structures of the apo DENV RdRp have been reported (Protein Data Bank 
codes 2J7U, 4HHJ and 4C11).[74, 87, 88] Additionally, the full length DENV NS5 structure as well as the 
NS5 dimer structure have been solved very recently (Protein Data Bank codes 4V0R and 5CCV).[89, 
90] In the available crystal structures, DENV RdRp is in the ‘closed’ conformation characteristic of 
primer-independent viral polymerases and shows a right-handed architecture consisting of three 
subdomains, fingers, palm and thumb (figure 20). 
 
 
Figure 20. View of the DENV RdRp (Protein Data Bank code 4HHJ).[52] The protein is displayed as 
ribbon and colours distinguish domains as follows: fingers in blue, palm in green and thumb in red; 
the two NLSs are shown in yellow. RdRp: RNA-dependent RNA polymerase; NLS: nuclear-
localisation sequence; P: priming loop. 
 
P 
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Although this overall structure is typical of known viral RNA polymerases, the additional presence 
of two nuclear-localisation sequences (NLS) at the N-terminal region (residues 320-368 and 369-
389) is a peculiarity of DENV RdRp compared to other flaviviral RdRp and is thought to influence 
the structural properties of the protein.[74] Interestingly, one of the two NLSs (residues 320-368) 
also interacts with the C-terminal domain of NS3, suggesting that the enzymes may modulate their 
respective activities.[74] Furthermore, the NLSs interact with the intracellular transport proteins 
importin-α and importin-β, allowing the DENV RdRp to enter the nucleus. However, the exact 
function of the localization of the polymerase in the nucleus remains yet to be clarified.[61, 74] The 
palm is the most conserved subdomain and contains the Gly-Asp-Asp catalytic active site (residues 
662-664). Asp553 is also involved in the mechanism of formation of the phosphodiester bond: it 
deprotonates the 3’-hydroxyl group of the nucleotide, generating the anion that attacks the α-
phosphate of the incoming nucleotide triphosphate (NTP).[84] The coordination of two Mg2+ ions by 
Asp533 via a molecule of water and by Asp664 in the active site is essential for the activity of the 
polymerase.[74] Although the exact role of the divalent cations remains uncertain, they may be 
important to position the incoming nucleotide.[61] The active site is encircled by several loops, 
named fingertips, that contribute to shaping the tunnel for the access of the ssRNA template from 
the top of the RdRp to the active site and keeping the protein in a ‘closed’ conformation, which is 
required in the initiation phase of the de novo RNA synthesis.[44] The fingertips region, which is at 
the top of the protein, constitutes a link between the fingers and the thumb and is characterised 
by a high degree of flexibility. An additional loop, the so-called priming loop (figure 20, P), 
contributes to maintaining the RdRp in the ‘closed’ conformation which is observed in the crystal 
structures. The priming loop P (residues 782-809) belongs to the thumb subdomain and projects 
towards the active site, which it partially occludes.[74] This loop, which is not present in primer-
dependent polymerases, is equivalent to the beta-loop observed in HCV RdRp[91] and is believed to 
be essential for de novo RNA synthesis and is thought to provide the platform that stabilises the 
initiation complex required for de novo RNA synthesis.[61] An aromatic amino acid of the priming 
loop P needs to stack against the nucleobase of the incoming NTP during the initiation phase. A 
conserved residue of tyrosine is thought to act as key priming residue in other primer-independent 
polymerases (Tyr448 in HCV NS5B)[84] whereas a tryptophan or an histidine may have this role in 
flavivirus polymerases (Trp795, His798 in DENV RdRp).[77, 84, 92] A second narrow tunnel through 
the centre of DENV RdRp, which is almost perpendicular to the tunnel of the ssRNA template, 
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allows the NTPs to access the catalytic site from the back of the polymerase, whereas the front of 
this tunnel is partially obstructed by the priming loop.[61] 
DENV RdRp hosts two zinc-binding sites in the fingers and thumb subdomains. The first Zn2+ ion, 
coordinated by Cys446, Cys449, His441 and Glu437, is also observed in the WNV RdRp crystal 
structure, whereas the second Zn2+ ion represents a peculiarity of DENV RdRp.[74, 84, 93] The binding 
site of this additional cation consists of His712, His714, Cys728 and Cys847 and is in close position 
to the expected binding site of the incoming NTP, in a hinge between the thumb and the palm.[74, 
84, 93] 
A concave surface is observed at the base of the fingers subdomain, close to the N-terminal region 
of the protein. It was suggested that this surface may accommodate the MTase domain of NS5.[74] 
However, a flexible linker was identified between the RdRp and MTase domains in the DENV RdRp 
crystal structure by Lim et al.,[88] and in the full length DENV NS5 crystal structure by Zhao et al.[89] 
and the NS5 dimer by Klema et al.[90] This inter-domain linker can adopt different conformations 
and thus allows the two globular domains to adopt various orientations and modulate their 
respective enzymatic activities.[88, 89, 90] 
De novo RNA synthesis involves the initial condensation of two nucleotides having complementary 
nucleobases to the two 3’-terminal nucleobases of the RNA template.[44, 74] As mentioned above, a 
‘closed’ conformation of the RdRp is required for stabilising the complex in the initiation phase 
and for catalysing the formation of the phosphodiester bond between the first two nucleotides.[44] 
As previously mentioned, the priming loop P is believed to represent the structural element that 
provides the initiation platform, however also the fingers subdomain may be involved in the 
network of interactions that stabilises the initiation complex.[84, 87] It has been hypothesised that 
the crystal structures of flavivirus polymerases capture the enzymes in a pre-initiation 
conformation.[84] Upon initiation of the RNA synthesis, concerted conformational changes of the 
fingers may occur and bring these loops in contact with the first NTPs in an initiation-competent 
‘closed’ conformation.[74, 84] 
After the dinucleotide stage of the synthesis of the RNA, the polymerase needs to undergo drastic 
conformational changes to an ‘open’ structure that allows for the elongation of the RNA growing 
strand and egress of the dsRNA from the front of the enzyme.[44, 74] As the priming loop P partially 
occludes the path of the dsRNA, it is thought to be the main site of conformational changes during 
the activity of the enzyme. A rotation of the thumb outwards may also occur during the activity of 
DENV RdRp, leading to a more open conformation. The Zn2+ ion located in the thumb subdomain 
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may play a role in the regulation of this rotation, and therefore in the transition from initiation to 
elongation.[84, 93] Details on the conformation of RdRp during the elongation phase are unknown, 
as a crystal structure of the flavivirus polymerase in complex with the newly synthesised dsRNA is 
not yet available. 
 
1.2.2 NUCLEOSIDE INHIBITORS 
DENV RdRp has an essential role in viral replication and may represent the ideal target for 
developing DAAs. As previously mentioned, two main strategies can be pursued for inhibiting the 
synthesis of viral RNA by the polymerase, using NNIs or NIs.[48, 50] Nucleoside analogues, which 
make up the most abundant class of marketed antiviral agents,[48, 50, 94] are prodrugs that become 
active upon intracellular conversion to their corresponding triphosphates by host cell kinases. The 
triphosphate form then targets the active site of the polymerase and acts as a competitive 
inhibitor by mimicking the natural NTP substrate of the enzyme. Finally, the triphosphate 
derivative is incorporated into the nascent RNA, either causing chain termination or inducing 
mutations in the new viral genome. NIs offer important advantages over other classes of antiviral 
drugs. Firstly, since NIs interact with the highly conserved active site of the polymerase, NIs have a 
higher barrier for the emergence of resistance compared to other DAAs.[48, 50, 65] Secondly, NIs are 
likely to be effective against a variety of related viruses, including the four serotypes of DENV, 
other flaviviruses and HCV, given the structural similarity of their polymerases.[48, 50, 65] 
On the other hand, the development of NIs is often challenging. Phosphorylation of the nucleoside 
analogue to mono-, di- and finally triphosphate are catalysed by host kinases. Therefore, the 
nucleoside analogue needs to be recognised by – and act as substrate of – cellular kinases, 
whereas the triphosphate derivate must selectively inhibit the viral polymerase. Moreover, as the 
antiviral activity of a potential NI is the result of several events, including cellular uptake via 
nucleoside transporters and intracellular activation by host kinases, the prediction of SAR of this 
class of compounds is often not a suitable approach for identifying potent compounds.[48, 50, 65] 
Another major challenge associated with NIs is their unpredictable toxicity in vivo. Toxicity due to 
inhibition of the mitochondrial polymerase γ in host cells has been observed as a common side 
effect, especially with deoxy-nucleoside analogues used in long-term treatment.[48] Although 
mitochondrial toxicity might not be a significant issue in the case of anti-DENV NIs, which are 
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typically ribose nucleosides administered for less than a week,[50] extensive in vivo studies need to 
be carried out to evaluate these kind of toxicities, which are often not observed in vitro.[48, 50] 
Furthermore, nucleoside analogues are polar compounds, and thus have poor membrane 
permeability which results in poor cellular uptake by passive diffusion and bioavailability in vivo.[48, 
50, 65] Finally, nucleoside analogues and their mono- and diphosphate derivatives are poor 
substrates of cellular kinases, resulting in an inefficient metabolism to the bioactive triphosphate. 
The first phosphorylation often represents the rate limiting step in the activation process and 
might compromise the antiviral activity of NIs.[48, 50, 95] 
 
1.2.2.1 Nucleoside and nucleotide prodrugs 
As described above, poor cellular permeation and limited phosphorylation are issues commonly 
encountered with nucleoside analogues. Poor cellular permeation could be overcome by a 
nucleoside prodrug approach. This method consists of the conjugation of a cleavable moiety, such 
as an ester, to the nucleoside in order to increase lipophilicity and improve pharmacokinetic 
properties of compounds.[48, 50, 96] However, nucleoside prodrugs may be poor substrates for 
metabolic enzymes, thus resulting in poor activation.[96] Furthermore, this prodrug strategy does 
not overcome the issue of an inefficient conversion of the nucleoside analogue to its 
monophosphate form. 
The nucleotide prodrug technology therefore aims at bypassing limiting first phosphorylation step 
by delivering the nucleotide monophosphate directly into cells. The nucleotide monophosphate 
itself is not a suitable candidate drug as the presence of negative charges at physiological pH make 
it unstable in biological media as well as highly hydrophilic and thus unable to diffuse across the 
cellular membrane.[95] However, the charges of the phosphate moiety can be masked by additional 
hydrophobic groups at the phosphorus centre.[48, 50, 95] The resulting nucleotide prodrug is a 
neutral molecule, which is characterised by increased lipophilicity compared to the parent 
nucleoside, and reaches the intracellular compartment by passive diffusion through the 
membrane. The nucleotide monophosphate is released following hydrolytic or enzymatic 
metabolism and trapped inside the cell due to the unprotected charges. Further phosphorylation 
steps of the mono- and diphosphate derivatives generate the biologically active NTP.[95] The 
application of the nucleotide prodrug approach improves pharmacokinetic properties and boosts 
biological activity of the parent nucleoside.[95] 
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Table 2. Summary of nucleotide monophosphate prodrug approaches. 
Prodrug approach Classes General structure 
Phosphotriester  Bis(pivaloyloxymethyl) (POM) 
 
 
 Bis(S-acylthioethyl) (SATE) 
Bis(dithiodiethyl) (DTE) 
 
 
 HepDirect 
 
 
 CycloSal 
 
 
Phosphoramidate ProTide (aryloxyphosphoramidate) 
 
 
 Phosphoramidate monoester 
 
 
 Cyclic phosphoramidate 
 
 
Phosphorodiamidate Phosphorodiamidate 
 
 
3’,5’-Cyclic prodrug 3’-5’-Cyclic triester and ProTide 
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Several methodologies have been developed to mask the hydrophilic phosphate with neutral 
lipophilic moieties and are summarised in table 2.[95, 97, 98] In this work the phosphoramidate 
ProTide approach will be described. 
The ProTide strategy was invented by McGuigan et al. and applied for the first time to the anti-HIV 
nucleoside analogue azidothymidine (AZT).[99] In these compounds, which are named ProTides, the 
negatively charged phosphate is masked by an amino acid alkyl or aryl ester and a second aryl 
moiety attached to the phosphorus centre (aryloxyphosphoramidate, figure 21). A ProTide 
presents three sites of possible modification: the aryl moiety, the amino acid and the ester. 
However, L-alanine is the most commonly used amino acid as it demonstrated a good biological 
profile,[100] whereas different combinations of the other two structural elements are generally 
explored in a series of ProTides to study the antiviral effect. A possible limitation of the 
phosphoramidate ProTide approach is the chirality of the phosphorus centre. ProTides are 
obtained as diastereoisomeric mixture (in approximately a 1:1 ratio) and separation of the two 
species, which are generally associated with different activity profiles, can be difficult. 
 
 
Figure 21. General structure of ProTides. 
 
The putative activation pathway of ProTides involves two enzymatic steps (scheme 1).[101] The first 
step is the hydrolysis of the amino acid ester moiety catalysed by an esterase or carboxypeptidase 
type enzyme. The nucleophilic carboxylate derivative undergoes spontaneous cyclisation, with the 
displacement of the aryl moiety and subsequent water-mediated opening of the unstable ring. The 
nucleotide monophosphate is released following hydrolysis of the N-P bond catalysed by a 
phosphoramidase type enzyme (hystidine triad nucleotide-binding protein, Hint).[101]  
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Scheme 1. Putative bioactivation pathway of a ProTide.[101] 
 
According to the proposed mechanism of bioactivation, both the initial ester hydrolysis and the 
amino acid cleavage need to be possible in order to deliver the nucleotide monophosphate 
intracellularly, and thus to observe biological activity. The requirement of two cellular enzymes 
may therefore represent a limitation of the ProTide approach. For example, the application of the 
phosphoramidate strategy to the broadly active antiviral agent RBV generated only poorly active 
ProTides (figure 22), suggesting poor metabolism of the prodrug to the active monophosphate 
form. Indeed, enzymatic assays and molecular modelling studies suggested that the intermediate 
metabolites of the RBV ProTides are not substrates of the human Hint enzyme.[102] 
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Figure 22. General structure of ribavirin ProTides. 
 
Similarly, the application of the ProTide approach to the 7-deaza analogue of 2’-C-methyl-6-O-
methylguanosine (figure 23), which is inactive against HCV due to poor cellular uptake and limited 
phosphorylation, failed to greatly restore the antiviral activity.[103] In contrast, the L-alanine 
neopentyl phosphoramidate ProTide of its 7-aza analogue (INX-08189 or BMS-986094, 19, figure 
23) progressed to clinical trials as an anti-HCV agent.[104] 
 
 
Figure 23. General structure of the 7-deaza-2’-C-methyl-6-O-methylguanosine ProTides compared 
to INX-08189 (19). 
 
Despite these specific difficulties associated with the phosphoramidate ProTide approach, this 
nucleotide prodrug strategy was applied to various anticancer and antiviral nucleoside 
analogues.[99, 100, 104, 105, 106, 107, 108] A remarkable example is the L-alanine benzyl phosphoramidate 
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of the anticancer drug Gemcitabine (NUC-1031, 20, figure 24), which was recently reported to 
bypass the resistance mechanisms that often limit the clinical use of the parent nucleoside.[106] 
NUC-1031 is currently in a clinical Phase III trial.[106]  
 
 
Figure 24. Structure of the Gemcitabine ProTide NUC-1031 (20). 
 
Finally, the phosphoramidate ProTide technique has been clinically validated by the approval of 
two antiviral drugs. In fact, the single diastereoisomer of the L-alanine isopropyl phosphoramidate 
of 2’-deoxy-2’-α-fluoro-2’-β-C-methyluridine, Sofosbuvir (PSI-7977, 21, figure 25) and of the acyclic 
phosphonate Tenofovir, Tenofovir alafenamide (GS-7340, 22, figure 25), are now in clinical use for 
the treatment of HCV and HIV infections respectively.[107, 108]  
 
 
Figure 25. Structures of Sofosbuvir (PSI-7977, 21) and Tenofovir alafenamide (GS-7340, 22). 
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1.2.2.2 Anti-DENV NIs 
Despite the difficulties linked to their development, NIs remains the most promising class of 
DAAs.[94] Cross-reactivity of NIs against HCV and DENV has been observed and repurposing has 
proved to be a valid strategy. 7-Deaza-2’-C-methyladenosine (23, figure 26), a potent inhibitor of 
HCV replication, was found to be broadly active against several members of the family Flaviviridae, 
including DENV (EC50 15 μM).
[109] Compared to the natural nucleoside, the inhibitor presents two 
modifications: i) the introduction of a 2’-C-methyl group (possibly able to sterically prevent the 
binding of the next incoming nucleotide), and ii) the carbon substitution of the N-7 position of the 
purine base, which increased the potency of the compound and significantly improved its 
pharmacokinetic properties. Indeed, the deamination by adenosine deaminase (ADA) to an 
inactive inosine derivative and the cleavage of the nucleoside by purine nucleoside phosphorylase 
(PNP) were found to be greatly reduced.[110, 111] Similarly, balapiravir (18, figure 26), a tri-
isobutyrate ester prodrug of 4’-azidocytidine (R1479) originally developed as a potential anti-HCV 
agent, showed anti-DENV activity in vitro[50] and was evaluated in a clinical Phase II trial.[83] 
Unexpectedly, treatment of DENV-infected patients with balapiravir failed to produce any 
significant improvement of symptoms and clinical evaluation of this cytidine analogue was 
terminated due to lack of potency.[83]  
 
 
Figure 26. Structures of 7-deaza-2’-C-methyladenosine (23) and balapiravir (18). 
 
A novel class of 2’-C-acetylene substituted adenosine analogues was identified by Novartis 
Institute for Tropical Diseases (NITD) as potent inhibitors of DENV replication both in vitro and in 
vivo.[81, 82, 112] NITD008 (17, figure 27) is the 7-deaza modification of adenosine combined with the 
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introduction of an acetylene at the 2’-position of the ribose moiety. NITD008 potently inhibited all 
the four DENV serotypes on different cell lines with submicromolar EC50, as well as other members 
of the family Flaviviridae, including HCV, and was not cytotoxic in vitro at concentrations of up to 
50 μM.[81] In vivo efficacy was examined in a dengue animal model: both multiple-dose 
treatment[81] and single-dose treatment[82] of DENV-infected mice with NITD008 suppressed peak 
viraemia and reduced cytokine elevation. Furthermore, the compound completely protected mice 
from death in a dengue mouse lethal model.[81, 82] Similarly, NITD449 (24, figure 27), the 7-
carbamoyl derivative of NITD008, showed an EC50 < 1 μM for all four DENV serotypes and related 
viruses (YFV, WNV, HCV) and was not cytotoxic in vitro at concentrations of up to 12.5 μM.[112] 
However, a prodrug approach was required in order to overcome the low level of bioavailability of 
NITD449 when orally dosed in animals and thus to evaluate the efficacy of the compound in vivo. 
The addition of isobutyric acid via cleavable ester linkage at the 3’ and 5’-O-positions of NITD449 
led to the prodrug NITD203 (25, figure 27), which exhibited improved pharmacokinetic 
properties.[112] Furthermore, NITD203 was rapidly converted to the active compound, was not 
cytotoxic in vitro at concentrations of up to 25 μM and selectively inhibited viruses within the 
family Flaviviridae at submicromolar levels of EC50.
[112] In vivo efficacy was demonstrated for 
NITD203 in a dengue viraemia mouse model.[112] Although none of the adenosine analogues 
showed cytotoxicity in over 100 biochemical assays, NITD008 and NITD203 did not reach a 
satisfactory no-observable-adverse-effect level (NOAEL) in 2-week in vivo toxicity studies.[81, 112] 
The causes of this unexpected toxicity are currently under investigation.[112] 
 
 
Figure 27. Structure of the 2’-C-acetylene 7-deazaadenosine analogues NITD008 (17), NITD449 
(24) and NITD203 (25). 
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Recently, a number of nucleoside analogues have been reported to inhibit the DENV RdRp activity 
in vitro.[113, 114, 115, 116, 117] The majority of the NIs against DENV are purine derivatives. The 
introduction of a carbon group at the 4’-position combined with various 7-deaza modifications of 
adenosine generated a small series of compounds (figure 28) with micromolar activity in vitro 
(EC50 from 5.55 to 10.06 μM).
[113] 
 
 
Figure 28. General structure of the anti-DENV 4’-C-methyl-7-deazaadenosine analogues. 
 
A novel class of 2-amino-2’-C-methyladenosine analogues (figure 29) showed an EC50 in the range 
from 5.0 to 9.5 μM.[114] All the nucleosides share a 2,6-diaminopurine heterobase, which is further 
modified at the N-6 position or 8-position, and the 2’-C-methyl moiety in the ribose. The main 
element of novelty in this family is represented by the presence of an additional substituent at the 
1’-anomeric position of the ribose. 
 
 
Figure 29. General structures of the anti-DENV 2,6-diaminopurine nucleosides. 
 
Tichý et al. focused on base-modified nucleosides and identified a novel class of benzo-fused 7-
deazaadenosine analogues (figure 30) as anti-DENV agents (EC50 from 14.8 to 39.6 μM).
[115] 
Additionally, the replacement of the 4-amino group with 5-membered hetaryl cycles, such as furyl 
and thienyl, yielded derivatives with submicromolar activity against DENV in vitro (figure 30).[116] 
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Figure 30. General structures of the anti-DENV benzo-fused derivatives of 7-deazaadenosine. 
 
Finally, the first example of an anti-DENV phosphoramidate ProTide was reported by Yeo et al. in 
2015.[117] In fact, the previously mentioned anti-HCV agent INX-08189 (19) inhibited DENV 
replication in vitro, suggesting that the application of the nucleotide prodrug approach may be 
useful for the development of a highly needed treatment of DENV infection. 
Collectively, these results exemplify the challenges associated with the development of safe and 
effective NIs, especially in the context of providing safe and effective anti-DENV therapeutics. 
Nevertheless, the nucleoside and nucleotide-based approaches are a promising strategy for 
inhibiting DENV replication and are going to be explored in this work. 
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1.3 MOLECULAR MODELLING 
1.3.1 THE DRUG DISCOVERY PROCESS 
A drug discovery programme is initiated due to an unmet medical need, in order to find a therapy 
for an untreated disease or to improve the existing treatment for a disease.[118] The starting point 
is the identification of a suitable drug target, often a protein such as an enzyme, a receptor, an ion 
channel or a transporter, but also a nucleic acid or a gene.[118, 119, 120] The ideal target 
macromolecule is closely linked to the illness, and should be safe and ‘druggable’, so that its 
function may be modulated by a drug molecule.[118] The properties of the drug target may differ 
depending on the disease that need to be addressed.[119] For instance, a total inhibition of an 
antimicrobial drug target is generally desired to induce death of a pathogen or to stop its 
replication in the human body. In this case, the target needs to be essential for survival of the 
target organism and selectively present in the pathogen, besides being ‘druggable’.[119] As the 
nature of the target may vary, also the drug may be a small molecule or a larger biological 
therapeutic, like a peptide or an oligonucleotide.[118] 
The following phase of the drug discovery process is hit identification and lead optimisation. The 
hit is a biologically active ‘drug-like’ molecule, typically showing an activity in the range 100 nM to 
5 μM.[118] Hit molecules can be identified in different ways, using HTS, virtual screening (VS) or 
other rational drug design methods. Generally whole series of hits are selected for progression 
towards the next step in the drug discovery process. In the field of small molecule drug discovery, 
a hit is usually a simple and low-weighted chemical entity.[118] This is of crucial importance because 
further optimisation of hit molecules usually involves an increase in molecular weight of the 
resulting drug candidate. In fact, several chemical analogues of the hit series need to be 
synthesised and evaluated for biological activity against the target, in the attempt to produce 
more potent and selective compounds as well as improve suboptimal pharmacokinetic properties 
(hit-to-lead phase). In this early stage of the drug discovery process, physicochemical properties, 
such as solubility and permeability through membranes, as well as in vitro absorption, distribution, 
metabolism and excretion (ADME) properties are being considered.[118] The most promising 
compound is being selected as lead compound, is further optimised by chemical modifications, 
and finally may progress to preclinical evaluation. Testing using in vivo models is useful to assess 
toxicology and ADME profiles, so as to verify whether the compound is safe and thus can advance 
to clinical evaluation and to estimate its initial dose in humans.[118] The three Phases of clinical 
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trials provide data on the safety and the efficacy of the drug candidate in larger and larger samples 
of the human population (table 3).[121] Eventually, if Phase I to III are completed successfully, the 
drug is approved for commercialisation and enters a fourth Phase, in which the effect of the new 
therapeutic is monitored continuously during its clinical use.[121] 
 
Table 3. Phases of clinical trials. 
Clinical trials Population Aims 
Phase I healthy volunteers to evaluate safety, tolerability at ascending dose regimens, 
pharmacokinetic properties 
Phase II hundreds of patients to evaluate efficacy compared to placebo or gold standard 
therapy in the market (when available) 
Phase III thousands of patients to strengthen statistics and confirm previous findings 
Phase IV 
(post approval) 
World’s population to monitor the drug after reaching the market 
(pharmacovigilance) 
 
The drug discovery process is long (between 12 and 15 years from the initial idea to the launch of 
the new medicine in the market) and expensive, with a cost of over £1 billion for a new drug.[118, 
122] Besides being time-consuming and costly, the process is characterised by a high risk of 
failure.[118, 122, 123] Clinical trials of drug candidates may be terminated unsuccesfully due to the lack 
of clinical efficacy or to toxicity issues in humans.[118, 122, 123] It was estimated that only one in ten 
drug candidates that advances to human evaluation is actually approved for commercialisation, 
meaning that the rate of failure once clinical trials are reached is as high as 90%.[118, 122] 
In the last 60 years, pharmaceutical progress has importantly contributed to extending life 
expectancy. From 1950 to 2014, 1 405 new therapeutics were approved for commercialisation, of 
which 1 249 are new molecular entities (NMEs), that refer to small molecule drugs, and 156 are 
new biologics license applications (BLAs).[122, 124] Despite a temporary rise in the number of Food 
and Drug Administration (FDA)-approvals between 1995 and 1999 and also an extraordinary peak 
of productivity in 2014,[124] the trend of new drug output remains linear, with companies 
delivering new therapeutics at a constant rate (24 new drugs per year on average).[122] However, 
the expenditure of production has seen an exponential increase, raising concerns about the 
sustainability of the pharmaceutical industries.[122] 
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1.3.2 MOLECULAR MODELLING APPROACHES 
Given the challenges associated with the development of novel drugs and the previously described 
‘pharmaceutical crisis’, there is a need for innovative techniques to reduce the time and costs as 
well as increase the success rate of the drug discovery process. Being based on computational 
technology, molecular modelling represents one of the possible answers to these issues. Being a 
rational method for drug design, it finds its antithesis in the experimental method, which is based 
on the discovery of new hits by chance, using HTS and combinatorial chemistry.[125, 119] 
In the field of the molecular modelling, computational techniques are applied to explain chemical 
systems in terms of mathematical models.[126] The model is indeed a simplified description of a 
complex system, such as the interactions of a target with its ligand, in mathematical terms. 
Computational calculations can be performed on the mathematical model and enable the 
prediction and the understanding of properties of the modelled system, starting from known 
properties at the atomic scale.[126] Molecular modelling may be involved at different stages of the 
drug discovery process, especially in the key steps of identification of hit series and optimisation of 
lead compounds.[127, 128] In order to elicit its biological effect, the drug molecule needs to interact 
with a specific target. This recognition of the drug and its target relies on the high level of 
complementarity between the ligand and a pocket in the target macromolecule, which are often 
mediated by the formation of hydrogen bonds and hydrophobic interactions.[127] Molecular 
modelling techniques allow for the prediction of these interactions, which is fundamental for any 
in silico drug design approach. The required time and costs for these computational techniques are 
radically reduced compared to the chemical synthesis and biological evaluation of large series of 
chemical compounds. In addition to pharmacodynamic properties, the behaviour of the drug in 
the human body from its administration to its excretion (ADME and toxicology profile) is essential 
for the biological activity of a drug. Computational techniques can be applied in this field as well, 
thus selecting and then optimising compounds, in a quick, safe, and cost-effective way.[127, 128] 
For these reasons, molecular modelling techniques have become of increasing importance in drug 
discovery over the past two decades.[119, 128, 129] The increasing computational power and 
calculation capacity further encourage the application of fast and inexpensive molecular modelling 
methods.[119, 125] Finally, the accuracy of mathematical models describing chemical systems is also 
improving allowing for the simulation of more complex molecular environments as well as for 
more precise and reliable results.[128] 
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In silico approaches in drug discovery may be broadly classified in structure-based and ligand-
based drug design, depending on the availability of the three-dimensional (3D) information of the 
macromolecular target. Structure-based approaches rely on the 3D structure of the target to 
optimise the binding of the drug to the target, whereas ligand-based approaches are preferable 
when a series of active compounds are available and can furnish information about the binding 
mode in the absence of the 3D structure.[127, 128] 
 
1.3.2.1 Structure-based drug design 
Structure-based drug design (SBDD) methodologies exploit the known 3D structure of the target, 
which is obtained experimentally or constructed using molecular modelling methods, to identify 
novel drugs and enhance their activity.[127, 128] The application of SBDD has seen a constant rise, 
thanks to the availability of a rapidly increasing number of proteins with a known 3D structure.[119, 
120, 128] Indeed, the sequencing of the human genome combined with advances in the 
methodologies for structure determination, such as X-ray crystallography and nuclear magnetic 
resonance (NMR) experiments, provides new potential drug targets at an accelerated rate, and 
thus new opportunities for the application of structure-based computational methods.[119, 128] 
Once the target with a known 3D structure has been chosen, the initial step of any SBDD study is 
the identification of a potential binding site for small molecules, a pocket, in the macromolecular 
target.[119] A variety of methodologies can be adopted, such as the modification of the structure of 
an initial ligand to maximise complementary interactions, the screening of a database of 
compounds in silico, or the de novo generation of potential hit molecules by positioning small 
fragments in the binding site and linking them together.[119, 127] 
Molecular docking is a widely used structure-based technique that consists of the prediction of the 
geometry of the ligand-target complex or, in other words, the binding mode of a small molecule in 
the designated pocket of the protein.[127, 128] The process applies search algorithms, known as 
docking algorithms, to define the ligand pose, which is the conformation and orientation of the 
small molecule within the binding site.[129] Conformations of the ligand are taken into account in 
the docking process to have sufficient accuracy of the results.[128, 129] Conformational changes of 
the target protein, loop fluctuation and movement of protein domains notably influence ligand 
binding. However, such a protein flexibility is normally not considered because flexible docking 
requires computationally expensive calculations.[125] In addition to docking algorithms, scoring 
functions are used to evaluate the interactions established in the ligand-target complex and, 
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ultimately, to predict binding affinity of the molecule on the basis of shape and electrostatic 
complementarities.[129] Scoring functions allow for ranking the docked conformations that were 
generated for each molecule. However, they are only approximate and a good score is not always 
indicative of high binding affinity.[119, 129] As a consequence, visual evaluation of the generated 
poses using computer graphics software is generally fundamental for the final selection of the best 
molecules.[119, 129] 
The docking process is the basis of both VS and de novo design.[119, 130] VS consists of the search for 
compounds having suitable geometry and electronic features to fit the specific binding site, using 
docking algorithms.[128, 130] Such an in silico screening is fast and allows for the screening of large 
virtual libraries in a short time.[128] 
The de novo generation method aims at the design of new molecules which are not present in the 
literature or compound databases.[119] It involves the docking of small fragments into the binding 
site of the target, followed by the assembly of the positioned fragment into a larger molecule.[119, 
127, 128] The fact that small fragments are capable of fully exploring the binding site represents an 
advantage of this methodology. On the other hand, the designed molecules are often very 
complex and their syntheses difficult to accomplish, which again limits the application of this 
procedure.[119, 128] 
Molecular dynamics (MD) simulation is a powerful structure-based technique, that aims at 
predicting the behaviour of a molecular system over time.[128, 131] The MD simulation is the 
generation of successive configurations of the system, in small time steps, and consists of the 
analysis of the trajectory of each atom of the molecular system through the simultaneous solution 
of the Newton’s second law of motion (equation 1).[131, 132] 
 
             
   
  
      
    
   
 
Equation 1. Newton’s second law of motion.[132] F = force, m = particle mass, a = acceleration, v = 
velocity, t = time, x = distance along one coordinate and i = 1 to N. 
 
The motion analysis is complemented by the calculation of energies, forces and potentials on 
atoms using mathematical functions named force fields.[131] The application of MD simulation 
techniques is particularly useful to evaluate the binding interactions in non-static ligand-target 
complexes, thus accounting for induced conformations, the stability of such complexes as well as 
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the conformational changes of macromolecules over time.[128] These investigations provide 
insights into processes that may be difficult to study empirically and that are often fundamental 
for in silico drug design studies. 
 
1.3.2.2 Ligand-based drug design 
Ligand-based drug design (LBDD) approaches are generally applied when the 3D information on 
the target is not available or, frequently, they are used in combination to structure-based 
techniques. LBDD methods rely on the chemical structure of drug-like molecules and on their 
empirical activity data.[127] 
One of the most significant LBDD method is based on the prediction of quantitative structure-
activity relationships (QSAR). The QSAR model is a mathematical function that correlates biological 
data available for a set of molecules to structure-derived properties that, importantly, are 
expressed in terms of numbers.[127, 128] These properties are known as molecular descriptors. They 
are deduced from the molecular formula, the two-dimensional (2D) or 3D chemical structures and 
may vary significantly. Some examples are molecular weight, partition coefficient, number of 
rotatable bonds, number of double bonds, volume and surface-related numerical properties.[127] 
The aims of QSAR predictions are to identify features that are important for activity and give 
indications on how to modify molecular descriptors to enhance their biological profile.[127] 
Molecular descriptors are of crucial importance also in the case of similarity search. The rationale 
behind this approach is that molecules binding to the same pocket of a target will show a certain 
degree of similarity.[128] Therefore, molecular databases can be screened in silico to search for 
molecules similar to a lead compound. The measurement of the degree of similarity (similarity 
coefficient) is achieved starting from the molecular descriptors, according to different 
mathematical methods.[127] 
Finally, in the pharmacophore search, a third LBDD technique, the in silico screening of molecular 
databases is performed on the basis of the presence and the relative positions of key chemical 
features of the ligand.[127] A pharmacophore is a set of chemical features (hydrogen bond donor 
and acceptor, hydrophobic and aromatic groups, anion and cation) that are essential for the 
interaction of the ligand with the target, often in a conformation-dependent spatial relationship 
(3D pharmacophore). The chemical features of molecules in databases are compared to the 
pharmacophore to identify potential ligands.[127] 
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1.4 AIMS AND OBJECTIVES 
The four serotypes of DENV represent a major health burden in the tropical and subtropical areas 
and are rapidly spreading to new countries. Half of the world population, accounting for 
approximately 3.9 billion people, is at risk of infection with DENV, raising considerable concern 
within the scientific community. The development of a vaccine has proven to be very challenging 
and the recently licensed dengue vaccine by Sanofi Pasteur provides limited benifits. To date, 
treatment of DENV infection is only symptomatic and unable to prevent the progression of the 
disease to life-threatening conditions. In consequence, the development of specific antiviral drugs 
which are effective against all four serotypes of DENV is of great importance. 
The overarching aim of this PhD project was the preparation of novel nucleoside and nucleotide 
analogues as potential anti-DENV agents aimed to inhibit the viral RdRp. To achieve this, the 
specific aims were as follows. 
 To create a model representative of the de novo initiation complex of DENV RdRp for the 
application of computer-aided drug design approaches. Although crystal structures of 
DENV RdRp have been solved, structural information on DENV RdRp in complex with the 
RNA template and the priming NTPs (de novo initiation complex) is currently not available. 
The construction of a model would provide a useful tool for the application of SBDD 
techniques. 
 To design families of nucleoside analogues using molecular modelling techniques, in 
particular by predicting the binding affinity of ribose-modified and heterobase-modified 
nucleosides for the active site of the DENV RdRp model, and by identifying novel acyclic 
scaffolds replacing the ribose moiety of the nucleosides. 
 To acquire knowledge on the mechanism of the RNA synthesis by the DENV RdRp through 
molecular modelling techniques, in particular by the application of MD simulation methods 
on representative complexes of the DENV RdRp in the different phases of RNA synthesis. 
 To synthesise nucleoside analogues and phosphoramidate ProTide derivatives. The ProTide 
nucleotide prodrug strategy is applied to overcome common issues of nucleosides, such as 
poor cell permeation, susceptibility to metabolic degradation, poor phosphorylation to 
active species and toxicity. An optimisation of the procedure for the synthesis of 
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phosphoramidate ProTides would ease the preparation of analogues within this class of 
biologically relevant compounds and is therefore investigated in this work. 
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2.1 MOLECULAR MODELLING STUDIES ON DENV RdRp 
2.1.1 DENV RdRp DE NOVO INITIATION COMPLEX 
Several crystal structures of DENV RdRp have been reported and show the polymerase domain in a 
‘closed’ conformation representative of a pre-initiation state.[1, 2, 3, 4] However, the crystal structure 
of DENV RdRp binding the nucleic acid has not been solved. A complete de novo initiation complex 
(ternary complex) of DENV RdRp would show the enzyme bound to an ssRNA template and 
priming nucleotides complementary to the 3’-end of the template, as well as to two Mg2+ ions in 
the active site. 
In the model of the de novo initiation complex proposed by Yap et al. in 2007 (figure 31),[1] a GTP-
binding site has been identified in the polymerase crystal structure and provides the priming (or de 
novo initiation) platform.[1, 5] A high concentration of GTP is required for initiating the RNA 
synthesis with the de novo mechanism, regardless of the exact nucleotide sequence at the 3’-end 
of the RNA template.[1, 5] As described in section 1.2.1, the nucleobase of the priming nucleotide 
(GTP) stacks against an aromatic residue of the priming loop (Trp795 in this model)[1] in the 
initiation site (i site). This interaction positions the priming nucleotide in a way that it can form 
base pairing Watson Crick hydrogen bonds with the nucleotide at the 3’-end of the RNA template. 
The triphosphate moiety of the GTP is coordinated by Ser710, Arg729 and Arg737 which are 
strictly conserved and in vicinity to the priming loop.[1] 
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Figure 31. The DENV RdRp de novo initiation complex model proposed by Yap et al.[1] Nucleotides 
are shown as green sticks and indicated by arrows. The priming GTP in the initiation (i) site stacks 
against Trp795, shown as sticks in yellow. GTP: guanosine triphosphate; NTP: nucleotide 
triphosphate. Figure reproduced under permission by the American Society for Microbiology. 
 
A second model of the DENV RdRp de novo initiation complex, proposed by Selisko et al. in 2012 
(figure 32),[6] describes a similar binding site for the priming NTP. The coordination of the 
triphosphate moiety of the priming nucleotide (ATP in this model) by Ser710, Arg729 and Arg737 
in the i site was confirmed. The 3’-hydroxyl group of the ATP is positioned close to the α-
phosphate of the incoming nucleotide (GTP) which occupies the catalytic site (i + 1). However, the 
nucleobase of the priming ATP stacks against a residue of histidine (His798) of the priming loop, 
rather than Trp795.[6] 
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Figure 32. The DENV RdRp de novo initiation complex model proposed by Selisko et al.[6] 
Nucleotides are shown as sticks in light grey. The priming ATP in the initiation (i) site stacks against 
His798 (shown as sticks in orange), and the second NTP is coordinated to the Mg2+ ions (Mg1 and 
Mg2, displayed as green spheres) in the catalytic (i + 1) site. ATP: adenosine triphosphate; GTP: 
guanosine triphosphate; NTP: nucleotide triphosphate. Figure reproduced from Selisko et al. 
under the Creative Commons Attribution license.[6] 
 
In conclusion, both models of the DENV RdRp de novo initiation complex highlight the key role of 
the priming loop in initiating the RNA synthesis. However, the crystal structure of the DENV RdRp 
ternary complex is still missing and would provide a precise characterisation of the residues 
responsible for the interaction with the dinucleotide in the priming (i) and catalytic (i + 1) sites.[5, 6] 
 
2.1.1.1 Construction of DENV RdRp de novo initiation complex model 
The availability of a model of the DENV RdRp de novo initiation complex would represent an 
essential tool for the design of novel nucleoside analogues. The procedure used in this work for 
the construction of the model of DENV polymerase binding the ssRNA template and the priming 
nucleotides was reported by Migliaccio et al.[7] for generating a model of HCV polymerase bound 
to the inhibitor 2’-C-methyladenosine triphosphate. The templates used by the authors[7] were the 
HCV NS5B crystal structure (Protein Data Bank code 1GX6) and the initiation complex crystal 
structure reported for the bacteriophage ɸ6 RdRp (Protein Data Bank code 1HI0). Similarly, the 
model for the DENV RdRp de novo initiation complex was built from the DENV polymerase crystal 
structure (Protein Data Bank code 4HHJ)[2] and the crystal structure of the HCV polymerase in 
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complex with a short dsRNA, published by Mosley et al. in 2012 (figure 33, Protein Data Bank code 
4E78).[8] 
 
 
Figure 33. Crystal structure of the HCV NS5B ternary complex (Protein Data Bank code 4E78).[8] 
The back view of the polymerase shows the double stranded RNA, displayed as sticks (nascent 
RNA in light blue, template RNA in pink). HCV NS5B. Hepatitis C virus non-structural protein 5B. 
 
Because of the structural similarity between the two polymerases, it was possible to use the 
available crystal structure for the HCV NS5B complex[8] as a template for the construction of the 
model of the ternary complex of DENV polymerase. The DENV polymerase crystal structure was 
superposed on the HCV ternary complex crystal structure[8] and the nucleic acid from the latter 
was imported into the active site of DENV polymerase. The growing strand was shortened to a 
dinucleotide, made of guanosine monophosphate (GMP) and 3’-deoxyguanosine monophosphate 
(3dGMP), in order to fit the smaller pocket of DENV polymerase, which is partially occluded by the 
priming loop. The dinucleotide was then divided into the priming nucleotide (GMP) in the i site 
and the second nucleotide (3dGMP) in the i + 1 site that was then converted to its triphosphate 
form in order to mimic the incoming NTP, the substrate of the polymerase for the formation of the 
first phosphodiester bond. As the used crystal structure of DENV polymerase[2] lacks the two 
cations required for the coordination of the triphosphate moiety of the incoming NTP, two 
magnesium ions were added to the active site and manually positioned in coordination with the 
three aspartate residue (Asp533, Asp663 and Asp664) identified by the crystallography data 
reported by Yap et al.[1] In order to use this model for the design of adenosine-based nucleoside 
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analogues, 3dGTP was converted to ATP and, as a consequence, the complementary cytidine in 
the template was converted to uridine to maintain the base-pairing hydrogen bonds (figure 34). 
The interactions between the 2’ and the 3’-hydroxyl groups and Asp538 as well as the base pairing 
interactions were enforced by high strength constraints. Finally, the model was refined through 
iterative cycles of energy minimisation. 
 
 
Figure 34. View of the priming (i) site and the active (i + 1) site of the DENV RdRp de novo initiation 
complex model. The priming nucleotide (GTP) and the RNA template are shown as sticks in light 
blue and pink, respectively; the incoming nucleotide (ATP) is shown in thick sticks and coloured in 
dark green; Asp538 is displayed as thick sticks in grey and the Mg2+ ions as red spheres. DENV 
RdRp: Dengue virus RNA-dependent RNA polymerase. GTP: guanosine triphosphate; 
ATP: adenosine triphosphate. 
 
2.1.1.2 Validation of the model 
The novel model was validated by docking studies of the phosphorylated forms of adenosine 
analogues that have been reported to be inhibitors of DENV polymerase. The molecules were 2’-C-
methyl-7-deazaadenosine,[9] the 2’-C-acetylene analogues series reported by Novartis Institute for 
Tropical Diseases,[10, 11, 12] 2-amino-2’-C-methyladenosine[13] and the novel series of benzo-fused 7-
deazaadenosine analogues reported by Tichý et al.[14, 15] These DENV RdRp inhibitors are described 
in paragraph 1.2.2.2 and the molecules submitted to the docking process are summarised in table 
20 in the APPENDIX. 
The docking results were evaluated based on the geometry of the complex whereas the ranking 
according to score values was not taken into account as the electrostatic interactions between the 
negatively charged phosphate moiety and the Mg2+ ions are dominant and render the scoring 
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functions unreliable.[16, 17] To overcome this issue, the best scoring poses generated by the docking 
algorithm were visually inspected to verify the presence of key geometrical features: the 
alignment of the adenosine analogue to the structure of the natural substrate (ATP), the presence 
of base pairing interactions with the complementary nucleotide in the RNA template, the 
coordination of the 2’ and the 3’-hydroxyl groups of the ribose to Asp538 and, finally, the 
positioning of the phosphate or triphosphate moiety in relation to the Mg2+ ions. Figure 35 shows 
the docking pose of the monophosphorylated compounds NITD008 and NITD449 superposed on 
ATP, and exemplifies the general binding mode of an adenosine analogue in the active site of the 
DENV RdRp de novo initiation model. 
 
A  
B  
Figure 35. Docking poses of 2’-C-ethynyl-7-deazaadenosine (NITD008, A) and the 7-carbamoyl 
derivative (NITD449, B) in the monophosphate form. The docked molecules and the natural 
substrate ATP are shown as sticks, in yellow and dark green respectively. ATP: adenosine 
triphosphate. 
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Overall, the phosphorylated adenosine analogues in both their monophosphate and triphosphate 
forms gave excellent docking results, confirming the reliability of the model. 
Additionally, in order to check the stability of the molecular system, the model was submitted to 
an MD simulation,[18] after modelling two loops (spanning residues from 406 to 420 and from 457 
to 469) that were missing in the original DENV RdRp crystal structure (Protein Data Bank code 
4HHJ).[2] 
The MD simulation was analysed by observing the behaviour of the protein and the Mg2+ ions over 
the time of the simulation. During the performed MD simulation, the overall structure did not 
undergo major structural changes. In particular, the Mg2+ ions maintained the coordination with 
the aspartate residues as well as with the triphosphate moiety of the incoming NTP. In addition, 
the interactions between the 2’ and 3’-hydroxyl groups of the ribose and Asp538 were not 
affected. Therefore, these results demonstrated the stability of the molecular system. 
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2.1.2 IN SILICO DESIGN OF NOVEL ADENOSINE ANALOGUES 
Docking of the phosphorylated form of adenosine analogues known to have anti-DENV activity 
was performed using the developed model of the DENV RdRp de novo initiation complex (see 
paragraph 2.1.1.2 for details) and gave excellent results, confirming that the model is reliable and 
may be used for the design of novel adenosine analogues in silico. Docking of families of adenosine 
analogues was performed in order to predict their binding affinity in the active site of DENV RdRp, 
and therefore their potential role as DENV inhibitors. Additionally, adenosine analogues in which 
the five-membered ring of the ribose moiety is replaced by a linear scaffold were selected after 
screening a database of molecular linkers and docked into the active site of the DENV RdRp model. 
 
2.1.2.1 Docking studies 
In order to identify the most promising modifications in the structure of ATP, the natural substrate 
of the polymerase, families of ribose-modified and purine-modified adenosine nucleoside 
analogues were submitted to docking studies using the model of the DENV RdRp de novo initiation 
complex. 
As previously described for the docking of known DENV RdRp inhibitors (paragraph 2.1.1.2), the 
geometry of the complex observed in the docking poses, rather than the associated scoring, was 
considered to evaluate docking results. Following visual inspection of the best docked 
conformations for each molecule, their binding mode was evaluated on the basis of the presence 
of key geometrical features, which were i) the alignment of the adenosine analogue to the 
reference structure of ATP; ii) the presence of base pairing interactions with the complementary 
nucleotide in the RNA template; iii) the interaction of the 2’ and 3’-hydroxyl groups of the ribose 
to Asp538 and iv) the coordination of the phosphate or triphosphate moiety to the Mg2+ ions. A 
good binding mode was assigned to the molecule when at least one docked conformation 
characterised by the presence of all listed geometrical features (i to iv) could be identified. A 
distorted conformation of the ribose ring compared to the reference structure of the natural 
substrate may compromise the exact alignment to ATP (feature i); however the binding mode may 
still be considered good if the other listed criteria (ii to iv) were fulfilled. Finally, when a major 
distortion of the overall conformation compared to the reference structure of ATP (feature i) was 
observed or the essential interactions with the template, the protein residues or the Mg2+ ions in 
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the active site (features ii to iv) were not present, a poor binding mode was assigned to the 
molecule. 
 
2.1.2.1.1 Ribose-modified 7-substituted 7-deazaadenosine analogues 
Based on the chemical structures of the known adenosine analogues showing anti-DENV activity 
(2’-C-methyl-7-deazaadenosine[9] and the 2’-C-acetylene derivatives series reported by NITD [10, 11, 
12]), modifications at the 7-deaza position in the purine base and the 2’-position in the ribose 
moiety were considered in the first family of compounds. 
The introduction of either methyl or ethynyl groups in the 2’-position was well tolerated by the 
active site of the DENV RdRp model in various 7-substituted 7-deazaadenosine analogues. 
Explored substituents at the 7-deaza position were halogens, carbamoyl, cyano and acetylene 
groups as well as the five-membered rings oxadiazole and pyrazole due to the presence of these 
moieties in the structures of various known anti-HCV or anti-DENV agents (summarised in table 4). 
1’-C-Substitution is a structural feature which was recently reported in a novel class of anti-DENV 
nucleoside analogues.[13] In order to explore the effect of this novel modification on the binding 
affinity, the substitution with either methyl or ethynyl groups was moved to the anomeric position 
of the 7-deazaadenosine analogues within the family. Good docking results were obtained for all 
docked molecules (table 4). 
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Table 4. Docking results for various 7-substituted 2’-C-methyl or 2’-C-acetylene 7-deazaadenosine 
analogues and corresponding 1’-C-substituted derivatives. 
 
X 2’-position 1’-position 
proton good binding good binding 
fluoro good binding good binding 
chloro good binding good binding 
bromo good binding good binding 
iodo good binding good binding 
carbamoyl good binding good binding 
cyano good binding good binding 
acetylene good binding good binding 
oxadiazole good binding good binding 
pyrazole good binding good binding 
 
Given the promising docking results of 1’-C-methyl and 1’-C-ethynyl modified 7-deazaadenosine 
analogues, the effect of the nature of the substituent at the anomeric position on the binding 
affinity was further investigated. Docking studies were performed with various 1’-substituted 7-
deazaadenosine derivatives, as summarised in table 5. 
Small, especially linear groups pointing inwards such as the cyano and acetylene moieties, gave 
good docking results (figure 36, A). The larger groups n-propyl and i-propyl were tolerated, 
however a distortion of the ribose moiety compared to the binding mode of ATP was required to 
fit the active site. In contrast, the anomeric substitution with a primary amine or a carbamoyl 
moiety was not accepted by the polymerase, as the base pairing interactions between the 7-
deazaadenine and the complementary base in the RNA template were lost (figure 36, B). 
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Table 5. Docking results for various 1’-C-substituted 7-deazaadenosine analogues. 
 
R 1’-position 
methyl good binding 
ethyl good binding 
vinyl good binding 
cyano good binding 
aminomethyl poor binding 
carbamoyl poor binding 
ethynyl good binding 
methylethynyl good binding 
chloroethynyl good binding 
n-propyl good binding* 
i-propyl good binding* 
hydroxymethyl good binding 
*A distortion of the ribose moiety was observed. 
  
2. RESULTS AND DISCUSSION  
83 
 
A   
B  
Figure 36. Docking poses of 1’-C-cyano-7-deazaadenosine (A) and the 1’-C-carbamoyl analogue (B) 
in the monophosphate form. The docked molecules and the natural substrate ATP are shown as 
sticks, in yellow and dark green respectively. The good binding mode of the former is compared to 
the poor one of the latter, in which the position of the nucleobase is twisted and the base pairing 
is lost. ATP: adenosine triphosphate. 
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Finally, the binding affinity of a family of 1’,2’-C,C-bis-substituted 7-deazaadenosine analogues was 
evaluated. The docked nucleosides bear a methyl group at the 2’-position and various substituents 
at the anomeric position, as summarised in table 6. Interestingly, all the molecules showed good 
docking results. However, only the introduction of small and linear substituents, such as methyl, 
ethyl, cyano and ethynyl groups did not cause a distortion of the ribose ring, which was in contrast 
with the vinyl or larger moieties. Figure 37 illustrates an example of docking pose of a 1’,2’-C,C-bis-
substituted 7-deazaadenosine analogue. 
 
Table 6. Docking results for various 1’-C-substituted 7-deaza-2’-C-methyladenosine analogues. 
 
R 1’-position 
methyl good binding 
ethyl good binding 
vinyl good binding* 
cyano good binding 
aminomethyl good binding* 
carbamoyl good binding* 
ethynyl good binding 
methylethynyl good binding* 
chloroethynyl good binding* 
n-propyl good binding* 
i-propyl good binding* 
hydroxymethyl good binding* 
*A distortion of the ribose moiety was observed. 
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Figure 37. Docking pose of 1’-C-acetylene-2’-C-methyl-7-deazaadenosine monophosphate. The 
docked molecule and the natural substrate ATP are shown as sticks, in yellow and dark green 
respectively. ATP: adenosine triphosphate. 
 
A small family of 2-amino-2’-C-methyladenosine analogues was also submitted to docking studies. 
The substitution of the methyl group with an ethynyl group as well as the introduction of the same 
carbon groups at the anomeric position produced 2-aminoadenosine analogues showing good 
binding modes (table 7). 
 
Table 7. Docking results for 2-aminoadenosine analogues substituted at the 2’-position and the 
anomeric position. 
 
R 2’-position 1’-position 
methyl good binding good binding 
ethynyl good binding good binding 
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2.1.2.1.2 Ribose-modified benzo-fused 7-deazaadenosine analogues 
The series of benzo-fused 7-deazaadenosine analogues reported to be active against DENV by 
Tichý et al.[14, 15] demonstrated that the active site of DENV RdRp is capable of accommodating 
nucleoside analogues which are substituted at the 7-deaza position with large groups. However, 
the ribose moiety in this series was unmodified. Therefore, series of ribose-modified derivatives 
were docked into the active site of the DENV RdRp de novo initiation model to investigate the 
effect on the binding affinity induced by the addition of carbon groups in the ribose moiety. 
Docking results for this family of compounds are summarised in table 8. 
The introduction of either methyl or ethynyl groups at the 2’-position of the nucleoside was 
generally well tolerated, as exemplified in figure 38. Similar results were observed when carbon 
groups were introduced at the anomeric position of the tricyclic adenosine analogues. Poor 
docking results were obtained exclusively for those analogues in which the primary amine in 4-
position was replaced by heterocyclic moieties (2-furyl, 2-thienyl or 2-benzofuryl). Whereas the 
ribose-unmodified analogues were reported to be active against DENV,[15] the 2’-C- or 1’-C-
substitution appeared to negatively affect the binding affinity of these novel derivatives. 
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Table 8. Docking results for ribose-modified benzo-fused 7-deazaadenosine analogues. 
 
Nucleobase 2’-position 1’-position 
4-W 5-X 6-Y methyl ethynyl methyl ethynyl 
amino H H good binding good binding good binding good binding 
amino chloro H good binding good binding good binding good binding 
amino H chloro good binding good binding good binding good binding 
amino n-butyl H good binding good binding good binding good binding 
amino H 3-thienyl good binding good binding good binding good binding 
amino H 2-benzofuryl good binding good binding good binding good binding 
2-furyl H chloro good binding good binding poor binding poor binding 
2-thienyl H chloro poor binding poor binding good binding poor binding 
2-benzofuryl H chloro good binding good binding good binding poor binding 
 
 
Figure 38. Docking pose of the 2’-C-methyl derivative of 4-amino-6-benzofuran-2-yl-9-β-D-
ribofuranosyl-pyrimido[4,5-b]indole monophosphate. The docked molecule and the natural 
substrate ATP are shown as sticks, in yellow and dark green respectively. The modification at the 
ribose moiety is tolerated and the large substituent at the benzo-fused 7-deazaadenine fit well in 
the active site. ATP: adenosine triphosphate.  
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2.1.2.2 Design of acyclic adenosine analogues 
In the model of the DENV RdRp de novo initiation complex, the ATP molecule is involved in key 
interactions in the catalytic site of the polymerase. The adenine base pairs with a complementary 
uracil base in the RNA template, the triphosphate moiety is coordinated by two catalytic ions of 
Mg2+ and the hydroxyl groups in 2’ and 3’- positions are engaged in hydrogen bond interactions 
with an aspartate residue (Asp538). The ribose ring provides a linker between the triphosphate 
and the nucleobase moieties of the NTP and the coordination of the free hydroxyl groups 
contributes to holding the substrate in the active site. An acyclic inhibitor of DENV RdRp should 
thus be engaged in similar interactions in the active site. Therefore, the adenine needs to interact 
with the complementary base in the RNA template, whilst the aliphatic moiety should contain a 
hydroxyl group holding the triphosphate moiety at the correct distance to coordinate with the 
Mg2+ ions, and a second hydrogen bond donor to maintain the additional interaction with the 
aspartate residue. These essential features of the linker between the nucleobase and the 
phosphorylated hydroxyl group may also be found in a linear scaffold, compared to the cyclic 
ribose scaffolds. Replacement of the five-membered ring of the ribose moiety by a linear linker 
represents an attractive strategy for the in silico design of acyclic nucleoside analogues as 
potential inhibitors of DENV RdRp. 
 
2.1.2.2.1 Scaffold replacement 
In the search for acyclic adenosine analogues, the model of the DENV RdRp de novo initiation 
complex was used to screen a database of linkers that could replace the ribose ring of ATP (26, 
figure 39) in the active site of the polymerase. The five carbon atoms, the oxygen atom and the 2’ 
and 3’-hydroxyl groups of the ribose constituted the scaffold used for the screening. 
 
 
Figure 39. Structure of ATP (26) showing the scaffold for the screening of a database of linkers. 
PPP: triphosphate. 
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Linkers were selected on the basis of three additional properties: a Tanimoto index of similarity 
with ATP less than 0.8, a molecular weight of the resulting nucleotide triphosphate analogue lower 
than 525 Da (comparable to the molecular weight of ATP of 507.18 Da), and the presence of a 
hydrogen bond donor mimicking the 3’-hydroxyl group of the original ribose ring. The thus 
performed screening resulted in 83 entries, of which twelve entries corresponded to linear 
fragments which are shown in figure 40. The most common scaffold was a four carbon 2,3-
unsaturated chain bearing different substituents on the alkene, namely hydroxymethyl and 
aminomethyl moieties (entries a – l, figure 40). 
 
 
Figure 40. Linear linkers resulting from the screening of a database of linkers for the replacement 
of the cyclic ribose moiety of the original nucleoside. 
 
2.1.2.2.2 Docking studies 
A prediction of the binding affinity of the twelve acyclic nucleoside analogues which resulted from 
the scaffold replacement was obtained by docking studies using the model of the DENV RdRp de 
novo initiation complex. Docking results were evaluated based on visual inspection of the best 
scoring poses for each docked molecule, while ranking according to the scoring was not taken in 
consideration because of the aforementioned unreliability of the scoring functions in the presence 
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of the Mg2+ cations. The evaluated geometrical features were: i) the correct position of the 
nucleobase, interacting with the corresponding nucleotide in the RNA template; ii) the 
coordination of the triphosphate moiety with the Mg2+ ions and iii) the position of the hydrogen 
bond donor in coordination to Asp538. When all listed geometrical features (i to iii) could be 
observed in the same docked conformation, a good binding mode was assigned to the molecule. 
On the other hand, the binding mode was considered poor when any of the listed geometrical 
features were not present. 
The results from the docking of the acyclic adenosine analogues, which are summarised in table 9, 
helped selecting the most promising linkers. The molecules containing entry e (27, figure 41) and 
entry g (28, figure 41) were chosen as target compounds because of their excellent docking 
results. Specifically, the acyclic adenosine analogue bearing the linear scaffold g was an attractive 
target compound due to the similarity of its binding mode in the active site of the model of DENV 
RdRp with the binding mode of the 1’-C-substituted adenosine analogues, which was previously 
predicted by docking studies (figure 36, A in paragraph 2.1.2.1.1). Furthermore, the synthetic 
accessibility of the linear scaffold e[19] and the possibility of applying the phosphoramidate ProTide 
approach to synthesised nucleosides were important factors for the selection of the target acyclic 
adenosine analogues. The synthetic strategies towards the selected acyclic adenosine analogues 
will be described in section 2.2.4. 
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Table 9. Docking results for acyclic adenosine analogues. 
 
Entry Docking result 
a poor binding 
b good binding 
c good binding 
d good binding 
e good binding 
f good binding 
g good binding 
h poor binding 
i good binding 
j good binding 
k poor binding 
l poor binding 
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A  
B 
 
Figure 41. Docking poses (A and B) and chemical structures of the selected acyclic adenosine 
analogues 27 and (R)-enantiomer 28. The docked molecules and the natural substrate ATP are 
shown as sticks, in yellow and dark green respectively. ATP: adenosine triphosphate. 
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2.1.3 MOLECULAR DYNAMICS SIMULATIONS 
Crystal structures of the DENV RdRp have been reported.[1, 2, 3, 4] Several loops contribute to 
keeping the polymerase in a closed conformation which is required in the initiation phase of the 
de novo RNA synthesis. In particular, these are the priming loop that projects towards the active 
site, and other very flexible loops at the top of the polymerase that link the thumb to the fingers, 
which are aptly named fingertips.[1] Details on the available crystal structures of DENV RdRp are 
described in section 1.2.1. It is assumed that the polymerase needs to undergo drastic 
conformational changes to adopt an open structure and accommodate the dsRNA in the 
elongation phase of the RNA synthesis.[1, 5, 6] However details on this transition are unknown as the 
polymerase domain in complex with the template and the nascent RNA strands (ternary complex) 
has not yet been crystallised. 
MD simulations were performed on the apo DENV RdRp domain and on different complexes of the 
polymerase bound to the nucleic acid with the aim of providing insights in the conformational 
changes of DENV polymerase during the synthesis of the RNA and, especially, of understanding the 
destiny of the priming loop in the open elongation-competent structure of the enzyme. 
The MD simulations were analysed visually by observing the behaviour of the different elements in 
the complex (protein, nucleic acid, cations) over time. First, the complex obtained from each MD 
simulation was superposed to the original starting complex (before the MD simulation). This 
allowed to check for the stability of the position of the two Mg2+ ions and of the overall structure 
of the protein, features that are indicative of a reliable simulation. Then, the movement of flexible 
loops of the protein and the formation of new interactions between residues of those loops and 
the nucleic acid were considered. These results are described in the following paragraphs as 
results of the MD simulation. 
 
2.1.3.1 Model of the complete apo DENV RdRp 
The available crystal structures of DENV polymerase[1, 2, 3, 4] are incomplete due to the presence of 
highly flexible loops. Therefore, the construction of a model of the complete apo structure of 
DENV polymerase was required before building the model of the ternary complex. In the crystal 
structure of DENV polymerase (Protein Data Bank code 4HHJ),[2] two loops were unsolved: a first 
loop spanning residues from 406 to 420 (loop L1, 15 residues) and a second loop spanning 
residues from 457 to 469 (loop L2, 13 residues). Both missing loops were modelled based on the 
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amino acid sequence. Additionally, two Mg2+ ions, which were missing in the original crystal 
structure, were added in the active site in coordination with Asp533, Asp663 and Asp664. This 
created model was refined by performing an MD simulation. 
During the MD simulation, the modelled loops (L1 and L2) as well as the priming loop P were 
flexible (figure 42). The priming loop (P) moved further towards the still empty active site. Overall, 
the stability of the molecular system was confirmed by the preservation of the coordination of the 
cations with the three aspartate residues (figure 43). 
 
 
Figure 42. Front view of the model of complete apo DENV RdRp after the MD simulation. The 
modelled loops (loops L1 and L2) are shown as ribbons in light green. DENV RdRp: Dengue virus 
RNA-dependent RNA polymerase; MD: molecular dynamics. 
  
L1 
L2 
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Figure 43. View of the active site of the model after the MD simulation showing the Mg2+ ions 
coordinating the side chain of three aspartate residues (533, 663, 664). The two cations are 
displayed as red spheres and the aspartate residues as blue sticks. DENV RdRp: Dengue virus RNA-
dependent RNA polymerase; MD: molecular dynamics. 
 
2.1.3.2 Model of the complete de novo initiation complex 
The model of the complete apo structure of DENV polymerase was used for building the model of 
the initiation complex, in which the polymerase binds a short dsRNA and an additional ssRNA that 
mimics the RNA template entering the active site. As described for the construction of the first 
model of the DENV RdRp de novo initiation complex (see paragraph 2.1.1.1), the short dsRNA was 
imported from the available crystal structure of HCV ternary complex.[8] The priming loop P in the 
apo structure of DENV polymerase projects towards the centre of the enzyme, thereby partially 
occupying the space for the nascent dsRNA. The conformation of the priming loop was modified, 
by deleting the loop from residues 782 to 809 and by modelling it based on the amino acid 
sequence in the presence of the imported dsRNA. The nucleic acid was further modified to build 
an extra ssRNA representative of the RNA template that reaches the active site through the 
putative tunnel at the top of the polymerase.[1, 2, 6] The ssRNA corresponding to the template was 
copied, bound to the existing template through a phosphodiester bond and positioned as 
described in the literature.[1, 2, 6] The two flexible loops (loops L1 and L2) were re-modelled to 
accommodate the ssRNA in the tunnel. An additional short loop from the thumb (spanning 
residues from 740 to 747, loop L3), which is solved in the crystal structure, also contributed to 
shaping the tunnel. The built initiation complex was submitted to an MD simulation. 
During the MD simulation, the priming loop P was further pushed outwards by the nucleic acid 
(figure 44). The re-modelled loops L1 and L2 were very flexible as well and moved further 
outwards, thus widening the tunnel for the entering template (figure 45). During the MD 
simulation, the hydrogen bonds between two pairs of heterobases in the dsRNA were lost, as 
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shown in figure 46, as the nucleotides had the possibility to move freely in the large space that 
was still available at the front of the polymerase. 
 
 
Figure 44. Front view of the DENV RdRp de novo initiation complex model after the MD simulation. 
Loops playing a crucial role in the initiation phase as specified in the text are shown as ribbons in 
light green. The RNA template and growing strand are displayed as ribbons and sticks and 
coloured in blue and in pink, respectively. DENV RdRp: Dengue virus RNA-dependent RNA 
polymerase; MD: molecular dynamics. 
 
 
Figure 45. View of the tunnel for the RNA template after the MD simulation. Three main loops, 
shown as green ribbons, encircle the ssRNA, displayed as blue sticks. MD: molecular dynamics. 
L1 
L2 L3 
P 
L1 
L3 
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Figure 46. View of the nucleic acid from the front of the RdRp after the MD simulation. The dsRNA 
is distorted and some base pairing interactions are lost during the MD simulation. The priming 
loop P is shown as ribbon in green, the RNA template and growing strand as sticks in blue and in 
pink, respectively. RdRp: RNA-dependent RNA polymerase; MD: molecular dynamics. 
 
2.1.3.3 Model of the elongation complex 
The initiation complex which resulted from the MD simulation was used for the creation of the 
ternary complex representative of the elongation phase of the synthesis of the RNA, when the 
polymerase binds a long dsRNA and the extra ssRNA template entering the active site. The long 
dsRNA was built starting from the 4-nucleotide long dsRNA from the crystal structure of the HCV 
ternary complex.[8] A copy of this molecule was bound to the existing one following the orientation 
of the double helix to obtain a 8-nucleotide long dsRNA, that was imported into the active site of 
the initiation complex. This new long dsRNA replaced the short one of the initiation complex 
(figure 44) and was linked to the ssRNA via a phosphodiester bond. The priming loop P was 
partially deleted (residues from 782 to 796) and re-modelled based on the amino acid sequence to 
accommodate the longer nucleic acid, which extended outwards at the front of the polymerase. 
The resulted complex was submitted to an MD simulation. 
All the base-pairing interactions were now maintained during the MD simulation and the long 
dsRNA moved without altering the double helix conformation (figure 47). In fact, the nucleic acid 
underwent a rotation that moved the growing strand upwards and in contact with the priming 
loop P, as illustrated in figure 48. In the elongation complex resulting from this last MD simulation, 
some residues of the priming loop P interacted with the growing strand: specifically, a residue of 
arginine (Arg792) coordinated the phosphate backbone of the growing strand, and while Trp795 
did not interact directly with the nucleic acid, this residue was nevertheless in a good position for 
stacking against the nucleobase of the priming nucleotide (figure 49). 
P 
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Figure 47. Front view of the DENV RdRp elongation complex model after the MD simulation. The 
long dsRNA passes through the protein and extends outwards at the front of the DENV RdRp. 
Important loops are shown as ribbons in light green. The RNA template and growing strand are 
displayed as ribbons and sticks and coloured in dark blue and in dark pink, respectively. DENV 
RdRp: Dengue virus RNA-dependent RNA polymerase; MD: molecular dynamics. 
 
 
Figure 48. Rotation of the nucleic acid during the MD simulation. The RNA template and the 
growing strand after the MD simulation, shown in ribbons and sticks and coloured in dark blue and 
pink, respectively, are superposed on the double stranded RNA before the MD simulation, 
displayed in ribbons and sticks in light blue and light pink, respectively. The growing strand in the 
elongation complex (dark pink) is in contact with the priming loop P, shown as green ribbon. MD: 
molecular dynamics. 
P 
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Figure 49. View of the growing strand and the priming loop P from the front of the RdRp. The 
ssRNA is shown as sticks coloured in dark pink. The priming loop P is displayed as green ribbon 
with residues of Arg792 and Trp795 as green sticks. RdRp: RNA-dependent RNA polymerase. 
 
2.1.3.4 Concluding remarks 
The set of MD simulations suggested that the conformational changes of specific loops of the 
DENV RdRp, especially the loop spanning residues from 406 to 420 (loop L1), and the priming loop 
P, play a crucial role in the activity of the polymerase. 
Figure 50 highlights the function of loop L1, showing the models of the DENV RdRp in the three 
phases of the replication of the RNA: pre-initiation (apo structure), initiation and elongation. In the 
apo structure, loop L1 hindered the top of the protein (A), then progressively moved outwards in 
the initiation complex (B) and the elongation complex (C), shaping the tunnel for the RNA 
template entering the active site from the top of the polymerase. 
 
A  B  C  
Figure 50. Top view of the models of the DENV RdRp in the pre-initiation (A), initiation (B) and 
elongation (C) phase of the RNA synthesis. Loop L1 is shown as green ribbon. DENV RdRp: Dengue 
virus RNA-dependent RNA polymerase. 
 
P 
2. RESULTS AND DISCUSSION  
100 
 
The key role of loop L1 in the transition to the elongation phase of the RNA synthesis was 
confirmed by the crystal structure of DENV polymerase in complex with the allosteric inhibitor 
NITD107 (29, figure 52), as reported by Noble et al. (Protein Data Bank code 3VWS).[2] A dimer of 
the inhibitor is positioned in the centre of the polymerase (figure 51) and interacts with residues 
of loop L1 (Phe412 and Thr413, figure 52). When the crystal structure was superposed to the 
model of the DENV de novo initiation complex, the overall structures of the proteins were in 
alignment whereas the crystallised loop L1 was blocked in a folded conformation pointing inwards. 
According to the authors,[2] NITD107 may act by preventing the conformational changes of the 
loop, thus blocking the tunnel of the RNA template. The results of the MD simulations performed 
in this work are in agreement with the suggested function of the loop. 
 
 
Figure 51. Front view of the crystal structure of the DENV RdRp binding the allosteric inhibitor 29 
(dimer). NITD107 is displayed as sticks in blue and loop L1 as ribbon in light green (Protein Data 
Bank code 3VWS).[2] DENV RdRp: Dengue virus RNA-dependent RNA polymerase. 
 
L1 
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Figure 52. Chemical structure of the allosteric inhibitor 29 reported by NITD (A) and view of the 
dimer of compound 29 from the back of the RdRp (B). Compound 29 is shown as sticks in blue and 
loop L1 as ribbon in light green, with the residues involved in the interaction (Phe412 and Thr413) 
with the inhibitor displayed as green sticks (Protein Data Bank code 3VWS).[2] RdRp: RNA-
dependent RNA polymerase. 
 
MD simulation studies also suggested that the flexibility of the priming loop P is important for the 
activity of the polymerase as well. Figure 53 shows the models of the DENV RdRp in the different 
phases of the RNA synthesis. The priming loop P moved from its initial position pointing inwards in 
the apo DENV RdRp (A) to an open conformation as the polymerase initiates the RNA synthesis (B) 
and elongates the dsRNA (C), allowing for its egress from the front of the polymerase. Additionally, 
the interaction between the priming loop P and the growing strand observed in this study 
confirmed the role of Arg792 and Trp795 of providing the priming platform for the initiating NTP, 
as it was previously suggested by various authors.[1, 20] 
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A  B  C  
Figure 53. Front view and top view of the models of the DENV RdRp in the pre-initiation (A), 
initiation (B) and elongation (C) phase of the RNA synthesis. The priming loop P is shown as green 
ribbon. DENV RdRp: Dengue virus RNA-dependent RNA polymerase. 
 
The results of the set of MD simulations provided useful information on the conformation of the 
DENV RdRp during the elongation phase of the synthesis of the RNA and may have important 
implications in the design of novel inhibitors of the viral polymerase. Similarly to NITD107, which 
targets the loop shaping the tunnel for the RNA template (loop L1), a potential allosteric inhibitor 
could interact with key residues of the priming loop, such as Arg792 and Trp795, and may act by 
blocking the conformational changes of the priming loop P, whose flexibility is essential for the 
viral replication. 
At the time of this studies, no allosteric inhibitors targeting the priming loop P of the DENV RdRp 
were reported. Very recently, two indipendent studies resulted in the identification of novel NNIs 
of DENV RdRp interacting with residues of the priming loop P. The lead compound 30 shown in 
figure 54 was selected by Tarantino et al.[21] The crystal structure of DENV RdRp in complex with 
the allosteric inhibitor revealed that the molecule interacts with residues of loop L1, as it was 
previously observed for compound 29. Additionally, unlike any other known NNIs, compound 30 
further extends towards the priming loop P, with an aromatic ring stacking against Trp795 (figure 
54, B, Protein Data Bank code 5IQ6).[21] 
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A  B 
 
Figure 54. Chemical structure of the allosteric inhibitor 30 reported by Tarantino et al. (A) and 
view of the molecule from the front of the RdRp (B).[21] Compound 30 is displayed as sticks in blue 
and the priming loop P as ribbon in light green (Protein Data Bank code 5IQ6).[21] 
RdRp: RNA-dependent RNA polymerase. 
 
A second allosteric inhibitor (31, figure 55) was designed by Yokokawa et al.[22] and occupies a 
pocket between the priming loop P and the thumb subdomain, as observed in the crystal structure 
of the DENV RdRp in complex with the molecule. In particular, compound 31 establishes a 
hydrogen bond interaction with the backbone of Trp795 (figure 55, B, Protein Data Bank code 
5I3P).[23] 
 
A  B  
Figure 55. Chemical structure of the allosteric inhibitor 31 reported by Yokokawa et al. (A)[22] and 
view of the molecule from the front of the RdRp (B).[23] Compound 31 is displayed as sticks in blue 
and the priming loop P as ribbon in light green (Protein Data Bank code 5I3P).[23] 
RdRp: RNA-dependent RNA polymerase. 
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As highlighted by the MD simulation studies which were described in this section, Trp795 in the 
priming loop P is a key residue for the recognition of the initiating NTP. The recently reported 
crystal structures showed two different allosteric inhibitors interacting with the priming loop P, 
specifically with Trp795, and confirmed the essential role of the priming loop P in the activity of 
the polymerase.[21, 22] The NNIs adopted a different orientation in respect of the priming loop P, 
suggesting that two nearby pockets may be exploited for the inhibition of the DENV RdRp. 
Nevertheless, both allosteric inhibitors identified by Tarantino et al.[21] and Yokokawa et al.[22] may 
act by stabilising the DENV RdRp in a ‘closed’ conformation, thus preventing the conformational 
changes required for the synthesis of the viral genome. 
In conclusion, the priming loop P was demonstrated to play an essential role in the viral 
replication. Therefore, targeting Trp795, Arg792 or other residues of the priming loop P may 
represent a novel strategy for the development of an effective agent against DENV. 
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2.2 SYNTHESIS OF NUCLEOSIDE AND NUCLEOTIDE ANALOGUES 
The following sections describe the synthesis of ribose-modified and nucleobase-modified 
nucleoside analogues as potential anti-DENV agents and the application of the phosphoramidate 
ProTide technology. 
Nucleosides investigated in this work are adenine-based, as the majority of known DENV RdRp 
inhibitors.[9, 10, 11, 12, 13, 14, 15] The most promising structurally modified analogues were identified by 
performing molecular modelling studies (see section 2.1.2 for details). Specifically, three families 
of adenosine analogues were selected: i) ribose-modified, ii) benzo-fused 7-deaza, and iii) acyclic 
adenosine analogues, and are illustrated in figure 56. 
 
 
Figure 56. General structures of the families of adenosine analogues whose syntheses were 
investigated in this work. 
 
In this work, the general strategy for the synthesis of nucleosides was a convergent method that 
offered the advantage of affording a variety of nucleosides by combining modified glycosylating 
agents, or linear aliphatic moieties in the case of acyclic adenosine analogues, to different 
nucleobases. 
As described in paragraph 1.2.2.1, the phosphoramidate ProTide approach represents a 
convenient method for delivering the nucleotide monophosphate intracellularly as it bypasses the 
rate limiting first phosphorylation step.[24, 25, 26]  
To date, only one nucleotide prodrug has been described in the literature as an anti-DENV 
agent.[27] Therefore, the field is still largely unexplored. In order to investigate the effect of the 
monophosphate prodrug on the antiviral activity and on the toxicity, often a major limitation 
associated with nucleoside inhibitors, of the parent nucleosides, the ProTide technique was 
applied to the commercially available reference compound 2’-C-methyladenosine and to the 
synthesised nucleosides. 
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The 5’-O-phosphoramidate derivatives are conventionally prepared by phosphorochloridate 
chemistry, according to procedures adapted from Van Boom et al.[28] and Uchiyama et al.[29] and 
optimised by the McGuigan research group.[30] The synthesis involves the coupling reaction 
between the parent nucleoside and an aryl amino acid phosphorochloridate, in the presence of a 
base (scheme 2).[30] The aryl amino acid phosphorochloridate is synthesised by reaction of an 
amino acid ester salt with an aryl phosphorodichloridate in the presence of Et3N.
[30] 
Two different strategies for the synthesis of ProTides were developed.[30] In the first method, 
tBuMgCl is used as a base in the coupling reaction to remove the proton from the 5’-hydroxyl 
group. The method is generally associated with relatively good yields and prevents the reaction to 
occur at the heterocyclic amine;[30] however, it lacks selectivity towards primary hydroxyl groups in 
the nucleoside. As a consequence, the reaction of the phosphorochloridate with the nucleoside 
may afford the desired 5’-O-phosphoramidate together with the 3’-O-phosphoramidate and the 
bis-3’,5’-O,O-phosphoramidates, depending on the nature of the nucleoside and the number of 
reagent equivalents used for the preparation.[30] In the second method, N-methylimidazole is used 
in place of the Grignard reagent tBuMgCl. This approach allows for the selective reaction of the 
phosphorochloridate at the 5’-hydroxyl group of the nucleoside. Therefore it is commonly applied 
in the case of parent nucleosides having two or more hydroxyl groups, and avoids additional steps 
of selective protection of reactive functionalities and their deprotection.[30] 
 
 
Scheme 2. Conventional synthesis of ProTides.[30] Reagents and conditions: i) Et3N, DCM, -78 °C to 
rt, 2-4h; ii) Nucleoside, tBuMgCl or NMI, THF, rt, 16-20h. 
 
Recently, a modified method was reported which is based on the use of the Grignard reagent 
tBuMgCl and alternative phosphoramidating reagents, such as pentafluorophenolate or p-
nitrophenolate derivatives (scheme 3). 
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Scheme 3. Alternative synthesis of ProTides.[31] Reagents and conditions: i) Nucleoside, tBuMgCl, 
THF, rt, 18h. 
 
The substitution of the chlorine with these different leaving groups in the reagents increases their 
stability compared to the conventionally employed phosphorochloridate, while maintaining 
sufficient reactivity in the coupling reaction with the nucleoside.[31] The ease of preparation and 
stability of the p-nitrophenolate reagents made this optimised method the first choice for the 
synthesis of specific ProTides of nucleoside analogues in this work. 
Regardless of the specific method employed for the preparation of ProTides, the final compounds 
are obtained as mixtures of two diastereoisomers, due to the chiral centre at the phosphorus.[30] 
The phosphoramidate ProTides prepared in this work were evaluated for their antiviral activity as 
diastereoisomeric mixtures. 
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2.2.1 SYNTHESIS OF PHOSPHORAMIDATING REAGENTS 
Various aryl phosphorodichloridate and amino acid ester salts can be synthesised and coupled in 
combinations, to obtain a series of different phosphoramidates of the parent nucleoside. In this 
work, the phosphorochloridates 35 and 36 were prepared from commercially available starting 
materials, phenyl phosphorodichloridate 34 and the corresponding L-alanine benzyl and isopropyl 
ester salts 32 and 33, respectively (scheme 4). The mixture was treated with Et3N in DCM under 
anhydrous conditions at low temperature (-78 °C).[30, 32] After 1 hour, the mixture was allowed to 
reach room temperature and allowed to react until full conversion. The disappearance of the 
phosphorodichloridate 34 was monitored by 31P NMR (a singlet at δ 3.99 ppm). The 
phosphorochloridate 35 was quickly purified by column chromatography whereas the isopropyl 
analogue 36 could be isolated by trituration in anhydrous Et2O. Both phosphorochloridates were 
obtained as mixtures of diastereoisomers in an even ratio, as confirmed by the presence of two 
peaks in the 31P NMR. 
 
 
Scheme 4. Synthesis of the phosphorochloridates 35 and 36. Reagents and conditions: i) Et3N, 
DCM, -78 °C to rt, 3h (35, 94% yield; 36, 95% yield). 
 
Additionally, the p-nitrophenolate phosphoramidating reagents were employed in this work as 
alternative to the conventionally used phosphorochloridates. The benzyl and isopropyl derivatives 
37 and 38 were synthesised from the previously prepared phosphorochloridates 35 and 36, 
respectively, by treatment with 4-nitrophenol and Et3N in DCM under anhydrous conditions at -78 
°C (scheme 5). 
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Scheme 5. Synthesis of the p-nitrophenolate phosporamidating reagents 37 and 38 from the 
phosphorochloridates 35 and 36. Reagents and conditions: i) 4-nitrophenol, Et3N, DCM, -78 °C to -
40 °C, 2h (37, 73% yield; 38, 63% yield). 
 
A second method for the synthesis of the p-nitrophenolate reagents 37 and 38 employs 
commercially available starting materials (scheme 6).[31] Treatment of 4-nitrophenyldichloro 
phosphate 39 with phenol in the presence of Et3N in DCM under anhydrous conditions at -78 °C, 
followed by the addition of the chosen L-Alanine ester salt 32 or 33, afforded the desired 
phosphoramidating reagents in excellent yields. Compounds 37 and 38 were purified by column 
chromatography and isolated from undesired side-products of the reaction. Indeed, the bis-
phenolate and bis-L-Alanine ester p-nitrophenolate phosphates were obtained in 2-3% yield and 
2% yield, respectively. 
 
 
Scheme 6. Synthesis of the p-nitrophenolate phosporamidating reagents 37 and 38 from 
commercially available starting materials. Reagents and conditions: i) phenol, Et3N, DCM, -78 °C, 
1h, then 32 or 33, Et3N, DCM, -50 °C to 0 °C, 3h (37, 90% yield; 38, 86% yield). 
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For the synthesis of ProTides from the prepared phosphoramidating reagents, refer to the sections 
describing the synthesis of the relative parent nucleoside (2.2.2, 2.2.3 and 2.2.4). 
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2.2.2 SYNTHESIS OF RIBOSE-MODIFIED ADENOSINE ANALOGUES 
This family of nucleosides included ribose-modified adenosine and 7-deazaadenosine analogues. 
The modification of the ribose ring was the introduction of a carbon group, such as the methyl 
group, at the 2’-position or at the anomeric position. The 2’-C-substitution is a common structural 
feature among antiviral agents[9, 33] and some 2’-C-methyl and 2’-C-acetylene modified adenosine 
analogues have been reported for their anti-DENV activity.[9, 10, 11, 12] In contrast, examples of 1’-C-
substituted nucleoside analogues are scarce in the literature as the introduction of a carbon 
substitutent at the anomeric position is synthetically challenging.[34, 35, 36, 37, 38] Nevertheless, this 
modification characterises a novel class of 2-aminoadenosine analogues showing anti-DENV 
activity in vitro.[13] Refer to paragraph 1.2.2.2 and table 20 in the APPENDIX for details on the 
biological properties of these compounds. 
In this work, the ribose-modification was combined with the replacement of the N-7 with a 
methine group (7-deaza modification) at the level of the nucleobase. The binding affinity of the 
nucleosides within the family was predicted using molecular docking methodologies, as described 
in paragraph 2.1.2.1. Figure 57 shows the structure of the ribose-modified adenosine analogues 40 
and 41, whose synthesis is described in this section. 
Finally, the phosphoramidate ProTide approach was applied to explore the possibility of enhancing 
the anti-DENV activity as well as decreasing the toxicity of nucleoside analogues. 
 
 
Figure 57. Structures of 40 and 41 as examples of ribose-modified nucleosides. 
 
2.2.2.1 Synthesis of 2’-C-modified 7-deazaadenosine analogues 
For the synthesis of 2’-C-modified nucleosides, both linear[39] and convergent[40, 41, 42] approaches 
have been reported. As already mentioned, the convergent method was adopted in this work as it 
is more flexible and allows for the introduction of the carbon substituent in a stereoselective 
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fashion, driven by the configuration of other functionalities in the ribose ring. An appropriate 
glycosylating agent is prepared first and can be coupled to different synthesised or commercially 
available heterobases, such as 6-chloropurine and 6-chloro-7-deazapurine. 
In order to introduce a carbon group by treatment with an organolithium reagent or an 
organomagnesium reagent, a ketone group in the 2-position of the sugar intermediate needs to be 
present. Furthermore, the addition reaction should give the 2-β-C-substituted ribose as the 
exclusive or major product. The stereochemistry of other substituents in the glycosylating agent 
plays a crucial role in the stereoselectivity of the addition, in particular the presence of a methoxy 
group in the 1-α-position allows for the stereoselective addition of the alkyl group in the 2-β-
position.[40, 41] The keto-compound 3,5-O-(tetraisopropyldisiloxane-1,3-diyl)-1-O-methyl-α-D-
ribofuran-2-ulose 45 was identified as a potential sugar intermediate. The attempted synthetic 
route is shown in scheme 7. 
 
 
Scheme 7. Synthetic route towards keto-sugar intermediates (45 and 47). Reagents and 
conditions: i) H2SO4, CH3OH, rt, 24h (α-anomer 43, 10% yield and β-anomer 44, 64% yield); ii) 
TIPDSCl2, pyridine; iii) oxidation; iv) TIPDSCl2, pyridine, 0 °C to rt, 1h (46, 67% yield); v) oxidation 
(see text for details). 
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Treatment of the inexpensive starting material D-ribose 42 with methanol in the presence of 
concentrated sulfuric acid[43] afforded 1-O-methyl-D-ribofuranose as a separable anomeric mixture 
with excellent yield. The configuration of the anomeric position was confirmed by comparison of 
experimental NMR spectroscopy data to the literature:[44] in the 1H NMR spectra, the anomeric 
proton appears as a singlet at δ 4.63 ppm in the β-anomer 44 and as a doublet at δ 4.71 ppm with 
a coupling constant of 2.2 Hz in the α-anomer 43; also in the 13C NMR spectra the signals of the 
anomeric carbon differ substantially (δ 108.0 ppm for the β-anomer 44, δ 104.8 ppm for the α-
anomer 43). However, the desired α-anomer 43 was only a minor product (ratio α:β was 1:6.5) 
and could not be separated from unreacted starting material. As compound 43 could not be 
isolated, the feasibility of the following steps were verified using the purified β-anomer 44 
(scheme 7). Before performing the oxidation of the 2-hydroxyl group to the ketone, it is necessary 
to protect the 3 and 5-hydroxyl groups using a protecting group that would be stable in the 
presence of Grignard reagents. 1,1,3,3-Tetraisopropyldisiloxane seemed an advantageous 
protecting group as it allowed for the selective protection of 3 and 5-positions of the 1-O-
substituted ribose, whereas the 2-hydroxyl group remained available for the following oxidation. 
Compound 44 was treated with 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane in anhydrous 
pyridine for 4 hours at room temperature.[45] Protected product 46 was obtained in moderate 
yield (30%) after purification by column chromatography. When the reaction time was prolonged 
to 16 hours,[46] several side-products were obtained and 46 could not be isolated after column 
chromatography. Finally, treatment with the disiloxane reagent over 1 hour at room 
temperature[44] provided 46 in good yield (67%) and the formation of side-products was not 
observed. 
The oxidation of the secondary alcohol of the TIPDS-protected sugar 46 was attempted using 
pyridinium chlorochromate (PCC, Corey-Suggs reagent).[47] Scheme 8 shows the mechanism of 
oxidation. The reaction occurs via an intermediate chromate ester that undergoes elimination to 
afford the carbon-oxygen double bond. Compound 46 was treated with PCC in DCM at room 
temperature for 24 hours. In a second attempt, the reaction with PCC was carried out in refluxing 
DCM for 16 hours. Reactions were monitored by mass spectrometry, however no conversion of 
the 2-hydroxyl group was observed. 
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Scheme 8. Mechanism of Corey-Suggs oxidation. 
 
In the Pfitzner-Moffatt oxidation, primary and secondary alcohols are oxidised by dimethyl 
sulfoxide activated by dicyclohexylcarbodiimide (DCC) in acidic conditions, as shown in scheme 9. 
Despite the sensitivity of the silyl ether to acidic conditions, the method has been used for the 
conversion of 3,5-O-(tetraisopropyldisiloxane-1,3-diyl)-1-O-methyl-α-D-ribofuranose to the 
corresponding ketone compound.[48] However, treatment of compound 46 with DCC in anhydrous 
DMSO and diethyl ether in acidic conditions gave an inseparable mixture of the desired ketone 
compound 47 and a second 2-ketosugar (20% overall yield, ratio 1:1). In fact, the absence of 
singlets at approximately δ 3.00 ppm for the 2-OH in the 1H NMR spectrum of the mixture 
demonstrated that the two species were oxidised at the 2-position. The side-product differs by the 
presence of a singlet at δ 4.39 ppm for the 5’-OH or 3’-OH, suggesting that its formation was due 
to the partial hydrolysis of the acid-labile protecting group from one hydroxyl group. The identity 
of products was further confirmed by mass spectrometry (m/z 427.2 [MNa+] and 445.2 [MNa+] 
observed for compound 47 and for the side-product, respectively). 
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Scheme 9. Mechanism of Pfitzner-Moffatt oxidation. 
 
Finally, the broadly used oxidising agent Dess-Martin periodinane (DMP) was employed. Although 
the Dess-Martin reagent offers mild oxidation of primary and secondary alcohols to aldehyde and 
ketone respectively, acetic acid is a by-product of the reaction (scheme 10). As a consequence, 
oxidation of the 2-hydroxyl group of compound 46 using DMP in DCM for 24 hours at room 
temperature[49] was associated with partial hydrolysis of the silyl ether due to the inherent acidic 
conditions, as observed in the Pfitzner-Moffatt oxidation, and an inseparable mixture of desired 
product and side-product was obtained (30% overall yield, ratio 2:1). When compound 46 was 
treated with DMP at 0 °C for 2 hours, no conversion occurred and the TIPDS-protected starting 
material 46 was recovered. In an attempt to isolate the desired product only, the reaction was 
quenched after 8 hours at room temperature. However, 1H NMR spectroscopy of the crude 
residue showed the presence of three species corresponding to the unreacted starting material 
46, the desired product 47 and a second 2-ketosugar (ratio 1:2:0.7). The side-product was 
obtained due to the cleavage of TIPDS-protecting group from one hydroxyl group, as previously 
observed in the Pfitzner-Moffatt oxidation. 
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Scheme 10. Mechanism of Dess-Martin periodinane oxidation. 
 
The attempts described above demonstrated that the 1,1,3,3-tetraisopropyldisiloxane was not a 
suitable protecting group in this work as compound 3,5-O-(tetraisopropyldisiloxane-1,3-diyl)-1-O-
methyl-β-D-ribofuran-2-ulose 47 could not be isolated. 
Protection of the 3’ and 5’-hydroxyl groups as 2,4-dichlorobenzyl ethers was found to be a valid 
alternative and the 2-ketone sugar intermediate 3,5-bis-O-(2,4-dichlorobenzyl)-1-O-methyl-α-D-
ribofuran-2-ulose 49 was easily obtained by treatment of commercially available 1-O-methyl-3,5-
bis-O-(2,4-dichlorobenzyl)-α-D-ribofuranose 48 with DMP in DCM at room temperature (scheme 
11).[42] The reaction was monitored by thin layer chromatography, which showed full conversion of 
the starting material after 72 hours. The following introduction of the methyl group in the 2-
position was carried out using either methyllithium or methylmagnesium bromide. Reaction of the 
keto-sugar with organolithium reagent (3 equivalents) in Et2O at -78 °C to room temperature for 4 
hours did not show a clean profile on thin layer chromatography and the 2-C-methyl derivative 
could not be isolated after column chromatography. Treatment with Grignard reagent (4 
equivalents) in Et2O at -55 °C to room temperature for 7 hours
[42] furnished 50 in 22% yield. As 
expected, the 1-O-methyl substituent in the α-position of the ribofuranose ring contributed to the 
stereochemistry of the addition, so that the 2-β-C-methyl derivative was the only product. In 
another attempt, two additions of methylmagnesium bromide were performed and the work-up 
procedure was changed from a filtration through celite pad to an extraction with Et2O. Although 
the ratio between the desired product and unreacted starting material did not vary, the yield of 
compound 50 increased to 54% thanks to the more appropriate work-up procedure. 
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Scheme 11. Synthesis of the 2’-C-methyl glycosylating agents 50. Reagents and conditions: i) DMP, 
DCM, 0 °C to rt, 72h (49, 90% yield); ii) CH3MgBr, Et2O, -78 °C to 0 °C, 7h (50, 54% yield). 
 
The application of the Vorbrüggen procedure is generally effective for the glycosylation of 7-N 
purines.[41, 50] In contrast, the coupling reaction of the glycosylating agent to 7-deaza purine 
analogues requires the generation of the nucleobase anion in situ.[42, 51]  
The ribofuranose 50 was converted to the corresponding 1-bromo derivative by treatment with 
hydrogen bromide/acetic acid in dichloromethane and reacted with an excess of the sodium salt 
of commercially available 6-chloro-7-deazapurine, which was formed in situ by reaction with 
sodium hydride.[42] The coupling step was initially performed over 1 day at room temperature and 
furnished the β-nucleoside 51 with 10% yield. A slightly greater yield (20%) was obtained by 
prolonging the reaction time to 60 hours (scheme 12). An optimisation of the glycosylation was 
achieved by adding the reactive 1-bromo intermediate directly to a mixture of 6-chloro-7-
deazapurine, potassium hydroxide and tris[2-(2-methoxyethoxy)ethyl]amine. These conditions are 
reported to yield stereospecifically the β-anomer[51] and allowed for the isolation of the desired 
compound 51 with an yield of approximately 40%. NMR spectra were in agreement with the 
literature and the anomeric identity was further confirmed by a 2D NOESY experiment showing 
correlation peaks between H-1’ and H-4’ as well as between H-3’ and H-8. 
The following deprotection was attempted by treatment of 51 with boron trichloride in DCM at 
low temperature.[42] However, degradation occurred and 52 was not obtained (scheme 12). 
 
2. RESULTS AND DISCUSSION  
118 
 
 
Scheme 12. Glycosylation of 6-chloro-7-deazapurine. Reagents and conditions: i) Procedure a: 
HBr/acetic acid, DCM, 0 °C to rt, 4h, then sodium salt of 6-chloro-7-deazapurine, CH3CN, rt, 60h 
(51, 20% yield); Procedure b: HBr/acetic acid, DCM, 0 °C to rt, 2h, then 6-chloro-7-deazapurine, 
KOH, TDA-1, CH3CN, rt, 1h (51, 39% yield); ii) BCl3, DCM, -78 °C to -20 °C, 3h, degradation. 
 
The BCl3-assisted cleavage of the 2,4-dichlorobenzyl ethers was attempted at an early stage of the 
synthetic route. However, the deprotection of the 2,4-dichlorobenzyl ethers of the glycosylating 
agent 50 (scheme 13) led to the degradation of the starting material. 
 
 
Scheme 13. Attempt of deprotection of the glycosylating agent 50. Reagents and conditions: i) 
BCl3, DCM, -78 °C to -30 °C, 4h, degradation. 
 
Alternatively, treatment of the β-nucleoside 51 with commercially available methanolic solution of 
ammonia (7M) over 48 hours at 85 °C afforded the protected 7-deazaadenosine derivative 54 in 
excellent yield (scheme 14) as well as the 6-O-methylinosine derivative 55 as a minor product of 
the reaction (figure 58). 
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Scheme 14. Amination and deprotection of the target nucleoside 2’-C-methyl-7-deazaadenosine 
56. Reagents and conditions: i) NH3, MeOH, 85 °C, 72h (54, 87% yield); ii) Procedure a: H2, Pd/C, 
MeOH, AcOH, rt, 48h (40, 70% yield); Procedure b: HCOONH4, Pd/C, MeOH, reflux, 16h (40, 77% 
yield). 
 
 
Figure 58. Side-product 55 isolated from the amination of compound 54. 
 
The following hydrogenolysis of the 2,4-dichlorobenzyl ethers furnished the target nucleoside 2’-C-
methyl-7-deazaadenosine 40 in good yield. Compound 40 could also be obtained by transfer 
hydrogenation with ammonium formate in refluxing methanol in the presence of 10% palladium 
on carbon (scheme 14). 1H and 13C NMR spectra of 40 were in agreement with the literature[42] 
and confirmed identity and anomeric configuration. Overall, the synthesis of 2’-C-methyl-7-
deazaadenosine consists of five steps with an overall yield of 6%. 
The anti-DENV activity and cytotoxicity in vitro of 2’-C-methyl-7-deazaadenosine 40 were 
evaluated by our collaborators (see section 2.3 for details). 
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2.2.2.2 Synthesis of 2’-C-methyladenosine and 7-deazaadenosine ProTides 
The nucleoside 2’-C-methyladenosine was originally developed as an anti-HCV agent (EC50 0.26 
μM), but did not undergo further development due to its poor oral bioavailability.[42] The 
application of the ProTide strategy to 2’-C-methyladenosine and to the 7-deaza analogue aims at 
reducing the toxicity and boosting the activity of the parent nucleosides. 
Without prior protection of the nucleoside, the ProTide bearing the L-alanine benzyl ester as 
amino acid moiety was synthesised according to the conventionally used procedure using tBuMgCl 
as a base.[30] Treatment of commercially available 56 with the phosphorochloridate 35 (refer to 
section 2.2.1 for the preparation of 35) in the presence of tBuMgCl afforded the 5’-O-
phosphoramidate 57 as main product of the coupling reaction (scheme 15). Purification by column 
chromatography and semi-preparative HPLC were required to remove traces of the parent 
nucleoside and of the 3’-O-phosphoramidate isomer. NMR spectroscopy and analytical HPLC 
confirmed the identity and purity (94%) of the phosphoramidate, that was obtained as an even 
mixture of two diastereoisomers in 9% yield. 
 
 
Scheme 15. Synthesis of 2’-C-methyladenosine ProTide 57. Reagents and conditions: i) tBuMgCl, 
phosphorochloridate 35, THF, rt, 72h (57, 9% yield). 
 
For the preparation of the ProTide of the previously synthesised 2’-C-methyl-7-deazaadenosine 40, 
a modified procedure was applied. The coupling to the phosphoramidate moiety bearing the L-
alanine isopropyl ester was carried out in DMF as solvent. Additionally, the p-nitrophenolate 
phosphoramidating reagent 38 (refer to section 2.2.1 for the preparation of 38) was employed in 
place of the conventional phosphorochloridate (scheme 16). Treatment of 40 with 1 equivalent of 
38 in the presence of tBuMgCl furnished the 5’-O-phosphoramidate 58 as sole product after 4 
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hours at room temperature. Purification by column chromatography allowed for the isolation of 
the ProTide 58 in 46% yield with a purity of 99% according to analitycal HPLC. 
 
 
Scheme 16. Synthesis of 2’-C-methyl-7-deazaadenosine ProTide 58. Reagents and conditions: i) 
tBuMgCl, p-nitrophenolate 38, DMF, rt, 4h (58, 46% yield). 
 
The anti-DENV activity and cytotoxicity in vitro of the synthesised 2’-C-methyladenosine ProTide 
57 and of the parent nucleoside 56 were evaluated by our collaborators (see section 2.3 for 
details). The prepared 2’-C-methyl-7-deazaadenosine ProTide 58 was also sent for biological 
evaluation and results are currently being awaited. 
 
2.2.2.3 Synthesis of 1’-C-modified adenosine analogues 
The first synthetic pathway towards 1’-C-substituted nucleosides involved photochemical radical 
reactions, by using high pressure mercury or tungsten lamps, either on the glycosylating agent[34] 
or on the intact nucleoside.[35] In 2002 Cappellacci et al.[37] reported a method for the synthesis of 
1’-C-methyladenosine based on the chemistry of organolithium compounds (scheme 17). 
According to the authors, the introduction of the methyl moiety at the anomeric position had 
been performed on 5-O-benzyl-2,3-O,O-benzylidene-D-ribono-1,4-lactone 59. Compound 60 had 
been converted to its acetoxy derivative 61, then coupled to 6-chloropurine in the presence of 
ethylaluminum dichloride to furnish the nucleoside as an anomeric mixture 62. Amination at the 
6-position of the purine, separation from the undesired α-anomer and finally deprotection of 
hydroxyl groups by hydrogenation had afforded the target molecule 41. 
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Scheme 17. Reported synthesis of 1’-C-methyladenosine 41.[37] Reagents and conditions: i) CH3Li, 
Et2O, -78 °C to rt, 45 min; ii) Ac2O, 4-(dimethylamino)pyridine, pyridine, rt, 48h; iii) 6-chloropurine, 
EtAlCl2, CH3CN, rt, 2h; iv) NH3, 60 °C, 5h; v) HCOONH4, 10% Pd/C, CH3OH, reflux. 
 
The protected D-ribono-1,4-lactone 59 used in the synthetic route described above was an 
attractive sugar intermediate in order to introduce carbon substituents at the anomeric position. 
Therefore, the synthesis of 59 was attempted, as illustrated in scheme 18. 
 
 
Scheme 18. 2,3-O,O-Benzylidene and 5-O-benzyl ether protection of D-ribonic acid 1,4-lactone 63. 
Reagents and conditions: i) benzaldehyde dimethyl acetal, POCl3, CH3CN, 0 °C, 1h (64 and 65, 68% 
yield) or benzaldehyde dimethyl acetal, SnCl2, DME, reflux, 1h (64 and 65, 40% yield); ii) benzyl 
bromide, NaH, THF, 0 °C-rt, 16h (67, 20% yield). SE: slow-eluting; FE: fast-eluting. 
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2,3-O,O-Benzylidene protection of commercially available D-ribonic acid 1,4-lactone 63 was 
carried out using phosphorus (V) oxychloride (2 equivalents) and benzaldehyde dimethyl acetal (1 
equivalent) in acetonitrile at 0 °C for 1 hour. The benzylidene protection induces the formation of 
a chiral carbon atom in the product, hence two diastereoisomers were obtained with a ratio 
between slow-eluting (SE) (R)-isomer 64 and fast-eluting (FE) (S)-isomer 65 of 3:1, which were 
separated by column chromatography. NMR spectra of the (R)-isomer 64 and (S)-isomer 65 were 
in agreement with the literature.[52] In one previous attempt performed with an excess of 
benzaldehyde dimethyl acetal (5 equivalents),[53] the free 5-hydroxyl group further reacted with 
benzaldehyde and methanol, a by-product of the reaction, leading to the formation of side-
product 66 as a mixture of four stereoisomers (scheme 19). The identity of side-product 66 was 
confirmed by mass spectrometry (the observed m/z was 379.1 [MNa+]). 
In another attempt, the 2,3-O,O-benzylidene protected intermediates 64 and 65 were prepared by 
treatment of 63 with benzaldehyde dimethyl acetal (1.2 equivalents) in the presence of the 
catalyst tin (II) chloride (0.2 equivalents) in refluxing 1,2-dimethoxyethane for 1 hour.[54] These 
conditions allowed for the isolation of the product in 40% yield as an even mixture of the two 
diastereoisomers 64 and 65. The use of fewer equivalents of the catalyst, as in the reported 
procedure,[54] led to a poor formation of the desired product whereas the replacement of 1,2-
dimethoxyethane with THF did not improve the yield of the mixture of 64 and 65. 
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Scheme 19. Mechanism of formation of side-product 66. 
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The following protection of the 5-hydroxyl group by benzyl ether was performed by treatment of 
the (R)-isomer 64 with benzyl bromide (1.2 equivalents) in the presence of sodium hydride in 
anhydrous THF at room temperature for 16 hours (scheme 18).[37] The reaction furnished 5-O-
benzyl-2,3-O,O-(R)-benzylidene-D-ribofuran-1-ulose 67 in poor yield (20%) as a large amount of 
the starting material was left unreacted. In an attempt to increase the yield, the reaction was 
carried out using an excess of benzyl bromide (2 equivalents) in the presence of sodium hydride 
and catalytic amount of tetrabutylammonium iodide.[54] After 24 hours at room temperature, no 
significant formation of 67 was observed, hence the reaction mixture was heated to 75 °C for 
additional 48 hours (monitoring by thin layer chromatography). In another attempt, the (R)-isomer 
64 was treated with an excess of benzyl bromide (2 equivalents) and sodium hydride at 75 °C for 
48 hours. In both cases, the formation of several side-products was observed and, among them, 
the desired product 67 could be isolated by column chromatography in poor yield (27% and 20% 
respectively). Further optimisation of the protection of the 5-hydroxyl group was not performed. 
The introduction of a carbon group at the anomeric position was attempted by treatment of 67 
with an excess of methyl lithium or ethynylmagnesium bromide (scheme 20). 
 
 
Scheme 20. Attempts of alkylation at the anomeric position resulted in the formation of side-
products, but not of the desired product (see text). Reagents and conditions: i) CH3Li (2.8 eq.), 
Et2O, -78 °C to rt, 3h or HCCMgBr (4.0 eq.), THF, -78 °C to rt, 3h. 
 
Both reactions led to the formation of the bis-alkylated side-product 70 and 71, respectively 
(scheme 21). In particular, in the NMR spectra of compound 71, which was purified and fully 
characterised, the two ethynyl moieties were clearly visible (two singlets at δ 2.57 ppm and δ 2.54 
ppm in the 1H NMR spectrum, two signals at δ 74.64 ppm and 72.20 ppm in the 13C NMR 
spectrum). Furthermore, the presence of two broad singlets in the 1H NMR spectrum (at δ 5.60 
ppm and at δ 3.57 – 3.54 ppm, overlapping with the multiplet of one H-5) suggested that opening 
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of the lactone ring had occurred. The identity of 71 was finally confirmed by mass spectrometry 
(the observed m/z was 401.1 [MNa+]). The formation of the bis-alkylated derivatives was assumed 
to be due to the further reaction of the mono-alkylated products with a second equivant of the 
organolithium compound or the Grignard reagent respectively, allowed by the equilibrium shown 
in scheme 21. The formation of the bis-alkylated side-product suggested that the number of 
equivalents of reagent and the reaction time may be crucial for the isolation of the desired mono-
alkylated derivative. 
 
 
Scheme 21. Equilibrium at the basis of the formation of bis-alkylated side-products 70 and 71. 
 
As a proof-of-concept, the synthesis of 2-O-acetyl-1-deoxy-D-psicofuranose 72 was attempted on 
a small scale (starting from 100 mg of 67) without purification of compounds (scheme 22). The 
protected lactone 67 was treated with 1.4 equivalent of methyl lithium in Et2O over 45 minutes.
[37] 
The reaction was quenched despite the incomplete conversion of the starting material according 
to thin layer chromatography to prevent the formation of the bis-alkylated side-product. The 1H 
NMR spectrum of the crude residue showed the presence of unreacted 67 together with the 
desired product 68 in a ratio of 1.4:1. The 1H NMR spectrum of compound 68 was characterised by 
the presence of a D2O-exchanging singlet at δ 4.95 ppm for the anomeric OH. The crude residue 
was used for the following acetylation, carried out with acetic anhydride and 4-(dimethylamino) 
pyridine in pyridine over 48 hours.[37] The disappearance of the singlet at δ 4.95 ppm in the 1H 
NMR spectrum of the crude residue showed that the acetylation had occurred. The identity of 72 
was confirmed by mass spectrometry (the observed m/z was 407.1 [MNa+]). The other species in 
the crude mixture were identified as the starting material 67 and the intermediate 68 (m/z 349.1 
[MNa+] and 365.1 [MNa+], respectively), whereas the bis-alkylated side-product 70 was not 
observed. Although 72 was not purified from the reaction mixture and was not submitted to 
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glycosylation, the performed reactions demonstrated the feasibility of the synthetic pathway 
towards 1-C-substituted ribose moieties. 
 
 
Scheme 22. Synthesis of the glycosylating agent 72 as proof-of-concept. Reagents and conditions: 
i) CH3Li (1.4 eq.), Et2O, -78 °C to 0 °C, 45 min; ii) Ac2O, 4-(dimethylamino)pyridine, pyridine, rt, 48h. 
 
As the protection of the 5-hydroxyl group of 64 as benzyl ether could not be optimised, the 
possibility of an alternative protective group was explored. According to the reported 
procedure,[37] the use of the benzyl ether and the benzylidene protecting groups offers the 
advantage of a simultaneous deprotection of all functionalities by catalytic transfer hydrogenation 
to furnish 1’-C-methyladenosine 41. On the other hand, the protection as silyl ether of the 5-OH of 
the lactone would allow for the selective deprotection of the functionality to provide the 
benzylidene-protected nucleoside, which represents a convenient precursor for the synthesis of 
phosphoramidate ProTides of 41. Furthermore, the fluoride-mediated cleavage of silyl ethers 
occurs under mild conditions and in particular avoids acidic conditions that are reported to cause 
cleavage of anomeric-substituted nucleoside analogues.[37, 38] 
The mixture of 64 and 65 was treated with tert-butylchlorodiphenylsilane in the presence of 1H-
imidazole in DMF to obtain an even mixture of two diastereoisomers 73 and 74, which could be 
separated by column chromatography (scheme 23). With the aim to define the configuration of 73 
and 74, the (S)-isomer 65, which was the FE diastereoisomer on silica gel, was converted into the 
corresponding (S)-isomer 74. By comparing the NMR spectra of the prepared (S)-isomer 74 and of 
the previously synthesised two species, the (S)-isomer 74 was identified as the SE diastereoisomer 
on silica gel. 
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Scheme 23. 5-O-Silylation of the 2,3-O,O-benzylidene protected lactone 64 and 65. Reagents and 
conditions: i) TBDPSiCl, 1H-imidazole, DMF, 0 °C to rt, 4h (73 and 74, 48% yield). SE: slow-eluting; 
FE: fast-eluting. 
 
The protection as tert-butyldiphenylsilyl ether may also be performed selectively on the 5-
hydroxyl group of D-ribonic acid 1,4-lactone 63, followed by the 2,3-O,O-benzylidene protection of 
the remaining free functionalities (scheme 24). In fact, the reaction of 63 with 1.1 equivalents of 
tert-butylchlorodiphenylsilane in the presence of 1H-imidazole in DMF led to the isolation of 
protected compound 75 in good yield. Additionally, the crude residue could be used in the 
subsequent step without the need for purification by column chromatography. The 5-O-silylated 
lactone 75 was further protected using benzaldehyde dimethyl acetal and tin (II) chloride in 
refluxing DME. When the benzylidene group was introduced on either the purified or the crude 
lactone 75, almost exclusively the (S)-isomer 74 was obtained in 55% yield, whereas traces of the 
(R)-isomer 73 were formed and could be removed by chromatographical purification. The method 
based on the 5-O-silylation followed by the 2,3-O,O-benzylidation was superior to the previously 
described procedure, not only because of higher obtained yields but also because of the possibility 
for easily isolation of 74 as one single diastereoisomer. 
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Scheme 24. 5-O-Silyl ether and 2,3-O,O-benzylidene protection of D-ribonic acid 1,4-lactone 63. 
Reagents and conditions: i) TBDPSiCl, 1H-imidazole, DMF, 0 °C to rt, 4h (75, 57% yield); ii) 
benzaldehyde dimethyl acetal, SnCl2, DME, reflux, 1h (74, 55% yield). 
 
The fully protected lactone 74 underwent alkylation using a 1.6M solution of methyllithium in Et2O 
(scheme 25). 
 
 
Scheme 25. Synthesis of the glycosylating agent 77. Reagents and conditions: i) CH3Li, Et2O/THF, -
78 °C to 0 °C, 1h (76, crude); ii) Ac2O, 4-(dimethylamino)pyridine, Et3N, DCM, rt, 48h (77, 48% 
yield). 
 
In the first attempt, alkylation using a slight excess of the organolithium reagent (1.4 equivalents) 
over 30 minutes at -78 °C followed by treatment with acetic anhydride (1 equivalent) and the 
catalyst 1-(dimethylamino)pyridine in pyridine[37] produced a mixture of species, among which the 
bis-acetylated bis-alkylated side-product 78 (figure 59) and the mono-alkylated intermediate 76 
were isolated with 34% yield and 20% yield, respectively. 
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Figure 59. Bis-acetylated bis-alkylated side-product 78. 
 
When 1 equivalent of methyllithium reagent was employed, full conversion of the starting 
material was observed over 1 hour at -78 °C and was not accompanied by the formation of the 
undesired bis-alkylated product (scheme 25). The crude mono-alkylated product 76 underwent 
acetylation by treatment with an excess of acetic anhydride and 4-(dimethylamino)pyridine in 
pyridine. Purification by column chromatography allowed for the isolation of the 2-O-acetyl-1-
deoxy-D-psicofuranose derivative 77 with 35% yield among other species. Furthermore, the NMR 
spectra of the crude 76 and of the purified acetylated derivative 77 demonstrated that the 
addition of the methyl moiety on the starting material 74 occurred in a stereoselective fashion. A 
2D NOESY experiment was performed on 76 and suggested that the β-D-psicofuranose derivative 
was obtained: indeed, the broad singlet at δ 4.89 ppm for the 2-hydroxyl group correlated with 
the two doublets of doublets at δ 3.79 and 3.61 ppm for the methylene group in the 6-position. 
In an attempt to increase the yield of the acetylation, compound 76 was treated with 
1.2 equivalents of acetic anhydride in the presence of 4-(dimethylamino)pyridine in pyridine. 
However, the reaction did not reach completion over 48 hours and furnished the product 77 in a 
low yield (20%). The reaction carried out using an excess of acetic anhydride (3 equivalents), 
4-(dimethylamino)pyridine and Et3N in DCM showed a clean profile and afforded 77 in 48% yield. 
The glycosylation of the 6-chloropurine was achieved by treatment with the prepared 2-O-acetyl-
1-deoxy-β-D-psicofuranose derivative 77 in the presence of ethylaluminum dichloride in 
acetonitrile (scheme 26). 
 
2. RESULTS AND DISCUSSION  
131 
 
 
Scheme 26. Glycosylation of 6-chloropurine using 77. Reagents and conditions: i) 6-chloropurine, 
EtAlCl2, CH3CN, rt, 2h (α-anomer and β-anomer 79/80, 40% yield; N-7 adduct, 17% yield) 
 
The reaction reached completion after 2 hours at room temperature and afforded an unseparable 
mixture of α-nucleoside and β-nucleoside 79/80 in 40% yield. The obtained nucleosides were 
hypothesised to be the N-9 coupling derivatives because they were the major products of the 
glycosylation reaction. A 2D NOESY experiment demonstrated that the major product in the 
mixture was the desired β-nucleoside 80: indeed, the doublet at δ 4.70 ppm of the H-4’ of the 
D-psicofuranose moiety correlated with the singlet at δ 8.44 ppm of the H-8. Furthermore, the 
observation of a correlation signal between the singlet at δ 6.05 ppm of the methyne of the 
2,3-O,O-benzylidene group and the singlet at δ 8.43 ppm of the H-8 belonging to the minor 
product demonstrated the α-anomeric configuration of the minor nucleoside 79 in the mixture. 
The ratio between the α and the β-nucleosides 79/80 was 1:1.7. A third nucleoside was isolated 
from the coupling reaction of 6-chloropurine with 77 in low yield (17%). Characterisation by NMR 
spectroscopy and mass spectrometry showed that the side-product was a structural isomer of 
nucleosides 79 and 80 (the observed m/z was 649.2 for [MNa+] as for 79/80), hypothesised as the 
N-7 coupling product. Additionally, a 2D NOESY experiment was performed, however the 
anomeric configuration could not be defined. 
The anomeric mixture of 79/80 was efficiently converted into the corresponding mixture of α and 
β-adenosine nucleosides 81/82 using a saturated (7M) methanolic solution of ammonia at 80 °C 
(scheme 27). 
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Scheme 27. Amination and 6’-O-deprotection of the anomeric mixture of nucleosides 79/80. 
Reagents and conditions: i) NH3, MeOH, 80 °C, 48h (α-anomer and β-anomer 81/82, 63% yield); ii) 
TBAF∙3H2O, THF, 0 °C, 2h (α-anomer and β-anomer 85/86, 85% yield). 
 
The reaction afforded the anomeric mixture of the 6-O-methyl inosine derivatives 83/84 as side-
products in 12% yield (figure 60). 
 
 
Figure 60. Side-products 83/84 isolated from the amination of 79/80. 
 
As the separation of the two anomers by column chromatography was unsuccessful, the mixture 
of α and β-nucleosides 81/82 underwent selective cleavage of the 6’-O-silyl ether by 
tetrabutylammonium fluoride in THF to obtain the corresponding 6’-O-deprotected mixture of 
85/86 (scheme 27). Also at this stage, the two anomers 85 and 86 showed identical 
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chromatographical behaviour and could not be separated. Figure 61 shows the 1H NMR of the 
mixture of α and β-nucleosides 85/86. 
 
 
Figure 61. 1H NMR of the mixture of α and β-nucleosides 85/86. 
 
In an attempt to improve the anomeric ratio during the glycosylation of the 6-chloropurine, the 
application of Vorbrüggen conditions was investigated (scheme 28). Silylation of the 6-
chloropurine by treatment with N,O-bis(trimethylsilyl)acetamide in refluxing acetonitrile was 
followed by the reaction with the glycosylating reagent 77 in the presence of trimethylsilyl triflate 
at low temperature (from -20 °C to 0 °C), according to a procedure that was reported for the 
preparation of 1’,4’-bis-substituted uridine analogues.[38] Althoug the reaction was not 
regioselective and afforded the hypothetised N-7 adduct as well, the desired β-nucleoside 80 was 
the only N-9 nucleoside formed and could be easily isolated in 14% yield after chromatographical 
purification. Therefore, the Vorbrüggen glycosylation by the 1-deoxy-β-D-psicofuranose derivative 
77 was found to occur with stereoselectivity. The 2’,3’-O,O-benzylidene group, rather than the 
methyl substituent at the anomeric position, may play a role in the stereoselective control of the 
reaction. However the exact role of the additional carbon group remains unclear as only one other 
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example of stereoselective glycosylation by anomeric-modified ribose moiety is reported in the 
literature to date.[38] 
The following amination and deprotection of the 6’-hydroxyl group of the β-nucleoside 80 were 
carried out according to the procedures previously developed for the anomeric mixture. 
Treatment with a saturated (7M) methanolic solution of ammonia at 80 °C, followed by the 
reaction with tetrabutylammonium fluoride in THF at 0 °C, provided the β-nucleoside 86 in good 
yield (scheme 28). 
 
 
Scheme 28. Stereoselective glycosylation of 77 followed by amination and 6’-O-deprotection. 
Reagents and conditions: i) 6-chloropurine, N,O-bis(trimethylsilyl)acetamide, CH3CN, rt to 50 °C, 
then TMSOTf, CH3CN, -20 °C to 0 °C, 1h (β-nucleoside 80, 14% yield; N-7 adduct, 8% yield); ii) NH3, 
MeOH, 80 °C, 48h (β-anomer 82, 66% yield); iii) TBAF∙3H2O, THF, 0 °C, 2h (β-anomer 86, 74% 
yield). 
 
The anomeric configuration of 86 was demonstrated by the observation of correlation signals of 
the singlet at δ 8.19 ppm of the H-2 with both multiplets at δ 3.43 – 3.37 ppm and 3.35 – 3.28 ppm 
for the 6’-methylene as well as with the triplet at δ 5.03 ppm for the 6’-OH in the 2D NOESY 
experiment. Furthermore, the 6-amino group did not show any correlation signals, suggesting that 
86 corresponded to the desired N-9 derivative. 
In contrast, the cleavage of the 3’,4’-O,O-benzylidene group (scheme 29) was not straightforward 
(table 10). Treatment of the protected nucleoside with ammonium formate in the presence of 
palladium on carbon as catalyst in refluxing methanol was reported to furnish the target 
nucleoside in high yield.[37] However, when up to 16 equivalents of ammonium formate and 80% 
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of palladium on carbon were used, only traces of the deprotected nucleoside 41 were formed 
according to thin layer chromatography and mass spectrometry. The attempts of deprotection 
using hydrogen gas (1 atm) catalysed by either palladium on carbon or palladium hydroxide on 
carbon were unsuccessful. Catalytic transfer hydrogenation conditions using a large excess of both 
ammonium formate and palladium on carbon were finally applied to the starting material 86 and 
allowed for the isolation of the target nucleoside 41 in a low yield of 18% after purification by 
column chromatography. 
 
 
Scheme 29. Cleavage of the 3’,4’-O,O-benzylidene group of the β-nucleoside 86. Reagents and 
conditions: i) HCOONH4, 10% Pd/C, CH3OH, reflux, 20h (41, 18% yield). 
 
Table 10. Attempts of cleavage of the 3’,4’-O,O-benzylidene group of β-nucleoside 86. 
Reagents and conditions Products 
HCOONH4 (8 eq.), 20% w/w Pd/C, CH3OH, reflux, 20h traces of 41 
HCOONH4 (8 eq.), 40% w/w Pd/C, CH3OH, reflux, 20h traces of 41 
HCOONH4 (16 eq.), 80% w/w Pd/C, CH3OH, reflux, 48h traces of 41 
HCOONH4 (48 eq.), 100% w/w Pd/C, CH3OH, reflux, 20h incomplete reaction (41, 18% yield) 
H2 (1 atm), 40% w/w Pd/C, EtOH, rt, 48h starting material 86 
H2 (1 atm), 80% w/w Pd(OH)2/C, EtOH, rt, 24h starting material 86 
 
The comparison of the 1H NMR spectrum of 41 to the available literature[37] confirmed that the β-
nucleoside isolated from the glycosylation reaction was the desired N-9 adduct, as previously 
suggested by NMR analysis performed on the precursor 86. 
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In conclusion, a synthetic procedure for the preparation of 1’-C-methyladenosine 41 was 
developed. The synthesis involved eight steps starting from the commercially available D-ribonic 
acid 1,4-lactone 63, with an overall yield less than 1%, and thus further optimisation of the 
method is required. 
The prepared nucleoside 41 was sent to our collaborators for biological evaluation in vitro (see 
section 2.3 for details). The results are currently being awaited. 
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2.2.3 SYNTHESIS OF BENZO-FUSED ADENOSINE ANALOGUES 
Benzo-fused 7-deaza adenosine analogues were designed by Tichý et al.[14, 15] as potential agents 
against RNA viruses, with the aim of exploring substitutions at the 7-deaza position of adenosine. 
As previously mentioned, some analogues within this family were found to inhibit DENV RdRp (see 
paragraph 1.2.2.2 and table 20 in the APPENDIX for details). Molecular modelling studies 
confirmed that the presence of large substituents at the 7-deaza position of adenosine, such as a 
benzene ring fused in a tricyclic heterobase, is well tolerated by the active site of the DENV RdRp 
(see paragraph 2.1.1.2 for details). In addition, docking studies suggested that modifications at the 
ribose moiety are compatible with the large tricyclic base (see paragraph 2.1.2.1). 
This section describes the synthesis of known benzo-fused 7-deazaadenosine analogues (87 and 
88, figure 62) and the application of the phosphoramidate ProTide strategy in an attempt to 
enhance their antiviral potency and overcome a reported issue of cytotoxicity of these 
compounds.[14, 15] Given the promising docking results, the combination of a modified glycosylating 
agent to the synthesised tricyclic heterobase was also explored. 
 
 
Figure 62. Structures of 87 and 88 as examples of tricyclic nucleosides. 
 
2.2.3.1 Synthesis of benzo-fused 7-deazaadenosine analogues 
For the preparation of benzo-fused 7-deazaadenosine analogues, such as 87 and 88, the synthesis 
of the corresponding pyrimido[4,5-b]indole heterocycles was performed, which was then followed 
by glycosylation, amination and deprotection steps. The synthesis of the tricyclic heterobases had 
been reported by Tichý et al.[15] in 2012. The strategy was applied to the synthesis of 4,6-dichloro 
97 as well as 4-chloro-9H-pyrimido[4,5-b]indole 98, starting from commercially available 2,4-
dichloronitrobenzene 89 and 2-chloronitrobenzene 90, respectively (scheme 30). 
2. RESULTS AND DISCUSSION  
138 
 
 
 
Scheme 30. Synthesis of pyrimido[4,5-b]indole heterocycles 97 and 98. Reagents and conditions: i) 
CNCH2COOEt, tBuOK, DMF, 70 °C, 16h (91, 77% yield; 92, 72% yield); ii) Zn, AcOH, rt, 4h (93, 89% 
yield; 94, crude); iii) formamide, 190 °C, 18h (95, 62% yield; 96, crude); iv) POCl3, reflux, 48h (97, 
83% yield; 98, 17% for last 3 steps). 
 
The first step was a nucleophilic aromatic substitution on the starting material by ethyl 
cyanoacetate, activated in situ by an excess of potassium tert-butoxide. In the reported procedure 
anhydrous THF had been used as solvent and the reaction mixture had been refluxed for 48 
hours.[15, 55] However, in this work, the reaction did not go to completion under these conditions 
and was characterised by a moderate yield (45% yield for 91, 35% yield for 92). When the reaction 
was performed in anhydrous DMF at 70 °C, full conversion of the starting material was observed 
after 16 hours with higher yields (77% yield for 91, 72% yield for 92). Additionally, purification by 
column chromatography was not required and the crude products could be used directly for the 
following step. Reduction of the nitro group by treatment with zinc dust in glacial acetic acid[15, 56] 
and spontaneous cyclisation of the amino intermediates afforded the desired indole derivatives 93 
and 94 in good yields. Cyclocondensation with formamide at 190 °C furnished the fused 
pyrimidone derivatives 95 and 96, which were then converted to 4,6-dichloro-9H-pyrimido[4,5-
b]indole 97 and 4-chloro-9H-pyrimido[4,5-b]indole 98 by treatment with phosphorus (V) 
oxychloride under reflux for 48 hours, monitored by thin layer chromatography. 
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The synthesis of 4-chloro-9H-pyrimido[4,5-b]indole 98 did not involve any purification of the 
intermediates, however was characterised by an overall yield of 12%. In contrast, the 4,6-dichloro 
analogue 97 was prepared with an overall yield of 35%. Purification by column chromatography of 
intermediate 95 was performed in order to isolate the desired product among several side-
products and significantly contributed to the increase in the yield of the subsequent step. The 
heterobase 97 was then submitted to glycosylation, amination and deprotection steps to obtain 
the target nucleoside 87, whereas the final steps towards nucleoside 88 were not performed 
because of the low-yielding synthesis of its precursor 98. 
In the reported procedure, the coupling reaction of a protected D-ribofuranose and a 9H-
pyrimido[4,5-b]indole derivative had been performed as a one-pot reaction according to the 
Vorbrüggen procedure.[15] The 4,6-dichloro-9H-pyrimido[4,5-b]indole 97 was coupled to 
commercially available 1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose (scheme 31): silylation of 
97 by N,O-bis(trimethylsilyl)acetamide and reaction with the glycosylating agent catalysed by 
trimethylsilyl triflate, were carried out in anhydrous acetonitrile under reflux and afforded 
nucleoside 99 in good yield (55%). The desired β-nucleoside could be separated by column 
chromatography from the α-nucleoside that was formed with a 10% yield (ratio α:β = 1:5). The 1H 
NMR and 13C NMR spectra of the β-nucleoside were in agreement with the literature.[15] NOESY 2D 
NMR experiments of both species were performed and further confirmed their anomeric identity: 
a correlation peak was observed between H-1’ and H-2’ in the α-anomer, whereas the anomeric 
proton of the β-anomer correlated to H-4’. 
 
 
Scheme 31. Glycosylation of 4,6-dichloro-9H-pyrimido[4,5-b]indole 97. Reagents and conditions: i) 
1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose, N,O-bis(trimethylsilyl)acetamide, TMSOTf, 60 °C, 
20h (99, 55% yield); ii) NH3, MeOH, 75 °C, 48h (87, 44%). 
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The last step was the amination of the 4-position and simultaneous cleavage of the protecting 
groups by treatment of 99 with a saturated (7M) methanolic solution of ammonia in a sealed tube 
at 75 °C for 48 hours (scheme 31). The target nucleoside benzo-fused 7-deazaadenosine analogue 
87 was isolated by filtration from the reaction mixture in 44% yield.[14] NMR spectra were in 
agreement with the literature reported for the β-nucleoside.[14] In the NOESY experiment, the 
observed correlation peaks between H-1’ and 2’-OH, H-2’ and the aromatic H-8 of the nucleobase 
as well as the absence of correlation between H-1’ and H-3’ confirmed that the desired β-
nucleoside was obtained. 
The anti-DENV activity and cytotoxicity in vitro of the synthesised tricyclic adenosine analogue 87 
were evaluated by our collaborators (see section 2.3 for details). 
 
2.2.3.2 Synthesis of benzo-fused adenosine analogue ProTides 
In order to increase the anti-DENV activity and reduce the cytotoxic effect of the parent 
nucleoside 87 (refer to section 2.3 for details), the phosphoramidate ProTide approach was 
applied (scheme 32). 
 
 
Scheme 32. Synthesis of benzo-fused adenosine analogue ProTides 100 and 101. Reagents and 
conditions: i) coupling reaction using phosphorochloridate or p-nitrophenolate reagents (see text 
for details). 
 
The coupling reaction was initially attempted on the unprotected nucleoside 87 according to the 
standand procedure using tBuMgCl as a base.[30] As previously mentioned, the method based on 
the use of the Grignard reagent does not provide selectivity towards primary hydroxyl groups, but 
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it is generally accociated with relatively high yields and the formation of the desired 5’-O-
phosphoramidate as main product of the reaction.[30] Compound 87 was treated with the 
phosphochloridate 35 (refer to section 2.2.1 for the preparation of 35) and tBuMgCl in anhydrous 
THF. However, purification by column chromatography led to the isolation of two species in very 
poor yield, which were showing similar chromatographic behaviour. In fact, the presence of two 
couples of peaks at the 31P NMR (at δ 3.44 ppm and 3.32 ppm, at δ 2.14 ppm and 2.01 ppm) 
suggested that the 5’-O-phoshoramidate and the 3’-O-phosphoramidate, each as a mixture of 
diastereoisomers, were obtained. Further purification by column chromatography of the mixture 
did not lead to the isolation of compound 100. 
The use of NMI in place of tBuMgCl for the preparation of ProTides generally allows for the 
selective reaction at the 5’-hydroxyl group of the parent nucleoside. In an attempt to avoid the 
formation of the undesired 3’-O-phosphoramidate and the inconvenient separation of the two 
couples of diastereoisomers, compound 87 was treated with the phosphochloridate 35 (refer to 
section 2.2.1 for the preparation of 35) in the presence of an excess of NMI in a mixture of THF 
and pyridine under anhydrous conditions. The reaction was characterised by poor conversion of 
the starting material, therefore the desired ProTide 100 could not be isolated after column 
chromatography. 
In a methodology study that will be described in section 2.2.5, innovative microwave irradiation 
(MWI) conditions for the preparation of ProTides were investigated. The methods using either 
NMI or the Grignard reagent tBuMgCl, conventionally carried out at room temperatute, were 
found to be compatible with heating by MWI and were applied for the synthesis of ProTide 101 
bearing the L-alanine isopropyl ester moiety. A mixture of the parent nucleoside 87 and the 
phosphorochloridate bearing the isopropyl ester moiety 36 (see section 2.2.1 for the synthesis of 
36) in the presence of an excess of NMI in a mixture of THF and pyridine was heated under MWI 
conditions at 65 °C for 4 hours. Progress of the reaction was monitored by thin layer 
chromatography, however poor conversion of the starting material 87 was observed and the 
ProTide 101 was not isolated after purification by column chromatography. Finally, nucleoside 87 
was treated with 1 equivalent of the p-nitrophenolate reagent 38 (refer to section 2.2.1 for the 
preparation of 38) in the presence of tBuMgCl in DMF. Heating of the reaction mixture by MWI at 
65 °C over 30 minutes, followed by purification by column chromatography, furnished the target 
ProTide 101 in 13% yield with a purity of 98% according to analytical HPLC.  
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The prepared tricyclic adenosine phosphoramidate 101 was sent to our collaborators for biological 
evaluation in vitro (see section 2.3 for details). The results are currently being awaited. 
 
2.2.3.3 Synthesis of ribose-modified benzo-fused 7-deazaadenosine analogues 
For the preparation of ribose-modified benzo-fused 7-deazaadenosine analogues, an appropriate 
glycosylating agent needed to be synthesised before the coupling to the pyrimido[4,5-b]indole 
heterocycles. Specifically, the synthetic strategy towards the tricyclic nucleoside bearing a methyl 
group at the 2’-position 102 (figure 63) was investigated. 
 
 
Figure 63. Structure of 2’-C-methyl substituted tricyclic nucleoside 102. 
 
The synthesis of the 2’-C-methyl glycosylating agent 107 for the following Vorbrüggen coupling 
reaction was accomplished according to a published procedure (scheme 33).[57] Commercially 
available 2-C-methyl-D-ribono-1,4-lactone 103 was treated with benzoyl chloride to obtain the 
fully protected lactone 104, that was used in the subsequent step without purification. Reduction 
of 104 using sodium bis(2-methoxyethoxy)aluminum dihydride (Red-Al®) afforded the anomeric 
mixtures of 105 and 106, whose formation was due to transbenzoylation. The mixture of four 
species was submitted without purification for the protection of the remaining free hydroxyl 
group as benzoyl ester. The glycosylating agent 1,2,3,5-tetra-O-benzoyl-2-C-methyl-D-ribofuranose 
107 was obtained in 35% yield after extraction and trituration. The synthetic pathway consists of 
three steps, does not involve purification by column chromatography of any of the intermediates 
and is characterised by an overall yield of 22%. 
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Scheme 33. Synthesis of the 2’-C-methyl glycosylating agent 107. Reagents and conditions: i) BzCl, 
4-(dimethylamino)pyridine, Et3N, DME, rt, 16h (104, 77% yield); ii) Red-Al®, EtOH, -5 °C, 1.5h (105 
and 106, 82% yield); iii) BzCl, 4-(dimethylamino)pyridine, Et3N, THF, 5 °C to rt, 24h (107, 35% yield). 
 
The glycosylating agent 107 was then used as an anomeric mixture for the coupling reaction with 
4,6-dichloro-9H-pyrimido[4,5-b]indole 97 (scheme 34). According to Vorbrüggen conditions for the 
glycosylation,[15] 97 was activated in situ by treatment with N,O-bis(trimethylsilyl)acetamide and 
reacted with 107 in the presence of the catalyst trimethylsilyl triflate to afford the protected β-
nucleoside 108 with a yield of 21%. Compound 108 was identified by NMR spectroscopy and mass 
spectrometry (the observed m/z was 696.2 [MH+]), whereas the anomeric configuration was not 
determined as the benzoyl protective groups interfere with the analysis of the 2D NOESY 
experiment. 
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Scheme 34. Glycosylation of 4,6-dichloro-9H-pyrimido[4,5-b]indole 97 using 107. Reagents and 
conditions: i) 97, N,O-bis(trimethylsilyl)acetamide, TMSOTf, 60 °C, 20h (108, 21% yield); ii) NH3, 
MeOH, 80 °C, 24h (102, 52% yield). 
 
Compound 108 underwent amination and deprotection by treatment with a saturated (7M) 
methanolic solution of ammonia at 80 °C for 24 hours (scheme 34). Chromatographical purification 
allowed for the isolation of the desired product 102 with 52% yield as well as the side-product 109 
with 14% yield (figure 64). Characterisation of the anomeric configuration was performed on the 
final nucleoside 102. A correlation signal between the singlet at δ 6.46 ppm for the H-1’ and the 
broad singlet at δ 5.00 ppm for the free hydroxyl group in the 2’-position was observed in the 2D 
NOESY experiment of 102; the lack of correlation of the singlet for the H-1’ with the methyl group 
in the 2’-position further confirmed that the desidered β-nucleoside was obtained. 
 
 
Figure 64. Side-product 109 isolated from the amination of compound 108. 
 
The prepared 2’-C-methyl benzo-fused nucleoside analogues 102 and 109 were sent to our 
collaborators for the biological evaluation in vitro (see section 2.3 for details) and the results are 
currently being awaited.  
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2.2.4 SYNTHESIS OF ACYCLIC ADENOSINE ANALOGUES 
Acyclic nucleoside analogues represent an important class of DAAs as exemplified by the fact that 
almost half of the nucleoside analogues approved to date as antiviral agents are acyclic 
nucleosides, acyclic nucleoside phosphonates (ANPs) or their prodrugs.[58, 59] 
With regard to DENV RdRp inhibitors, this field is still unexplored. With the aim of identifying 
potential anti-DENV acyclic nucleoside analogues, molecular modelling studies were performed 
using the model of the DENV RdRp de novo initiation complex. As previously described, two 
scaffolds replacing the 5-membered ring of the ribose were selected following screening of a 
database of linear linkers and docking studies (see paragraph 2.1.2.2 for details). The 
corresponding adenosine derivatives 27 and (R)-enantiomer of 28 are shown in figure 65 and are 
representative of two families of acyclic adenosine analogues, whose synthesis is reported in this 
section. 
 
 
Figure 65. Acyclic adenosine analogues 27 and (R)-enantiomer of 28 designed in silico. 
 
2.2.4.1 Synthesis of acyclic adenosine analogues – first scaffold 
Compound 1-[3,3’-bis-(hydroxymethyl)-prop-2-enyl]adenine 27 (figure 66) had been developed as 
an unsaturated derivative of pencyclovir 110 (figure 66), an acyclic guanosine analogue approved 
for the treatment of herpes simplex virus (HSV) and varicella zoster virus (VZV).[58] The additional 
double bond had been introduced to mimic the carbocycle of the naturally occurring antibiotic 
neplanocin A 111 (figure 64).[19] 
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Figure 66. Structures of pencyclovir 110 and neplanocin A 111 as rationale for compound 27.[19] 
 
In this work, the synthesis of 27 and 7-deaza analogues involved the alkylation of a 6-chloropurine 
base by primary allylic halides, which were synthesised according to the four steps pathway shown 
in scheme 35. 
 
 
Scheme 35. Synthesis of the allylic halides 116 and 117. Reagents and conditions: i) TBDMSCl, 
Et3N, 4-(dimethylamino)pyridine, DCM, 0 °C to rt, 24h (113, 87% yield); ii) triethyl 
phosphonoacetate, NaH, THF, 0 °C to rt, 2h (114, 94% yield); iii) DIBALH, DCM, -20 °C to 0 °C, 1h 
(115, 79% yield); iv) attempts of bromination (116, see text) or pTsCl, 4-(dimethylamino)pyridine, 
Et3N, DCM, rt, 4h (117, 40% yield). 
 
The inexpensive starting material 1,3-dihydroxyacetone 112, which is commercially available as a 
dimer, was initially protected as tert-butyldimethylsilyl ethers. In the reported procedure[19] the 
protection had been performed using tert-butyldimethylchlorosilane in the presence of 1H-
imidazole in anhydrous DMF. However formation of 113 occured neither when the reaction was 
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monitored by thin layer chromatography over 60 hours, nor when a second addition of both 
reagents was performed over 96 hours. In these attempts, the starting material was converted to 
a more lipophilic product that could not be extracted from the aqueous phase during the work-up. 
In a third attempt, the protected 1,3-dihydroxyacetone 113 was obtained after treatment of the 
starting material 112 with tert-butyldimethylchlorosilane and Et3N in anhydrous Et2O for 72 hours 
in poor yield (26%). Finally, the reaction was performed using tert-butyldimethylchlorosilane in the 
presence of Et3N and 4-(dimethylamino)pyridine in anhydrous DCM and afforded the desired 
product 113 after 24 hours in good yield (87%). 
The following reaction of 113 with triethyl phosphonoacetate in the presence of sodium hydride in 
THF, according to Wittig-Emmons conditions, furnished the ethyl ester derivative 3,3’-bis-(tert-
butyldimethylsilyloxymethyl)prop-2-en-1-oate 114 with excellent yield (94%). Reduction to the 
allylic primary alcohol 115 was carried out using DIBALH and was characterised by a good yield 
(79%). 
According to the published procedure,[19] the conversion of 115 to the bromo derivative 116 had 
been accomplished using N-bromosuccinimide and triphenylphosphine in DCM. Although 
attempts of bromination of the allylic alcohol 115 were performed using a variety of bromine 
sources, the desired product 116 could not be obtained in good yield. As summarised in table 11, 
bromination of the allylic alcohol of 115 using N-bromosuccinimide or carbon tetrabromide was 
associated with several side-reactions. After treatment with 2 equivalents of N-bromosuccinimide, 
the allylic bromide 116 was isolated from the mixture of species in 14% yield. Treatment with 
phosphorus tribromide did not lead to the formation of 116 according to the 1H NMR spectrum of 
the crude residue, whereas treatment with bromotrimethylsilane in DCM led to the formation of a 
mixture of deprotected species. 
  
2. RESULTS AND DISCUSSION  
148 
 
Table 11. Attempts of bromination of the allylic primary alcohol 115. 
Reagents and conditions Products 
N-Bromosuccinimide (1.07 eq.), Ph3P (1.1 eq.), DCM, 0 °C to rt, 4h mixture of species 
N-Bromosuccinimide (2.0 eq.), Ph3P (1.1 eq.), DCM, 0 °C to rt, 4h bromide 116 (14% yield) 
Bromotrimethylsilane (1.2 eq.), DCM, 0 °C to rt, 6h deprotected species 
Bromotrimethylsilane (1.2 eq.), DCM, 0 °C to rt, 1h deprotected species 
CBr4 (1.25 eq.) Ph3P (1.5 eq.), DCM, 0 °C to rt, 1h mixture of species 
PBr3 (2 x 0.5 eq.), Et3N (2 x 2.0 eq.), DCM, 0 °C to rt, 20h mixture of species 
 
In contrast, chlorination of 115 was easily achieved by treatment with p-toluenesulfonyl chloride, 
in the presence of 4-(dimethylamino)pyridine and Et3N in DCM
[60] with 40% yield. Conversion into 
the chloro derivative 117 was confirmed by NMR spectroscopy. The upfield shift of the signals of 
the methylene bound to the halogen atom was observed in both the 1H NMR and 13C NMR 
spectra: the doublet integrating for two protons, which overlapped with the singlet of 3-CH2, 
shifted from δ 4.15 ppm to δ 4.12 ppm in the 1H NMR spectrum, the singlet for the carbon atom 
shifted from δ 58.70 ppm to δ 39.67 ppm in the 13C NMR spectrum (figure 67). 
 
 
Figure 67. Expansion of the 13C NMR of the allylic chloride 117 (red) superimposed to the 13C NMR 
of the allylic alcohol 115 (blue). 
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The coupling reaction of the allylic chloride 117 with commercially available 6-chloropurine 118 
was performed in the presence of caesium carbonate as a base catalyst in DMF.[19] Alkylation of 
118 provided the desired N-9 adduct 119 in 56% yield (scheme 36). The NMR spectra of 119 were 
in agreement with the literature[19] and confirmed the identity of the compound. The N-7 alkylated 
isomer was obtained as a minor product of the reaction (23% yield), with a ratio N-9:N-7 of 2.5:1. 
Deprotection of the tert-butyldimethylsilyl groups using tetrabutylammonium fluoride trihydrate 
in THF at low temperature (-10 °C to 0 °C) furnished 120 in excellent yield (94%). The following 
amination by treatment with a saturated (7M) methanolic solution of ammonia at 75 °C over 48 
hours afforded 27 in 56% yield. 
 
 
Scheme 36. Alkylation of 6-chloropurine 118. Reagents and conditions: i) Cs2CO3, allylic chloride 
117, DMF, rt, 20h (119, 56% yield; N-7 adduct, 23% yield); ii) TBAF∙3H2O, THF, -10 °C to 0 °C, 2h 
(120, 94% yield); iii) NH3, MeOH, 75 °C, 48h (27, 56% yield). 
 
To investigate the possibility of increasing anti-DENV activity and selectivity of acyclic adenosine 
analogues, structurally modified heterobases were combined to the linear linker. The general 
procedure of alkylation was applied to a series of 6-chloro-7-deazapurine derivatives. Besides the 
commercially available 6-chloro-7-deazapurine 121 and the benzo-fused 7-deaza-6-chloropurine 
97 (refer to paragraph 2.2.3.1 for the synthesis of 97), the methyl 7-carboxylate derivative 123 was 
used in the alkylation procedure as well. This heterobase was selected because it is a readily 
accessible intermediate for the synthesis of 7-carbamoyl-7-deazaadenosine analogues, such as the 
DENV RdRp inhibitor NITD449 (see paragraph 1.2.2.2 for details). A two-step synthetic procedure 
for 123 had been reported by Chen et al.[11] and was performed in this work (scheme 37). 
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Scheme 37. Synthesis of methyl 7-deaza-6-chloropurine-7-carboxylate 123. Reagents and 
conditions: i) N-bromosuccinimide, DCM, rt, 3h (122, 72% yield); ii) n-butyllithium, THF, -78 °C, 
0.5h, then methyl chloroformate, -78 °C to rt, 3h (123, 61% yield). 
 
Commercially available 6-chloro-7-deazapurine 121 was converted into the 7-bromo derivative 
122 by treatment with N-bromosuccinimide with 72% yield. Lithium-bromine exchange and 
following reaction of the organolithium compound (generated in situ) with the carbonyl group of 
methyl chloroformate afforded the methyl 7-carboxylate derivative 123 in good yield (61%). 
The alkylation of 6-chloro-7-deazapurine 121 and the synthesised analogues 97 and 123 is 
illustrated in schemes 38 and 39. 
 
 
Scheme 38. Alkylation of 6-chloro-7-deazapurine 121 and methyl 7-carboxylate derivative 123. 
Reagents and conditions: i) Cs2CO3, allylic chloride 117, DMF, rt, 20h (124, 69% yield; 125, 78% 
yield); ii) TBAF∙3H2O, THF, -10 °C to 0 °C, 2h (126, 76% yield; 127, 100% yield); iii) NH4OH aq. 
solution, 1,4-dioxane, 90 °C, 48h (128, 85% yield) or NH3, MeOH, 75 °C, 48h (129, 34% yield). 
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Scheme 39. Alkylation of 4,6-dichloro-9H-pyrimido[4,5-b]indole 97. Reagents and conditions: i) 
Cs2CO3, allylic chloride 117, DMF, rt, 20h (130, 65% yield); ii) TBAF∙3H2O, THF, -10 °C to 0 °C, 2h 
(131, 71% yield); iii) NH3, MeOH, 75 °C, 48h (132, 26% yield). 
 
Compounds 124, 125 and 130 were obtained in good yields (from 65% to 78%) and submitted to 
the TBAF-mediated cleavage of silyl ethers (schemes 38 and 39). Amination of the deprotected 
acyclic purine nucleosides 127 and 131 by treatment with a saturated (7M) methanolic solution of 
ammonia at 75 °C over 48 hours afforded the corresponding target nucleosides 129 and 132 in 
moderate yields. For the preparation of the 7-deazaadenine analogue 128, the application of the 
standard procedure using the methanolic ammonia solution did not lead to the isolation of the 
desired product. A different procedure consisting of treatment of 126 with a 30% aqueous 
ammonia solution in 1,4-dioxane then allowed for full conversion of the starting material and 
furnished the target nucleoside 128 in excellent yield after chromatographical purification. 
Before applying the phosphoramidate ProTide approach to the acyclic nucleoside analogues, an 
optimisation of the synthesis of the representative compounds 27 and 128 was performed 
(schemes 40 and 41). In an attempt to improve the yield of the coupling with the heterobase, the 
allylic alcohol 115 was converted into the mesylate derivative by treatment with methanesulfonyl 
chloride in the presence of Et3N in Et2O at low temperature (from -78 °C to 0 °C). Filtration of the 
reaction mixture was crucial to avoid the further conversion of the mesylate intermediate to the 
chloro derivative 117. The mesylate intermediate was used directly in the reaction with either 6-
chloropurine 118 or 6-chloro-7-deazapurine 121 in the presence of caesium carbonate in DMF to 
afford 119 and 124, respectively, allowing for a substancial increase of the yield compared to the 
previously described method (32% and 40% against 22% and 28% for two steps from the allylic 
alcohol 115 to 119 and 124, respectively). 
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Scheme 40. Optimised synthesis of the acyclic nucleoside 27. Reagents and conditions: i) allylic 
alcohol 115, MsCl, Et3N, Et2O, -78 °C to 0 °C, 3h, then Cs2CO3, DMF, rt, 20h (119, 32% yield; N-7 
adduct, 17% yield); ii) TBAF∙3H2O, THF, -10 °C to 0 °C, 2h (120, 94% yield); iii) NH4OH aq. solution, 
1,4-dioxane, 90 °C, 48h (27, 90% yield). 
 
 
Scheme 41. Optimised synthesis of the acyclic nucleoside 128. Reagents and conditions: i) allylic 
alcohol 115, MsCl, Et3N, Et2O, -78 °C to 0 °C, 3h, then Cs2CO3, DMF, rt, 20h (124, 40% yield); ii) 80% 
aq. AcOH, THF, rt, 24h (126, 80% yield); iii) NH4OH aq. solution, 1,4-dioxane, 90 °C, 48h (127, 85% 
yield). 
 
The optimised procedure for preparation of the adenosine analogue 27 involved fluoride-
mediated deprotection, followed by amination carried out using a 30% aqueous ammonia solution 
in 1,4-dioxane at 90 °C (scheme 40). Trituration of the crude compound in ethanol afforded 27 in 
90% yield. In the optimised synthesis of the acyclic 7-deaza nucleoside 128, the cleavage of the 
tert-butyldimethylsilyl ethers in acidic conditions was found to be superior to the previously 
described method based on the use of tetrabutylammonium fluoride. In fact, treatment of 124 
with a 80% aqueous acetic acid solution in THF at room temperature afforded the fully 
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deprotected nucleoside 126 in excellent yield and was used directly in the amination step without 
need for chromatographical purification (scheme 41). 
The anti-DENV activity and cytotoxicity in vitro of the synthesised acyclic adenosine and 7-
deazaadenosine analogues 27, 128, 129 and 132 were evaluated by our collaborators (see section 
2.3 for details). 
 
2.2.4.2 Synthesis of acyclic adenosine analogue ProTides 
The phosphoramidate ProTide strategy was applied to the acyclic nucleoside analogues with the 
aim to boost the anti-DENV activity of the adenosine analogue 27 as well as to overcome an issue 
of cytotoxicity common among the nucleosides within this family. Additionally, the nucleotide 
prodrug approach may improve the biological profile of inactive acyclic nucleoside analogues, such 
the 7-deaza derivative 128 (refer to section 2.3 for details). The linear scaffold designed to replace 
the ribose moiety is characterised by the presence of two primary hydroxyl groups with similar 
reactivity towards the phosphoramidating reagent, regardless of the employed methodology. 
According to the predicted binding mode of the acyclic adenosine analogues in the active site of 
the DENV RdRp (see paragraph 2.1.2.2 for details), phosphorylation of the hydroxyl group in trans 
position of the alkene should occur. Therefore, the trans mono-O-phosphoramidate (figure 68) 
represents the target nucleotide prodrug. The O-O-cyclic phosphoramidate (figure 68) is a 
nucleotide prodrug of interest as well, due to the similarity to 3’-O-5’-O-cyclic phosphate ester 
nucleotide prodrugs that were recently reported as anti-HCV agents.[61, 62, 63] 
 
 
Figure 68. General structures of target phosphoramidate ProTides. 
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The bis-O,O-phosphoramidates and the cis isomer mono-O-phosphoramidate are side-products of 
the coupling reaction performed on unprotected acyclic adenosine analogues (figure 69). 
 
 
Figure 69. General structures of the phosphoramidate side-products of the coupling reaction. 
 
For the preparation of phosphoramidate ProTides of acyclic nucleosides, the method based on 
tBuMgCl and p-nitrophenolate reagent was first investigated (scheme 42). The acyclic adenosine 
analogue 27 was treated with 1 equivalent of 38 (refer to section 2.2.1 for the preparation of 38) 
in the presence of tBuMgCl in DMF. Complete consumption of the starting material was achieved 
in few hours at room temperature and the corresponding O-O-cyclic L-alanine isopropyl ester 
phosphoramidate 133 was isolated in 39% yield with a purity of 96% according to analytical HPLC. 
The same reaction conditions were successfully applied to the 7-deazaadenosine analogue 128 
and provided the O-O-cyclic phosphoramidate 134 in 26% yield with a purity of 96% according to 
analytical HPLC. 
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Scheme 42. Synthesis of O-O-cyclic phosphoramidate ProTides 133 and 134. Reagents and 
conditions: i) tBuMgCl, p-nitrophenolate reagent 38, DMF, 4h (133, 39% yield; 134, 26% yield). 
 
With the aim to facilitate the preparation of the desired trans mono-O-phosphoramidate ProTides, 
the deprotection of only one of the hydroxyl groups of 124 was attempted using aqueous acetic 
acid solution (scheme 43). Different ratios between acetic acid, water and THF were explored, as 
summarised in table 12, and the reactions were monitored by thin layer chromatography. 
Deprotection of both functionalities occurred simultaneously when the fully protected nucleoside 
124 was treated at room temperature, whereas no conversion of the starting material was 
observed upon reaction at 0 °C. Traces of the mono-protected species 135 and 136 were formed 
according to thin layer chromatography and NMR spectroscopy when acetic acid, water and THF 
were used at a ratio of 2:1:1, however the fully deprotected compound 126 was the main product 
of the reaction and the mono-protected intermediates 135 and 136 could not be isolated. 
 
 
Scheme 43. Attempts of partial deprotection of acyclic nucleoside 124. Reagents and conditions: i) 
as in table 12. 
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Table 12. Attempts of partial deprotection of acyclic nucleoside 124. 
Reagents and conditions Products 
AcOH, H2O, THF (4:1:1), rt, 24h fully deprotected 126 
AcOH, H2O, THF (4:1:1), 0 °C, 6h fully protected 124 
AcOH, H2O, THF (2:3:1), rt, 24h fully deprotected 126 
AcOH, H2O, THF (2:1:1), rt, 48h fully deprotected 126 and traces of mono-protected 135 and 136 
 
As a procedure for the partial deprotection of acyclic nucleosides could not be developed, the 
synthesis of trans mono-O-phosphoramidates was attempted on unprotected acyclic nucleosides. 
The application of innovative MWI conditions (refer to section 2.2.5 for a description of the 
developed methodology) to the preparation of this class of phosphoramidates was investigated 
(scheme 44). 
 
 
Scheme 44. Synthesis of mono-O-phosphoramidate ProTides 137, 138 and 139. Reagents and 
conditions: i) NMI, phosphorochloridate 36, THF/pyridine, MWI (300W), 50 °C, 10 min (137, 3% 
yield; 138, 6% yield) or NMI, phosphorochloridate 35, THF/pyridine, MWI (300W), 50 °C, 30 min 
(139, 4% yield). 
 
When the reaction mixture containing the acyclic adenosine analogue 27, phosphorochloridate 36 
(1.7 equivalents) (see section 2.2.1 for the preparation of 36) and an excess of NMI in THF and 
pyridine was heated by MWI at 50 °C for a time as short as 10 minutes, the starting material was 
converted into three different products according to thin layer chromatography. Intense 
chromatographical purification allowed for the separation of the bis-O,O-phosphoramidates (14% 
yield, 140 in section 4.2.5) and a mixture of cis and trans mono-O-phosphoramidates (17% yield). 
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The number of equivalents of phosphoramidating reagent was found to influence the ratio of bis-
O,O-phosphoramidates and mono-O-phosphoramidate. In fact, a slight reduction of the number of 
equivalents from 1.7 to 1.5 halved the amount of the undesired bis-O,O-phosphoramidates 140 
(6% yield) whereas the mixture containing the cis and the trans mono-O-phosphoramidates was 
obtained in a comparable yield of 13% after purification by column chromatography. In order to 
separate the mixture of the two isomers, repetitive purification by column chromatography was 
performed and allowed for the isolation of the FE isomer, that was characterised by two signals at 
δ 2.91 and 2.79 ppm in the 31P NMR spectrum, in 3% yield. The isolated ProTide was characterised 
by NMR spectroscopy and mass spectrometry (the observed m/z was 527.2 for [MNa+]). The 
methylene bearing the phosphoramidate moiety could be distinguished thanks to the coupling 
between its carbon atom and the phosphorus atom observed in the 13C NMR spectrum: in fact, the 
CH2OP appeared as a triplet at δ 68.27 ppm due to the overlapping of the two doublets (one for 
each diastereoisomer), whereas the CH2 bound to the free hydroxyl group was characterised by 
two singlets at δ 57.31 ppm and δ 57.28 ppm. In the 2D HSQC spectrum, the apparent triplet for 
the CH2OP in the 
13C NMR spectrum correlated to the multiplet for the methylene group at δ 4.62 
– 4.54 ppm in the 1H NMR spectrum. Finally, the 2D NOESY experiment allowed for the 
characterisation of the configuration of isomer. The observation of a correlation signal between 
the multiplet for the methylene bearing the phosphoramidate moiety and the proton in the 2-
position demonstrated that the desired trans isomer of the alkene 137 was obtained (figure 70). 
 
 
Figure 70. The NOESY correlation signal observed for the trans mono-O-phosphoramidate 137. 
 
The trans mono-O-phosphoramidate of the acyclic 7-deazaadenosine analogue 128 were prepared 
and characterised as described for the ProTide 137 (scheme 44). The reaction of 128 with the 
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phosphorochloridate bearing the isopropyl ester 36 in the presence of NMI in a mixture of THF 
and pyridine under MWI conditions, followed by purification by column chromatography, afforded 
the ProTide 138 in 6% yield as well as the bis-O,O-phosphoramidates in 4% yield (141 in section 
4.2.5) as a side-product. Similarly, the benzyl ester derivatives 139 were obtained from the 
microwave-assisted coupling reaction between the parent nucleoside 128 and the 
phosphorochloridate 35 (scheme 44). Intense chromatographical purification furnished the 
desired product in 4% yield and the bis-O,O-phosphoramidates in 5% yield (142 in section 4.2.5). 
Previous attempts for the synthesis of trans mono-O-phosphoramidate ProTides of acyclic 
nucleosides were performed using NMI under conventionally used conditions.[30] The 7-
deazaadenosine derivative 128 was treated with the phosphorochloridate 35 (see section 2.2.1 for 
the preparation of 35) and an excess of NMI either in THF or in a mixture of THF and pyridine at 
room temperature. However, the formation of phosphoramidate products was not observed 
despite the long reaction time (40 hours). These observations demonstrated that heating by MWI 
significantly increased the reactivity of the acyclic nucleoside analogues in the coupling with the 
phosphorochloridate, despite the lack of selectivity between the two primary alcohol groups. 
The synthesised trans mono-O-phosphoramidates 137, 138 and 139 were found to be prone to 
spontaneous conversion to the corresponding O-O-cyclic phosphoramidates. The instability was 
confirmed by analytical HPLC analysis, which revealed the formation of a second set of 
diastereoisomers with the same retention times observed for compounds 133 and 134. In the case 
of ProTide 139, the identity of the second species was confirmed by mass spectrometry: in fact, 
the m/z of 458.2 and 480.2 were observed for the O-O-cyclic phosphoramidate bearing the L-
alanine benzyl ester moiety ([MH+] and [MNa+], respectively). Further decomposition may also 
occur over time, as suggested by the presence of a third peak in the HPLC chromatogram of the 
ProTides 138 and 139, corresponding to a more hydrophilic product that could not be identified. 
The prepared O-O-cyclic Protides 133 and 134, the trans mono-O-phosphoramidate ProTides 137, 
138 and 139 as well as the corresponding bis-O,O-phosphoramidates 140, 141 and 142 were sent 
to our collaborators for biological evaluation in vitro (see section 2.3 for details). The results are 
currently being awaited. 
 
2.2.4.3 Synthesis of acyclic adenosine analogues – second scaffold 
The structural modification of the acyclic adenosine analogue 28 is the additional methyl group in 
the position corresponding to the α-anomeric position of nucleosides. For the preparation of 28, 
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alkylation of 6-chloropurine 118 by the secondary allylic chloride 146 was initially attempted 
(scheme 45). 
 
 
Scheme 45. Synthesis of the secondary allylic chloride 146. Reagents and conditions: i) N-methoxy-
N-methyldiethylphosphonoacetate, NaH, THF, 0 °C to rt, 1h (143, 87% yield); ii) MeLi, Et2O, -78 °C 
to 0 °C, 2h (144, 73% yield); iii) DIBALH, DCM, -20 °C to 0 °C, 1h (145, 60% yield); iv) MsCl, pyridine, 
0 °C to rt, 2h (146, 33% yield). 
 
The secondary allylic chloride 146 was synthesised from the protected 1,3-dihydroxyacetone 113, 
whose preparation was described in paragraph 2.2.4.1. The N-methoxy-N-methylamide (Weinreb 
amide) derivative 143 was prepared under Wittig-Emmons conditions[64] as intermediate for the 
synthesis of the ketone 144. The derivatisation to the Weinreb amide is an effective strategy for 
the synthesis of ketones,[65] as this functional group reduces the propensity of Grignard reagents 
or organolithium compounds to overadd to the substrate, thus preventing the formation of a 
tertiary alcohol.[65] 
The reactivity of methyl lithium towards the previously prepared ester intermediate 114 and 
towards the Weinreb amide 143 were compared. Treatment of 114 with one equivalent of methyl 
lithium at -78 °C led to the isolation of the bis-adduct 147 (scheme 46), whereas no traces of the 
ketone compound 144 were observed in the 1H NMR spectrum of the crude residue. 
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Scheme 46. Reaction of the ester intermediate 114 with methyl lithium. Reagents and conditions: 
i) MeLi (1.0 eq.), Et2O, -78 °C, 2h (147, crude). 
 
The presence of a singlet integrating for six protons at δ 1.28 ppm in the 1H NMR spectrum 
confirmed the identity of side-product 147. In contrast, the nucleophilic addition of methyl lithium 
to the Weinreb amide 143 afforded the desired ketone 144 (scheme 45) as only product of the 
reaction in good yield (73%). 
The following reduction of 144 was accomplished by treatment with DIBALH and furnished the 
allylic secondary alcohol 145 in 60% yield. A second compound was isolated in 15% yield and 
identified as the isomer 148 (scheme 47), whose formation was due to transsilylation. Compared 
to the 1H NMR spectrum of compound 145, in the 1H NMR spectrum of 148 the multiplet for the 
H-2 shifted upfield (from δ 4.62 – 4.56 to 4.59 to δ 3.71 – 3.66 ppm) and two doublets of doublets 
were observed at δ 2.09 and 1.80 ppm for one of the methylene groups in 4-position, rather than 
the singlet at δ 4.06 ppm observed in 145. Additionally, the free hydroxyl group gave a broad 
singlet at δ 3.73 ppm, rather than at δ 2.45 ppm observed for the 2-OH of 145. The identity of the 
isomers was confirmed by mass spectrometry (the observed m/z was 383.2 [MNa+]). 
 
 
Scheme 47. Reduction of the ketone 144 associated with transsilylation. Reagents and conditions: 
i) DIBALH, DCM, -20 °C to 0 °C, 1h (145, 60% yield, 148, 15% yield). 
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For the chlorination of the secondary allylic alcohol 145 (scheme 48), the conditions previously 
employed for the preparation of the primary allylic chloride 117 were applied (refer to paragraph 
2.2.4.1). However, treatment of 145 with p-toluenesulfonyl chloride, in the presence of 4-
(dimethylamino)pyridine and Et3N in DCM did not lead to the formation of the corresponding 
chloro derivative 146. In contrast, the use of methanesulfonyl chloride and Et3N in DCM at room 
temperature provided the secondary allylic chloride 146 in 24% yield. A better yield (33%) could be 
obtained by performing the reaction with methanesulfonyl chloride in pyridine. As described for 
the primary allylic chloride 117, an upfield shift of the methyne bound to the chlorine atom was 
observed in the 13C NMR spectrum, from δ 63.65 ppm to δ 52.97 ppm. 
 
 
Scheme 48. Chlorination of the secondary allylic alcohol 145. Reagents and conditions: i) MsCl, 
pyridine, 0 °C to rt, 2h (146, 33% yield). 
 
The secondary allylic chloride 146 was used in the coupling reaction with the heterobase (scheme 
49). 6-Chloropurine 118 was treated with 146 in the presence of caesium carbonate in DMF over 
20 hours. However, the formation of the alkylated product 149 was observed neither at room 
temperature nor at higher temperature (60 °C or 120 °C). 
 
 
Scheme 49. Synthesis of the acyclic nucleoside 149 from the secondary allylic chloride 146. 
Reagents and conditions: i) Cs2CO3, allylic chloride 146, DMF (see text for details). 
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Therefore, the synthesis of the target compound 149 via the mesylate derivative of 145 was 
attempted by treating the secondary allylic alcohol 145 with methanesulfonyl chloride in the 
presence of Et3N in Et2O at low temperature (from -78 °C to 0 °C). These conditions were not 
successful and the mesylate intermediate could not be prepared. 
Finally, Mitsunobu reaction conditions were employed (scheme 50):[66] the coupling reaction 
between the alcohol 145 and 6-chloropurine 118 was carried out in the presence of 
triphenylphosphine and di-isopropyl azodicarboxilate in THF at reflux and afforded the desired 
product 149 in 22% yield. Performing the reaction in refluxing 1,4-dioxane failed to improve the 
yield as compound 149 could not be isolated among other species. 
 
 
Scheme 50. Synthesis of the target acyclic nucleoside 28 as enantiomeric mixture from the 
secondary allylic alcohol 145. Reagents and conditions: i) allylic alcohol 145, Ph3P, DIAD, THF, 
reflux, 20h (149, 22% yield); ii) 80% aq. AcOH, THF, rt, 24h (150, 71% yield); iii) NH4OH aq. solution, 
1,4-dioxane, 90 °C, 40h (28, 64% yield). 
 
The target nucleoside 28 was obtained as a mixture of two enantiomers, following deprotection of 
the tert-butyldimethylsilyl groups in acidic conditions and amination that was performed by 
treatment with a 30% aqueous ammonia solution in 1,4-dioxane at 90 °C (scheme 50). 
The prepared acyclic adenosine analogue 28 was sent to our collaborators for biological evaluation 
in vitro (see section 2.3 for details) and the results are currently being awaited. 
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2.2.5 MICROWAVE-ASSISTED SYNTHESIS OF PROTIDES 
Nucleoside analogues represent an important class of anticancer and antiviral agents.[59] They are 
prodrugs that become active upon intracellular conversion to their triphosphate derivative in a 
cascade of phosphorylation catalysed by cellular kinases. The triphosphate nucleotide analogue 
then acts a competitive inhibitor of RNA or DNA polymerases, by mimicking the natural substrates 
of the enzymes, and is incorporated into the nascent nucleic acid.[59] 
The development of effective nucleoside analogues is often a challenging process. Besides being 
toxic and sensitive to metabolic degradation, these compounds are polar and thus they have 
limited membrane permeability, resulting in both low bioavailability and cellular uptake by passive 
diffusion. Furthermore, nucleoside analogues as well as their monophosphate and diphosphate 
derivatives are poor substrates of cellular kinases resulting in an inefficient conversion to the 
bioactive triphosphates. In particular, the first phosphorylation generally represents the rate-
limiting step in the cascade of activation and may compromise the biological activity of the 
nucleoside analogue.[25, 26] 
To overcome these common limitations, nucleotide prodrug strategies have been developed. 
These prodrugs deliver the monophosphate directly into cells, therefore bypassing the first 
phosphorylation.[25, 26] The negative charges of the monophosphate moiety are masked by 
hydrophobic groups resulting in a neutral and lipophilic molecule. The prodrug reaches the 
intracellular compartment by passive diffusion and releases the monophosphate nucleotide into 
cells, where it is further phosphorylated to the bioactive triphosphate. As a consequence, the 
application of nucleotide prodrug strategies has the potential to improve the pharmacokinetic 
properties and boost the biological activity of the parent nucleoside.[26] The developed nucleotide 
monophosphate prodrug approaches are summarised in paragraph 1.2.2.1. 
Among the number of available strategies, the phosphoramidate ProTide technology has gained 
validation in the clinic and currently represents the most promising pronucleotide approach. 
Remarkable examples of the success of phosphoramidate ProTides include the anti-HCV agent 
Sofosbuvir (PSI-7977, 21, figure 71)[67] and Tenofovir alafenamide (GS-7340, 22, figure 71), which 
was recently approved for the treatment of HIV infections.[68] 
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Figure 71. Structures of Sofosbuvir (PSI-7977, 21) and Tenofovir alafenamide (GS-7340, 22). 
 
Structurally, the ProTide consists of an amino acid alkyl or aryl ester, most commonly L-alanine 
isopropyl or benzyl esters, and a second aryl moiety attached to the phosphorus centre in a chiral 
molecule.[26, 30] The common methods for the preparation of phosphoramidate ProTides involve 
the coupling reaction between the parent nucleoside and the chosen aryl amino acid 
phosphorochloridate in the presence of a base, namely NMI or tBuMgCl (scheme 51).[30] 
 
 
Scheme 51. Standard synthesis of phosphoramidate ProTides.[30] Reagents and conditions: i) 
tBuMgCl or NMI, solvent(s), rt, 16-20h. 
 
These procedures are conventionally used, however they are characterised by major limitations: i) 
use of labile reagents; ii) long reaction time at room temperature; iii) need for additional steps of 
protection and deprotection; iv) inefficient conversion especially of highly modified nucleoside 
analogues; v) need for intense purification procedures, resulting in low yields. 
Microwave-assistance has become an increasingly popular method to carry out a variety of 
reactions within short times and has been demonstrated to provide better yields and higher 
selectivity in nucleoside chemistry.[69] With the aim of developing an improved method for the 
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synthesis of phosphoramidate ProTides, the application of innovative MWI conditions was 
investigated and is described in the following section (scheme 52). 
 
 
Scheme 52. Microwave-assisted synthesis of phosphoramidate ProTides. Reagents and conditions: 
i) tBuMgCl or NMI, solvent(s), MWI. 
 
2.2.5.1 Synthesis of phosphoramidating reagents 
As the stability of the sensitive phosphorochloridate reagent of the type of 35 and 36 was 
uncertain, alternative phosphoramidating reagents containing phenolate and p-nitrophenolate as 
leaving groups were prepared to test their reactivity in the coupling reaction (scheme 52). The 
ideal phosphoramidating reagent should be more stable than the phosphorochloridate, while 
maintaining sufficient reactivity towards the 5’-hydroxyl group of the nucleoside. The syntheses of 
the phosphorochloridates 35 and 36 bearing the L-alanine benzyl and isopropyl ester moieties 
were accomplished as previously described in section 2.2.1, starting from the corresponding 
L-alanine benzyl and isopropyl ester salts 32 and 33, respectively. The p-nitrophenolate derivatives 
37 and 38 were synthesised either from the corresponding phosphorochloridate or from 
4-nitrophenyldichlorophosphate, phenol and the chosen L-alanine ester salt, according to 
procedures that were described in section 2.2.1. 
The phosphoramidating reagents 152 and 154 characterised by the phenolate as leaving group 
were prepared from commercially available starting materials, diphenylchlorophosphate 151 and 
the corresponding L-alanine benzyl and isopropyl ester salts 32 and 33, respectively (scheme 53). 
The reaction was carried out in the presence of Et3N in DCM under anhydrous conditions and was 
monitored by 31P NMR. The appearance of a single 31P signal at δ -2.79 ppm or at δ -2.81 ppm 
suggested the formation of the phenolate reagents 152 and 153, which were obtained in high 
yields (96% and 83% respectively) after chromatographical purification. 
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Scheme 53. Synthesis of the phenolate phosphoramidating reagents 152 and 153. Reagents and 
conditions: i) Et3N, DCM, -78 °C to rt, 3h (152, 96% yield; 153, 83% yield). 
 
2.2.5.2 Synthesis of ProTides 
To explore the potential of microwave-assistance in the synthesis of phosphoramidate ProTides, 
the natural nucleoside adenosine was chosen as a starting model. 
According to the conventional procedures for the synthesis of phosphoramidate ProTides, the use 
of a different base, NMI or tBuMgCl, affects the reaction outcome.[30] The latter does not provide 
selectivity towards primary hydroxyl groups, whereas the former allows the coupling reaction to 
occur exclusively at the 5’-hydroxyl group of the nucleoside. As a consequence, the method based 
on the use of NMI is generally applied on unprotected nucleosides in the presence of multiple 
reactive functionalities.[30] 
First, the applicability of microwave-assistance for the preparation of phosphoramidate ProTides 
was probed using NMI on the unprotected nucleoside adenosine 154 (scheme 54). Irradiation of 
the reaction mixture containing the phosphorochloridate 35 in 1,4-dioxane at 85 °C for a short 
time of 15 minutes allowed for complete consumption of the starting material 154 according to 
thin layer chromatography, however the desired 5’-O-phosphoramidate 155 was only furnished in 
a very low yield of 4% after chromatographical purification. Additionally, a mixture of bis-O,O-
phosphoramidate adducts was obtained (2% yield). These results suggested that the method 
based on the use of NMI lacks efficiency and selectivity at high temperature and under MWI 
conditions. 
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Scheme 54. Microwave-assisted synthesis of the phosphoramidate ProTide 155 using NMI. 
Reagents and conditions: i) NMI, dioxane, MWI (300W), 85 °C, 15 min (155, 4% yield). 
 
Following this, the application of microwave-assistance to the method based on the use of the 
Grignard reagent was investigated on 2’,3’-O,O-protected adenosine 156. The 2’ and 3’-hydroxyl 
groups of adenosine were protected by treatment of the nucleoside 154 with acetone and a 
commercially available 70% aqueous solution of perchloric acid (scheme 55), as described in a 
reported procedure.[70] Full conversion into the desired isopropylidene derivative 156 was 
observed when the mixture was reacted for 30 minutes at room temperature according to thin 
layer chromatography. Purification by column chromatography allowed for the isolation of 156 in 
high yield (95%). 
 
 
Scheme 55. 2’,3’-O,O-isopropylidene protection of adenosine 154. Reagents and conditions: i) 70% 
aq. HClO4, acetone, rt, 30 min (156, 95% yield). 
 
When 2’,3’-O,O-isopropylidene adenosine 156 in a mixture of THF and NMP in the presence of 
tBuMgCl and of the phosphorochloridate 35 was heated at 65 °C by MWI for a short time of 15 
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minutes, the desired product was isolated in 28% yield after purification by column 
chromatography as compared with 55% yield from the corresponding reaction carried out by 
conventional heating over a time of 2 hours at 55 °C (scheme 56). These results suggested that the 
method based on the use of the Grignard reagent was compatible with the application of 
microwave-assistance even when the sensitive phosphorochloridate 35 was employed. 
The reactivity of the two alternative phosphoramidating reagents was then evaluated under MWI 
conditions and compared to the corresponding reactions performed by conventional heating 
(scheme 56). Both reactions irradiated and conventionally heated carried out in the presence of 
the phenolate derivatives 152 and 153 were inefficient. However, the use of the p-nitrophenolate 
derivatives 37 and 38 allowed for the complete and clean conversion of the parent nucleoside 156 
into the 2’,3’-O,O-protected adenosine phosphoramidate ProTides 157 and 158, respectively. The 
yields obtained for 157 and 158 from the reactions by MWI and by conventional heating were 
found to be comparable. Furthermore, a time of only 2 minutes was found to be sufficient for the 
full consumption of the starting material 156, as compared with 30 minutes by conventional 
heating. 
To evaluate the influence of NMP, the coupling reactions were performed under the same 
conditions in the absence of the second solvent (scheme 56). The reactions, both irradiated as well 
as conventionally heated, did not reach completion, resulting in lower yields as well as in 
purification issues. Therefore, NMP was demonstrated to substantially affect the reaction 
outcome. 
  
2. RESULTS AND DISCUSSION  
169 
 
 
Scheme 56. Synthesis of the phosphoramidate ProTides 157 and 158 using tBuMgCl. Reagents and 
conditions: i) tBuMgCl (2 equivalents), solvent(s) as described in table 13. 
 
Table 13. Microwave-assisted synthesis of the phosphoramidate ProTides 157 and 158 using 
tBuMgCl compared to reactions by conventional heating. 
 Conventional heating to 55 °C Heating by MWI to 65 °C 
Phosphoramidating 
reagent (equivalents) 
Solvent(s) Time Product(s) Time Product(s) 
35 (2) THF/NMP 2h 157 (55%) 15 min 157 (28%) 
36 (2) THF/NMP  15 min 158 (52%) 2 min 158 (36%) 
37 (2) THF/NMP  30 min 157 (46%) 2 min 157 (41%) 
38 (2) THF/NMP  30 min 158 (77%) 2 min 158 (67%) 
152 (2) THF/NMP  8h 
(incomplete) 
mixture of 
species 
1h 
(incomplete) 
mixture of 
species 
153 (2) THF/NMP  8h 
(incomplete) 
158 (15%) 1h 
(incomplete) 
158 (28%) 
37 (2) THF 8h 
(incomplete) 
mixture of 
species 
1h 
(incomplete) 
mixture of 
species  
 
Finally, the obtained 2’,3’-O,O-isopropylidene phosphoramidate ProTide 157 was submitted to the 
final step of deprotection under acidic conditions. Treatment of 157 with a 60% aqueous solution 
of acetic acid at 95 °C over 16 hours afforded the deprotected phosphoramidate ProTide 155 in a 
moderate yield of 40% (scheme 57).[71] The process of protection of the parent nucleoside 154, 
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coupling with the phosphoramidate reagent 37 followed by the cleavage of the isopropylidene 
protected group was characterised by a low yield of 15%, thus the multi-step synthesis of 155 was 
inconvenient. 
 
 
Scheme 57. Deprotection of 2’,3’-O,O-isopropylidene phosphoramidate ProTide 157. Reagents 
and conditions: i) 60% aq. AcOH, 95 °C, 16h (155, 40% yield). 
 
With the aim of reducing the number of steps and increasing the overall yield, the application of 
the microwave-assisted method using tBuMgCl and the p-nitrophenolate reagent 37, selected 
from the previously described study, was investigated on the unprotected nucleoside 154 (scheme 
58). When 154 was treated with 2 equivalents of tBuMgCl and 37 in a mixture of THF and NMP 
and irradiated by microwave at 65 °C, the reaction proceeded smoothly and reached completion 
within 5 minutes. The 5’-O-phosphoramidate 155 was furnished in approximately 40% yield after 
purification by column chromatography. The increase of the amount of tBuMgCl to 3 equivalents 
resulted in a fast and clean reaction, characterised by a similar yield for the desired product 155. 
However, when an even larger excess of tBuMgCl (4 equivalents) was employed a mixture of 
species was obtained according to thin layer chromatography and 31P NMR spectroscopy, 
suggesting that the selectivity towards the 5’-hydroxyl group was lost. 
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Scheme 58. Synthesis of the phosphoramidate ProTide 155 using tBuMgCl and the 
p-nitrophenolate 37. Reagents and conditions: i) tBuMgCl, solvent(s) as described in table 14. 
 
Table 14. Microwave-assisted synthesis of the phosphoramidate ProTide 155 using tBuMgCl and 
the p-nitrophenolate 37 (2 equivalents) compared to reactions by conventional heating. 
 Conventional heating to 55 °C Heating by MWI to 65 °C 
Reagent 
(equivalents) 
Solvent(s) Time Product(s) Time Product(s) 
tBuMgCl (2) THF/NMP 1h 155 (49%) 5 min 155 (38%) 
tBuMgCl (3) THF/NMP 1h 155 (42%) 2 min 155 (40%) 
tBuMgCl (4) THF/NMP  1h mixture of species 2 min mixture of species 
tBuMgCl (2) THF 20h 
(incomplete) 
155 (47%) 1h 
(incomplete) 
155 (14%) 
 
Microwave-assistance induced a reduction of the reaction time from 1 hour with conventional 
heating to as low as 2 minutes. Of note, the yields obtained under MWI conditions were 
comparable with the corresponding conventionally heated reactions (table 14). Furthermore, 
comparable yields were afforded with the reactions performed on the 2’,3’-O,O-protected 
adenosine 156 (table 13). Therefore, the one-step methodology on the unprotected nucleoside 
154 was found to be highly efficient under MWI conditions as well as superior to the protection-
coupling-deprotection method. 
In conclusion, in the course of this PhD, an improved methodology for the preparation of 
phosphoramidate ProTides was developed under MWI conditions. The application of the method 
to the model nucleoside adenosine was demonstrated using the Grignard reagent tBuMgCl. 
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Noteworthy points of the innovative method include the use of stable phosphoramidating 
reagents, the reduction in reaction time and the ease of chromatographical purification thanks to 
the full consumption of the parent nucleoside. 
Following the described study, the microwave-assisted synthesis of phosphoramidate ProTides 
was further optimised by Dr Cinzia Bordoni at the School of Pharmacy and Pharmaceutical 
Sciences, Cardiff University, and Dr Elisa Azzali at the School of Pharmacy, University of Parma. 
Further studies were carried out by our collaborators to validate the applicability of the 
methodology to the other natural nucleosides cytidine, uridine, thymidine and guanosine (figure 
72). 
 
 
Figure 72. General structures of natural nucleoside ProTides and possible bis-O,O-
phosphoramidates side-products. 
 
The microwave-assisted coupling reactions were compared to the corresponding conventionally 
heated reactions on the basis of the percentage of formation of the phosphoramidate products, 
which was measured by analytical HPLC of the reaction mixture. The main results of these studies 
are summarised in the following tables (tables 15, 16, 17 and 18). 
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Scheme 59. Synthesis of cytidine phosphoramidate ProTide 160. Reagents and conditions: i) as 
described in table 15. 
 
Table 15. Microwave-assisted synthesis of cytidine phosphoramidate ProTide 160 compared to 
reactions by conventional heating. 
 Conventional heating to 55 °C Heating by MWI to 65 °C 
Reagents 
(equivalents) 
Solvent(s) Time 
HPLC analysis 
Time 
HPLC analysis 
159 160 bis 159 160 bis 
tBuMgCl (3) 
37 (2) 
DMF 4h - 45% 3% 30 min 19% 81% - 
NMI (6.3) 
35 (3) 
THF/pyridine 24h 89% 11% - 30 min 89% 8% - 
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Scheme 60. Synthesis of uridine phosphoramidate ProTide 162. Reagents and conditions: i) as 
described in table 16. 
 
Table 16. Microwave-assisted synthesis of uridine phosphoramidate ProTide 162 compared to 
reactions by conventional heating. 
 Conventional heating to 55 °C Heating by MWI to 65 °C 
Reagents 
(equivalents) 
Solvent(s) Time 
HPLC analysis 
Time 
HPLC analysis 
161 162 bis 161 162 bis 
tBuMgCl (3) 
37 (2) 
THF/NMP 5.5h 62% 38% - 30 min 66 29% 5% 
NMI (6.3) 
35 (3) 
THF 4.5h 13% 28% 59% 35 min 42% 50% 8% 
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Scheme 61. Synthesis of thymidine phosphoramidate ProTide 164. Reagents and conditions: i) as 
described in table 17. 
 
Table 17. Microwave-assisted synthesis of thymidine phosphoramidate ProTide 164 compared to 
reactions by conventional heating. 
 Conventional heating to 55 °C Heating by MWI to 65 °C 
Reagents 
(equivalents) 
Solvent(s) Time 
HPLC analysis 
Time 
HPLC analysis 
163 164 bis 163 164 bis 
tBuMgCl (2) 
37 (2) 
DMF 40 min 5% 29% 66% 20 min 30% 45% 25% 
NMI (6.3) 
35 (3) 
THF 4h 13% 72% 14% 5 min 1% 70% 29% 
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Scheme 62. Synthesis of guanosine phosphoramidate ProTide 166. Reagents and conditions: i) as 
described in table 18. 
 
Table 18. Microwave-assisted synthesis of guanosine phosphoramidate ProTide 166 compared to 
reactions by conventional heating. 
 Conventional heating to 55 °C Heating by MWI to 65 °C 
Reagents 
(equivalents) 
Solvent(s) Time 
HPLC analysis 
Time 
HPLC analysis 
165 166 bis 165 166 bis 
tBuMgCl (4) 
37 (4) 
DMF 4h - 12% 3% 30 min 18% 79% 3% 
NMI (6.3) 
35 (3) 
THF/pyridine 24h 51% 49% - 35 min 87% 13% - 
 
Microwave-assistance was successfully applied to the synthesis of phosphoramidate ProTides. 
Different reagents, solvents and reaction conditions were explored for the natural nucleosides, 
which were employed as models. 
In the course of this PhD, this innovative methodology found great utility in the preparation of 
phosphoramidate ProTides of structurally modified nucleoside analogues as described in 
paragraphs 2.2.3.2 and 2.2.4.2. 
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2.3 BIOLOGICAL EVALUATION 
The anti-DENV activity and cytotoxicity of the synthesised nucleosides and phosphoramidate 
ProTides were tested in vitro by Dr Joachim J. Bugert, Institute for Microbiology, Armed Forces 
Medical Academy in Munich. 
The virus-induced cytopathic effect (CPE) inhibition assay[72] was performed to evaluate the 
antiviral activity (EC50) in DENV-infected cells (human hepatoma cells, Huh7). The reduction of the 
viability of non-infected cells was measured to evaluate the cytotoxicity (CC50) of compounds. The 
nucleoside 2’,5’-di-O-trityluridine 167 (figure 73) was reported to be selectively active against 
flaviviruses[72] and was adopted as reference compound in the cell-based assays. The available 
biological data for the synthesised compounds are summarised in table 19. 
 
 
Figure 73. Structure of the reference compound 2’,5’-di-O-trityluridine 167. 
 
Table 19. The anti-DENV activity (EC50) and cytotoxicity (CC50) of synthesised compounds in CPE-
reduction assays. 
Compounds EC50
a CC50
a 
40 > 10 μM 5 μM 
56 8.96/10.40 μM > 20 μM 
57 4.50/4.58 μM > 20 μM 
87 > 10 μM 10 μM 
27 9.1 μM 10 μM 
128 > 10 μM 10 μM 
129 > 10 μM 10 μM 
132 > 10 μM 10 μM 
reference compoundb 9.50 μM > 10 μM 
aHuman hepatoma cells (Huh7) were used. b2’,3’-di-O-trityluridine.[72] 
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Figure 74. Structure of 2’-C-methyladenosine ProTide 57. 
 
The nucleoside 2’-C-methyladenosine 56 was poorly active against DENV, showing an EC50 of 
8.96/10.40 μM. However, the corresponding phenyl L-alanine benzyl ester phosphoramidate 57 
(figure 74) was characterised by a two-fold increase of the anti-DENV activity (EC50 4.50/4.58 μM), 
compared to the parent nucleoside 56 and to 2’,3’-di-O-trityluridine. Therefore, the application of 
the phosphoramidate ProTide approach to 56 was successful in increasing the activity of the 
parent nucleoside 56, suggesting that the activity of that compound was limited by 
pharmacokinetics factors, such as poor cellular permeation, intracellular conversion to inactive 
metabolites and poor activation by host kinases. 
The 2’-C-methyl-7-deazaadenosine 40 and the benzo-fused 7-deazaadenosine analogue 87 were 
found to be inactive against DENV and were found to elicit a certain degree of cytotoxicity (CC50 5 
μM and 10 μM, respectively). As observed for 56, the application of the phosphoramidate ProTide 
strategy may improve the pharmacokinetic properties of the parent nucleosides 40 and 87. 
However, the biological data for the corresponding phenyl L-alanine isopropyl ester 
phosphoramidates 58 and 101, respectively, are still missing. 
When comparing the biological profile of the 7-deaza analogue 40 to the N-7 analogue 56, it is 
interesting to note that the 7-deaza modification of the nucleobase resulted in a loss of potency 
and a significant increase of cytotoxicity (CC50 5 μM). 
Within the series of acyclic nucleoside analogues, the adenosine derivative 27 showed an anti-
DENV activity that was comparable to the nucleoside 2’-C-methyladenosine 56 and to the 
reference compound, with an EC50 of 9.1 μM. However, this poor antiviral activity of 27 was also 
accompanied by cytotoxicity (CC50 10 μM). The 7-deaza, the methyl 7-carboxylate and the benzo-
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fused 7-deaza analogues 128, 129 and 132 failed to inhibit DENV and were also found to be 
cytotoxic (CC50 10 μM). 
The biological data for the trans mono-O-phosphoramidates 137, 138 and 139 as well as the O-O-
cyclic phosphoramidates 133 and 134 are not available yet, therefore the capability of the 
phosphoramidate ProTide approach to boost the in vitro anti-DENV activity of the acyclic 
adenosine analogues 27 and 128 remains to be explored. 
Currently, the prepared nucleosides and nucleotide phosphoramidates are also being evaluated 
for their inhibiting effect on ZIKV, a member of the genus flavivirus that is the cause of an 
increasing number of infections worldwide.[73, 74] Besides the great concern for the recent re-
emergence of ZIKV, the availability of the virus as well as the ease of the cell-based assays 
prompted the biological evaluation of the compounds against ZIKV. Furthermore, the active site of 
RdRp is highly conserved among flaviviruses, therefore nucleoside and nucleotide analogues 
designed as anti-DENV agents may show an antiviral activity against related viruses such as ZIKV. 
The anti-ZIKV activity of the 2’-C-methyladenosine ProTide 57 was determined in ZIKV-infected 
cells (human lung carcinoma cells, A549) using xCELLigence system (figure 75). This system 
monitors the cells by measuring their electrical impedance. The loss of tight junctions between 
cells, which is induced by the viral infection (virus-induced CPE), can then be measured as a 
reduction of electric resistance of the cells (A in figure 75). The L-dideoxy furanopyrimidine bicyclic 
nucleoside analogue (L-ddBCNA) cf2642 168 (figure 76), which was originally developed as an 
autophagy inhibitor effective against vaccinia and measles viruses,[75] was employed as reference 
compound. In the presence of an antiviral agent such as cf2642, the reduction of the virus-induced 
CPE decreases the loss of tight junctions between cells and therefore an increase of the electric 
resistance (violet line, B in figure 75) is observed. Natural killer cells (pink line, figure 75) were 
used as a positive control. Similarly, the 2’-C-methyladenosine ProTide 57 was found to inhibit 
ZIKV (blue line, B in figure 75). Finally, a synergistic effect was observed when 57 was combined 
with cf2642 (light green line, B in figure 75). 
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Figure 75. Inhibition of ZIKV by the 2’-C-methyladenosine ProTide 57 and synergistic effect of 57 
with the reference compound cf2642 168. Solid line: time of addition of ZIKV and 
compounds/natural killer cells; dotted line: time selected for comparison of treatments; 
A: reduction of electric resistance due to virus-induced cytopathic effect; B: effect of treatments. 
Figure and data by Dr Joachim J. Bugert. 
 
 
Figure 76. Structure of the autophagy inhibitor cf2642 168, which was employed as reference 
compound. 
 
The EC50 of the 2’-C-methyladenosine ProTide 57 and of the combination of 57 with the L-ddBCNA 
cf2642 168 were determined to be 4 ± 0.2 μM and 1 ± 0.2 μM, respectively, whereas the 
cytotoxicity was found to be very low with CC50 values > 20 μM for the single-drug treatments. The 
promising results obtained for the combination of the RdRp inhibitor 2’-C-methyladenosine 
Pink: natural killer cells 
Dark green: ZIKV 
Blue: ZIKV + 57 
Violet: ZIKV + reference compound 168 
Light green: ZIKV + 57 + reference compound 168 
 
Human lung carcinoma cells (A549) and xCELLigence system were used. 
A 
B 
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ProTide 57 with the autophagy inhibitor cf2642 168 warrant further investigation towards an 
effective treatment of ZIKV infection. 
Finally, the biological data obtained for the 2’-C-methyladenosine ProTide 57 highlight the great 
utility of the nucleotide phosphoramidate ProTide strategy against DENV as well as closely related 
viruses. 
  
2. RESULTS AND DISCUSSION  
182 
 
2.4 REFERENCES 
[1] T. L. Yap, T. Xu, Y.-L. Chen, H. Malet, M.-P. Egloff, B. Canard, S. G. Vasudevan, J. Lescar. Crystal 
structure of the dengue virus RNA-dependent RNA polymerase catalytic domain at 1.85-angstrom 
resolution. J. Virol., 81(9): 4753-4765, 2007. 
[2] C. G. Noble, S. P. Lim, y.-L- Chen, C. W. Liew, L. Yap, J. Lescar, P.-Y. Shi. Conformational 
flexibility of the dengue virus RNA-dependent RNA polymerase revealed by a complex with an 
inhibitor. J. Virol., 87(9): 5291-5295, 2013. 
[3] S. P. Lim, J. H. Koh, C. C. Seh, C. W. Liew, A. D. Davidson, L. S. Chua, R. Chandrasekaran, T. C. 
Cornvik, P.-Y. Shi, J. Lescar. A crystal structure of the dengue virus NS5 polymerase delineates 
inter-domain amino acids that enhance its thermostability and de novo initiation activities. J. Biol. 
Chem., 288: 31105-31114, 2013. 
[4] Y. Zhao, T. S. Soh, J. Zheng, K. W. K. Chan, W. W. Phoo, C. C. Lee, M. Y. F. Tay, K. Swaminathan, 
T. C. Cornvik, S. P. Lim, P.-Y. Shi, J. Lescar, S. G. vasudevan, D. Luo. A crystal structure of the 
dengue virus NS5 protein reveals a novel inter-domain interface essential for protein flexibility and 
virus replication. PLoS Pathog., 11(3): e1004682, 2015. 
[5] K. H. Choi, M. G. Rossmann. RNA-dependent RNA polymerases from Flaviviridae. Curr. Opin. 
Struct. Biol., 19 : 746-751, 2009. 
[6] B. Selisko, S. Potisopon, R. Agred, S. Priet, I. Varlet, Y. Thillier, C. Sallamand, F. Debart, J.-j. 
Vasseur, B. Canard. Molecular basis for nucleotide conservation at the ends of the Dengue virus 
genome. PLoS Phatog., 8(9): e1002912, 2012. 
[7] G. Migliaccio, J. E. Tommassini, S. S. Carroll, L. Tomei, S. Altamura, B. Bhat, L. Bartholomew, M. 
R. Bosserman, A. Ceccacci, L. F. Colwell, R. Cortese, R. De Francesco, A. B. Eldrup, K. L. Getty, X. S. 
Hou, R. L. LaFemina, S. W. Ludmerer, M. MacCoss, D. R. McMasters, M. W. Stahlhut, D. B. Olsen, D. 
J. Hazuda, O. A. Flores. Characterization of resistance to non-obligate chain-terminating 
ribonucleoside analogs that inhibit Hepatitis C Virus replication in vitro. J. Biol. Chem., 278: 49164-
49170, 2003. 
[8] R. T. Mosley, T. E. Edwards, E. Murakami, A. M. Lam, R. L. Grice, J. Du, M. J. Sofia, P. A. Furman, 
M. J. Otto. Structure of Hepatitis C virus polymerase in complex with primer-template RNA. J. 
Virol., 86: 6503-6511, 2012. 
[9] D. B. Olsen, A. B. Eldrup, L. Bartholomew, B. Bhat, M. R. Bosserman, A. Ceccacci, L. F. Colwell, J. 
F. Fay, O. A. Flores, K. L. Getty, J. A. Grobler, R. L. LaFemina, E. J. Markel, G. Migliaccio, M. Prhavc, 
2. RESULTS AND DISCUSSION  
183 
 
M. W. Stahlhut, J. E. Tomassini, M. MacCoss, D. J. Hazuda, S. S. Carroll. A 7-deaza-adenosine 
analog is a potent and selective inhibitor of hepatitis C virus replication with excellent 
pharmacokinetic properties. Antimicr. Agents Chemother., 48(10): 3944-3953, 2004. 
[10] Z. Yin, Y.-L. Chen, W. Schul, Q.-Y. wang, F. Gu, J. Duraiswamy, R.R. Kondreddi, P. 
Niyomrattanakit, S. B. Lakshminarayana, A. Goh, H. Y. Xu, W. Liu, B. Liu, J. Y. H. Lim, C. Y. Ng, M. 
Qing, C. C. Lim, A. Yip, G. Wang, W. L. Chan, H. P. Tan, K. Lin, B. Zhang, G. Zou, K. A. Bernard, C. 
Garrett, K. Beltz, M. Dong, M. Weaver, H. He, A. Pichota, V. Dartois, T. H. Keller, P.-Y. Shi. An 
adenosine nucleoside inhibitor of dengue virus. Proc. Natl. Acad. Sci., 106(48): 20435-20439, 2009. 
[11] Y.-L. Chen, Z. Yin, J. Duraiswamy, W. Schul, C. C. Lim, H. Y. Xu, M. Qing, A. Yip, G. Wang, W. L. 
Chan, H. P. Tan, M. Lo, S. Liung, R. R. Kondreddi, R. Rao, H. Gu, H. He, T. H. Keller, P.-Y. Shi. 
Inhibition of dengue virus RNA synthesis by an adenosine nucleoside. Antimicrob. Agents 
Chemother., 54(7): 2932-2939, 2010. 
[12] Y.-L. Chen, Z. Yin, S. B. Lakshminarayana, M. Qing, W. Schul, J. Duraiswamy, R. R. Kondreddi, A. 
Goh, H. Y. Xu, A. Yip, B. Liu, M. Weaver, V. Dartois, T. H. Keller, P.-Y. Shi. Inhibition of dengue virus 
by an ester prodrug of an adenosine analog. Antimicrob. Agents Chemother., 54(8): 3255-3261, 
2010. 
[13] L. Bassit, P. Chatterjee, B. Kim, S. J. Coats, R. F. Schinazi. 2,6-Diaminopurine nucleosides are a 
novel class of anti-DENV inhibitors. First International Symposium of Human Vector-Borne Diseases 
HVBD DART. December 12-13, 2013. 
[14] M. Tichý, R. Pohl, E. Tloust’ová, J. Weber, G. Bahador, Y.-J. Lee, M. Hocek. Synthesis and 
biological activity of benzo-fused 7-deazaadenosine analogues. 5- and 6-substituted 4-amino- or 4-
alkylpyrimido[4,5-b]indole ribonucleosides. Bioorg. Med. Chem., 21: 5362-5372, 2013. 
[15] M. Tichý, R. Pohl, H. Y. Xu, Y.-L. Chen, F. Yokokawa, P.-Y. Shi, M. Hocek. Synthesis and antiviral 
activity of 4,6-disubstituted pyrimido[4,5-b]indole ribonucleosides. Bioorg. Med. Chem., 20: 6123-
6133, 2012.  
[16] A. C. Anderson. The process of structure-based drug design. Chem. Biol., 10: 787-797, 2003. 
[17] D. B. Kitchen, H. Decornez, J. R. Furr, J. Bajorath. Docking and scoring for drug discovery: 
methods and applications. Nat. Rev. Drug Discov., 3: 935-949, 2004. 
[18] A. R. Leach. Molecular dynamics simulation methods. Molecular modelling – Principles and 
applications. Pearson Education Limited, Harlow, 2nd edition: 353-409, 2001. 
[19] J. H. Hong, H. O. Kim, H. R. Moon, L. S. Jeong. Synthesis and antiviral activity of fluoro-
substituted apio dideoxynucleosides. Arch. Pharm. Res., 24(2): 95-99, 2001. 
2. RESULTS AND DISCUSSION  
184 
 
[20] G. Lu, P. Gong. Crystal structure of the full-length Japanese encephalitis virus NS5 reveals a 
conserved methyltransferase-polymerase interface. PLoS Phatog., 9(8): e1003549, 2013. 
[21] D. Tarantino, R. Cannalire, E. Mastrangelo, R. Croci, G. Querat, M. L. Barreca, M. Bolognesi, G. 
Manfroni, V. Cecchetti, M. Milani. Targeting flavivirus RNA dependent RNA polymerase through a 
pyridobenzothiazole inhibitor. Antiviral Res., 134: 226-235, 2016. 
[22] F. Yokokawa, S. Nilar, C. G. Noble, S. P. Lim, R. Rao, S. Tania, G. Wang, G. Lee, J. Hunziker, R. 
Karuna, U. Manjunatha, P.-Y. Shi, P. W. Smith. Discovery of potent non-nucleoside inhibitors of 
dengue viral RNA-dependent RNA polymerase from a fragment hit using structure-based drug 
design. J Med Chem., 59(8): 3935-3952, 2016. 
[23] S. P. Lim, C. G. Noble, C. C. Seh, T. S. Soh, A. E. Sahili, G. K. Y. Chan, J. Lescar, R. Arora, T. 
Benson, S. Nilar, U. Manjunatha, K. F. Wan, H. Dong, X. Xie, P.-Y. Shi, F. Yokokawa. Potent allosteric 
dengue virus NS5 polymerase inhibitors: mechanism of action and resistance profiling. PLoS 
Pathog., 12(8): e1005737, 2016. 
[24] C. G. Noble, Y.-L. Chen, H. Dong, F. Gu, S. P. Lim, W. Schul, Q.-Y. Wang, P.-Y. Shi. Strategies for 
development of dengue virus inhibitors. Antiviral Res., 85: 450-462, 2010. 
[25] S. P. Lim, Q.-Y. Wang, C. G. Noble, Y.-L. Chen, H. Dong, B. Zou, F. Yokokawa, S. Nilar, P. Smith, 
D. Beer, J. Lescar, P.-Y. Shi. Ten years of dengue drug discovery: progress and prospects. Antiviral 
Res., 100: 500-519, 2013. 
[26] U. Pradere, E. C. Garnier-Amblard, S. J. Coats, F. Amblards, R. F. Schinazi. Synthesis of 
nucleoside phosphate and phosphonate prodrugs. Chem. Rev., 114: 9154-9218, 2014. 
[27] K. L. Yeo,Y.-L. Chen, H. Y. Xu, H. Dong, Q.-Y. Wang, F. Yokokawa, P.-Y. Shi. Synergistic 
suppression of dengue virus replication using a combination of nucleoside analogs and nucleoside 
synthesis inhibitors. Antimicrob. Agents. Chemother., 59(4): 2086-2093, 2015. 
[28] J. H. Boom, P. M. Burgers, R. Crea, W. C. M. Luyten, A. B. J. Vink, C. B. Reese. Phosphorylation 
of nucleoside derivatives with aryl phosphoramidochloridate. Tetrahedron, 31: 2953-2959, 1975. 
[29] M. Uchiyama, Y. Aso, R. Noyori, Y. Hayakawa. O-selective phosphorylation of nucleosides 
without N-protection. J. Org. Chem., 58: 373-379, 1993. 
[30] M. Serpi, K. Madela, F. Pertusati, M. Slusarczyk. Synthesis of phosphoramidate prodrugs: 
ProTide approach. Curr. Protoc. Nucleic Acid Chem., supplement 53, 15.5.1-15.5.15, June 2013. 
[31] B. S. Ross, P. Ganapadi Reddy, H.-R. Zhang, S. Rachakonda, M. J. Sofia. Synthesis of 
diastereomerically pure nucleotide phosphoramidates. J. Org. Chem., 76: 8311-8319, 2011. 
2. RESULTS AND DISCUSSION  
185 
 
[32] M. Derudas, D. Carta, A. Brancale, C. Vanpouille, A. Lisco, L. Margolis, J. Balzarini, C. 
McGuigan. The application of phosphoramidate ProTide technology to acyclovir confers anti-HIV 
inhibition. J. Med. Chem., 52: 5520-5530, 2009. 
[33] S. S. Carroll, D. B. Olsen. Nucleoside analog inhibitors of hepatitis C virus replication. Infect. 
Disord. Drug Targets, 6(1): 17-29, 2006. 
[34] V. Uteza, G.-R. Chen, J. Le Quan Tuoi. G. Descotes, B. Fenet, A. Grouiller. Synthesis and 
structure determination of the first 1’-C-cyano-β-D-nucleosides. Tetrahedron, 49(38): 8579-8588, 
1993. 
[35] T. Kodama, S. Shuto, M. Nomura, A. Matsuda. An efficient method for the preparation of 1’-α-
branched-chain sugar pyrimidine ribonucleosides from uridine: the first conversion of a natural 
nucleoside into 1’-substituted ribonucleosides. Chem. Eur. J., 7(11): 2332-2340, 2001. 
[36] K. Haraguchi, Y. Itoh, H. Tanaka, K. Yamaguchi, T. Miyasaka. Anomeric manipulation of 
nucleosides: stereospecific entry to 1’-C-branched uracil nucleosides. Tetrahedron Lett., 34(43): 
6913-6916, 1993. 
[37] L. Cappellacci, G. Barboni, M. Palmieri, M. Pasqualini, M. Grifantini, B. Costa, C. Martini, P. 
Franchetti. Ribose-modified nucleosides as ligands for adenosine receptors: synthesis, 
conformational analysis, and biological evaluation of 1’-C-methyl adenosine analogues. J. Med. 
Chem., 45 (6): 1196-1202, 2002. 
[38] G. Sautrey, D. Bourgeois, C. Périgaud. Diastereoselective synthesis of (±)-1’,4’-
dimethyluridine. Org. Biomol. Chem., 8, 378-383, 2010.  
[39] A. Matsuda, H. Itoh, K. Takenuki, T. Sasaki, T. Ueda. Alkyl addition reaction of pyrimidine 2’-
ketonucleosides: synthesis of 2’-branched-chain sugar pyrimidine nucleosides (nucleosides and 
nucleotides. LXXXI). Chem. Pharm. Bull., 36(3): 945-953, 1988. 
[40] J.-L. Girardet, E. Gunic, C. Esler, D. Cieslak, Z. Pietrzkowski, G. Wang. Synthesis and cytotoxicity 
of 4-amino-5-oxopyrido[2,3-d]pyrimidine nucleosides. J. Med. Chem., 43: 3704-3713, 2000. 
[41] R. E. Harry-O'kuru, J. M. Smith, M. S. Wolfe. A short, flexible route toward 2'-C-branched 
ribonucleosides. J. Org. Chem., 62: 1754-1759, 1997. 
[42] A. B. Eldrup, M. Prhavc, J. Brooks, B. Bhat, T. P. Prakash, Q. Sing, S. Bera, N. Bhat, P. Dande, P. 
D. Cook, C. F. Bennett, S. S. Carroll, R. G. Ball, M. Bosserman, C. Burlein, L. F. Colwell, J. F. Fay, O. A. 
Flores, K. Getty, R. L. LaFemina, J. Leone, M. MacCoss, D. R. McMasters, J. E. Tommassini, D. Von 
Langen, B. Wolanski, D. B. Olsen. Structure-activity relationship of heterobase-modified 2’-C-
2. RESULTS AND DISCUSSION  
186 
 
methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication. J. Med. Chem., 47: 5284-
5297, 2004. 
[43] T. Maeda, H. Uehara, N. Harada, M. Katsurada, M. Sano. Process for producing 5-
deoxyribofuranose derivatives by hydrogenation of 5-deoxy-5-haloribofuranose. API Corporation, 
Japan. WO 2009044886 A1, Apr 09, 2009. 
[44] G. Parmentier, G. Schmitt, F. Dolle, B. Luu. A convergent synthesis of 2'-O-methyl uridine. 
Tetrahedron, 50(18): 5361-5368, 1994. 
[45] F. W. D'Souza, J. D. Ayers, P. R. McCarren, T. L. Lowary. Arabinofuranosyl oligosaccharides 
from mycobacteria: synthesis and effect of glycosylation on ring conformation and hydroxymethyl 
group rotamer populations. J. Am. Chem. Soc., 122(7): 1251-1260, 2000. 
[46] S. D. Osborne, V. E. C. Powers, D. A. Rusling, O. Lack, K. R. Fox, T. Brown. Selectivity and 
affinity of triplex-forming oligonucleotides containing 2'-aminoethoxy-5-(3-aminoprop-1-
ynyl)uridine for recognizing At base pairs in duplex DNA. Nucleic Acids Res., 32(15): 4439-4447, 
2004. 
[47] Y. Cen, A. A. Sauve. Transition state of ADP-ribosylation of acetyllysine catalyzed by 
Archaeoglobus fulgidus Sir2 determined by kinetic isotope effects and computational approaches. 
J. Am. Chem. Soc., 132(35): 12286-12298, 2010. 
[48] G. Wang, J. L. Girardet, E. Gunic. Conformationally locked nucleosides. Synthesis and 
stereochemical assignments of 2'-C,4'-C-bridged bicyclonucleosides. Tetrahedron, 55: 7707-7724, 
1999. 
[49] N. S. Li, J. Lu, J. A. Piccirilli. Efficient synthesis of methyl 3,5-di-O-benzyl-alpha-D-
ribofuranoside and application to the synthesis of 2'-C-beta-alkoxymethyluridines. Org. Lett., 
9(16): 3009-3012, 2007. 
[50] C. Simons. Synthesis of conventional D-nucleosides. Nucleoside mimetics – Their chemistry 
and biological properties. Advanced Chemistry Texts, Gordon and Breach Science Publishers, 
volume 3: 29-62, 2001. 
[51] F. Seela, B. Westermann, U. Bindig. Liquid-liquid and solid-liquid phase-transfer glycosylation 
of pyrrolo[2,3-d]pyrimidines: stereospecific synthesis of 2-deoxy-β-D-ribofuranosides related to 2’-
deoxy-7-carbaguanosine. J. Chem. Soc. Perkin Trans., 1: 697-702, 1988. 
[52] S.-Y. Han, M. M. Joullié. Investigations of the formation of cyclic acetal and ketal derivatives of 
D-ribono-1,4-lactone and 2-deoxy-D-ribono-1,4-lactone. Tetrahedron, 49(2): 349-362, 1993. 
2. RESULTS AND DISCUSSION  
187 
 
[53] E. Klein, S. Mons, A. Valleix, C. Mioskowski, L. Lebeau. Synthesis of Enzymatically non-
hydrolyzable analogues of dinucleoside triphosphates Ap3A and Gp3G. J. Org.Chem., 67(1): 146-
153, 2002. 
[54] M. S. Valle, A. Tarrade-Matha, P. Dauban, R. H. Dodd. Regioselective electrophilic substitution 
of 2,3-aziridino-γ-lactones: preliminary studies aimed at the synthesis of α,α-disubstituted α- or β-
amino acids. Tetrahedron, 64: 419-432, 2008. 
[55] F. Stazi, W. Maton, D. Castoldi, P. Westerduin, O. Curcuruto, S. Bacchi. Efficient methods for 
the synthesis of arylacetonitriles. Synthesis, 19: 3332-3338, 2010. 
[56] K. Kobayashi, T. Komatsu, Y. Yokoi, H. Konishi. Synthesis of 2-aminoindole-3-carboxylic acid 
derivatives by the copper(I) iodide catalyzed reaction of N-2-iodophenyl)formamides with 
malononitrile or cyanoacetates. Synthesis, 5: 764-768, 2011. 
[57] R. Storer, A. Moussa, N. Chaudhuri, F. Waligora. Process for the production of 2’-branched 
nucleosides. Idenix Cayman Limited. WO 2004052899 A2. Jun 24, 2004. 
[58] E. De Clercq. Antiviral drugs in current clinical use. J. Clin. Virol., 30: 115-133, 2004. 
[59] L. P. Jordheim, D. Durantel, F. Zoulim, C. Dumontet. Advances in the development of 
nucleoside and nucleotide analogues for cancer and viral diseases. Nat. Rev. Drug Disc., 12: 447-
464, 2013. 
[60] D. R. Haines, C. K. H. Tseng, V. E. Marquez. Synthesis and biological activity of unsaturated 
carboacyclic purine nucleoside analogues. J. Med. Chem., 30(5): 943-947, 1987. 
[61] T. H. M. Jonckers, A. Tahri, L. Vijgen, J. M. Berke, S. Lachau-Durand, B. Stoops, J. Snoeys, L. 
Leclercq, L. Tambuyzer, T. Lin, K. Simmen, P. Raboisson. Discovery of 1-((2R,4aR,6R,7R,7aR)-2-
isopropoxy-2-oxidodihydro-4H,6H-spiro[furo[3,2-d][1,3,2]dioxaphosphinine-7,2’-oxetan]-6-
yl)pyrimidine-2,4(1H,3H)-dione (JNJ-54257099), a 3’-5’-cyclic phosphate ester prodrug pf 2’-deoxy-
2’-spirooxetane uridine triphosphate useful for HCV inhibition. J. Med. Chem., 59(12): 5790-5798, 
2016. 
[62] E. Gunic, J.-L. Girardet, K. Ramasamy, V. Stoisavljevic-Petkov, S. Chow, L.-T. Yeh, R. K. 
Hamatake, A. Raney, Z. Hong. Cyclic monophosphate prodrugs of base-modified 2’-C-methyl 
ribonucleosides as potent inhibitors of hepatitis C virus RNA replication. Bioorg. Med. Chem. Lett., 
17: 2452-2455, 2007. 
[63] P. Reddy, B. Chun, H. Zhang, S. Rachakonda, B. S. Ross, M. J. Sofia. Stereoselective synthesis of 
PSI-352938: a β-D-2’-deoxy-2’-α-fluoro-2-β-C-methyl-3’-5’-cyclic phosphate nucleotide prodrug for 
the treatment of HCV. J. Org. Chem., 76: 3782-3790, 2011. 
2. RESULTS AND DISCUSSION  
188 
 
[64] D. F. Netz, J. L. Seidel. Diethyl (N-methoxy-N-methylcarbamoylmethyl)phosphonate – a useful 
Emmons-Horner Wittig reagent. Tetrahedron Lett., 33(15): 1957-1958, 1992. 
[65] M. Mentzel, H. M. R. Hoffmann. N-methoxy-N-methylamides (Weinreb amides) in modern 
organic synthesis. J. prakt. Chem., 339: 517-524, 1997. 
[66] M. Bessières, O. Sari, V. Roy, D. Warszycki, A. J. Bojarski, S. P. Nolan, R. Snoeck, G. Andrei, R. F. 
Schinazi, L. A. Agrofoglio. Sonication-assisted synthesis of (E)-2-methyl-but-2-enyl nucleoside 
phosphonate prodrugs. ChemistrySelect, 1: 3108, 2016. 
[67] M. J. Sofia, D. Bao, W. Chang, J. Du, D. Nagarathnam, S. rachakonda, P. G. Reddy, B. S. Ross, P. 
Wang, H.-R. Zhang, S. Bansal, C. Espiritu, M. Keilman, A. M. Lam, H. M. M. Steuer, C. Niu, M. J. 
Otto, P. A. Furman. Discovery of a β-D-2’-deoxy-2’-α-fluoro-2’-β-C-methyluridine nucleotide 
prodrug (PSI-7977) for the treatment of hepatitis C virus. J. Med. Chem., 53: 7202-7218, 2010. 
[68] A. S. Ray, M. W. Fordyce, J. M. Hitchcock. Tenofovir alafenamide: a novel prodrug of tenofovir 
for the treatment of Human Immunodeficiency virus. Antiviral Res., 125, 63-70, 2016. 
[69] V. Roy, U. Pradère, L. A. Agrofoglio. Microwave-assisted synthesis of nucleosides and their 
precursors. Future Med. Chem., 2, 177-192, 2010. 
[70] J.-H. Cho, S. J. Coats, R. F. Schinazi. Efficient synthesis of exo-N-carbamoyl nucleosides: 
application to the synthesis of phosphoramidate prodrugs. Org. Lett., 14(10): 2488-2491, 2012. 
[71] C. McGuigan, P. Perrone, K. Madela, J. Neyts. The phosphoramidate ProTide approach greatly 
enhances the activity of β-2’-C-methylguanosine against hepatitis C virus. Bioorg. Med. Chem. 
Lett., 19: 4316-4320, 2009. 
[72] T. De Burghgraeve, B. Selisko, S. Kaptein, G. Chatelain, P. Leyssen, Y. Debing, M. Jacobs, A. Van 
Aerschot, B. Canard, J. Neyts. 3’,5’-di-O-trityluridine inhibits in vitro flavivirus replication. Antiviral 
Res., 98: 242-247, 2013. 
[73] World Health Organisation. Zika virus. Fact sheet, updated September 2016. 
http://www.who.int/mediacentre/factsheets/zika/en, accessed January 2017. 
[74] World Health Organisation. WHO statement on the first meeting of the International Health 
Regulations (2005) (IHR 2005) Emergency Committee on Zika virus and observed increase in 
neurological disorders and neonatal malformations. WHO statement, 1st February 2016. 
http://www.who.int/mediacentre/news/statements/2016/1st-emergency-committee-zika/en/, 
accessed January 2017. 
2. RESULTS AND DISCUSSION  
189 
 
[75] C. McGuigan, K. Hinsinger, L. Farleigh, R. N. Pathirana. Novel antiviral activity of L-dideoxy 
bicyclic nucleoside analogues versus vaccinia and measles viruses in vitro. J. Med. Chem., 56: 1311-
1322, 2013. 
 
  
 
 
 
 
 
 
 
 
 
3 CONCLUSIONS 
 
  
3. CONCLUSIONS 
191 
 
The development of effective antiviral therapeutics for the treatment of DENV infection has been 
a major field of research in the last decades. The RdRp represents one of the most attractive 
targets for the identification of potent and selective anti-DENV agents. Therefore, the overarching 
aim of this PhD project was the in silico design and synthesis of RdRp targeted nucleoside and 
nucleotide analogues as potential inhibitors of viral replication. 
With the aim of providing an essential tool for the application of computer-aided drug design 
approaches, a model of the DENV RdRp de novo initiation complex was generated using molecular 
modelling techniques and validated through docking studies on known DENV RdRp inhibiting 
nucleoside analogues. 
Docking studies on families of nucleoside analogues were performed using the novel model and 
were used to select the most promising structural modifications of the natural nucleoside 
adenosine. In particular, DENV RdRp accepted modifications at the 7-deaza position of the 
nucleobase, from the substitution with a variety of functional groups to the addition of a benzene 
ring to form a tricyclic heterocycle. In addition, the introduction of carbon groups at the 2’ and 1’-
positions of the ribose ring was examined. The combination of modified nucleobases and C-
substituted ribose moieties was generally well tolerated by the active site of the DENV RdRp. LBDD 
approaches, such as scaffold replacement and pharmacophore search, were combined with the 
docking process to design acyclic nucleoside analogues in which the ribose moiety was replaced by 
allylic linkers. Taken together, molecular modelling studies led to the creation of a novel model of 
the DENV RdRp and the identification of three families of nucleoside analogues as potential RdRp 
inhibitors. 
To investigate the mechanistic aspects of the DENV RdRp activity, different complexes of the DENV 
RdRp and the nucleic acid, which are representative of the pre-initiation, initiation and elongation 
phases of the RNA synthesis, were modelled and submitted to MD simulations. This study allowed 
for the identification of the main loops of the enzyme that are involved in its conformational 
changes during the synthesis of the viral genome. Specifically, residues that may interact with the 
priming NTP in the de novo initiation phase were identified. The results highlighted the role of 
specific key loops, including the priming loop, in the DENV RdRp activity and provided valuable 
knowledge for future drug design studies. 
With regards to the preparation of nucleosides, the synthetic strategies towards the three families 
of adenosine analogues that were selected by the molecular modelling studies were investigated. 
These families were the ribose-modified, the benzo-fused and finally the acyclic derivatives. The 
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conditions for the preparation of nucleotide phosphoramidate ProTides of specific members of 
these families were studied as well. 
 The first, ribose-modified, family included 2’-C-substituted and 1’-C-substituted nucleoside 
analogues. A convergent method consisting of five steps was developed for the 
preparation of 2’-C-substituted 7-deazaadenosine analogues. The strategy was successfully 
applied to the synthesis of 2’-C-methyl-7-deazaadenosine. The combination of 7-modified 
7-deaza 6-chloropurines with different 2’-C-substituted glycosylating agents could furnish 
various adenosine derivatives as potential anti-DENV agents. The ProTide approach was 
applied to commercially available 2’-C-methyladenosine and the synthesised 7-deaza 
analogue. Standard conditions were employed for the preparation of the former. In 
contrast, a newly developed method, which was based on the use of an alternative solvent 
and a p-nitrophenolate reagent, was applied to 2’-C-methyl-7-deazaadenosine and allowed 
for a significant increase in yield compared to standard conditions. 
The synthetic route towards 1’-C-substituted nucleosides, a largely unexplored class of 
compounds, was developed and consists of eight steps. The method successfully furnished 
1’-C-methyladenosine. However, an optimisation of the synthetic procedures would be 
required to ease the preparation of nucleoside analogues within this family and their 
corresponding nucleotide phosphoramidates. Furthermore, docking studies suggested that 
1’,2’-C,C-bis-substituted adenosine analogues may represent attractive antiviral agents. 
Further investigations will be required to adapt the developed procedure for the synthesis 
of this novel class of nucleosides. 
 The second family were the benzo-fused 7-deazaadenosine analogues bearing natural or 
2’-C-substituted ribose moieties. A published procedure consisting of six steps was 
employed to prepare one derivative in which the ribose ring was unmodified. The 
application of the ProTide strategy to this class of tricyclic nucleosides was novel, and 
therefore was investigated on the prepared derivative. The application of innovative MWI 
conditions, which were developed in an independent methodology study, proved to be 
essential for the synthesis of the phosphoramidate prodrug of the benzo-fused 7-
deazaadenosine analogue. 
The preparation of the 2’-C-substituted derivative involved the glycosylation of the tricyclic 
heterobase by a modified glycosylating agent, whose synthesis required three steps. 
Docking studies suggested that nucleosides bearing various substituents at the level of the 
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benzo-fused purine base may fit well in the active site of DENV RdRp. Both the prepared 
tricyclic nucleosides could be used as intermediates in the synthesis of these nucleosides. 
 The third family were acyclic adenosine analogues characterised by two allylic scaffolds 
replacing the ribose ring. The initially developed synthetic strategy for the first scaffold was 
based on the alkylation of the heterobase using the appropriate allylic chloride, which was 
synthesised using a four step method. The following coupling to a variety of purine bases 
afforded a series of novel acyclic adenosine analogues. Further investigations resulted in an 
optimised procedure for the synthesis of these acyclic nucleosides. The preparation of 
ProTides of this class of acyclic nucleosides was inconvenient due to the presence of two 
primary hydroxyl groups in the linear linker. Nevertheless, suitable MWI conditions were 
identified for the synthesis of the desired trans mono-O-phosphoramidates of the 
adenosine and 7-deazaadenosine derivatives. To overcome the issue of selectivity of the 
coupling reaction with the phosphoramidating reagent, the corresponding cyclic O-O-
phosphoramidates were synthesised as well. 
With regards to the second scaffold, the synthetic route that was previously developed for 
the nucleosides containing the first scaffold was adapted in order to introduce a methyl 
group in the 1-position of the allylic linker. The method consisting of seven steps was 
successfully applied to the synthesis of the corresponding acyclic adenosine analogue. 
As previously mentioned, innovative MWI conditions for the preparation of phosphoramidate 
ProTides were investigated in this work. First, the applicability of the microwave-assistance was 
demonstrated on unmodified adenosine, which was employed as a model nucleoside. Then, the 
conditions were successfully applied to the synthesis of phosphoramidate ProTides of structurally 
modified analogues as potential anti-DENV agents. The new methodology has proven of great 
utility in the preparation of phosphoramidate ProTides of nucleoside analogues and was superior 
than conventionally used methods for the reaction time and, in some cases, for the reaction yield. 
Finally, preliminary data from the biological evaluation, which as of yet are only available for a 
limited number of the synthesised nucleosides and nucleotides, confirmed that the 
phosphoramidate ProTide approach represents a useful strategy for boosting the antiviral activity 
of adenosine analogues in infected cells. The 2’-C-methyladenosine ProTide inhibited the 
cytopathy by DENV as well as the closely related ZIKV in vitro. Further characterisation of the 
antiviral activity of the ProTide in ZIKV-infected cells revealed that a significant synergistic effect is 
observed in combination with an autophagy inhibitor. These encouraging results warrant further 
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development of both antiviral agents and suggested that the combination of two drugs, of which 
one is an NI targeting the viral RdRp, may provide potent inhibition of the replication of 
flaviviruses. 
In conclusion, this PhD study has provided a novel model of the DENV RdRp de novo initiation 
complex. As demonstrated in this work, the new model is a valuable tool for in silico design of 
novel NIs of DENV RdRp. An increased understanding of the mechanism of RNA synthesis by the 
viral RdRp was achieved and will aid future in silico design studies on NNIs of DENV RdRp. Finally, 
the synthetic procedures for the preparation of novel nucleoside analogues and nucleotide 
phosphoramidate ProTides, which were developed in the course of this PhD, give access to a 
variety of biologically relevant compounds. 
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4.1 COMPUTATIONAL METHODS 
4.1.1 METHODS – SECTION 2.1.1 
The crystal structures of the DENV RdRp and the HCV NS5B in complex with the nucleic acid were 
downloaded from the Protein Data Bank website (codes 4HHJ and 4E78, respectively).[1, 2] Water 
molecules, non-catalytic ions and glycerol were removed using MOE2014.09. The model of the 
DENV RdRp de novo initiation complex was built using the same modelling program, as described 
in paragraph 2.1.1.1. Modifications on the nucleic acid were applied using the MOE Builder tool. 
The Mg2+ ions were imported from Protein Data Bank code 2J7U[3] and re-positioned manually 
using MOE2014.09. Minimisation of the protein complex was performed with AMBER99 force 
field, using MOE2014.09. 
Docking simulations of DENV RdRp inhibitors were performed using Protein-Ligand ANT System 
(PLANTS). Small molecule databases were prepared using MOE2014.09. The nucleotides 
monophosphate and triphosphate were designed with the Builder tool and energy minimised with 
MMFF94x force field. Databases were converted to a format PLANTS-compatible. To identify the 
docking site, the centre was set at the oxygen atom of ATP with radius of 10Å. In each docking 
simulation, 20 poses were generated and visually inspected using MOE2014.09. 
The MD simulation on the model of the DENV RdRp de novo initiation complex was performed 
using the application Desmond of Schrӧdinger Maestro 9.5. Firstly, the missing loops in the protein 
(spanning residues from 406 to 420 and from 457 to 469) were constructed using the MOE 
Structure Preparation tool. Secondly, the protein complex was prepared with the Protein 
Preparation Wizard tool using Schrӧdinger Maestro 9.5. The model system was built by employing 
an orthorhombic box of 10Å side and by adding molecules of water as SPC solvent model. The 
total charges of the system were neutralised by adding 2 Na2+ ions. Solvation was run using 
OPLS_2005 force field. An initial energy minimization was performed to relax the system before 
the MD simulation. The maximum number of iterations was set at 2 000 steps. The MD simulation 
was 50 ns long and trajectory and energy values were recorded every 100 ps (500 steps). The 
simulation was run in NPT conditions (constant number of atoms N, pressure P and temperature 
T) at the temperature of 300 K and pressure of 1.01325 bar. 
Results were visually inspected using VMD 1.9.1. Additionally, the final step of the MD simulation 
and the system before the MD simulation were superposed using MOE2014.09.  
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4.1.2 METHODS – SECTION 2.1.2 
Docking simulations of nucleoside analogues were performed using Protein-Ligand ANT System 
(PLANTS). Small molecule databases were prepared using MOE2014.09. The nucleotides 
monophosphate were designed with the Builder tool and energy minimised with MMFF94x force 
field. Databases were converted to a format PLANTS-compatible. To identify the docking site, the 
centre was set at the oxygen atom of ATP with radius of 10Å. In each docking simulation, 5 poses 
were generated and visually inspected using MOE2014.09. 
The scaffold replacement was performed using MOE2014.09. The database of linkers that was 
used for the screening was available in MOE2014.09. Linkers were selected for a Tanimoto index 
of similarity less than 0.8, a molecular weight of the corresponding NTP less than 525 Da and for 
the essential feature of hydrogen bond donor (pharmacophore). The pharmacophore was built 
using MOE2014.09. 
Docking simulations of acyclic nucleoside analogues were performed using Protein-Ligand ANT 
System (PLANTS). Small molecule databases were prepared using MOE2014.09. The nucleotides 
triphosphate were designed with the Builder tool and energy minimised with MMFF94x force field. 
Databases were converted to a format PLANTS-compatible. To identify the docking site, the centre 
was set at the oxygen atom of ATP with radius of 10Å. In each docking simulation, 20 poses were 
generated and visually inspected using MOE2014.09. 
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4.1.3 METHODS – SECTION 2.1.3 
All MD simulations were performed using the application Desmond of Schrӧdinger Maestro 9.5. 
Protein complexes were prepared with the Protein Preparation Wizard tool using Schrӧdinger 
Maestro 9.5. The model system was built by employing an orthorhombic box of 10Å side and by 
adding molecules of water as SPC solvent model. The total charges of the system were neutralised 
by adding either Na+ or Cl- ions. Solvation was run using OPLS_2005 force field. An initial energy 
minimization was performed to relax the system before the MD simulation. The maximum number 
of iterations was set at 2 000 steps. The MD simulation was 50 ns long and trajectory and energy 
values were recorded every 100 ps (500 steps). The simulation was run in NPT conditions 
(constant number of atoms N, pressure P and temperature T) at the temperature of 300 K and 
pressure of 1.01325 bar. Results were visually inspected using VMD 1.9.1. Additionally, the final 
step of the MD simulation and the system before the MD simulation were superposed using 
MOE2014.09. 
For the model of the complete apo DENV RdRp, the DENV RdRp crystal structure, downloaded 
from the Protein Data Bank website (codes 4HHJ),[1] was used. Water molecules, non-catalytic ions 
and glycerol were removed using MOE2014.09. The missing loops in the protein (spanning 
residues from 406 to 420 and from 457 to 469) were constructed using the MOE Structure 
Preparation tool. The Mg2+ ions were imported from Protein Data Bank code 2J7U[3] and re-
positioned manually using MOE2014.09. The protein complex was prepared following the 
standard procedure, by adding 8 Cl- ions to neutralise the molecular system, minimised and 
submitted to the MD simulation. 
For the construction of the model of the complete de novo initiation complex, the final step of the 
previous MD simulation was used. Using MOE2014.09, the water molecules (SPC) were removed 
and the nucleic acid was imported from the crystal structure of the HCV NS5B complex, 
downloaded from the Protein Data Bank website (codes 4E78).[2] Using the same modelling 
program, an incomplete nucleotide present in the original crystal structure was bound to a copy of 
the ssRNA and the molecules of 3dGTP were converted to GMP. Loops spanning residues from 406 
to 420 (loop L1), from 457 to 469 (loop L2) and the priming loop (residues 782 to 809) were 
deleted and constructed using the MOE Loop Modeller tool. The de novo method was applied to 
generate multiple loop conformations, setting RMSD limit at 0.5, loop limit at 100 and energy 
window at 5.0. The new conformations were inspected visually to select the most conservative 
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and appropriate conformations for each loop. The protein complex was prepared following the 
standard procedure, by adding 11 Na+ ions to neutralise the molecular system, minimised and 
submitted to the MD simulation. 
For the construction of the model of the elongation complex, the nucleic acid of the crystal 
structure of the HCV NS5B complex, downloaded from the Protein Data Bank website (codes 
4E78),[2] was duplicated and the copy bound to the original one to build the 8-nucleotide long 
dsRNA, using MOE2014.09. The molecules of 3dGTP were converted to GMP. The dsRNA was 
minimised using AMBER99 force field and imported into the final step of the previous MD 
simulation, after removing the water molecules (SPC). Part of the priming loop spanning residues 
from 782 to 796 was deleted and constructed using the MOE Loop Modeller tool. The de novo 
method was applied to generate multiple loop conformations, setting RMSD limit at 0.25, loop 
limit at 100 and energy window at 5.0. The new conformations were inspected visually and the 
most conservative one was selected. The protein complex was minimised using AMBER99 force 
field. The protein complex was prepared following the standard procedure, by adding 14 Na+ ions 
to neutralise the molecular system, minimised and submitted to the MD simulation. 
The crystal structure of the DENV RdRp bound to the allosteric inhibitor NITD107 was downloaded 
from the Protein Data Bank website (code 3VWS)[1] and superposed to the final step of the MD 
simulation on the elongation complex using MOE2014.09. 
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4.2 SYNTHETIC PROCEDURES 
4.2.1 GENERAL INFORMATION 
All reagents and anhydrous solvents were used as supplied from Sigma-Aldrich, Fisher Scientific or 
other commercial sources without further purification or treatment. 
Reactions under MWI conditions were performed in a CEM Discover microwave system in closed 
vessel mode. 
Thin layer chromatography (TLC) was carried out on commercial Merck silica gel 60 F254 plates. 
Compounds were visualized under UV light (254 nm) or potassium permanganate stain. 
Column chromatography was performed using Fisher Scientific silica gel 60A particle size 35-70 
micron as a stationary phase. Flash column chromatography was performed on a Interchim 
PuriFlash 430 using high performance silica gel particle size 50 micron cartridges. 
Melting points were measured on a Griffin 220V melting point apparatus. 
1H NMR spectra were recorded on a BrukerAvance Ultra Shield (500 MHz) spectrometer and 
tetramethylsilane was used as the internal standard. 13C NMR spectra were recorded on a 
BrukerAvance Ultra Shield (126 MHz) spectrometer and the solvent resonance was employed as 
the internal standard. 31P NMR spectra were recorded on a BrukerAvance Ultra Shield (202 MHz) 
spectrometer and were proton-decoupled. MestReNova (v6.0.2-5475) NMR processing software 
was used for the assignment of peaks and calculation of coupling constants. Chemical shifts δ are 
given in ppm (parts per million) relative to the internal standard and accompanied by multiplicity 
(s for singlet, br s for broad singlet, d for doublet, t for triplet, q for quartet and m for multiplet), 
coupling constants JH,H in Hz and relative assignment. 
Low resolution mass spectrometry (MS) was performed on a Bruker MicroTOF-LC in positive mode 
and electron spray ionization (ES+). High resolution mass spectrometry (HRMS) was performed as 
a service by Cardiff University (School of Chemistry). 
Reverse-phase analytical and semi-preparative high performance liquid chromatography (HPLC) 
experiments were carried out on a Variant ProStar (LC work station – Varian ProStar 335LC 
detector, Varian fraction collector, ProStar 201 delivery system) using a XSelect CSH C18 (5 μm, 4.6 
x 150 mm) column and a Variant Pursuit XRs 5C18 (150 x 21.2 mm) column, respectively. Galaxie 
Chromatography Data System was used as software. Elution systems used were: mobile phase 
water/methanol in gradient from 10% to 100% of methanol in 30 minutes (system 1), mobile 
phase water/methanol in gradient from 100% to 70% of water in 15 minutes, then to 100% 
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methanol in 15 minutes (system 2) for analytical experiments; mobile phase water/acetonitrile in 
gradient from 10% to 100% of acetonitrile in 30 minutes (system 3) for semi-preparative 
experiments. 
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4.2.2 PROCEDURES AND SPECTRAL DATA – SECTION 2.2.1 
 
 
C16H17ClNO4P, MW 353.74 
 
N-(chlorophenoxyphosphinyl)-L-alanine benzyl ester (35).[4] 
L-alanine benzyl ester p-tosylate salt 32 (0.50 g, 1.42 mmol) was suspended in anhydrous 
dichloromethane under an argon atmosphere and phenyl dichlorophosphate 34 (0.21 mL, 1.42 
mmol) was added at room temperature. The mixture was cooled to -78 °C before adding 
triethylamine (0.40 mL, 2.84 mmol) dropwise. After stirring 1 hour at -78 °C, the reaction mixture 
was allowed to attain room temperature and stirred for additional 2 hours. The solvent was 
removed under reduced pressure and the crude residue was purified by quick column 
chromatography on silica gel eluting with hexane/ethylacetate (50:50 v/v) to obtain compound 35 
(0.47 g, 94% yield) as a colourless oil. 
31P NMR (202 MHz, CDCl3) δ 8.03, 7.79. 
1H NMR (500 MHz, CDCl3) δ 7.31 – 7.10 (m, 10H, Harom), 5.12, 5.10 (2s, 2H, CH2(C6H5)), 4.57 – 4.46 
(m, 1H, NH), 4.22 – 4.06 (m, 1H, CHCH3), 1.43, 1.42 (2d, J = 7.0 Hz, 3H, CHCH3). 
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C12H17ClNO4P, MW 305.69 
 
N-(chlorophenoxyphosphinyl)-L-alanine isopropyl ester (36).[5] 
L-alanine isopropyl ester hydrochloride 33 (1.00 g, 5.97 mmol) was dissolved in anhydrous 
dichloromethane under an argon atmosphere and phenyl dichlorophosphate 34 (0.90 mL, 5.97 
mmol) was added at room temperature. The mixture was cooled to -78 °C before adding 
triethylamine (1.66 mL, 11.93 mmol) dropwise. After stirring 1 hour at -78 °C, the reaction mixture 
was allowed to attain room temperature and stirred for additional 2 hours. The solvent was 
removed under reduced pressure. The crude residue was suspended in anhydrous diethyl ether 
under an argon atmosphere and stirred for 15 minutes, then filtered under vacuo protected by a 
flow of nitrogen. The ethereal filtrate was evaporated under reduced pressure to obtain 
compound 36 (1.81 g, 95% yield) as a colourless oil. 
31P NMR (202 MHz, CDCl3) δ 8.09, 7.72. 
1H NMR (500 MHz, CDCl3) δ 7.34 – 7.16 (m, 5H, Harom), 5.06 – 4.97 (m, 1H, H-iPr), 4.29, 4.21 (2 br 
s, 1H, NH), 4.13 – 3.99 (m, 1H, CHCH3), 1.43, 1.42 (2d, J = 2.4 Hz, 1H, CHCH3), 1.23 – 1.18 (m, 6H, 2 
CH3-iPr). 
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C22H21N2O7P, MW 456.39 
 
N-[(4-nitrophenoxy)phenoxyphosphinyl]-L-alanine benzyl ester (37).[6] 
Procedure a: 
A solution of 35 (0.66 g, 1.87 mmol) in anhydrous dichloromethane was cooled to -78 °C under a 
nitrogen atmosphere (solution A). In another flask, 4-nitrophenol (0.29 mg, 2.05 mmol) was 
suspended in dichloromethane and triethylamine (0.52 mL, 3.73 mmol) was added dropwise at 
room temperature under a nitrogen atmosphere (solution B). The resulting solution (solution B) 
was added slowly to solution A at -78 °C under a nitrogen atmosphere. The reaction mixture was 
stirred at a temperature from -78 °C to -40 °C for 2 hours, then the solvent was removed under 
reduced pressure. The crude residue was suspended in diethyl ether and stirred for 15 minutes, 
then filtered under vacuo. The ethereal filtrate was evaporated under reduced pressure and the 
crude residue was purified by flash column chromatography on silica gel (hexane to 
hexane/ethylacetate 80:20 v/v) to obtain compound 37 (0.62 g, 73% yield) as a colourless oil. 
Procedure b: 
A solution of 4-nitrophenyldichlorophosphate 39 (1.00 g, 3.91 mmol) in dichloromethane was 
cooled to -78 °C under a nitrogen atmosphere (solution A). In another flask, phenol (0.37 g, 3.91 
mmol) was dissolved in dichloromethane and triethylamine (0.60 mL, 4.30 mmol) was added 
dropwise at room temperature under a nitrogen atmosphere (solution B). Solution B was added 
slowly to solution A at -78 °C under a nitrogen atmosphere. The resulting solution was stirred at -
78 °C for 1 hour, then added to a stirred solution of L-alanine benzyl ester p-tosylate salt 32 (1.37 
g, 3.91 mmol) in dichloromethane at -50 °C. Triethylamine (1.14 mL, 8.21 mmol) was added 
dropwise at -50 °C and the resulting reaction mixture was stirred for 1 hour at the same 
temperature, then allowed to attain 0 °C and stirred for additional 2 hours. The solvent was 
removed under reduced pressure. The crude residue was suspended in ethylacetate and stirred 
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for 15 minutes, then filtered under vacuo. The filtrate was evaporated under reduced pressure 
and the crude residue was purified by flash column chromatography on silica gel (hexane to 
hexane/ethylacetate 80:20 v/v) to obtain compound 37 (1.61 g, 90% yield) as a colourless oil. 
31P NMR (202 MHz, CDCl3) δ -3.22, -3.35. 
1H NMR (500 MHz, CDCl3) δ 8.08 (m, 2H, Harom), 7.31 – 7.09 (m, 12H, Harom), 5.10 – 5.00 (m, 2H, 
CH2(C6H5)), 4.17 – 3.95 (m, 2H, NH and CHCH3), 1.34, 1.33 (2d, J = 4.0 Hz, 3H, CHCH3). 
 
 
C19H23N2O7P, MW 408.34 
 
N-[(4-nitrophenoxy)phenoxyphosphinyl]-L-alanine isopropyl ester (38).[7, 8] 
Procedure a: 
A solution of 36 (1.76 g, 5.76 mmol) in anhydrous dichloromethane was cooled to -78 °C under a 
nitrogen atmosphere (solution A). In another flask, 4-nitrophenol (0.80 g, 5.76 mmol) was 
suspended in dichloromethane and triethylamine (1.6 mL, 11.51 mmol) was added dropwise at 
room temperature under a nitrogen atmosphere (solution B). The resulting solution (solution B) 
was added slowly to solution A at -78 °C under a nitrogen atmosphere. The reaction mixture was 
stirred at a temperature from -78 °C to -40 °C for 2 hours, then the solvent was removed under 
reduced pressure. The crude residue was suspended in diethyl ether and stirred for 15 minutes, 
then filtered under vacuo. The ethereal filtrate was evaporated under reduced pressure and the 
crude residue was purified by flash column chromatography on silica gel (hexane to 
hexane/ethylacetate 75:25 v/v) to obtain compound 38 (1.49 g, 63% yield) as a colourless oil. 
Procedure b: 
A solution of 4-nitrophenyldichlorophosphate 39 (2.00 g, 7.81 mmol) in dichloromethane was 
cooled to -78 °C under a nitrogen atmosphere (solution A). In another flask, phenol (0.74 g, 7.81 
mmol) was dissolved in dichloromethane and triethylamine (1.20 mL, 8.59 mmol) was added 
dropwise at room temperature under a nitrogen atmosphere (solution B). Solution B was added 
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slowly to solution A at -78 °C under a nitrogen atmosphere. The resulting solution was stirred at -
78 °C for 1 hour, then added to a stirred solution of L-alanine isopropyl ester hydrochloride 33 
(1.31 g, 7.81 mmol) in dichloromethane at -50 °C. Triethylamine (2.30 mL, 16.41 mmol) was added 
dropwise at -50 °C and the resulting reaction mixture was stirred for 1 hour at the same 
temperature, then allowed to attain 0 °C and stirred for additional 2 hours. The solvent was 
removed under reduced pressure. The crude residue was suspended in ethylacetate and stirred 
for 15 minutes, then filtered under vacuo. The filtrate was evaporated under reduced pressure 
and the crude residue was purified by flash column chromatography on silica gel (hexane to 
hexane/ethylacetate 75:25 v/v) to obtain compound 38 (2.72 g, 86% yield) as a colourless oil. 
31P NMR (202 MHz, CDCl3) δ -3.15, -3.19. 
1H NMR (500 MHz, CDCl3) δ 8.25 (m, 2H, Harom), 7.44 – 7.35 (m, 4H, Harom), 7.28 – 7.21 (m, 3H, 
Harom), 5.08 – 4.98 (m, 1H, H-iPr), 4.17 – 4.06 (m, 1H, CHCH3), 3.93 (m, 1H, NH), 1.43, 1.41 (2d, J = 
2.9 Hz, 3H, CHCH3), 1.26, 1.24 (2d, J = 4.2 Hz, 6H, 2 CH3-iPr). 
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4.2.3 PROCEDURES AND SPECTRAL DATA – SECTION 2.2.2 
 
 
C6H12O5, MW 164.16 
 
1-O-Methyl-β-D-ribofuranose (44).[8] 
To a stirred suspension of D-ribose 42 (4,00 g, 26.60 mmol) in anhydrous methanol (40 mL) 
concentrated sulfuric acid (0.26 mL, 2.66 mmol) was added dropwise at -5°C under a nitrogen 
atmosphere. The reaction mixture was allowed to attain room temperature and the resulting clear 
solution was stirred for 24 hours. Then the solution was neutralised with the addition of sodium 
acetate (0.66 g, 7.98 mmol) and concentrated under reduced pressure. The cloudy oily residue 
was purified by column chromatography on silica gel eluting with ethyl acetate/methanol (90:10 
v/v) to obtain compound 44 (2.81 g, 64% yield) as a colourless syrup. 
1H NMR (500 MHz, DMSO-d6) δ 4.95 (br s, 1H, 2-OH), 4.76 (d, J3-OH,3 = 4.8 Hz, 1H, 3-OH), 4.63 (s, 1H, 
H-1), 4.58 (t, J5-OH,5 = 5.6 Hz, 1H, 5-OH), 3.86 – 3.81 (m, 1H, H-3), 3.78 – 3.70 (m, 2H, H-4 and H-2), 
3.54 – 3.49 (m, 1H, H-5a), 3.38 – 3.32 (m, 1H, H-5b), 3.23 (s, 3H, 1-OCH3). 
13C NMR (126 MHz, DMSO-d6) δ 108.03 (CH, C1), 83.55 (CH, C4), 74.20 (CH, C2), 70.92 (CH, C3), 
63.14 (CH2, C5), 54.21 (CH3, 1-OCH3). 
 
 
C18H38O6Si2, MW 406.66 
 
3,5-O-(Tetraisopropyldisiloxane-1,3-diyl)-1-O-methyl-β-D-ribofuranose (46).[8] 
Compound 44 (0.51 g, 3.11 mmol) was dried by several coevaporations with anhydrous 
acetonitrile and dissolved in anhydrous pyridine (8 mL). The solution was cooled to 0 °C and 1,3-
dichloro-1,1,3,3-tetraisopropyldisiloxane (0.90 mL, 2.80 mmol) was added dropwise under an 
argon atmosphere. Then the cooling bath was removed and the reaction mixture was stirred at 
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room temperature for 1 hour. The solvent was evaporated and the residue was dissolved in ethyl 
acetate (50 mL), washed with water (50 mL) and brine (50 mL). The organic layer was dried over 
anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by 
column chromatography on silica gel eluting with hexane/ethyl acetate (80:20 v/v) to give 
compound 46 (0.85 g, 67% yield) as a colourless syrup. 
1H NMR (500 MHz, CDCl3) δ 4.83 (s, 1H, H-1), 4.51 (apparent t, 1H, H-4), 4.09 – 4.00 (m, 3H, H-2, H-
3 and H-5a), 3.77 (dd, J = 10.9, 9.1 Hz, 1H, H-5b), 3.33 (s, 3H, 1-OCH3), 2.99 (s, 1H, 2-OH), 1.14 – 
1.03 (m, 28H, 4 CH-iPr and 8 CH3-iPr). 
13C NMR (126 MHz, CDCl3) δ 107.28 (CH, C1), 82.64, 75.77 (2 CH, C2 and C3), 75.00 (CH, C4), 66.15 
(CH2, C5), 54.85 (CH3, 1-OCH3), 17.48, 17.39, 17.36, 17.33, 17.15, 16.99, 16.96, 16.93 (8 CH3, 8 CH3-
iPr), 13.28, 12.82, 12.59 (3 CH, 4 CH-iPr). 
 
 
C20H18Cl4O5, MW 480.17 
 
3,5-Bis-O-(2,4-dichlorobenzyl)-1-O-methyl-α-D-ribofuran-2-ulose (49).[9] 
To a stirred suspension of Dess-Martin periodinane (1.13 g, 2.65 mmol) in anhydrous 
dichloromethane (8 mL) was added a solution of commercially available 1-O-methyl-3,5-bis-O-(2,4-
dichlorobenzyl)-α-D-ribofuranose 48 (0.80 g, 1.66 mmol) in anhydrous dichloromethane (6 mL) 
dropwise at 0 °C under a nitrogen atmosphere. The suspension was stirred at this temperature for 
0.5 hour and then at room temperature for 72 hours. The mixture was diluted with diethyl ether 
(15 mL), poured into a solution of Na2S2O3∙5H2O (3 g) in saturated aqueous NaHCO3 solution (30 
mL) and stirred for 0.5 hour. The phases were separated and the aqueous solution was further 
extracted with diethyl ether (2 x 30 mL). The combined organic layer was washed with saturated 
aqueous NaHCO3 solution (50 mL), water (50 mL) and brine (50 mL), dried over anhydrous Na2SO4, 
filtered and concentrated to dryness. The oily residue was purified by column chromatography on 
silica gel eluting with hexane/ethyl acetate (60:40 v/v) to give compound 49 (0.72 g, 90% yield) as 
a colourless oil. 1H NMR (500 MHz, CDCl3) δ 7.33 – 7.22 (m, 4H, Harom), 7.20 – 7.09 (m, 2H, 
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Harom), 4.93 (d, Jgem = 12.5 Hz, 1H, H-CH(C6H3Cl2)), 4.78 (d, J1,3 = 1.0 Hz, 1H, H-1), 4.69 (d, Jgem = 
12.5 Hz, H, H-CH(C6H3Cl2)), 4.50 (d, Jgem = 13.0 Hz, 1H, H-CH(C6H3Cl2)), 4.60 (d, Jgem = 13.0 Hz, H, H-
CH(C6H3Cl2)), 4.29 (ddd, J4,3 = 8.3 Hz, J4,5b = 3.4 Hz, J4,5a = 2.5 Hz, 1H, H-4), 4.12 (dd, J3,4 = 8.4, J3,1 = 
1.2 Hz, 1H, H-3), 3.85 (dd, J5a,5b = 11.3 Hz, J5a,4 = 2.4 Hz, 1H, H-5a), 3.72 (dd, J5b,5a = 11.3 Hz, J5b,4 = 
3.6 Hz, 1H, H-5b), 3.41 (s, 3H, 1-OCH3). 
13C NMR (126 MHz, CDCl3) δ 207.25 (C, C=O), 134.45, 134.11, 133.96, 133.89, 133.56, 133.47 (6 C, 
Carom), 130.59, 129.91, 129.22, 127.16 (4 CH, Carom), 98.71 (CH, C1), 77.80 (CH, C4), 76.31 (CH, 
C3), 70.19 (CH2, CH2(C6H3Cl2)), 69.47 (CH2, CH2(C6H3Cl2)), 68.91 (CH2, C5), 55.87 (CH3, 1-OCH3). 
 
 
C21H22Cl4O5, MW 496.21 
 
3,5-Bis-O-(2,4-dichlorobenzyl)-2-C-methyl-1-O-methyl-α-D-ribofuranose (50).[9] 
A solution of 3.0M methylmagnesium bromide in diethyl ether (0.83 mL, 2.50 mmol) was diluted 
in diethyl ether (4.5 mL) and cooled to -55°C, before adding dropwise a solution of compound 49 
(0.30 g, 0.63 mmol) in diethyl ether (2 mL) under a nitrogen atmosphere. The reaction mixture was 
allowed to warm to -30 °C and stirred at -30 °C to -15°C for 2 hours, then a solution of 3.0M 
methylmagnesium bromide in diethyl ether (0.83 mL, 2.50 mmol) was added dropwise. The 
reaction mixture was allowed to attain 0 °C, stirred for additional 5 hours and quenched with 
saturated NH4Cl aqueous solution (50 mL). After vigorous stirring over 30 minutes at room 
temperature, the mixture was extracted with diethyl ether (3 x 50 mL). The combined organic 
layer was washed with water (60 mL) and brine (60 mL), dried over anhydrous Na2SO4, filtered and 
concentrated to dryness. The crude oily residue was purified by column chromatography on silica 
gel eluting with hexane/ethyl acetate (70:30 v/v) to give compound 50 (0.17 g, 54% yield) as a 
colourless oil. 
1H NMR (500 MHz, CDCl3) δ 7.34 – 7.25 (m, 4H, Harom), 7.19 – 7.10 (m, 2H, Harom), 4.72 (d, Jgem = 
13.2 Hz, 1H, H-CH(C6H3Cl2)), 4.56 – 4.50 (m, 3H, H-CH(C6H3Cl2) and CH2(C6H3Cl2)), 4.43 (s, 1H, H-1), 
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4.10 (apparent q, 1H, H-4), 3.58 (d, J5,4 = 4.6 Hz, 2H, H-5a and H-5b), 3.37 (s, 3H, 1-OCH3), 3.33 (d, 
J3,4 = 4.2 Hz, 1H, H-3), 3.25 (s, 1H, 2-OH), 1.27 (s, 3H, 2-CH3). 
13C NMR (126 MHz, CDCl3) δ 134.40, 134.26, 133.95, 133.91, 133.56, 133.46 (6 C, Carom), 130.11, 
129.80, 129.14, 129.12, 127.09 (5 CH, Carom), 107.42 (CH, C1), 82.86 (CH, C3), 81.96 (CH, C4), 
76.85 (C, C2), 70.70 (CH2, C5), 70.03 (CH2, CH2(C6H3Cl2)), 69.72 (CH2, CH2(C6H3Cl2)), 55.20 (CH3, 1-
OCH3), 24.69 (CH3, 2-CH3). 
 
 
C26H22Cl5N3O4, MW 617.74 
 
6-Chloro-7-deaza-9-[3,5-bis-O-(2,4-dichlorobenzyl)-2-C-methyl-β-D-ribofuranosyl]purine (51).[9] 
Procedure a: 
To a solution of compound 50 (0.10 g, 0.20 mmol) in anhydrous dichloromethane (3 mL) at 0 °C 
was added dropwise a solution of 5.7M bromine hydride in acetic acid (0.21 mL, 1.21 mmol) under 
an argon atmosphere. The resulting solution was stirred at 0 °C for 1 hour, then allowed to attain 
room temperature and stirred for additional 3 hours. After full conversion of the starting material 
(monitored by TLC), the solution was evaporated under reduced pressure and coevaporated with 
anhydrous toluene (3 x 0.5 mL). The oily residue was dissolved in anhydrous acetonitrile (0.5 mL) 
and added to a stirring solution of the sodium salt of 6-chloro-7-deazapurine 121 in acetonitrile 
(generated in situ from commercially available 6-chloro-7-deazapurine 121 (0.09 g, 0.60 mmol) in 
anhydrous acetonitrile (10 mL), and sodium hydride 60% dispersion in mineral oil (0.02 g, 0.60 
mmol), after vigorously stirring for 4 hours at room temperature under a nitrogen atmosphere). 
The combined mixture was stirred at room temperature for 60 hours, then evaporated to dryness. 
The residue was suspended in water (30 mL) and extracted with ethyl acetate (3 x 30 mL). The 
combined organic layer was washed with water (50 mL) and brine (50 mL), dried over anhydrous 
Na2SO4, filtered and concentrated to dryness. The crude residue was purified by column 
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chromatography on silica gel eluting with hexane/ethyl acetate (70:30 v/v) to give compound 51 
(0.021 g, 17% yield) as a colourless foam. 
Procedure b: 
To a solution of compound 50 (0.52 g, 1.04 mmol) in anhydrous dichloromethane (20 mL) at 0 °C 
was added dropwise a solution of 5.7M bromine hydride in acetic acid (1.22 mL, 6.97 mmol) under 
a nitrogen atmosphere. The resulting solution was allowed to attain room temperature and stirred 
for 2 hour. After full conversion of the starting material (monitored by TLC), the solution was 
evaporated under reduced pressure and coevaporated with anhydrous toluene (2 mL). The oily 
residue was dissolved in anhydrous acetonitrile (2 mL) and added to a stirring suspension of 6-
chloro-7-deazapurine 121 (0.16 g, 1.04 mmol), potassium hydroxide 85% powder (0.21 g, 3.12 
mmol) and tris[2-(2-methoxyethoxy)ethyl]amine (0.07 mL, 0.21 mmol) in anhydrous acetonitrile 
(20 mL) under a nitrogen atmosphere at room temperature. The reaction mixture was stirred for 1 
hour, then filtered under vacuo and the filtrate was concentrated to dryness. The crude residue 
was purified by flash column chromatography on silica gel (hexane to hexane/ethyl acetate 70:30 
v/v) to give compound 51 (0.25 g, 39% yield) as a colourless foam. 
1H NMR (500 MHz, CDCl3) δ 8.56 (s, 1H, H-2), 7.61 (d, J8,7 = 3.7 Hz, 1H, H-8), 7.37 – 7.16 (m, 6H, 
Harom), 6.47 (d, J7,8 = 3.7 Hz, 1H, H-7), 6.34 (s, 1H, H-1’), 4.71 (d, Jgem = 12.0 Hz, 1H, H-CH(C6H3Cl2)), 
4.65 (d, Jgem = 12.1 Hz, 1H, H-CH(C6H3Cl2)), 4.61 (d, Jgem = 12.6 Hz, 1H, H-CH(C6H3Cl2)), 4.56 (d, Jgem = 
12.6 Hz, 1H, H-CH(C6H3Cl2)), 4.22 (dt, J4’,3’ = 7.9 Hz, J4’,5’ = 2.7 Hz, 1H, H-4’), 4.17 (d, J3’,4’ = 8.0 Hz, 
1H, H-3’), 3.91 (dd, J5’a,5’b = 10.9, J5’a,4’ = 2.5 Hz, 1H, H-5’a), 3.72 (dd, J5’b,5’a = 10.9 Hz, J5’b,4’ = 2.9 Hz, 
1H, H-5’b), 3.09 (s, 1H, 2’-OH), 0.86 (s, 3H, 2’-CH3). 
13C NMR (126 MHz, CDCl3) δ 152.26 (C, Carom), 150.96 (C, Carom), 150.86 (CH, C2), 134.99, 
134.53, 134.17, 134.12, 133.79, 133.32 (6 C, Carom), 130.76, 130.35, 129.55, 129.51, 127.35, 
127.24 (6 CH, Carom), 126.83 (CH, C8), 117.99 (C, Carom), 100.33 (CH, C7), 90.93 (CH, C1’), 80.90 
(CH, C3’), 80.22 (CH, C4’), 79.36 (C, C2’), 70.54 (CH2, CH2(C6H3Cl2)), 70.21 (CH2, CH2(C6H3Cl2)), 68.94 
(CH2, C5’), 21.11 (CH3, 2’-CH3). 
 
4. EXPERIMENTAL PART 
212 
 
 
C26H24Cl4N4O4, MW 598.31 
 
7-Deaza-3’,5’-bis-O-(2,4-dichlorobenzyl)-2’-C-methyladenosine (54). 
Compound 51 (0.18 g, 0.29 mmol) was dissolved in a saturated (7M) solution of ammonia in 
methanol (10 mL). The reaction mixture was stirred in a screw-cap pressure glass tube at 80 °C for 
48 hours, then cooled to room temperature. The solvent was evaporated and the crude residue 
was purified by column chromatography on silica gel eluting with hexane/ethylacetate (10:90 v/v 
to 0:100 v/v) to obtain the protected adenosine analogue 54 (0.15 g, 87% yield) as a white foam; 
mp: 60-62 °C. 
1H NMR (500 MHz, CDCl3) δ 8.23 (s, 1H, H-2), 7.35 – 7.26 (m, 5H, Harom and H-8), 7.16 (ddd, 2H, 
Harom), 6.25 (s, 1H, H-1’), 6.23 (d, J7,8 = 3.7 Hz, 1H, H-7), 5.23 (br s, 2H, 4-NH2), 4.74 (d, Jgem = 12.3 
Hz, 1H, H-CH(C6H3Cl2)), 4.65 (d, Jgem = 12.3 Hz, 1H, H-CH(C6H3Cl2)), 4.60 (d, Jgem = 12.8 Hz, 1H, H-
CH(C6H3Cl2)), 4.56 (d, Jgem = 12.8 Hz, 1H, H-CH(C6H3Cl2)), 4.26 – 4.20 (m, 1H, H-4’), 4.13 (d, J3’,4’ = 7.7 
Hz, 1H, H-3’), 3.88 (dd, J5’a,5’b = 10.8 Hz, J5’a,4’ = 2.7 Hz, 1H, H-5’a), 3.73 (dd, J5’b,5’a = 10.8 Hz, J5’b,4’ = 
3.4 Hz, 1H, H-5’b), 0.90 (s, 3H, 2’-CH3). 
13C NMR (126 MHz, CDCl3) δ 156.73 (C, Carom), 151.83 (CH, C2), 150.32 (C, Carom), 134.65, 
134.21, 134.09, 133.96, 133.87, 133.71 (6 C, Carom), 130.64, 130.16, 129.38, 129.34, 127.26, 
127.16 (6 CH, Carom), 122.43 (CH, C8), 103.52 (C, Carom), 98.34 (CH, C7), 91.16 (CH, C1’), 81.57 
(CH, C3’), 80.19 (CH, C4’), 79.28 (C, C2’), 70.33 (CH2, CH2(C6H3Cl2)), 70.09 (CH2, CH2(C6H3Cl2)), 69.38 
(CH2, C5’), 21.29 (CH3, 2’-CH3). 
 
4. EXPERIMENTAL PART 
213 
 
 
C27H25Cl4N3O5, MW 613.32 
 
7-Deaza-3’,5’-bis-O-(2,4-dichlorobenzyl)-2’-C-methyl-6-O-methylinosine (55). 
Compound 55 was isolated as a side-product of the synthesis of compound 54 and obtained as a 
white powder (0.018 g, 10% yield); mp: 71-73 °C. 
1H NMR (500 MHz, CD3OD) δ 8.38 (s, 1H, H-2), 7.64 (d, J8,7 = 3.7 Hz, 1H, H-8), 7.53 (d, J = 8.3 Hz, 1H, 
Harom), 7.49 – 7.43 (m, 3H, Harom), 7.35 – 7.31 (m, 2H, Harom), 6.47 (d, J7,8 = 3.7 Hz, 1H, H-7), 
6.34 (s, 1H, H-1’), 4.83 (d, 1H, Jgem = 12.7 Hz, 1H, H-CH(C6H3Cl2)), 4.73 (d, Jgem = 12.7 Hz, 1H, H-
CH(C6H3Cl2)), 4.70 (d, Jgem = 12.6 Hz, 1H, H-CH(C6H3Cl2)), 4.62 (d, Jgem = 12.6 Hz, 1H, H-CH(C6H3Cl2)), 
4.30 (m, 1H, H-4’), 4.27 (d, J3’,4’ = 8.7 Hz, 1H, H-3’), 4.12 (s, 3H, 4-OCH3), 4.00 (dd, J5’a,5’b = 11.1 Hz, 
J5’a,4’ = 1.9 Hz, 1H, H-5’a), 3.82 (dd, J5’b,5’a = 11.1 Hz, J5’b,4’ = 2.6 Hz, 1H, H-5’b), 0.92 (s, 3H, 2’-CH3). 
13C NMR (126 MHz, CD3OD) δ 163.07, 151.52 (2 C, Carom), 150.41 (CH, C2), 134.47, 134.34, 
134.08, 134.04, 133.93, 133.63 (6 CH, Carom), 130.94, 130.68, 128.87, 128.69, 126.96, 126.94 (6 C, 
Carom), 123.69 (CH, C8), 105.55 (C, Carom), 98.70 (CH, C7), 91.22 (CH, C1’), 80.44 (CH, C3’), 79.98 
(CH, C4’), 79.11 (C, C2’), 69.73 (CH2, CH2(C6H3Cl2)), 69.51 (CH2, CH2(C6H3Cl2)), 68.53 (CH2, C5’), 
52.94 (CH3, 4-OCH3), 19.55 (CH3, 2’-CH3). 
MS (ES+) m/z 614.1 [MH+], 636.1 [MNa+]. 
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C12H16N4O4, MW 280.28 
 
7-Deaza-2’-C-methyladenosine (40).[9] 
Procedure a: 
To a solution of compound 54 (0.11 g, 0.18 mmol) in anhydrous methanol and 10% glacial acetic 
acid, palladium on carbon (10% w/w, 0.011 g) was added and the reaction mixture was stirred 
under an hydrogen atmosphere (1 atm) for 48 hours (monitored by TLC). Then the reaction 
mixture was filtered through a celite pad, that was washed with methanol. The filtrate was 
evaporated and the crude residue was purified by column chromatography on silica gel eluting 
with ethylacetate/methanol (90:10 v/v) to obtain the nucleoside 40 (0.036 g, 70% yield) as a white 
foam; mp: 218-220 °C (lit. 222 °C). 
Procedure b: 
To a solution of 54 (0.32 g, 0.54 mmol) in anhydrous methanol, ammonium formate (0.27 g, 4.28 
mmol) and palladium on carbon (20% w/w, 0.064 g) were added under a nitrogen atmosphere and 
the reaction mixture was heated at reflux for 16 hours, then cooled to room temperature and 
diluted with methanol. The suspension was filtered and the filtrate concentrated to dryness. The 
crude residue was purified by flash column chromatography on silica gel (ethylacetate to 
ethylacetate/methanol 90:10 v/v) to obtain the nucleoside 40 (0.12 g, 77% yield) as a white foam. 
1H NMR (500 MHz, CD3OD) δ 8.11 (s, 1H, H-2), 7.50 (d, J8,7 = 3.7 Hz, 1H, H-8), 6.63 (d, J7,8 = 3.7 Hz, 
1H, H-7), 6.24 (s, 1H, H-1’), 4.14 (d, J3’,4’ = 8.8 Hz, 1H, 3’-H), 4.06 – 4.02 (m, 2H, H-4’ and H-5’a), 3.87 
(dd, J5’b,5’a = 12.9 Hz, J5’b,4’ = 3.8 Hz, 1H, H-5’b), 0.83 (s, 3H, 2’-CH3). 
13C NMR (126 MHz, CD3OD) δ 159.04 (C, Carom), 152.13 (CH, C2), 150.58 (C, Carom), 123.59 (CH, 
C8), 104.66 (C, Carom), 100.73 (CH, C7), 93.30 (CH, C1’), 83.75 (CH, C4’), 80.50 (C, C2’), 73.98 (CH, 
C3’), 61.48 (CH2, C5’), 20.00 (CH3, 2’-CH3). 
MS (ES+) m/z 281.1 [MH+]. 
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C27H31N6O8P, MW 598.54 
 
2’-C-Methyladenosine 5’-O-[phenyl-(benzyloxy-L-alaninyl)] phosphate (57). 
Commercially available 2’-C-methyl adenosine 56 (0.045 g, 0.16 mmol) was suspended in 
anhydrous tetrahydrofuran (0.3 mL) under an argon atmosphere and tert-butylmagnesium 
chloride 1M in tetrahydrofuran (0.16 mL, 0.16 mmol) was added dropwise at room temperature. 
After stirring 30 minutes, a solution of the phosphorochloridate 35 (0.11 g, 0.32 mmol) in 
anhydrous tetrahydrofuran (0.7 mL) was added slowly. The reaction mixture was stirred at room 
temperature for 48 hours (monitored by TLC), then the solvent was evaporated under reduced 
pressure and the residue was washed three times with chloroform. The crude residue was purified 
by column chromatography on silica gel eluting with chloroform/methanol (92:8 v/v) to isolate the 
titled compound. Compound 57 was further purified by semi-preparative HPLC (system 3) and 
obtained as a white solid (0.009 g, 9% yield). 
31P NMR (202 MHz, CD3OD) δ 4.01, 3.75. 
1H NMR (500 MHz, CD3OD) δ 8.24 - 8.22 (m, 2H, H-2 and H-8), 7.35 – 7.17 (m, 10H, Harom), 6.13, 
6.11 (2s, 1H, H-1’), 5.16 – 5.02 (m, 2H, CH2(C6H5)), 4.57 – 4.44 (m, 2H, H-4’ and H-5’a), 4.27 – 4.18 
(m, 2H, H-3’ and H-5’b), 4.07 – 3.99 (m, 1H, CHCH3), 1.35 – 1.32 (m, 3H, CHCH3), 0.96, 0.93 (2s, 3H, 
2’-CH3). 
13C NMR (126 MHz, CD3OD) δ 174.80 (d, JC-C-N-P = 4.4 Hz, C, C=O), 174.61 (d, JC-C-N-P = 5.4 Hz, C, 
C=O), 157.42, 157.41 (C, Carom), 154.02, 153.99 (CH, C2), 152.19, 152.13 (C, Carom), 150.44, 
150.37 (C, Carom), 140.73, 140.46 (CH, C8), 137.24, 137.19 (C, Carom), 130.81, 130.78, 129.56, 
129.53, 129.35, 129.29, 129.24, 129.13, 128.27, 128.00, 126.15, 121.45, 121.44, 121.42, 121.40 
(CH, Carom) 120.38 (C, Carom), 93.37, 93.08 (CH, C1’), 82.26 (d, JC-C-0-P = 8.2 Hz, CH, C4’), 82.06 (d, 
JC-C-0-P = 7.8 Hz, CH, C4’), 80.02, 79.94 (C, C2’), 74.46, 73.93 (CH, C3’), 67.95, 67.89 (CH2, CH2(C6H5)), 
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67.31 (d, JC-O-P = 5.2 Hz, CH2, C5’), 66.39 (d, JC-O-P = 4.8 Hz, CH2, C5’), 51.77, 51.60 (CH, CHCH3), 
20.51 (d, JC-C-N-P = 6.2 Hz, CH3, CHCH3), 20.26 (d, JC-C-N-P = 7.2 Hz, CH3, CHCH3), 20.16 (CH3, 2’-CH3). 
HPLC (system 1) tR = 22.91, 23.24 min. 
HPLC (system 2) tR = 22.36 min. 
MS (ES+) m/z 621.18 [MNa+]. 
HRMS calculated for C27H32N6O8P: 599.2019; found 599.2037. 
 
 
C24H32N5O8P, MW 549.51 
 
7-Deaza-2’-C-methyladenosine 5’-O-[phenyl-(isopropoxy-L-alaninyl)] phosphate (58). 
Compound 40 (0.05 g, 0.18 mmol) was dissolved in anhydrous dimethylformamide (1 mL) under a 
nitrogen atmosphere and tert-butylmagnesium chloride 1M in tetrahydrofuran (0.18 mL, 0.18 
mmol) was added dropwise at room temperature. After stirring 10 minutes, a solution of the 
compound 38 (0.07 g, 0.18 mmol) in anhydrous dimethylformamide (1 mL) was added slowly. The 
reaction mixture was stirred for 4 hours at room temperature, then quenched by adding water 
(0.5 mL) slowly. The mixture was concentrated under reduced pressure by coevaporation with 
toluene. The crude residue was purified by flash column chromatography on silica gel 
(dichloromethane to dichloromethane/methanol 93:7 v/v) to isolate the titled compound. 
Compound 58 was further purified by flash column chromatography on silica gel (dichloromethane 
to dichloromethane/methanol 93:7 v/v) and obtained as a colourless wax (0.045 g, 46% yield). 
31P NMR (202 MHz, CDCl3) δ 3.38, 3.11. 
1H NMR (500 MHz, CDCl3) δ 8.19 (s, 1H, H-2), 7.22 – 7.13 (m, 4H, Harom), 7.05 – 6.93 (m, 2H, 
Harom and H-8), 6.32 – 6.22 (m, 1H, H-7 and H-1’), 5.81, 5.77 (2 br s, 2H, 6-NH2), 4.93 – 4.83 (m, 
1H, H-iPr), 4.62 – 4.32 (m, 3H, NH, H-5’a and H-5’b), 4.18 – 4.12 (m, 1H, H-3’), 3.98 – 3.89 (m, 2H, 
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CHCH3 and H-4’), 1.26, 1.25 (s, 3H, CHCH3), 1.12 – 1.04 (m, 3H, 2 CH3-iPr), 0.71, 0.69 (2 s, 3H, 2’-
CH3). 
13C NMR (126 MHz, CDCl3) δ 173.24, 173.19, 173.14 (C, C=O), 156.91, 156.89 (C, Carom), 151.55, 
151.48 (CH, C2), 150.71, 150.66 (C, Carom), 149.69, 149.58 (C, Carom), 129.75 (CH, Carom), 
125.04, 124.97 (CH, C8), 121.84, 121.71, 120.13, 120.11, 120.09, 120.07 (CH, Carom), 103.43, 
103.35 (C, Carom), 99.16 (CH, C7), 91.43, 91.27 (CH, C1’), 80.70, 80.64 (CH, C3’), 73.93, 73.58 (CH, 
C4’), 69.34, 69.28 (CH, CH-iPr), 65.89, 65.85 (d, JC-O-P = 4.4 Hz, CH2, C5’), 65.26, 65.23 (d, JC-O-P = 4.1 
Hz, CH2, C5’), 50.48, 50.36 (CH, CHCH3), 21.65, 21.57 (CH3, 2 CH3-iPr), 20.93, 20.89 (d, JC-C-N-P = 5.1 
Hz, CH3, CHCH3), 20.84, 20.80 (d, JC-C-N-P = 5.2 Hz, CH3, CHCH3), 19.89, 19.86 (CH3, 2’-CH3). 
HPLC (system 1) tR = 21.51, 21.54 min. 
HPLC (system 2) tR = 27.23, 27.84 min. 
MS (ES+) m/z 550.2 [MH+], 572.2 [MNa+]. 
 
 
C12H12O5, MW 236.22 
 
2,3-O-(R,S)-Benzylidene-D-ribonic-γ-lactone (64 and 65).[10] 
Procedure a: 
To a stirred suspension of D-ribonic acid 1,4-lactone 63 (0.40 g, 2.70 mmol) in anhydrous 
acetonitrile (10 mL) was added benzaldehyde dimethyl acetal (0.40 mL, 2.70 mmol) under an 
argon atmosphere at 0 °C, followed by the addition of phosphorus (V) oxychloride (0.50 mL, 5.40 
mmol) dropwise at the same temperature. The initial suspension was stirred for 1 hour at 0 °C. 
The resulting solution was poured slowly into iced saturated aqueous NaHCO3 solution (30 mL) 
and stirred for 1.5 h at 0 °C. The solvent was distilled off and the aqueous solution was extracted 
with ethyl acetate (3 x 30 mL), the combined organic layer was washed with water (30 mL) and 
brine (30 mL), dried over anhydrous Na2SO4, filtered and concentrated to dryness under reduced 
pressure. The residue was purified by column chromatography on silica gel eluting with 
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hexane/ethyl acetate (70:30 v/v to 40:60 v/v) to give (R)-isomer 64 (SE) and (S)-isomer 65 (FE) as 
white powders (0.44 g, 68% yield, SE:FE = 3:1). 
Procedure b: 
To a stirred suspension of D-ribonic acid 1,4-lactone 63 (0.40 g, 2.70 mmol) in anhydrous 
dimethoxyethane (2 mL) was added benzaldehyde dimethyl acetal (0.50 mL, 3.24 mmol) and 
anhydrous tin(II) chloride (0.10 g, 0.54 mmol) under a nitrogen atmosphere at room temperature. 
The reaction mixture was heated at reflux for 1 hour, then cooled to room temperature and 
evaporated under reduced pressure. The crude residue was purified by flash column 
chromatography on silica gel (hexane to hexane/ethyl acetate 60:40 v/v) to give (R)-isomer 64 (SE) 
and (S)-isomer 65 (FE) as white powders (0.26 g, 41% yield, SE:FE = 1:1). 
(R)-isomer 64 (SE):  
1H NMR (500 MHz, DMSO-d6) δ 7.45 – 7.40 (m, 5H, Harom), 5.97 (s, 1H, CH(C6H5)), 5.42 (t, J5-OH,5 = 
4.9 Hz, 1H, 5-OH), 4.96 – 4.90 (m, 2H, H-2 and H-3), 4.79 (t, J4,5 = 2.1 Hz, 1H, H-4), 3.72 (ddd, J5a,5b = 
12.0 Hz, J5a,5-OH = 4.7 Hz, J5a,4 = 1.8 Hz, 1H, H-5a), 3.66 (ddd, J5b,5a = 12.0 Hz, J5b,5-OH = 5.0 Hz, J5b,4 = 
2.7 Hz, 1H, 5b-H). 
13C NMR (126 MHz, DMSO-d6) δ 173.48 (C, C=O), 135.83 (C, Carom), 129.83, 128.40, 126.71 (3 CH, 
Carom), 105.04 (CH, CH(C6H5)), 81.83 (CH, C4), 79.83, 75.19 (2 CH, C2 and C3), 60.36 (CH2, C5). 
(S)-isomer 65 (FE): 
1H NMR (500 MHz, DMSO-d6) δ 7.51 – 7.40 (m, 5H, Harom), 5.94 (s, 1H, CH(C6H5)), 5.37 (t, J5-OH,5 = 
5.0 Hz, 1H, 5-OH), 5.12 (d, J2,3 = 5.7 Hz, 1H, H-2), 4.83 (d, J3,2 = 5.8 Hz, 1H, H-3), 4.80 (t, J4,5 = 2.2 Hz, 
1H, H-4), 3.72 (ddd, J5a,5b = 12.1 Hz, J5a,5-OH = 4.8 Hz, J5a,4 = 2.2 Hz, 1H, H-5a), 3.65 (ddd, J5b,5a = 12.1 
Hz, J5b,5-OH = 5.2 Hz, J5b,4 = 2.9 Hz, 1H, H-5b). 
13C NMR (126 MHz, DMSO-d6) δ 173.29 (C, C=O), 136.13 (C, Carom), 129.70, 128.34, 126.66 (3 CH, 
Carom), 103.59 (CH, CH(C6H5), 84.35 (CH, C4), 77.39 (CH, C3), 75.64 (CH, C2), 60.57 (CH2, C5). 
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C19H18O5, MW 326.34 
 
5-O-Benzyl-2,3-O-(R)-benzylidene-D-ribonic-γ-lactone (67).[11] 
To a cold (0 °C) solution of (R)-isomer 64 (0.40 g, 1.69 mmol) in anhydrous tetrahydrofuran (8 mL), 
sodium hydride 60% dispersion in mineral oil (0.082 g, 2.03 mmol) was added portionwise over 5 
minutes under a nitrogen atmosphere. Then benzyl bromide (0.24 mL, 2.03 mmol) was added 
dropwise at the same temperature. The reaction mixture was allowed to attain room temperature 
and stirred for 16 hours. Ice was added slowly, then the reaction mixture was poured into ice-
water and extracted with dichloromethane (3 x 30 mL). The combined organic layer was washed 
with water (60 mL) and brine (60 mL), dried over anhydrous Na2SO4, filtered and concentrated to 
dryness. The crude residue was purified by column chromatography on silica gel eluting with 
petroleum ether/ethyl acetate (80:20 v/v) to give 67 (0.14 g, 20% yield) as a white powder. 
1H NMR (500 MHz, DMSO-d6) δ 7.45 – 7.31 (m, 10H, Harom), 5.98 (s, 1H, CH(C6H5)), 5.01 (d, J3,2 = 
5.8 Hz, 1H, H-3), 4.94 (t, J4,3 = 2.3 Hz, 1H, H-4), 4.91 (d, J2,3 = 5.8 Hz, 1H, H-2), 4.56 (s, 2H, 
CH2(C6H5)), 3.80 (dd, J5a,5b = 10.8 Hz, J5a,4 = 2.1 Hz, 1H, H-5a), 3.71 (dd, J5b,5a = 10.8 Hz, J5b,4 = 2.6 Hz, 
1H, H-5b). 
13C NMR (126 MHz, DMSO-d6) δ 173.38 (C, C=O), 137.62, 135.67 (2 C, Carom), 129.90, 128.42, 
128.38, 127.68, 127.35, 126.70 (6 CH, Carom), 105.30 (CH, CH(C6H5)), 80.22 (CH, C4), 79.70 (CH, 
C3), 75.15 (CH, C2), 72.61 (CH2, CH2(C6H5)), 68.72 (CH2, C5). 
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C28H30O5Si, MW 474.62 
 
5-O-(tert-butyldiphenylsilyl)-2,3-O-(R,S)-benzylidene-D-ribonic-γ-lactone (73 and 74). 
To a solution of the mixture of (R)-isomer 64 and (S)-isomer 65 (0.25 g, 1.05 mmol) and 1H-
imidazole (0.16 g, 2.30 mmol) in anhydrous dimethylformamide (2 mL) cooled to 0 °C, tert-
butyldiphenylsilyl chloride (0.41 mL, 1.57 mmol) was added dropwise under a nitrogen 
atmosphere. After stirring 10 minutes at 0 °C, the reaction mixture was allowed to attain room 
temperature and stirred for 4 hours. The reaction mixture was poured into water (40 mL) and 
ethyl acetate (40 mL), the aqueous phase was separated and further extracted with ethyl acetate 
(2 x 40 mL). The combined organic layer was washed several times with brine (150 mL), dried over 
anhydrous MgSO4, filtered and concentrated to dryness. The crude residue was purified by flash 
column chromatography on silica gel (hexane/ethyl acetate 97:3 v/v to hexane/ethyl acetate 90:10 
v/v) to give (R)-isomer 73 (FE) and (S)-isomer 74 (SE) (0.24 g, 48% yield) as colourless oils. 
(R)-isomer 73 (FE): 
1H NMR (500 MHz, CDCl3) δ 7.56 – 7.51 (m, 4H, Harom), 7.40 – 7.28 (m, 11H, Harom), 5.87 (s, 1H, 
CH(C6H5)), 5.05 (d, J = 5.7 Hz, 1H), 4.76 (d, J = 5.7 Hz, 1H), 4.66 – 4.64 (m, 1H, H-4), 3.83 (dd, J5a,5b = 
11.6 Hz, J5a,4 = 2.0 Hz, 1H, H-5a), 3.69 (dd, J5b,5a = 11.5 Hz, J5b,4 = 1.1 Hz, 1H, H-5b), 0.96 (s, 9H, 
tBuSi). 
13C NMR (126 MHz, CDCl3) δ 173.10 (C=O), 135.66 (CH, Carom), 135.59 (C, Carom), 135.48 (CH, 
Carom), 132.23, 131.50 (2 C, Carom), 130.30, 129.95, 128.56, 128.12, 126.54 (5 CH, Carom), 
104.68 (CH, CH(C6H5)), 84.24 (CH, C4), 77.87 (CH), 76.48 (CH), 63.80 (CH2, C5), 26.82 (CH3, 3 CH3-
tBuSi), 19.14 (C, C-tBuSi). 
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(S)-isomer 74 (SE): 
1H NMR (500 MHz, CDCl3) δ 7.60 – 7.50 (m, 4H, Harom), 7.42 – 7.25 (m, 11H, Harom), 5.90 (s, 1H, 
CH(C6H5)), 4.96 (d, J = 5.8 Hz, 1H), 4.83 (d, J = 5.8 Hz, 1H), 4.62 (s, 1H, H-4), 3.85 (d, J5a,5b = 11.4 Hz, 
1H, H-5a), 3.70 (d, J5b,5a = 11.5 Hz, 1H, H-5b), 0.98 (s, 9H, tBuSi). 
13C NMR (126 MHz, CDCl3) δ 172.99 (C, C=O), 135.66, 135.50 (2 CH, Carom), 135.24, 132.26, 131.45 
(3 C, Carom), 130.29, 130.13, 128.58, 128.10, 126.88 (5 CH, Carom), 106.71 (CH, CH(C6H5)), 81.65 
(CH, C4), 80.08 (CH), 76.00 (CH), 63.62 (CH2, C5), 26.82 (CH3, 3 CH3-tBuSi), 19.13 (C, C-tBuSi). 
MS (ES+) m/z 497.2 [MNa+]. 
 
 
C21H26O5Si, MW 386.51 
 
5-O-(tert-butyldiphenylsilyl)-D-ribonic-γ-lactone (75).[12] 
To a solution of D-ribonic acid 1,4-lactone 63 (0.40 g, 2.70 mmol) and 1H-imidazole (0.40 g, 5.94 
mmol) in anhydrous dimethylformamide (3 mL) cooled to 0 °C, tert-butyldiphenylsilyl chloride 
(0.77 mL, 2.97 mmol) was added dropwise under a nitrogen atmosphere. After stirring 30 minutes 
at 0 °C, the reaction mixture was allowed to attain room temperature and stirred for 6 hours. The 
reaction mixture was poured into water (20 mL) and ethyl acetate (20 mL), the aqueous phase was 
separated and further extracted with ethyl acetate (2 x 20 mL). The combined organic layer was 
washed several times with brine (80 mL), dried over anhydrous MgSO4, filtered and concentrated 
to dryness to give compound 75 (0.60 g, 57% yield) as a white solid, that was used in the next step 
without purification. For analysis, the crude residue was purified by flash column chromatography 
on silica gel (dichloromethane to dichloromethane/methanol 90:10 v/v). 
1H NMR (500 MHz, CDCl3) δ 7.71 – 7.66 (m, 4H, Harom), 7.45 – 7.40 (m, 6H, Harom), 5.05 (br s, 1H, 
OH), 4.95 (d, J = 5.5 Hz, 1H, H-2), 4.61 (d, J = 5.5 Hz, 1H, H-3), 4.54 (s, 1H, H-4), 4.46 (br s, 1H, OH), 
3.90 (dd, J5a,5b = 11.8 Hz, J5a,4 =2.6 Hz, 1H, H-5a), 3.85 (dd, J5b,5a = 11.7 Hz, J5b,4 = 1.8 Hz, 1H, H-5b), 
1.07 (s, 9H, tBuSi). 
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C28H30O5Si, MW 474.62 
 
5-O-(tert-butyldiphenylsilyl)-2,3-O-(S)-benzylidene-D-ribonic-γ-lactone (74). 
To a stirred solution of crude compound 75 (0.25 g, 0.64 mmol) in anhydrous dimethoxyethane (2 
mL) was added benzaldehyde dimethyl acetal (0.12 mL, 0.76 mmol) and anhydrous tin(II) chloride 
(0.024 g, 0.13 mmol) under a nitrogen atmosphere at room temperature. The reaction mixture 
was heated at reflux for 45 minutes, then cooled to room temperature and evaporated under 
reduced pressure. The crude residue was purified by flash column chromatography on silica gel 
(hexane/ethyl acetate 97:3 v/v to hexane/ethyl acetate 90:10 v/v) to give (S)-isomer 74 (0.12 g, 
40% yield) as a colourless oil. 
1H NMR (500 MHz, CDCl3) δ 7.60 – 7.50 (m, 4H, Harom), 7.42 – 7.25 (m, 11H, Harom), 5.90 (s, 1H, 
CH(C6H5)), 4.96 (d, J = 5.8 Hz, 1H), 4.83 (d, J = 5.8 Hz, 1H), 4.62 (s, 1H, H-4), 3.85 (d, J5a,5b = 11.4 Hz, 
1H, H-5a), 3.70 (d, J5b,5a = 11.5 Hz, 1H, H-5b), 0.98 (s, 9H, tBuSi). 
 
 
C29H34O5Si, MW 490.66 
 
6-O-(tert-butyldiphenylsilyl)-3,4-O-(S)-benzylidene-1-deoxy-β-D-psicofuranose (76). 
A solution of compound 74 (0.22 g, 0.46 mmol) in anhydrous tetrahydrofuran was cooled to -78 °C 
under a nitrogen atmosphere before adding a solution of 1.6M methyllithium in diethylether (0.28 
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mL, 0.46 mmol) dropwise. The reaction mixture was stirred at -78 °C for 1 hour, then quenched 
with a 10% NH4Cl aqueous solution (10 mL) and extracted with dichloromethane (3 x 20 mL). The 
combined organic layer was washed with brine (60 mL), dried over anhydrous MgSO4, filtered and 
concentrated to dryness to give compound 76 (0.22 g, 100% yield) as a colourless oil. The crude 
residue was used in the following step without purification. For analysis, the crude residue was 
purified by flash column chromatography (hexane to hexane/ethyl acetate 80:20 v/v). 
1H NMR (500 MHz, CDCl3) δ 7.63 – 7.57 (m, 5H, Harom), 7.43 – 7.28 (m, 10H, Harom), 5.74 (s, 1H, 
CH(C6H5)), 4.89 (br s, 1H, 2-OH), 4.85 (dd, J4,3 = 6.2 Hz, J4,5 = 1.0 Hz, 1H, H-4), 4.57 (d, J3,4 = 6.2 Hz, 
1H, H-3), 4.28 (m, 1H, H-5), 3.79 (dd, J6a,6b = 11.4 Hz, J6a,5 = 2.6 Hz, 1H, H-6a), 3.61 (dd, J6b,6a = 11.4 
Hz, J6b,5 = 2.7 Hz, 1H, H-6b), 1.55 (s, 3H, H-1), 1.02 (s, 9H, tBuSi). 
13C NMR (126 MHz, CDCl3) δ 136.10 (C, Carom), 135.81, 135.63 (2 CH, Carom), 131.60, 131.50 (2 C, 
Carom), 130.48, 130.28, 129.86, 128.49, 128.18, 128.11, 127.02 (7 CH, Carom), 106.58 (C, C2), 
106.27 (CH, CH(C6H5)), 88.49 (CH, C3), 85.64 (CH, C5), 82.73 (CH, C4), 65.64 (CH2, C6), 26.90 (CH3, 3 
CH3-tBuSi), 21.69 (CH3, C1), 19.17 (CH, C-tBuSi). 
MS (ES+) m/z 513.2 [MNa+]. 
 
 
C31H36O6Si, MW 532.70 
 
2-O-Acetyl-6-O-(tert-butyldiphenylsilyl)-3,4-O-(S)-benzylidene-1-deoxy-β-D-psicofuranose (77). 
To a stirred solution of compound 76 (0.22 g, 0.45 mmol) in anhydrous dichloromethane under a 
nitrogen atmosphere, 4-(dimethylamino)pyridine (0.055 g, 0.45 mmol) and acetic anhydride (0.13 
mL, 1.34 mmol) were added at room temperature. Then triethylamine (0.2 mL, 1.34 mmol) was 
added dropwise at the same temperature and the reaction mixture was stirred for 48 hours, then 
poured into ice-cold water (10 mL). The aqueous phase was extracted with dichloromethane (3 x 
10 mL). The combined organic layer was washed with saturated NaHCO3 aqueous solution and 
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brine, dried over anhydrous MgSO4, filtered and concentrated to dryness. The crude residue was 
purified by flash column chromatography on silica gel (hexane to hexane/ethyl acetate 90:10 v/v) 
to give compound 77 (0.12 g, 48% yield) as a colourless oil. 
1H NMR (500 MHz, CDCl3) δ 7.60 – 7.56 (m, 5H, Harom), 7.44 – 7.41 (m, 2H, Harom), 7.36 – 7.27 
(m, 8H, Harom), 5.76 (s, 1H, CH(C6H5)), 4.79 (d, J = 6.2 Hz, 1H), 4.75 (d, J = 6.2 Hz, 1H), 4.45 (dd, J5,6b 
= 9.0 Hz, J5,6a = 5.4 Hz, 1H, H-5), 3.70 (dd, J6a,6b = 10.2 Hz, J6a,5 = 5.4 Hz, 1H, H-6a), 3.52 (t, J6b,6a = 
10.2 Hz, 1H, H-6b), 1.70 (s, 3H, COCH3), 1.66 (s, 3H, H-1), 0.99 (s, 9H, tBuSi).
 
13C NMR (126 MHz, CDCl3) δ 169.40 (C, C=O), 135.88 (C, Carom), 135.61 (CH, Carom), 133.26, 
132.93 (2 C, Carom), 129.91, 128.48, 127.83, 127.06 (4 CH, Carom), 113.36 (C, C2), 106.51 (CH, 
CH(C6H5)), 86.42 (CH), 85.60 (CH), 82.92 (CH), 63.84 (CH2, C6), 26.87 (CH3, 3 CH3-tBuSi), 22.21 (CH3, 
C1), 19.61 (CH3, COCH3), 19.27 (C, C-tBuSi). 
MS (ES+) m/z 555.2 [MNa+]. 
 
 
C34H35ClN4O4Si, MW 627.20 
 
6-chloro-9H-[6-O-(tert-butyldiphenylsilyl)-3,4-O-(S)-benzylidene-1-deoxy-α,β-D-
psicofuranosyl)]purine (79/80). 
To a stirred mixture of compounds 77 (0.29 g, 0.54 mmol) and 6-chloropurine 118 (0.18 g, 1.18 
mmol) in anhydrous acetonitrile under a nitrogen atmosphere, a 1.8M solution of ethylaluminum 
dichloride (0.95 mL, 1.72 mmol) was added dropwise at room temperature. The reaction mixture 
was stirred for 2 hours at the same temperature, then poured into an ice-cold mixture of 
saturated NaHCO3 aqueous solution (20 mL) and dichloromethane (35 mL) and stirred vigorously 
for 10 minutes. The mixture was filtered through a celite pad and washed with dichloromethane. 
The separated organic layer was washed with saturated NaHCO3 aqueous solution and brine, dried 
over anhydrous MgSO4, filtered and concentrated to dryness. The crude residue was purified by 
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flash column chromatography on silica gel (hexane to hexane/ethyl acetate 80:20 v/v) to give the 
anomeric mixture 79/80 (0.14 g, 40% yield) as a colourless oil. 
1H NMR (500 MHz, CDCl3) δ 8.70 (s, 1H, H-2 β), 8.65 (s, 1H, H-2 α), 8.44 (s, 1H, H-8 β), 8.43 (s, 1H, 
H-8 α), 7.65 – 7.17 (m, 30H, Harom), 6.05 (s, 1H, CH(C6H5) α), 5.92 (s, 1H, CH(C6H5) β), 5.75 (d, J3’,4’ 
= 6.0 Hz, 1H, H-3’ α), 5.63 (d, J3’,4’ = 6.4 Hz, 1H, H-3’ β), 4.78 – 4.74 (m, 1H, H-4’ α), 4.70 (d, J4’,3’ = 
6.4 Hz, 1H, H-4’ β), 4.60 (t, J5’,6’ = 3.8 Hz, 1H, H-5’ β), 4.50 – 4.45 (m, 1H, H-5’ α), 3.64 (d, J = 4.7 Hz, 
2H, H-6’a and H-6’b β), 3.62 – 3.59 (m, 2H, H-6’a and H-6’b α), 1.81 (s, 3H, H-1’ α), 1.72 (s, 3H, H-1’ 
β), 0.88 (s, 9H, tBuSi α), 0.84 (s, 9H, tBuSi β). 
13C NMR (126 MHz, CDCl3) δ 151.71 (CH, C2 β), 151.66 (CH, C2 α), 151.18, 151.13, 150.52, 150.50 
(4 C, Carom), 143.69 (CH, C8 α and β), 135.54, 135.52, 135.50, 135.44 (4 CH, Carom), 135.27 (C, 
Carom α and β), 133.03, 132.98, 132.21, 132.18 (4 C, Carom), 130.17, 130.13, 130.11, 130.08, 
130.06, 129.95, 129.90, 128.57, 128.56, 128.09, 127.93, 127.83, 126.81, 126.62 (14 CH, Carom), 
107.03 (CH, CH(C6H5) β), 105.18 (CH, CH(C6H5) α), 100.17 (C, C2’ β), 99.85 (C, C2’ α), 85.89 (CH, C5’ 
α), 85.83 (CH, C5’ β), 85.61 (CH, C3’ β), 84.59 (CH, C3’ α), 83.11 (CH, C4’ β), 81.60 (CH, C4’α), 63.90 
(CH2, C6’ β), 63.80 (CH2, C6’ α), 26.83 (CH3, 3 CH3-tBuSi α and β), 25.29 (CH3, C1’ β), 24.39 (CH3, C1’ 
α), 19.12 (C, C-tBuSi α), 19.08 (C, C-tBuSi β). 
MS (ES+) m/z 649.2 [MNa+]. 
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C34H37N5O4Si, MW 607.77 
 
9H-[6-O-(tert-butyldiphenylsilyl)-3,4-O-(S)-benzylidene-1-deoxy-α,β-D-psicofuranosyl)]adenine 
(81/82). 
The anomeric mixture 79/80 (0.05 g, 0.08) was dissolved in a saturated (7M) solution of ammonia 
in methanol (1 mL). The reaction mixture was stirred in a screw-cap pressure glass tube at 80 °C 
for 48 hours, then cooled to room temperature. The solvent was evaporated and the crude 
residue was purified by flash column chromatography on silica gel (dichloromethane to 
dichloromethane/methanol 98:2 v/v) to give the anomeric mixture 81/82 (0.03 g, 63% yield) as a 
colourless oil. 
1H NMR (500 MHz, CDCl3) δ 8.32 (s, 1H, H-2 β), 8.27 (s, 1H, H-2 α), 8.13 (s, 1H, H-8 β), 8.11 (s, 1H, 
H-8 α), 7.54 – 7.21 (m, 30H, Harom), 6.03 (s, 1H, CH(C6H5) α), 5.93 (s, 1H, CH(C6H5) β), 5.88 (d, J3’,4’ 
= 5.9 Hz, 1H, H-3’ α), 5.79 – 5.73 (m, 5H, H-3’ β, 6-NH2 α and β), 4.79 (d, J4’,3’ = 5.5 Hz, 1H, H-4’ α), 
4.70 (d, J4’,3’ = 6.3 Hz, 1H, H-4’ β), 4.58 – 4.54 (m, 1H, H-5’ β), 4.47 – 4.43 (m, 1H, H-5’ α), 3.65 – 
3.52 (m, 4H, H-6’a and H-6’b α and β), 1.80 (s, 1H, H-1’ α), 1.73 (s, 1H, H-1’ β), 0.93 (s, 9H, tBuSi α), 
0.90 (s, 9H, tBuSi β). 
13C NMR (126 MHz, CDCl3) δ 155.49 (C, Carom), 152.82 (CH, C2 β), 152.74 (CH, C2 α), 149.05, 
149.00 (2 C, Carom), 138.95 (CH, C8 β), 138.92 (CH, C8 α), 136.25, 135.66 (2 C, Carom), 135.53, 
135.51 (2 CH, Carom), 132.61, 132.56, 132.53 (3 C, Carom), 130.01, 129.97, 129.79, 129.76, 
128.46, 127.84, 127.82, 126.88, 126.73 (9 CH, Carom), 121.00, 120.93 (2 C, Carom), 106.95 (CH, 
CH(C6H5) β), 104.95 (CH, CH(C6H5) α), 99.31 (C, C2’ β), 99.13 (C, C2’ α), 85.83 (CH, C5’ β), 85.78 (CH, 
C5’ α), 85.51 (CH, C3’ β), 84.41 (CH, C3’ α), 82.94 (CH, C4’ β), 81.89 (CH, C4’ α), 63.84 (CH2, C6’ α), 
63.78 (CH2, C6’ β), 26.83 (CH3, 3 CH3-tBuSi α and β), 25.04 (CH3, C1’ β), 24.35 (CH3, C1’ α), 19.16 (C, 
C-tBuSi α), 19.13 (C, C-tBuSi β). 
MS (ES+) m/z 608.3 [MH+], 630.3 [MNa+]. 
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C35H38N4O5Si, MW 622.79 
 
6-O-methyl-9H-[6-O-(tert-butyldiphenylsilyl)-3,4-O-(S)-benzylidene-1-deoxy-α,β-D-
psicofuranosyl)]hypoxanthine (83/84). 
The anomeric mixture 83/84 was isolated as a side-product of the synthesis of the anomeric 
mixture 81/82 and obtained as a colourless oil (0.006 g, 12% yield). 
1H NMR (500 MHz, CDCl3) δ 8.51 (s, 1H, H-2 β), 8.45 (s, 1H, H-2 α), 8.25 (s, 1H, H-8 β), 8.23 (s, 1H, 
H-8 α), 7.54 – 7.21 (m, 30H, Harom), 6.04 (s, 1H, CH(C6H5) α), 5.93 (s, 1H, CH(C6H5) β), 5.82 (d, J3’,4’ 
= 6.0 Hz, 1H, H-3’ α), 5.71 (d, J3’,4’ = 6.4 Hz, 1H, H-3’ β), 4.80 – 4.76 (m, 1H, H-4’ α), 4.73 – 4.69 (m, 
1H, H-4’ β), 4.56 (t, J5’,6’ = 4.7 Hz, 1H, H-5’ β), 4.47 – 4.43 (m, 1H, H-5’ α), 4.12 (s, 6H, 6-OCH3 α and 
β), 3.65 – 3.54 (m, 4H, H-6’a and H-6’b α and β), 1.80 (s, 3H, H-1’ α), 1.73 (s, 3H, H-1’ β), 0.92 (s, 
9H, tBuSi α), 0.89 (s, 9H, tBuSi β). 
13C NMR (126 MHz, CDCl3) δ 161.11 (C, Carom α and β), 151.91 (CH, C2 β), 151.83 (CH, C2 α), 
150.85 (C, Carom α), 150.82 (C, Carom β), 140.55 (CH, C8 β), 140.52 (CH, C8 α), 136.20 (C, Carom α 
and β), 135.57, 135.55, 135.49 (3 CH, Carom), 132.61, 132.53, 132.51, 132.47 (4 C, Carom), 130.01, 
129.97, 129.94, 129.84, 129.80, 128.49, 127.86, 127.82, 126.87, 126.70 (10 CH, Carom), 123.00 (C, 
Carom β), 122.93 (C, Carom α), 107.04 (CH, CH(C6H5) β), 105.03 (CH, CH(C6H5) α), 99.49 (C, C2’ β), 
99.28 (C, C2’ α), 85.76 (CH, C5’ β), 85.71 (CH, C5’ α), 85.65 (CH, C3’ β), 84.57 (CH, C3’ α), 83.00 (CH, 
C4’ β), 81.84 (CH, C4’α), 63.83 (CH2, C6’ α), 63.78 (CH2, C6’ β), 54.17 (CH3, 6-OCH3 α and β), 26.84 
(CH3, 3 CH3-tBuSi α and β), 25.04 (CH3, C1’ β), 24.27 (CH3, C1’ α), 19.15 (C, C-tBuSi α), 19.12 (C, C-
tBuSi β). 
MS (ES+) m/z 645.3 [MNa+], 623.3 [MH+]. 
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C18H19N5O4, MW 369.37 
 
9H-[3,4-O-(S)-benzylidene-1-deoxy-α,β-D-psicofuranosyl)]adenine (85/86). 
A solution of the anomeric mixture 81/82 (0.087 g, 0.14 mmol) in tetrahydrofuran was cooled to 0 
°C before adding a solution of tetrabutylammonium fluoride trihydrate (0.054 g, 0.17 mmol) in 
tetrahydrofuran dropwise. The reaction mixture was stirred at the same temperature for 2 hours, 
then concentrated to dryness under reduced pressure. The crude residue was purified by flash 
column chromatography on silica gel (dichloromethane to dichloromethane/methanol 96:4 v/v) to 
give the anomeric mixture 85/86 (0.045 g, 85% yield) as a white powder. 
1H NMR (500 MHz, CD3OD) δ 8.41 (s, 1H, H-2 α), 8.40 (s, 1H, H-2 β), 8.23 (s, 1H, H-8 α and β), 7.62 
– 7.59 (m, 2H, Harom β), 7.56 – 7.53 (m, 2H, Harom α), 7.47 – 7.41 (m, 3H, Harom α and β), 6.18 
(s, 1H, CH(C6H5) α), 6.02 (s, 1H, CH(C6H5) β), 5.80 (d, J3’,4’ = 6.1 Hz, 1H, H-3’ α), 5.73 (d, J3’,4’ = 6.5 Hz, 
1H, H-3’ β), 5.02 (dd, J4’,3’ = 6.1 Hz, J4’,5’ = 3.2 Hz, 1H, H-4’ α), 4.92 (dd, J4’,3’ = 6.5 Hz, J4’,5’ = 2.2 Hz, 
1H, H-4’ β), 4.62 – 4.58 (m, 1H, H-5’ β), 4.54 (m, 1H, H-5’ α), 3.71 – 3.60 (m, 4H, H-6’a and H-6’b α 
and β), 1.93 (s, 3H, H-1’ α), 1.84 (s, 3H, H-1’ β). 
13C NMR (126 MHz, CD3OD) δ 155.86 (C, Carom α and β), 152.05 (CH, C2 β), 152.02 (CH, C2 α), 
148.46 (C, Carom α), 148.41 (C, Carom β), 139.20 (CH, C8 α and β), 136.72 (C, Carom α), 136.08 (C, 
Carom β), 129.38, 129.28, 128.05, 128.00, 126.54, 126.48 (6 CH, Carom), 119.89 (C, Carom α and 
β), 106.77 (CH, CH(C6H5) β), 104.77 (CH, CH(C6H5) α), 98.93 (C, C2’ α and β), 86.26 (CH, C5’ β), 
85.85 (CH, C5’ α), 85.72 (CH, C3’ β), 84.71 (CH, C3’ α), 82.72 (CH, C4’ β), 81.60 (CH, C4’α), 61.76 
(CH2, C6’ α), 61.64 (CH2, C6’ β), 23.32 (CH3, C1’ β), 22.72 (CH3, C1’ α). 
MS (ES+) m/z 370.2 [MH+], 392.2 [MNa+]. 
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C34H35ClN4O4Si, MW 627.20 
 
6-chloro-9H-[6-O-(tert-butyldiphenylsilyl)-3,4-O-(S)-benzylidene-1-deoxy-β-D-
psicofuranosyl)]purine (80). 
To a suspension of 6-chloropurine 118 (0.28 g, 1.82 mmol) in anhydrous acetonitrile was added 
N,O-bis(trimethylsilyl)acetamide (0.92 mL, 3.77 mmol) at room temperature under a nitrogen 
atmosphere. The resulting solution was heated to 50 °C for 1 hour, then cooled to room 
temperature. A solution of compound 77 (0.48 g, 0.91 mmol) in anhydrous acetonitrile was added 
at room temperature. The solution was then cooled to -20 °C before adding trimethylsilyl 
trifluoromethanesulfonate (0.16 mL, 0.91 mmol) dropwise. The reaction mixture was stirred at a 
temperature from -20 °C to 0 °C for 1 hour, then quenched by adding saturated NaHCO3 aqueous 
solution and diluted with dichloromethane. The layers were separated and the organic phase was 
washed with water and brine, dried over anhydrous MgSO4, filtered and concentrated to dryness. 
The crude residue was purified by flash column chromatography on silica gel (hexane to 
hexane/ethyl acetate 80:20 v/v) to give compound 80 (0.08 g, 14% yield) as a colourless oil. 
1H NMR (500 MHz, CDCl3) δ 8.81 (s, 1H, H-2), 8.54 (s, 1H, H-8), 7.64 – 7.59 (m, 2H, Harom), 7.55 (d, 
J = 7.2 Hz, 4H, Harom), 7.49 – 7.40 (m, 5H, Harom), 7.35 (t, J = 7.4 Hz, 4H, Harom), 6.04 (s, 1H, 
CH(C6H5)), 5.75 (d, J3’,4’ = 6.4 Hz, 1H, H-3’), 4.83 – 4.81 (m, 1H, H-4’), 4.70 (t, J5’,6’ = 4.3 Hz, 1H, H-5’), 
3.78 – 3.70 (m, 2H, H-6’a and H-6’b), 1.84 (s, 3H, H-1’), 0.96 (s, 9H, 3 CH3-tBuSi). 
13C NMR (126 MHz, CDCl3) δ 151.69 (CH, C2), 151.17, 150.52 (2 C, Carom), 143.64 (CH, C8), 135.53, 
135.43 (2 CH, Carom), 135.33, 133.06, 132.25 (3 C, Carom), 130.13, 130.06, 129.91, 128.53, 
127.90, 127.81.126.79 (7 CH, Carom), 107.06 (CH, CH(C6H5)), 100.11 (C, C2’), 85.86 (CH, C3’), 85.60 
(CH, C5’), 83.05 (CH, C4’), 63.88 (CH2, C6’), 26.83 (CH3, 3 CH3-tBuSi), 25.20 (CH3, C1’), 19.08 (C, C-
tBuSi). 
MS (ES+) m/z 649.2 [MNa+]. 
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C34H37N5O4Si, MW 607.77 
 
9H-[6-O-(tert-butyldiphenylsilyl)-3,4-O-(S)-benzylidene-1-deoxy-β-D-psicofuranosyl)]adenine 
(82). 
Compound 82 was prepared as described for the anomeric mixture 81/82 from 80 (0.26 g, 0.41 
mmol). The crude residue was purified by flash column chromatography on silica gel 
(dichloromethane to dichloromethane/methanol 99:1 v/v) to give compound 82 (0.17 g, 66% 
yield) as a colourless oil. 
1H NMR (500 MHz, CDCl3) δ 8.43 (s, 1H, H-2), 8.23 (s, 1H, H-8), 7.64 – 7.53 (m, 6H, Harom), 7.48 – 
7.40 (m, 5H, Harom), 7.35 (dd, J = 16.1, 7.8 Hz, 4H, Harom), 6.03 (s, 1H, CH(C6H5)), 5.87 (d, J3’,4’ = 
6.4 Hz, 1H, H-3’), 5.67 (s, 2H, 6-NH2), 4.80 (d, J4’,3’ = 6.3 Hz, 1H, H-4’), 4.66 (t, J5’,6’ = 5.0 Hz, 1H, H-
5’), 3.72 (dd, J6’a,6’b = 11.3 Hz, J6’a,5’ = 5.9 Hz, 1H, H-6’a), 3.67 (dd, J6’b,6’a = 11.3 Hz, J6’b,5’ = 5.3 Hz, 1H, 
H-6’b), 1.83 (s, 3H, H-1), 1.01 (s, 9H, 3 CH3-tBuSi). 
13C NMR (126 MHz, CDCl3) δ 155.42 (C, Carom), 152.83 (CH, C2), 148.99 (C, Carom), 138.96 (CH, 
C8), 135.64 (C, Carom), 135.53, 135.49 (2 CH, Carom), 132.54, 132.53 (2 C, Carom), 130.01, 129.97, 
129.80, 128.46, 127.84, 127.81, 126.88 (7 CH, Carom), 120.98 (C, Carom), 106.95 (CH, CH(C6H5)), 
99.31 (C, C2’), 85.83 (CH, C5’), 85.51 (CH, C3’), 82.94 (CH, C4’), 63.78 (CH2, C6’), 26.82 (CH3, 3 CH3-
tBuSi), 25.05 (CH3, C1), 19.13 (C, C-tBuSi). 
MS (ES+) m/z 608.3 [MH+], 630.3 [MNa+]. 
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C35H38N4O5Si, MW 622.79 
 
6-O-methyl-9H-[6-O-(tert-butyldiphenylsilyl)-3,4-O-(S)-benzylidene-1-deoxy-β-D-
psicofuranosyl)]hypoxanthine (84). 
Compound 84 was isolated as a side-product of the synthesis of compound 82 and obtained as a 
colourless oil (0.011 g, 4% yield). 
1H NMR (500 MHz, CDCl3) δ 8.61 (s, 1H, H-2), 8.35 (s, 1H, H-8), 7.59 (dd, J = 17.2, 9.0 Hz, 6H, 
Harom), 7.48 – 7.39 (m, 5H, Harom), 7.38 – 7.32 (m, 4H, Harom), 6.04 (s, 1H, CH(C6H5)), 5.82 (d, 
J3’,4’ = 6.2 Hz, 1H, H-3’), 4.81 (d, J4’,3’ = 6.2 Hz, 1H, H-4’), 4.67 (t, J5’,6’ = 4.9 Hz, 1H, H-5’), 4.23 (s, 3H, 
6-OCH3), 3.73 (dd, J6’a,6’b = 11.3 Hz, J6’a,5’ = 5.9 Hz, 1H, H-6’a), 3.68 (dd, J6’b,6’a = 11.3 Hz, J6’b,5’ = 5.2 
Hz, 1H, H-6’b), 1.84 (s, 3H, H-1’), 1.00 (s, 9H, 3 CH3-tBuSi). 
13C NMR (126 MHz, CDCl3) δ 161.11 (C, Carom), 151.91 (CH, C2), 150.82 (C, Carom), 140.56 (CH, 
C8), 135.57, 135.49 (2 CH, Carom), 132.51, 132.46 (2 C, Carom), 130.01, 129.94, 129.84, 128.49, 
127.85, 127.82, 126.87 (7 CH, Carom), 122.99 (C, Carom), 107.04 (CH, CH(C6H5)), 99.49 (C, C2’), 
85.75 (CH, C5’), 85.65 (CH, C3’), 83.00 (CH, C4’), 63.78 (CH2, C6’), 54.17 (CH3, 6-OCH3), 26.84 (CH3, 
3 CH3-tBuSi), 25.04 (CH3, C1), 19.11 (C, C-tBuSi). 
MS (ES+) m/z 645.3 [MNa+], 623.3 [MH+]. 
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C18H19N5O4, MW 369.37 
 
9H-[3,4-O-(S)-benzylidene-1-deoxy-β-D-psicofuranosyl)]adenine (86). 
Compound 86 was prepared as described for the anomeric mixture 85/86 from 82 (0.16 g, 0.26 
mmol). The crude residue was purified by flash column chromatography on silica gel 
(dichloromethane to dichloromethane/methanol 97:3 v/v) to give compound 86 (0.07 g, 74% 
yield) as a white powder; mp: 181-183 °C. 
1H NMR (500 MHz, DMSO-d6) δ 8.19 (s, 1H, H-2), 8.09 (s, 1H, H-8), 7.53 – 7.48 (m, 2H, Harom), 7.42 
– 7.38 (m, 3H, Harom), 7.19 (s, 2H, 6-NH2), 5.91 (s, 1H, CH(C6H5)), 5.65 (d, J3’,4’ = 6.4 Hz, 1H, H-3’), 
5.03 (t, J6’-OH,6’ = 5.0 Hz, 1H, 6’-OH), 4.79 (d, J4’,3’ = 6.4 Hz, 1H, H-4’), 4.39 (t, J5’,6’ = 5.5 Hz, 1H, H-5’), 
3.43 – 3.37 (m, 1H, H-6’a), 3.35 – 3.28 (m, 1H, H-6’b), 1.64 (s, 3H, H-1). 
13C NMR (126 MHz, DMSO-d6) δ 156.59 (C, Carom), 152.71 (CH, C2), 148.85 (C, Carom), 138.83 
(CH, C8), 136.48 (C, Carom), 130.21, 128.95, 127.32 (3 CH, Carom), 120.51 (C, Carom), 106.13 (CH, 
CH(C6H5)), 98.59 (C, C2’), 86.61 (CH, C5’), 85.64 (CH, C3’), 83.01 (CH, C4’), 61.61 (CH2, C6’), 24.60 
(CH3, C1). 
MS (ES+) m/z 370.2 [MH+], 392.2 [MNa+]. 
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C11H15N5O4, MW 281.27 
 
9H-(1-deoxy-β-D-psicofuranosyl)adenine (41).[11] 
To a solution of 86 (0.03 g, 0.081 mmol) in anhydrous methanol, ammonium formate (0.25 g, 3.90 
mmol) and palladium on carbon (100% w/w, 0.03 g) were added under a nitrogen atmosphere and 
the reaction mixture was heated at reflux for 20 hours, then cooled to room temperature and 
diluted with methanol. The suspension was filtered and the filtrate concentrated to dryness. The 
crude residue was purified by flash column chromatography on silica gel (dichloromethane to 
dichloromethane/methanol 87:13 v/v) to obtain compound 41 (0.004 g, 18% yield) as a white 
powder; mp: > 230 °C. 
1H NMR (500 MHz, DMSO-d6) δ 8.39 (s, 1H, H-2), 8.13 (s, 1H, H-8), 7.22 (s, 2H, 6-NH2), 5.68 (d, J = 
4.5 Hz, 1H, OH), 5.24 – 5.17 (m, 1H, OH), 4.96 (d, J = 6.2 Hz, 1H, OH), 4.64 – 4.60 (m, 1H, H-3’), 4.03 
– 3.84 (m, 2H, H-4’ and H-5’), 3.80 – 3.73 (m, 1H, H-6’a), 3.59 – 3.52 (m, 1H, H-6’b), 1.75 (s, 3H, H-
1’). 
MS (ES+) m/z 304.3 [MNa+], 282.3 [MH+]. 
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4.2.4 PROCEDURES AND SPECTRAL DATA – SECTION 2.2.3 
 
 
C11H9ClN2O4, MW 268.65 
 
Ethyl 2-(5-chloro-2-nitrophenyl)-2-cyanoacetate (91).[13] 
To a cold (0 °C) solution of ethyl cyanoacetate (4.43 mL, 41.66 mmol) in anhydrous 
dimethylformamide, potassium tert-butoxide (7.01 g, 62.49 mmol) was added portionwise under a 
nitrogen atmosphere. The resulting white suspension was allowed to attain room temperature 
and stirred for 30 minutes, before adding a solution of 2,4-dichloronitrobenzene 89 (4.00 g, 20.83 
mmol) in 3 mL of anhydrous dimethylformamide dropwise at room temperature. The reaction 
mixture was heated to 70 °C for 16 hours (monitored by TLC), then was allowed to cool to room 
temperature and poured into ice-water. The aqueous mixture was acidified to pH 2 with HCl 6M 
and extracted with diethyl ether (3 x 100 mL). The combined organic layer was washed several 
times with brine (200 mL), dried over anhydrous MgSO4, filtered and concentrated under reduced 
pressure to obtain a dark oil (4.32 g, 77% yield). The crude compound 91 was used in the next step 
without purification. For analysis, the crude residue was purified by column chromatography on 
silica gel eluting with hexane/ethyl acetate (80:20 v/v). 
1H NMR (500 MHz, DMSO-d6) δ 8.32 (d, J = 8.1 Hz, 1H, Harom), 7.91 – 7.87 (m, 2H, Harom), 6.23 (s, 
1H, H-2), 4.24 (q, J = 7.1 Hz, 2H, CH2CH3), 1.20 (t, J = 7.1 Hz, 3H, CH2CH3). 
13C NMR (126 MHz, DMSO-d6) δ 163.51 (C, C=O), 145.40 (C, CN), 139.53 (C, C5), 132.97 (CH, 
Carom), 131.09 (CH, Carom), 128.03 (CH, Carom), 127.67 (C, Carom), 114.81 (C, Carom), 63.09 
(CH2, CH2CH3), 40.89 (CH, C2), 13.73 (CH3, CH2CH3). 
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C11H10N2O4, MW 234.21 
 
Ethyl 2-(2-nitrophenyl)-2-cyanoacetate (92).[14] 
Compound 92 was prepared as described for 91 from 2-chloronitrobenzene 90 (2.0 g, 12.69 mmol) 
and obtained as a dark oil (2.14 g, 72% yield). The crude compound 92 was used in the next step 
without purification. For analysis, the crude residue was purified by column chromatography on 
silica gel eluting with hexane/ethyl acetate (90:10 v/v to 70:30 v/v). 
1H NMR (500 MHz, DMSO-d6) δ 8.28 (d, J = 8.2 Hz, 1H, Harom), 7.92 (dd, J = 10.8, 4.3 Hz, 1H, 
Harom), 7.81 – 7.75 (m, 2H, Harom), 6.24 (s, 1H, H-2), 4.23 (q, J = 7.1 Hz, 2H, CH2CH3), 1.20 (t, J = 
7.1 Hz, 3H, CH2CH3). 
13C NMR (126 MHz, DMSO-d6) δ 164.01 (C, C=O), 146.74 (C, CN), 135.24 (CH, Carom), 133.15 (CH, 
Carom), 131.15 (CH, Carom), 125.99 (CH, Carom), 125.67 (C, Carom), 115.35 (C, Carom), 62.89 
(CH2, CH2CH3), 41.23 (CH, C2), 13.75 (CH3, CH2CH3). 
 
 
C11H11ClN2O2, MW 238.67 
 
Ethyl 2-amino-5-chloro-1H-indole-3-carboxylate (93).[15] 
To a solution of crude 91 (2.53 g, 9.42 mmol) in glacial acetic acid, zinc dust (1.85 g, 16.92 mmol) 
was added slowly at room temperature under a nitrogen atmosphere. The mixture was stirred for 
4 hours without external heating (reaction is exothermic), then filtered through a celite pad. The 
pad was washed with acetic acid (400 mL) and the solution was evaporated. The residue was 
washed with water and dried under reduced pressure to obtain compound 93 as a brown powder 
(2.00 g, 89% yield), that was used in the following step without purification. 
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1H NMR (500 MHz, DMSO-d6) δ 11.34 (s, 1H, 1-NH), 7.56 (s, 1H, Harom), 7.12 (d, J = 8.3 Hz, 1H, 
Harom), 6.97 (dd, J = 8.3, 2.0 Hz, 1H, Harom), 6.94 (s, 2H, 2-NH2), 4.25 (q, J = 7.1 Hz, 2H, CH2CH3), 
1.33 (t, J = 7.1 Hz, 3H, CH2CH3). 
13C NMR (126 MHz, DMSO-d6) δ 164.82 (C, C=O), 150.69 (C, Carom), 130.33 (C, Carom), 125.36 (C, 
Carom), 123.42 (C, Carom), 118.89 (CH, Carom), 117.08 (CH, Carom), 107.93 (CH, Carom), 79.14 (C, 
Carom), 58.32 (CH2, CH2CH3), 14.69 (CH3, CH2CH3). 
 
 
C11H12N2O2, MW 204.23 
 
Ethyl 2-amino-1H-indole-3-carboxylate (94).[15] 
Compound 94 was prepared as described for 93 from crude compound 92 (2.01 g, 8.58 mmol) and 
obtained as a brown powder, that was used directly in the next step. 
1H NMR (500 MHz, DMSO-d6) δ 11.19 (s, 1H, 1-NH), 7.63 (d, J = 7.4 Hz, 1H, Harom), 7.13 (d, J = 7.2 
Hz, 1H, Harom), 6.99 (dtd, J = 19.5, 7.3, 1.2 Hz, 2H, Harom), 6.79 (s, 2H, 2-NH2), 4.24 (q, J = 7.1 Hz, 
2H, CH2CH3), 1.33 (t, J = 7.1 Hz, 3H, CH2CH3). 
13C NMR (126 MHz, DMSO-d6) δ 165.31 (C, C=O), 150.14 (C, Carom), 131.70 (C, Carom), 121.89 (C, 
Carom), 120.87 (CH, Carom), 119.34 (CH, Carom), 118.02 (CH, Carom), 106.62 (CH, Carom), 79.25 
(C, Carom), 58.07 (CH2, CH2CH3), 14.70 (CH3, CH2CH3). 
 
 
C10H6ClN3O, MW 219.63 
 
6-chloro-3H-pyrimido[4,5-b]indol-4(9H)-one (95).[13] 
A suspension of crude compound 93 (2.00 g, 8.38 mmol) in formamide (8.0 mL, 201.4 mmol) was 
heated to 180 °C for 18 hours under a nitrogen atmosphere. The reaction mixture was cooled to 
room temperature and filtered under vacuo. The dark brown residue was washed with water, 
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dried under reduced pressure and purified by column chromatography on silica gel eluting with 
chloroform/methanol (92:8 v/v) to give 95 as an orange powder (0.73 g, 62% yield); mp: 182-184 
°C (lit 188-193 °C). 
1H NMR (500 MHz, DMSO-d6) δ 12.36 (br s, 1H, NH), 12.30 (br s, 1H, NH), 8.16 (s, 1H, H-2), 7.93 (d, 
J5,7 = 1.9 Hz, 1H, H-5), 7.50 (d, J8,7 = 8.6 Hz, 1H, H-8), 7.35 (dd, J7,8 = 8.6 Hz, J7,5 = 2.1 Hz, 1H, H-7). 
13C NMR (126 MHz, DMSO-d6) δ 158.06 (C, C=O), 154.39 (C, Carom), 148.21 (CH, C2), 133.88 (C, 
Carom), 125.44 (C, Carom), 123.98 (CH, C7), 123.21 (C, Carom), 119.50 (CH, C5), 113.25 (CH, C8), 
99.68 (C, Carom). 
 
 
C10H7N3O, MW 185.18 
 
3H-Pyrimido[4,5-b]indol-4(9H)-one (96).[13] 
Compound 96 was prepared as described for 95 from crude compound 94 (1.75 g, 8.58 mmol) and 
obtained as dark powder, that was used directly in the next step. 
1H NMR (500 MHz, DMSO-d6) δ 12.19 (br s, 1H, NH), 12.16 (br s, 1H, NH), 8.13 (s, 1H, H-2), 8.00 (d, 
J5,6 = 7.7 Hz, 1H, H-5), 7.48 (d, J8,7 = 8.1 Hz, 1H, H-8), 7.36 – 7.31 (m, 1H, Harom), 7.27 – 7.21 (m, 
1H, Harom). 
13C NMR (126 MHz, DMSO-d6) δ 158.20 (C, C=O), 153.61 (C, Carom), 147.42 (CH, C2), 135.32 (C, 
Carom), 124.02 (CH, Carom), 122.03 (C, Carom), 121.00 (CH, Carom), 120.55 (CH, C5), 111.57 (CH, 
C8), 100.06 (C, Carom). 
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C10H5Cl2N3, MW 238.07 
 
4,6-Dichloro-9H-pyrimido[4,5-b]indole (97).[13] 
Compound 95 (0.72 g, 3.28 mmol) was suspended in phosphorus (V) oxychloride (10 mL, 108.2 
mmol) under a nitrogen atmosphere and the suspension was heated at reflux for 48 hours 
(monitored by TLC). The reaction mixture was cooled to room temperature and the solvent 
evaporated under reduced pressure. The residue was diluted carefully with ice-cold water in a ice-
bath and slowly neutralised with 10% aqueous ammonia to pH 7, then filtered under vacuo. The 
crude residue was washed with cold water, then with HCl 1M and again with cold water. After 
drying under reduced pressure the titled compound was obtained as a brown powder that was 
purified by flash colum chromatography on silica gel (hexane/acetone/isopropanol 89:10:1 v/v) to 
give compound 97 as a yellow powder (0.65 g, 83% yield); mp: > 230 °C (lit. > 300 °C). 
1H NMR (500 MHz, DMSO-d6) δ 12.94 (s, 1H, 9-NH), 8.82 (s, 1H, H-2), 8.23 (s, 1H, H-5), 7.67 (m, 2H, 
H-7 and H-8). 
13C NMR (126 MHz, DMSO-d6) δ 156.26 (C, Carom), 154.51 (CH, C2), 151.81, 136.98 (2 C, Carom), 
128.33 (CH, Carom), 125.93 (C, C6), 121.45 (CH, C5), 118.90 (C, Carom), 113.97 (CH, Carom), 
110.42 (C, Carom). 
 
 
C10H6ClN3, MW 203.63 
 
4-Chloro-9H-pyrimido[4,5-b]indole (98).[13] 
Compound 98 was prepared as described for 97 from crude compound 96 (1.59 g, 8.58 mmol). 
The crude residue was purified by flash colum chromatography on silica gel 
(hexane/acetone/isopropanol 94:5:1 v/v) to give compound 98 as a yellow powder (0.33 g, 17% 
yield for last three steps); mp: > 230 °C (lit. 258 °C). 
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1H NMR (500 MHz, DMSO-d6) δ 12.73 (s, 1H, NH), 8.74 (s, 1H, H-2), 8.23 (d, J5,6 = 7.8 Hz, 1H, H-5), 
7.62 – 7.58 (m, 2H, H-7 and H-8), 7.39 (ddd, J6,5 = 8.0 Hz, J6,7 = 6.0 Hz, J6,8 = 2.2 Hz, 1H, H-6). 
13C NMR (126 MHz, DMSO-d6) δ 156.44 (C, Carom), 154.37 (CH, C2), 151.70, 138.96 (2 C, Carom), 
128.88 (CH, C7), 122.88 (CH, C5), 122.16 (CH, C6), 118.14 (C, Carom), 112.75 (CH, C8), 111.54 (C, 
Carom). 
 
 
C36H25Cl2N3O7, MW 681.11 
 
4,6-Dichloro-9-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-pyrimido[4,5-b]indole (99).[13] 
N,O-Bis(trimethylsilyl)acetamide (0.10 mL, 0.42 mmol) was added to a suspension of compound 97 
(0.10 g, 0.42 mmol) in anhydrous acetonitrile at room temperature under a nitrogen atmosphere. 
After 10 minutes, trimethylsilyl trifluoromethanesulfonate (0.15 mL, 0.84 mmol) was added 
dropwise, followed by the addition of 1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose (0.21 g, 
0.42 mmol). The reaction mixture was heated to 60 °C for 20 hours, then cooled to room 
temperature and partioned between water and ethylacetate. The aqueous phase was further 
extracted with ethylacetate (2 x 20 mL), the combined organic layer was washed with saturated 
NaHCO3 aqueous solution (40 mL) and water (40 mL), dried over anhydrous MgSO4, filtered and 
concentrated. The crude residue was purified by column chromatography on silica gel eluting with 
hexane/ethyl acetate (70:30 v/v) to give compound 99 (0.16 g, 55% yield) as a white foam; mp: 
160 – 162 °C (lit. 164 – 165 °C). 
1H NMR (500 MHz, DMSO-d6) δ 8.81 (s, 1H, H-2), 8.30 (d, J5,7 = 2.1 Hz, 1H, H-5), 8.15 (d, J8,7 = 8.9 
Hz, 1H, H-8), 8.02 – 7.98 (m, 2H, Harom), 7.93 – 7.90 (m, 2H, Harom), 7.86 – 7.83 (m, 2H, Harom), 
7.71 – 7.66 (m, 2H, Harom), 7.63 – 7.60 (m, 2H, Harom and H-7), 7.51 – 7.48 (m, 4H, Harom), 7.44 
– 7.41 (m, 2H, Harom), 7.02 (d, J1’,2’ = 4.5 Hz, 1H, H-1’), 6.60 (dd, J2’,3’ = 6.5 Hz, J2’,1’ = 4.5 Hz, 1H, H-
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2’), 6.37 (t, J3’,2’ = J3’,4’ = 6.6 Hz, 1H, H-3’), 4.93 – 4.89 (m, 1H, H-4’), 4.86 (dd, J5’b,5’a = 12.3 Hz, J5’b, 4’ = 
3.1 Hz, 1H, H-5’b), 4.69 (dd, J5’a,5’b  = 12.3 Hz, J5’a, 4’ = 4.2 Hz, 1H, H-5’a). 
13C NMR (126 MHz, DMSO-d6) δ 165.30 (C, C=O), 164.77 (C, C=O), 164.58 (C, C=O), 155.33 (C, 
Carom), 154.36 (CH, C2), 152.47, 136.84 (2 C, Carom), 133.87 (CH, Carom), 133.53, 129.39, 129.29 
(3 CH, Carom), 129.15 (C, Carom), 129.10, 128.73, 128.68, 128.67 (4 CH, Carom), 128.59 (CH, C7), 
128.42, 127.42 (2 C, Carom), 121.74 (CH, C5), 119.18 (C, Carom), 113.72 (CH, C8), 111.51 (C, 
Carom), 86.24 (CH, C1’), 78.73 (CH, C4’), 72.20 (CH, C2’), 70.10 (CH, C3’), 62.87 (CH2, C5’). 
 
 
C15H15ClN4O4, MW 350.76 
 
4-Amino-6-chloro-9-β-D-ribofuranosyl-pyrimido[4,5-b]indole (87).[16] 
Compound 99 (0.15 g, 0.22 mmol) was dissolved in a saturated (7M) solution of ammonia in 
methanol (10 mL). The reaction mixture was stirred in a screw-cap pressure glass tube at 75 °C for 
48 hours, then cooled to room temperature and filtered under vacuo to isolate pure compound 87 
(0.034 g, 44% yield) as white crystals; mp: > 230 °C. 
1H NMR (500 MHz, DMSO-d6) δ 8.51 (d, J5,7 = 2.0 Hz, 1H, H-5), 8.31 (s, 1H, H-2), 7.89 (d, J8,7 = 8.8 
Hz, 1H, H-8), 7.46 (br s, 2H, 4-NH2), 7.40 (dd, J7,8 = 8.8 Hz, J7,5 = 2.0 Hz, 1H, H-7), 6.34 (d, J1’,2’ = 7.3 
Hz, 1H, H-1’), 5.41 (dd, J5’-OH,5’a = 6.3 Hz, J5’-OH,5’b = 4.7 Hz, 1H, 5’-OH), 5.20 (d, J2’-OH,2’ = 6.6 Hz, 1H, 
2’-OH), 5.14 (d, J3’OH,3’ = 4.6 Hz, 1H, 3’-OH), 4.78 (dd, J2’,1’ and 2’,3’ = 12.9 Hz, J2’,2’-OH = 6.6 Hz, 1H, H-2’), 
4.19 (dd, J = 7.3, 5.3 Hz, 1H, H-3’), 3.97 (dd, J4’,5’b and 4’,3’ = 6.2 Hz, J4’,5’a = 3.2 Hz, 1H, H-4’), 3.74 – 
3.69 (m, 1H, H-5’b), 3.64 (ddd, J5’a,5’b = 11.8 Hz, J5’a,5’-OH = 6.4 Hz, J5’a,4’ = 3.6 Hz, 1H, H-5’a). 
13C NMR (126 MHz, DMSO-d6) δ 157.77, 155.68 (2 C, Carom), 155.01 (CH, C2), 134.54, 125.86 (2 C, 
Carom), 124.42 (CH, C7), 121.54 (C, Carom), 120.59 (CH, C5), 113.07 (CH, C8), 95.11 (C, Carom), 
87.08 (CH, C1’), 85.47 (CH, C4’), 70.63 (CH, C2’), 70.26 (CH, C3’), 61.81 (CH2, C5’). 
MS (ES+) m/z 351.1 [MH+]. 
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C27H31ClN5O8P, MW 619.99 
 
4-Amino-6-chloro-9-β-D-ribofuranosyl-pyrimido[4,5-b]indole 5’-O-[phenyl-(isopropoxy-L-
alaninyl)] phosphate (101). 
Compound 87 (0.052 g, 0.15 mmol) was suspended in anhydrous dimethylformamide (1.5 mL) in a 
10 mL sealed microwave tube under a nitrogen atmosphere and tert-butylmagnesium chloride 1M 
in tetrahydrofuran (0.14 mL, 0.15 mmol) was added dropwise at room temperature. After stirring 
10 minutes, a solution of compound 38 (0.06 g, 0.15 mmol) in anhydrous dimethylformamide (0.8 
mL) was added slowly. The reaction mixture was stirred for 30 minutes under MWI (100 W, 65 °C), 
then cooled to room temperature and quenched by adding water (0.5 mL) slowly. The mixture was 
concentrated under reduced pressure by coevaporation with toluene. The crude residue was 
purified by flash column chromatography on silica gel (dichloromethane to 
dichloromethane/methanol 90:10 v/v) to isolate the titled compound. Compound 101 was further 
purified by flash column chromatography on silica gel (dichloromethane to 
dichloromethane/methanol 92:8 v/v) and obtained as a white powder (0.012 g, 13% yield). 
31P NMR (202 MHz, CD3OD) δ 3.80, 3.69. 
1H NMR (500 MHz, CD3OD) δ 8.20, 8.19 (2 s, 1H, H-2), 8.12, 8.11 (2 d, J5,7 = 1.9 Hz, 1H, H-5), 7.66, 
7.63 (d, J8,7 = 8.8 Hz, 1H, H-8), 7.30 – 7.24 (m, 1H, H-7), 7.22 – 7.16 (m, 2H, Harom), 7.10 – 7.03 (m, 
3H, Harom), 6.33, 6.31 (2 d, J1’,2’ = 6.1 Hz, 1H, H-1’), 4.92, 4.88 (2 m, 1H, H-2’), 4.78 – 4.71 (m, 1H, 
H-iPr), 4.47 – 4.43 (m, 1H, H-3’), 4.40 – 4.25 (m, 2H, H-5’a and H-5’b), 4.15 – 4.09 (m, 1H, H-4’), 
3.78 – 3.71, 3.70 – 3.63 (2 m, 1H, CHCH3), 1.15 – 0.99 (m, 9H, CHCH3 and 2 CH3-iPr). 
13C NMR (126 MHz, CD3OD) δ 173.15 (d, JC-C-N-P = 4.5 Hz, C, C=O), 172.96 (d, JC-C-N-P = 5.5 Hz, C, 
C=O), 157.75, 157.74, 155.93, 155.88 (C, Carom), 154.60, 154.56 (CH, C2), 150.76, 150.70, 135.02, 
134.97 (C, Carom), 129.34, 129.32 (CH, Carom), 127.25 (C, Carom), 125.04, 124.98, 124.74, 124.74, 
124.68, 124.67 (CH, Carom), 121.80, 121.73 (C, Carom), 120.36, 120.33 (CH, C5), 119.97, 119.96, 
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119.94, 119.93 (CH, Carom), 112.60, 112.43 (CH, C8), 95.95 (C, Carom), 88.36, 88.20 (CH, C1’), 
82.47, 82.43 (d, JC-C-O-P = 6.8 Hz, CH, C4’), 82.40, 82.36 (d, JC-C-O-P = 6.6 Hz, CH, C4’), 71.08, 71.02 
(CH, C2’), 69.81, 69.56 (CH, C3’), 68.73, 68.70 (CH, CH-iPr), 66.47, 66.43 (d, JC-O-P = 5.4 Hz, CH2, C5’), 
65.94, 65.90 (d, JC-O-P = 5.2 Hz, CH2, C5’), 50.31, 50.16 (CH, CHCH3), 20.55, 20.47 (CH3, 2 CH3-iPr), 
19.11, 19.06 (d, JC-C-N-P = 6.3 Hz, CH3, CHCH3), 18.97, 18.91 (d, JC-C-N-P = 7.2 Hz, CH3, CHCH3). 
HPLC (system 1) tR = 25.71, 26.08 min. 
HPLC (system 2) tR = 29.59, 29.81 min. 
MS (ES+) m/z 620.2 [MH+], 642.2 [MNa+]. 
 
 
C27H22O8, MW 474.46 
 
2,3,5-Tri-O-benzoyl-2-C-methyl-D-ribonic-γ-lactone (104).[17] 
To a solution of commercially available 2-C-methyl-D-ribono-1,4-lactone 103 (1.00 g, 6.17 mmol) in 
anhydrous dimethoxy ethane was added 4-(dimethylamino)pyridine (0.15 g, 1.23 mmol) and 
triethylamine (11.6 mL, 8.33 mmol) at room temperature under a nitrogen atmosphere. The 
resulting solution was stirred for 30 minutes, then cooled to -5 °C and benzoyl chloride (3.2 mL, 
27.76 mmol) was added dropwise. The reaction mixture was allowed to attain room temperature 
and stirred for 16 hours. Ice-cold water (15 mL) was added and stirring was continued for 30 
minutes, then the mixture was filtered under vacuo and washed with cold water. The crude 
product was vigorously stirred with tert-butyl methyl ether (20 mL) for 30 minutes, then filtered 
under vacuo, washed with tert-butyl methyl ether (20 mL) and dried to obtain compound 104 
(2.27 g, 77% yield) as a white solid. 
1H NMR (500 MHz, CDCl3) δ 8.06 (dd, J = 8.2, 1.0 Hz, 2H, Harom), 7.95 (dd, J = 8.2, 1.1 Hz, 2H, 
Harom), 7.75 (dd, J = 8.3, 1.1 Hz, 2H, Harom), 7.63 – 7.59 (m, 1H, Harom), 7.53 – 7.41 (m, 4H, 
Harom), 7.34 (t, J = 7.8 Hz, 2H, Harom), 7.20 (t, J = 7.9 Hz, 2H, Harom), 5.54 (d, J3,4 = 5.9 Hz, 1H, H-
3), 5.22 – 5.18 (m, 1H, H-4), 4.83 (dd, J5a,5b = 12.4 Hz, J5a,4 = 3.2 Hz, 1H, H-5a), 4.72 (dd, J5b,5a = 12.4 
Hz, J5b,4 = 4.1 Hz, 1H, H-5b), 1.98 (s, 3H, 2-CH3). 
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13C NMR (126 MHz, CDCl3) δ 172.62 (C, C=O), 165.97, 165.88, 165.39 (3 C, C=O), 133.85, 133.71, 
133.51, 129.92, 129.69, 129.63 (6 CH, Carom), 129.25 (C, Carom), 128.59, 128.42, 128.31 (3 CH, 
Carom), 127.86, 127.80 (2 C, Carom), 79.49 (CH, C3), 75.34 (C, C2), 72.51 (CH, C4), 63.15 (CH2, C5), 
23.65 (CH3, 2-CH3). 
 
 
C27H24O8, MW 476.47 
 
2,3,5-Tri-O-benzoyl-2-C-methyl-β-D-ribofuranose (105 and 106).[17] 
A solution of Red-Al® 65wt.% in toluene (2.0 mL, 6.56 mmol) was diluted with anhydrous toluene 
(2 mL) under a nitrogen atmosphere and cooled to 0 °C, then a solution of anhydrous ethanol 
(0.38 mL, 6.56 mmol) in anhydrous toluene (1.6 mL) was added dropwise over a period of 5 
minutes. The resulting solution was stirred at 0 °C for 15 minutes, then 2 mL of the thus prepared 
reagent were added dropwise to a cold (-5 °C) solution of 104 in anhydrous toluene over a period 
of 10 minutes, under a nitrogen atmosphere. The reaction mixture was stirred at the same 
temperature for 1.5 hours, then quenched with acetone (0.2 mL), water (15 mL) and HCl 1M 
aqueous solution (15 mL) at 0 °C and allowed to attain room temperature. The mixture was 
extracted with ethyl acetate (3 x 30 mL). The combined organic layer was washed with brine (60 
mL), dried over anhydrous MgSO4, filtered and concentrated under reduced pressure to obtain 
compound 105 and 106 (0.39 g, 82% yield) as a colourless oil. The crude mixture of products was 
used for the following step without purification. 
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C34H28O9, MW 580.58 
 
1,2,3,5-Tetra-O-benzoyl-2-C-methyl-β-D-ribofuranose (107).[17] 
To a solution of the mixture of crude compounds 105 and 106 (0.39 g, 0.82 mmol) and 4-
(dimethylamino)pyridine (0.01 g, 0.08 mmol) in anhydrous tetrahydrofuran, triethylamine (0.60 
mL, 4.09 mmol) was added dropwise at room temperature under a nitrogen atmosphere. The 
solution was cooled to 5 °C before adding benzoyl chloride (0.20 mL, 1.64 mmol) dropwise. The 
reaction mixture was allowed to attain room temperature and stirred for 24 hours, then was 
quenched by adding ice-cold water (10 mL) and saturated NaHCO3 aqueous solution (10 mL), 
extracted with ethyl acetate (3 x 50 mL). The combined organic layer was washed with water (50 
mL) and brine (50 mL), dried over anhydrous MgSO4, filtered and concentrated under reduced 
pressure. The crude product was vigorously stirred with tert-butyl methyl ether (5 mL) for 5 
minutes, then heptanes (5 mL) and water (0.1 mL) were added and the suspension was vigorously 
stirred for additional 2 hours. The solid was filtered under vacuo, washed with heptane/tert-butyl 
methyl ether (1:1 v/v, 10 mL), then with tert-butyl methyl ether (5 mL) and dried to obtain 
compound 107 (0.17 g, 35% yield) as a white solid. 
1H NMR (500 MHz, CDCl3) δ 8.07 – 8.02 (m, 4H, Harom), 7.99 (dd, J = 8.3, 1.2 Hz, 2H, Harom), 7.82 
(dd, J = 8.3, 1.2 Hz, 2H, Harom), 7.54 (td, J = 7.5, 0.9 Hz, 3H, Harom), 7.44 – 7.36 (m, 7H, Harom), 
7.09 (dd, J = 8.1, 7.6 Hz, 2H, Harom), 6.99 (s, 1H, H-1), 5.88 (d, J3,4 = 8.1 Hz, 1H, H-3), 4.74 – 4.69 
(m, 1H, H-4), 4.61 (dd, J5a,5b = 12.1 Hz, J5a,4 = 4.1 Hz, 1H, H-5a), 4.47 (dd, J5b,5a = 12.1, J5b,4 = 4.8 Hz, 
1H, H-5b), 1.88 (s, 3H, 2-CH3). 
13C NMR (126 MHz, CDCl3) δ 166.11, 165.64, 164.81, 164.56 (4 C, C=O), 133.78, 133.64, 133.48, 
132.96 (4 CH, Carom), 130.31 (C, Carom), 129.95, 129.94, 129.79, 129.64 (4 CH, Carom), 129.47, 
129.26, 128.94 (3 C, Carom), 128.65, 128.63, 128.56, 128.18 (4 CH, Carom), 97.90 (CH, C1), 86.71 
(C, C2), 78.62 (CH, C3), 76.26 (CH, C4), 63.94 (CH2, C5), 16.91 (CH3, 2-CH3). 
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C37H27Cl2N3O7, MW 696.53 
 
4,6-Dichloro-9-(2,3,5-tri-O-benzoyl-2-C-methyl-β-D-ribofuranosyl)-pyrimido[4,5-b]indole (108). 
N,O-Bis(trimethylsilyl)acetamide (0.10 mL, 0.42 mmol) was added to a suspension of compound 97 
(0.10 g, 0.42 mmol) in anhydrous acetonitrile at room temperature under a nitrogen atmosphere. 
After 10 minutes, trimethylsilyl trifluoromethanesulfonate (0.15 mL, 0.84 mmol) was added 
dropwise, followed by the addition of compound 107 (0.24 g, 0.42 mmol). The reaction mixture 
was heated to 60 °C for 20 hours, then cooled to room temperature and partioned between water 
and ethylacetate. The aqueous phase was further extracted with ethylacetate (2 x 20 mL), the 
combined organic layer was washed with saturated NaHCO3 aqueous solution (40 mL) and water 
(40 mL), dried over anhydrous MgSO4, filtered and concentrated. The crude residue was purified 
by column chromatography on silica gel eluting with hexane/ethyl acetate (60:40 v/v) to give 
compound 108 (0.06 g, 21% yield) as a colourless oil. 
1H NMR (500 MHz, CDCl3) δ 9.10 (s, 1H, H-2), 8.59 (d, J5,7 = 2.0 Hz, 1H, H-5), 8.42 – 8.39 (m, 2H, H-8 
and Harom), 8.35 – 8.32 (m, 2H, Harom), 8.24 – 8.20 (m, 2H, Harom), 8.13 (d, J7,8 = 8.9 Hz, 1H, H-
7), 7.85 – 7.77 (m, 4H, Harom), 7.73 – 7.69 (m, 4H, Harom), 7.67 – 7.63 (m, 3H, Harom), 7.55 (m, 
2H, Harom), 7.41 (s, 1H, H-1’), 5.24 (dd, J5’a,5’b = 11.9 Hz, J5’a,4’ = 3.6 Hz, 1H, H-5’a), 5.17 (dd, J5’b,5’a = 
11.9 Hz, J5’b,4’ = 6.4 Hz, 1H, H-5’b), 5.13 – 5.06 (m, 2H, H-3’ and H-4’), 1.85 (s, 3H, 2’-CH3). 
13C NMR (126 MHz, CDCl3) δ 166.25 (C, C=O), 165.65 (C, C=O), 165.53 (C, C=O), 155.36 (C, Carom), 
153.99 (CH, C2), 153.47 (C, Carom), 137.77 (C, Carom), 135.11 (CH, C8), 133.77, 133.73, 133.21 (3 
CH, Carom), 130.06 (C, Carom), 129.93, 129.91, 129.71 (3 CH, Carom), 129.59 (C, Carom), 129.09, 
129.01, 128.64, 128.59, 128.38 (5 CH, Carom), 125.45 (CH, C7), 122.74 (CH, C5), 119.80, 112.74 (2 
C, Carom), 89.02 (CH, C1’), 87.19 (C, C2’), 76.32 (CH), 63.99 (CH2, C5’), 18.19 (CH3, 2’-CH3). 
MS (ES+) m/z 696.2 [MH+]. 
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C16H17ClN4O4, MW 364.78 
 
4-Amino-6-chloro-9-(2-C-methyl-β-D-ribofuranosyl)-pyrimido[4,5-b]indole (102). 
Compound 108 (0.19 g, 0.27 mmol) was dissolved in a saturated (7M) solution of ammonia in 
methanol (4 mL). The reaction mixture was stirred in a screw-cap pressure glass tube at 80 °C for 
24 hours, then cooled to room temperature. The solvent was evaporated under reduced pressure 
and the crude residue was purified by flash column chromatography on silica gel 
(dichloromethane to dichloromethane/methanol 90:10 v/v) to isolate the titled compound. 
Compound 102 was further purified by flash column chromatography on silica gel 
(dichloromethane to dichloromethane/methanol 90:10 v/v) and obtained as a white powder 
(0.052 g, 52% yield); mp: > 230 °C. 
1H NMR (500 MHz, DMSO-d6) δ 8.50 (s, 1H, H-5), 8.31 (s, 1H, H-2), 7.95 (d, J8,7 = 8.4 Hz, 1H, H-8), 
7.46 (br s, 2H, 4-NH2), 7.39 (d, J7,8 = 8.4 Hz, 1H, H-7), 6.46 (s, 1H, H-1’), 5.24 (d, J3’,4’ = 7.0 Hz, 1H, H-
3’), 5.21 (br s, 1H, OH), 5.00 (br s, 1H, OH), 4.17 (br s, 1H, OH), 3.91 – 3.84 (m, 2H, H-4’ and H-5’a), 
3.82 – 3.75 (m, 1H, H-5’b), 0.69 (s, 3H, 2’-CH3). 
13C NMR (126 MHz, DMSO-d6) δ 158.21 (C, Carom), 155.54 (CH, C2), 135.10 (C, Carom), 126.30 (C, 
Carom), 124.91 (CH, C7), 121.83 (C, Carom), 121.04 (CH, C5), 92.94 (CH, C1’), 82.47 (CH, C4’), 78.54 
(C, C2’), 73.94 (CH, C3’), 60.42 (CH2, C5’), 21.07 (CH3, 2’-CH3). 
HPLC (system 1) tR = 19.20 min. 
HPLC (system 2) tR = 25.82 min. 
MS (ES+) m/z 365.1 [MH+]. 
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C17H18ClN3O5, MW 379.79 
 
6-Chloro-4-methoxy-9-(2-C-methyl-β-D-ribofuranosyl)-pyrimido[4,5-b]indole (109). 
Compound 109 was isolated as a side-product of the synthesis of compound 102 and obtained as 
an off-white powder (0.015 g, 14% yield); mp: > 230 °C. 
1H NMR (500 MHz, DMSO-d6) δ 8.71 (s, 1H, H-2), 8.12 (d, J8,7 = 8.6 Hz, 1H, H-8), 8.01 (d, J5,7 = 2.1 
Hz, 1H, H-5), 7.52 (dd, J7,8 = 8.6 Hz, J7,5 = 2.1 Hz, 1H, H-7), 6.53 (s, 1H, H-1’), 5.29 (d, J3’,4’ = 6.7 Hz, 
1H, H-3’), 5.10 (t, J = 5.1 Hz, 1H, OH), 5.07 (br s, 1H, OH), 4.22 (s, 3H, 4-OCH3), 4.16 (br s, 1H, OH), 
3.94 – 3.86 (m, 2H, H-4’ and H-5’a), 3.85 – 3.79 (m, 1H, H-5’b), 0.70 (s, 3H, 2’-CH3). 
13C NMR (126 MHz, DMSO-d6) δ 164.32, 156.50 (2 C, Carom), 155.32 (CH, C2), 135.86 (C, Carom), 
126.74 (C, Carom), 126.66 (CH, C7), 121.64 (CH, C5), 120.51 (C, Carom), 98.82 (CH, C8), 93.17 (CH, 
C1’), 82.62 (CH, C4’), 78.53 (C, C2’), 74.09 (CH, C3’), 60.45 (CH2, C5’), 54.73 (CH3, 4-OCH3), 21.07 
(CH3, 2’-CH3). 
HPLC (system 1) tR = 26.54 min. 
HPLC (system 2) tR = 30.38 min. 
MS (ES+) m/z 380.1 [MH+], 402.1 [MNa+]. 
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4.2.5 PROCEDURES AND SPECTRAL DATA – SECTION 2.2.4 
 
 
C15H34O3Si2, MW 318.60 
 
Bis-(tert-butyldimethylsilyloxy)-acetone (113).[18] 
To a solution of 1,3-dihydroxyacetone 112 dimer (0.80 g, 4.44 mmol) and 4-(dimethylamino)-
pyridine (1.36 g, 11.10 mmol) in anhydrous dichloromethane, triethylamine (1.86 ml, 13.32 mmol) 
was added at room temperature under a nitrogen atmosphere. The solution was cooled to 0 °C 
and tert-butyldimethylchlorosilane (3.35 g, 22.20 mmol) was added slowly. The reaction mixture 
was allowed to attain room temperature and stirred for 24 hours. Then a saturated aqueous 
NaHCO3 solution (20 mL) and extracted with petroleum ether (3 x 30 mL), the combined organic 
layer was washed with water (50 mL) and brine (50 mL), dried over anhydrous MgSO4, filtered and 
concentrated under reduced pressure. The residue was purified by column chromatography on 
silica gel eluting with hexane/ethyl acetate (97:3 v/v) to give compound 113 (2.46 g, 87% yield) as 
a colourless syrup. 
1H NMR (500 MHz, CDCl3) δ 4.32 (s, 4H, 2 CH2), 0.83 (s, 18H, 2 tBuSi), 0.00 (s, 12H, 4 CH3Si). 
13C NMR (126 MHz, CDCl3) δ 208.51 (C, C=O), 67.87 (CH2, 2 CH2), 25.74 (CH3, 6 CH3-tBuSi), 18.30 (C, 
2 C-tBuSi), -5.58 (CH3, 4 CH3Si). 
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C19H40O4Si2, MW 388.69 
 
Ethyl 3,3’-bis-(tert-butyldimethylsilyloxymethyl)prop-2-en-1-oate (114).[18] 
Triethylphosphonoacetate (1.70 ml, 8.51 mmol) was added dropwise to a suspension of sodium 
hydride 60% dispersion in mineral oil (0.34 g, 8.51 mmol) in anhydrous tetrahydrofuran at 0 °C 
under a nitrogen atmosphere. The reaction mixture was stirred at room temperature for an hour, 
before cooling to 0 °C and adding slowly a solution of 113 (2.46 g, 7.74 mmol) in anhydrous 
tetrahydrofuran (1 mL). The reaction mixture was allowed to attain room temperature and stirred 
for 2 hours, then poured into water (30 mL) and extracted with ethyl acetate (3 x 30 mL), the 
combined organic layer was washed with water (30 mL) and brine (30 mL), dried over anhydrous 
MgSO4, filtered and concentrated under reduced pressure. The residue was purified by column 
chromatography on silica gel eluting with hexane/ethyl acetate (96:4 v/v) to give compound 114 
(2.83 g, 94% yield) as a colourless oil. 
1H NMR (500 MHz, CDCl3) δ 5.90 – 5.88 (m, 1H, H-2), 4.79 – 4.77 (m, 2H, 3-CH2), 4.35 – 4.33 (m, 
2H, 3-CH2), 4.06 (q, J = 7.1 Hz, 2H, CH2CH3), 1.19 (t, J = 7.1 Hz, 3H, CH2CH3), 0.84 (s, 9H, tBuSi), 0.80 
(s, 9H, tBuSi), -0.00 (s, 6H, 2 CH3Si), -0.03 (s, 6H, 2 CH3Si). 
13C NMR (126 MHz, CDCl3) δ 166.57 (C, C=O), 161.44 (C, C3), 111.92 (CH, C2), 63.22 (CH2, 3-CH2), 
61.53 (CH2, 3-CH2), 59.72 (CH2, CH2CH3), 25.91 (CH3, 3 CH3-tBuSi), 25.78 (CH3, 3 CH3-tBuSi), 18.39 
(C, C-tBuSi), 18.16 (C, C-tBuSi), 14.31 (CH3, CH2CH3), -5.49 (CH3, 2 CH3Si), -5.59 (CH3, 2 CH3Si). 
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C17H38O3Si2, MW 346.65 
 
3,3’-Bis-(tert-butyldimethylsilyloxymethyl)prop-2-en-1-ol (115).[19] 
To a solution of 114 (2.52 g, 6.48 mmol) in anhydrous dichloromethane, a 1M solution of DIBALH 
in cyclohexane (13.6 mL, 13.62 mmol) was added slowly at -20 °C and the reaction mixture was 
stirred for 1 hour in the dry ice-acetone bath at the temperature of -20 °C to 0 °C. Then, methanol 
(15 mL) was added and the mixture poured into 10% Rochelle salt aqueous solution (200 mL) and 
ethyl acetate (200 mL). The two-phase solution was stirred vigorously for 1 hour at room 
temperature, until the two phases were clearly separated. The organic layer was separated, 
washed with brine/water (1:1 v/v, 2 x 100 mL), dried over MgSO4, filtered and concentrated in 
vacuo. The residue was purified by column chromatography on silica gel eluting with hexane/ethyl 
acetate (90:10 v/v) to give compound 115 (1.58 g, 79% yield) as a colourless syrup. 
1H NMR (500 MHz, CDCl3) δ 5.73 (t, J2,1 = 6.8 Hz, 1H, H-2), 4.15 – 4.13 (m, 4H, 3-CH2 and H-1), 4.08 
(s, 2H, 3-CH2), 2.04 (s, 1H, 1-OH), 0.84 (s, 9H, tBuSi), 0.83 (s, 9H, tBuSi), 0.01 (s, 6H, 2 CH3Si), -0.00 
(s, 6H, 2 CH3Si). 
13C NMR (126 MHz, CDCl3) δ 141.17 (C, C3), 125.41 (CH, C2), 64.86 (CH2, 3-CH2), 59.41 (CH2, 3-CH2), 
58.70 (CH2, C1), 25.94 (CH3, 3 CH3-tBuSi), 25.85 (CH3, 3 CH3-tBuSi), 18.40 (C, C-tBuSi), 18.25 (C, C-
tBuSi), -5.34 (CH3, 2 CH3Si), -5.41 (CH3, 2 CH3Si). 
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C17H37BrO2Si2, MW 409.55 
 
3,3’-Bis-(tert-butyldimethylsilyloxymethyl)prop-2-enyl bromide (116).[20] 
To a solution of 115 (0.18 g, 0.52 mmol) and triphenylphosphine (0.15 g, 0.57 mmol) in anhydrous 
dichloromethane, N-bromosuccinimide (0.18 g, 1.03 mmol) was added slowly at 0 °C under a 
nitrogen atmosphere. The reaction mixture was allowed to attain room temperature and stirred at 
room temperature for 4 hours, then diluted with dichloromethane. The organic layer was washed 
with water (10 mL) and brine (10 mL), dried over anhydrous MgSO4, filtered and concentrated 
under reduced pressure. The residue was purified by column chromatography on silica gel eluting 
with hexane/ethyl acetate (98:2 v/v) to give compound 116 (0.03 g, 14% yield) as a colourless oil. 
1H NMR (500 MHz, CDCl3) δ 5.78 (t, J2,1 = 8.6 Hz, 1H, H-2), 4.20 (s, 2H, 3-CH2), 4.14 (s, 2H, 3-CH2), 
4.04 (d, J1,2 = 8.6 Hz, 2H, H-1), 0.85 (s, 9H, tBuSi), 0.83 (s, 9H, tBuSi), 0.01 (s, 6H, 2 CH3Si), 0.00 (s, 
6H, 2 CH3Si). 
13C NMR (126 MHz, CDCl3) δ 142.64 (C, C3), 119.84 (CH, C2), 63.08 (CH2, 3-CH2), 57.71 (CH2, 3-CH2), 
26.42 (CH2, C1), 24.90 (CH3, 3 CH3-tBuSi), 24.85 (CH3, 3 CH3-tBuSi), 17.36 (C, C-tBuSi), 17.22 (C, C-
tBuSi), -6.38 (CH3, 2 CH3Si), -6.43 (CH3, 2 CH3Si). 
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C17H37ClO2Si2, MW 365.10 
 
3,3’-Bis-(tert-butyldimethylsilyloxymethyl)prop-2-enyl chloride (117). 
To a solution of 115 (0.25 g, 0.72 mmol) in anhydrous dichloromethane at room temperature 
under a nitrogen atmosphere were added 4-(dimethylamino)pyridine (0.053 g, 0.43 mmol), p-
toluenesulfonyl chloride (0.16 g, 0.86 mmol) and triethylamine (0.12 mL, 0.86 mmol) in sequence. 
The reaction mixture was stirred at room temperature for 4 hour, then quenched with a diluted 
aqueous solution of NaHCO3 and extracted with dichloromethane (3 x 20 mL). The combined 
organic layer was washed with brine (50 mL), dried over anhydrous MgSO4, filtered and 
concentrated under reduced pressure. The crude residue was purified by column chromatography 
on silica gel eluting with hexane/ethyl acetate (98:2 v/v) to give compound 117 (0.11 g, 40% yield) 
as a colourless oil. 
1H NMR (500 MHz, CDCl3) δ 5.69 (t, J2,1 = 8.1 Hz, 1H, H-2), 4.17 (s, 2H, 3-CH2), 4.14 – 4.11 (m, 4H, H-
1 and 3-CH2), 0.84 (s, 9H, tBuSi), 0.82 (s, 9H, tBuSi), 0.00 (s, 6H, 2 CH3Si), -0.00 (s, 6H, 2 CH3Si). 
13C NMR (126 MHz, CDCl3) δ 143.18 (C, C3), 120.95 (CH, C2), 64.13 (CH2, 3-CH2), 58.93 (CH2, 3-CH2), 
39.67 (CH2, C1), 25.93 (CH3, 3 CH3-tBuSi), 25.84 (CH3, 3 CH3-tBuSi), 18.39 (C, C-tBuSi), 18.24 (C, C-
tBuSi), -5.36 (CH3, 2 CH3Si), -5.42 (CH3, 2 CH3Si). 
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C22H39ClN4O2Si2, MW 483.19 
 
1-[3,3’-Bis-(tert-butyldimethylsilyloxymethyl)-prop-2-enyl]6-chloropurine (119).[20] 
Procedure a: 
To a suspension of 6-chloropurine 118 (0.15 g, 0.99 mmol) and caesium carbonate (0.18 g, 0.56 
mmol) in anhydrous dimethylformamide was added a solution of compound 117 (0.16 g, 0.43 
mmol) in anhydrous dimethylformamide at room temperature under a nitrogen atmosphere. The 
reaction mixture was stirred overnight, then was added of water (10 mL) and diluted with ethyl 
acetate (10 mL). The organic phase was separated and washed several times with brine (10 mL), 
dried over MgSO4, filtered and concentrated under reduced pressure. The crude residue was 
purified by column chromatography on silica gel eluting with hexane/ethyl acetate (80:20 v/v) to 
give compound 119 (0.13 g, 63% yield) as a colourless oil. 
Procedure b: 
A solution of compound 117 (3.20 g, 9.24 mmol) in anhydrous diethyl ether was cooled to -78 °C 
under a nitrogen atmosphere, before adding triethylamine (3.86 mL, 27.73 mmol) and 
methanesulfonyl chloride (1.43 mL, 18.48 mmol) dropwise. The reaction mixture was stirred for 3 
hours at a temperature from -78 °C to 0 °C, then filtered under vacuo and washed with diethyl 
ether. The filtrate was evaporated and the residue was dissolved in dichloromethane and washed 
with water and brine, dried over anhydrous MgSO4, filtered and concentrated under reduced 
pressure. The crude residue was dissolved in anhydrous dimethylformamide and added to a 
stirred suspension of 6-chloropurine 118 (3.29 g, 21.26 mmol) and caesium carbonate (3.92 g, 
12.02 mmol) in anhydrous dimethylformamide at room temperature under a nitrogen 
atmosphere. The reaction mixture was stirred overnight, then was added of water (100 mL) and 
diluted with ethyl acetate (100 mL). The organic phase was separated and washed several times 
with brine (100 mL), dried over MgSO4, filtered and concentrated under reduced pressure. The 
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crude residue was purified by flash column chromatography on silica gel (hexane to 
hexane/acetone 80:20 v/v) to give compound 119 (1.41 g, 32% yield) as a colourless oil. 
1H NMR (500 MHz, CDCl3) δ 8.70 (s, 1H, H-2base), 8.14 (s, 1H, H-8base), 5.76 (t, J2,1 = 7.4 Hz, 1H, H-2), 
5.03 (d, J1,2 = 7.5 Hz, 2H, H-1), 4.33 (s, 2H, 3-CH2), 4.15 (s, 2H, 3-CH2), 0.86 (s, 9H, tBuSi), 0.83 (s, 9H, 
tBuSi), 0.06 (s, 6H, 2 CH3Si), -0.00 (s, 6H, 2 CH3Si). 
13C NMR (126 MHz, CDCl3) δ 151.80 (CH, C2base), 151.67 (C, Carom), 150.79 (C, Carom), 145.03 (CH, 
C8base), 144.84 (C, C3), 131.54 (C, Carom), 117.71 (CH, C2), 64.26 (CH2, 3-CH2), 59.54 (CH2, 3-CH2), 
40.93 (CH2, C1), 25.81 (CH3, 6 CH3-tBuSi), 18.29 (C, C-tBuSi), 18.23 (C, C-tBuSi), -5.44 (CH3, 4 CH3Si). 
 
 
C10H11ClN4O2, MW 254.67 
 
1-[3,3’-Bis-(hydroxymethyl)-prop-2-enyl]6-chloropurine (120).[20] 
To a solution of 119 (0.24 g, 0.49 mmol) in tetrahydrofuran, tetrabutylammonium fluoride 
trihydrate (0.37 g, 1.18 mmol) was slowly added at -10 °C. The reaction mixture was stirred at -10 
°C to 0 °C for 2 hours, then concentrated to dryness under reduced pressure. The crude residue 
was purified by column chromatography on silica gel eluting with dichloromethane/methanol 
(92:8 v/v) to give compound 120 (0.12 g, 94% yield) as a white powder. 
1H NMR (500 MHz, DMSO-d6) δ 8.80 (s, 1H, H-2base), 8.70 (s, 1H, H-8base), 5.69 (t, J2,1 = 7.3 Hz, 1H, H-
2), 5.06 (d1,2, J = 7.3 Hz, 2H, H-1), 4.87 (t, J = 5.5 Hz, 1H, 3-CH2OH), 4.81 (t, J = 5.6 Hz, 1H, 3-CH2OH), 
4.18 (d, J = 5.4 Hz, 2H, 3-CH2), 3.98 (d, J = 4.7 Hz, 2H, 3-CH2). 
13C NMR (126 MHz, DMSO-d6) δ 152.17 (C, Carom), 151.99 (CH, C2base), 149.44 (C, Carom), 147.72 
(CH, C8base), 145.86 (C, C3), 131.31 (C, Carom), 118.35 (CH, C2), 62.76 (CH2, 3-CH2), 57.58 (CH2, 3-
CH2), 41.34 (CH2, C1). 
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C10H13N5O2, MW 235.24 
 
1-[3,3’-Bis-(hydroxymethyl)-prop-2-enyl]adenine (27).[20] 
Procedure a: 
Compound 120 (0.10 g, 0.38 mmol) was dissolved in a saturated (7M) solution of ammonia in 
methanol (5 mL). The reaction mixture was stirred in a screw-cap pressure glass tube at 75 °C for 
48 hours, then cooled to room temperature and concentrated to dryness. The crude residue was 
purified by column chromatography on silica gel eluting with dichloromethane/methanol (90:10 
v/v) to give compound 27 (0.051 g, 56% yield) as a white powder; mp: 176-177 °C. 
Procedure b: 
Compound 120 (0.60 g, 2.36 mmol) was suspended in a 28-30% aqueous ammonia solution (4 mL) 
and 1,4-dioxane (4 mL). The reaction mixture was stirred in a screw-cap pressure glass tube at 90 
°C for 48 hours, then cooled to room temperature and concentrated to dryness by co-evaporation 
with ethanol. The crude residue was stirred in ethanol for 20 minutes and filtered under vacuo to 
give compound 27 (0.50 g, 90% yield) as a white powder. 
1H NMR (500 MHz, DMSO-d6) δ 8.15 (s, 1H, H-2base), 8.13 (s, 1H, H-8base), 7.22 (br s, 2H, 6-NH2), 
5.63 (t, J2,1 = 7.3 Hz, 1H, H-2), 4.98 (t, J = 5.6 Hz, 1H, 3-CH2OH), 4.90 (d, J1,2 = 7.3 Hz, 2H, H-1), 4.80 
(t, J = 5.6 Hz, 1H, 3-CH2OH), 4.16 (d, J = 5.5 Hz, 2H, 3-CH2), 3.97 (d, J = 5.6 Hz, 2H, 3-CH2). 
13C NMR (126 MHz, DMSO-d6) δ 156.44 (C, Carom), 152.82 (CH, C2base), 149.66 (C, Carom), 144.90 
(C, C3), 141.01 (CH, C8base), 119.45 (CH, C2), 119.22 (C, Carom), 62.82 (CH2, 3-CH2), 57.38 (CH2, 3-
CH2), 40.39 (CH2, C1). 
HPLC (system 2) tR = 13.61 min. 
MS (ES+) m/z 258.1 [MNa+]. 
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C6H3BrClN3, MW 232.47 
 
7-Bromo-6-chloro-7-deazapurine (122).[21] 
N-bromosuccinimide (1.40 g, 7.81 mmol) was added slowly to a stirred suspension of 6-chloro-7-
deazapurine 121 (1.00 g, 6.51 mmol) in anhydrous dichlomethane (20 mL) and the mixture was 
reacted at room temperature for 3 hours. The yellow suspension was concentrated under reduced 
pressure, added of water (50 mL) and filtered. The residue was washed with additional water and 
dichloromethane, dried under vacuo to obtain compound 122 as an off-white solid (1.09 g, 72% 
yield). The product was used in the next step without further purification. 
1H NMR (500 MHz, DMSO-d6) δ 12.99 (br s, 1H, 9-NH), 8.64 (s, 1H, H-2), 7.97 (s, 1H, H-8). 
13C NMR (126 MHz, DMSO-d6) δ 150.93 (C, C4), 150.88 (CH, C2), 150.16 (C, C6), 128.61 (CH, C8), 
113.61 (C, C5), 85.76 (C, C7). 
 
 
C8H6ClN3O2, MW 211.61 
 
Methyl 6-chloro-7-deazapurine-7-carboxylate (123).[21] 
To a stirred solution of 122 (1.00 g, 4.30 mmol) in anhydrous tetrahydrofuran cooled to -78 °C was 
added dropwise a solution of 1.6M n-butyllithium in hexane (5.65 mL, 9.03 mmol) under an argon 
atmosphere. The solution was reacted for 30 minutes at -78°C, before adding methyl 
chloroformate (0.30 mL, 3.87 mmol) dropwise at the same temperature. Then the reaction 
mixture was allowed to attain room temperature and stirred for 3 hours. The reaction was 
quenched by adding saturated aqueous NH4Cl solution. The organic solvent was distilled off and 
the aqueous phase was extracted with ethyl acetate (3 x 150 mL). The combined organic layer was 
washed with water (300 mL), brine (300 mL), dried over anhydrous Na2SO4, filtered and 
evaporated to dryness. The residue was purified by column chromatography on silica gel eluting 
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with petroleum ether/ethyl acetate (50:50 v/v) to give compound 123 as a white solid (0.56 g, 61% 
yield); mp: 178-180 °C. 
1H NMR (500 MHz, DMSO-d6) δ 13.28 (br s, 1H, 9-NH), 8.69 (s, 1H, H-2), 8.41 (s, 1H, H-8), 3.83 (s, 
3H, OCH3). 
13C NMR (126 MHz, DMSO-d6) δ 162.20 (C, C=O), 153.24 (C, C4), 151.32 (C, C6), 151.23 (CH, C2), 
135.52 (CH, C8), 113.67 (C, C5), 105.84 (C, C7), 51.31 (CH3, OCH3). 
 
 
C23H40ClN3O2Si2, MW 482.21 
 
1-[3,3’-Bis-(tert-butyldimethylsilyloxymethyl)-prop-2-enyl]6-chloro-7-deazapurine (124). 
Procedure a: 
Compound 124 was prepared as described for 119 (procedure a) from 117 (0.16 g, 0.45 mmol) and 
6-chloro-7-deazapurine 121 (0.16 g, 1.03 mmol). The crude residue was purified by flash column 
chromatography on silica gel (hexane to hexane/ethyl acetate 97:3 v/v) to give compound 124 
(0.15 g, 69% yield) as a colourless oil. 
Procedure b: 
Compound 124 was prepared as described for 119 (procedure b) from 115 (0.46 g, 1.34 mmol) and 
6-chloro-7-deazapurine 121 (0.47 g, 1.34 mmol). The crude residue was purified by flash column 
chromatography on silica gel (hexane/acetone 95:5 v/v to hexane/acetone 80:20 v/v) to give 
compound 124 (0.34 g, 52% yield) as a colourless oil. 
1H NMR (500 MHz, CDCl3) δ 8.60 (s, 1H, H-2base), 7.27 (d, J8,7 = 3.6 Hz, 1H, H-8base), 6.57 (d, J7,8 = 3.6 
Hz, 1H, H-7base), 5.72 – 5.67 (m, 1H, H-2), 4.98 (d, J1,2 = 7.4 Hz, 2H, H-1), 4.32 (s, 2H, 3-CH2), 4.16 (d, 
J3-CH2,H-2 = 0.8 Hz, 2H, 3-CH2), 0.87 (s, 9H, tBuSi), 0.84 (s, 9H, tBuSi), 0.06 (s, 6H, 2 CH3Si), -0.00 (s, 
6H, 2 CH3Si). 
13C NMR (126 MHz, CDCl3) δ 152.00 (C, Carom), 150.87 (C, Carom), 150.57 (CH, C2base), 143.44 (C, 
C3), 128.76 (CH, C8base), 119.44 (CH, C2), 117.60 (C, Carom), 99.51 (CH, C7base), 64.39 (CH2, 3-CH2), 
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59.24 (CH2, 3-CH2), 41.47 (CH2, C1), 25.84 (CH3, 6 CH3-tBuSi), 18.33 (C, C-tBuSi), 18.26 (C, C-tBuSi), -
5.41 (CH3, 4 CH3Si). 
 
 
C11H12ClN3O2, MW 253.68 
 
1-[3,3’-Bis-(hydroxymethyl)-prop-2-enyl]6-chloro-7-deazapurine (126). 
Procedure a: 
Compound 126 was prepared as described for 120 from 124 (0.13 g, 0.29 mmol). The crude 
residue was purified by flash column chromatography on silica gel (dichloromethane to 
dichloromethane/methanol 98:2 v/v) to give compound 126 (0.05 g, 76% yield) as a white powder. 
Procedure b: 
A 80% aqueous solution of acetic acid (25 mL) was added to a stirred solution of compound 124 
(1.48 g, 3.07 mmol) in tetrahydrofuran (5 mL). The reaction mixture was stirred for 24 hour at 
room temperature, then concentrated to dryness by co-evaporation with ethanol to give 
compound 126 (0.78 g, 100% yield) as a white powder. The crude residue was used in the 
following step without purification. 
1H NMR (500 MHz, DMSO-d6) δ 8.65 (s, 1H, H-2base), 7.75 (d, J8,7 = 3.6 Hz, 1H, H-8base), 6.66 (d, J7,8 = 
3.6 Hz, 1H, H-7base), 5.63 (t, J2,1 = 7.2 Hz, 1H, H-2), 5.04 (d, J1,2 = 7.3 Hz, 2H, H-1), 4.79 (t, J = 5.4 Hz, 
1H, 3-CH2OH), 4.72 (t, J = 5.6 Hz, 1H, 3-CH2OH), 4.18 (d, JCH2,OH = 5.4 Hz, 2H, 3-CH2), 3.98 (dd, JCH2,OH 
= 5.5 Hz, JCH2,2 = 1.1 Hz, 2H, 3-CH2). 
13C NMR (126 MHz, DMSO-d6) δ 151.08 (C, Carom), 150.74 (C, Carom), 150.69 (CH, C2base), 145.03 
(C, C3), 131.52 (CH, C8base), 119.46 (CH, C2), 117.27 (C, Carom), 98.97 (CH, C7base), 62.89 (CH2, 3-
CH2), 57.59 (CH2, 3-CH2), 41.99 (CH2, C1). 
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C11H14N4O2, MW 234.25 
 
1-[3,3’-Bis-(hydroxymethyl)-prop-2-enyl]7-deaza-adenine (128). 
Compound 126 (0.035 g, 0.14 mmol) was suspended in a 28-30% aqueous ammonia solution (1.5 
mL) and 1,4-dioxane (1.5 mL). The reaction mixture was stirred in a screw-cap pressure glass tube 
at 90 °C for 48 hours, then cooled to room temperature and concentrated to dryness by co-
evaporation with ethanol. The crude residue was purified by flash column chromatography on 
silica gel (dichloromethane to dichloromethane/methanol 90:10 v/v). The isolated product was 
further purified by flash column chromatography on silica gel (dichloromethane to 
dichloromethane/methanol 90:10 v/v) to give compound 128 (0.03 g, 85% yield) as a white 
powder; mp: 167-169 °C. 
1H NMR (500 MHz, DMSO-d6) δ 8.05 (s, 1H, H-2base), 7.14 (d, J8,7 = 3.5 Hz, 1H, H-8base), 6.95 (br s, 
2H, 6-NH2), 6.53 (d, J7,8 = 3.5 Hz, 1H, H-7base), 5.56 (t, J2,1 = 7.3 Hz, 1H, H-2), 4.97 (t, J = 5.6 Hz, 1H, 3-
CH2OH), 4.85 (d, J1,2 = 7.3 Hz, 2H, H-1), 4.76 (t, J = 5.6 Hz, 1H, 3-CH2OH), 4.14 (d, J = 5.5 Hz, 2H, 3-
CH2), 3.97 – 3.95 (m, 2H, 3-CH2). 
13C NMR (126 MHz, DMSO-d6) δ 157.92 (C, Carom), 151.94 (CH, C2base), 149.58 (C, Carom), 143.78 
(C, C3), 124.26 (CH, C8base), 120.68 (CH, C2), 102.89 (C, Carom), 98.98 (CH, C7base), 62.90 (CH2, 3-
CH2), 57.33 (CH2, 3-CH2), 41.18 (CH2, C1). 
HPLC (system 1) tR = 10.05 min. 
MS (ES+) m/z 257.1 [MNa+], 235.1 [MH+]. 
HRMS calculated for C11H15N4O2: 235.1195; found 235.1186. 
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C25H42ClN3O4Si2, MW 540.24 
 
Methyl 1-[3,3’-bis-(tert-butyldimethylsilyloxymethyl)-prop-2-enyl]6-chloro-7-deazapurine 7-
carboxylate (125). 
Compound 125 was prepared as described for 119 (procedure a) from 117 (0.22 g, 0.60 mmol) and 
123 (0.29 g, 1.38 mmol). The crude residue was purified by column chromatography on silica gel 
eluting with hexane/ethyl acetate (90:10 v/v) to give compound 125 (0.25 g, 78% yield) as a white 
powder. 
1H NMR (500 MHz, CDCl3) δ 8.64 (s, 1H, H-2base), 8.00 (s, 1H, H-8base), 5.71 – 5.67 (m, 1H, H-2), 5.01 
(d, J1,2 = 7.5 Hz, 2H, H-1), 4.30 (s, 2H, 3-CH2), 4.15 (br s, 2H, 3-CH2), 3.85 (s, 3H, OCH3), 0.86 (s, 9H, 
tBuSi), 0.83 (s, 9H, tBuSi), 0.05 (s, 6H, 2 CH3Si), -0.00 (s, 6H, 2 CH3Si). 
13C NMR (126 MHz, CDCl3) δ 162.62 (C, C=O), 153.18 (C, Carom), 152.27 (C, Carom), 151.24 (CH, 
C2base), 144.66 (C, C3), 135.78 (CH, C8base), 118.40 (CH, C2), 114.90 (C, Carom), 106.95 (C, Carom), 
64.45 (CH2, 3-CH2), 59.44 (CH2, 3-CH2), 51.49 (CH3, OCH3), 41.90 (CH2, C1), 25.85 (CH3, 3 CH3-tBuSi), 
25.83 (CH3, 3 CH3-tBuSi), 18.33 (C, C-tBuSi), 18.27 (C, C-tBuSi), -5.41 (CH3, 2 CH3Si), -5.46 (CH3, 2 
CH3Si). 
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C13H14ClN3O4, MW 311.72 
 
Methyl 1-[3,3’-bis-(hydroxymethyl)-prop-2-enyl]6-chloro-7-deazapurine 7-carboxylate (127). 
Compound 127 was prepared as described for 120 from 125 (0.25 g, 0.46 mmol). The crude 
residue was purified by flash column chromatography on silica gel (dichloromethane to 
dichloromethane/methanol 97:3 v/v) to give compound 127 (0.14 g, 100% yield) as a yellow 
powder. 
1H NMR (500 MHz, DMSO-d6) δ 8.78 (s, 1H, H-2base), 8.50 (s, 1H, H-8base), 5.68 (t, J2,1 = 7.3 Hz, 1H, H-
2), 5.12 (d, J1,2 = 7.3 Hz, 2H, H-1), 4.85 (br s, 1H, 3-CH2OH), 4.79 (br s, 1H, 3-CH2OH), 4.21 (s, 2H, 3-
CH2), 4.01 (s, 2H, 3-CH2), 3.87 (s, 3H, OCH3). 
13C NMR (126 MHz, DMSO-d6) δ 162.40 (C, C=O), 152.26 (C, Carom), 152.01 (C, Carom), 151.59 
(CH, C2base), 145.92 (C, C3), 138.12 (CH, C8base), 118.61 (CH, C2), 114.51 (C, Carom), 105.74 (C, 
Carom), 62.89 (CH2, 3-CH2), 57.61 (CH2, 3-CH2), 51.86 (CH3, OCH3), 42.48 (CH2, C1). 
 
 
C13H16N4O4, MW 292.29 
 
Methyl 1-[3,3’-bis-(hydroxymethyl)-prop-2-enyl]7-carboxylate-7-deaza-adenine (129). 
Compound 127 (0.14 g, 0.46 mmol) was dissolved in a saturated (7M) solution of ammonia in 
methanol (5 mL). The reaction mixture was stirred in a screw-cap pressure glass tube at 75 °C for 
72 hours, then cooled to room temperature and concentrated to dryness. The crude residue was 
purified by flash column chromatography on silica gel (dichloromethane to 
dichloromethane/methanol 90:10 v/v). The isolated product was further purified by column 
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chromatography on silica gel eluting with dichloromethane/methanol (95:5 v/v) to give compound 
129 (0.04 g, 34% yield) as an off-white powder; mp: 182-184 °C. 
1H NMR (500 MHz, DMSO-d6 δ 8.17 (s, 1H, H-2base), 8.03 (s, 1H, H-8base), 7.83 (br s, 1H, NH2-H), 7.43 
(br s, 1H, NH2-H), 5.60 (t, J2,1 = 7.4 Hz, 1H, H-2), 4.92 (m, 3H, H-1 and 3-CH2OH), 4.80 (t, J = 5.6 Hz, 
1H, 3-CH2OH), 4.14 (d, J = 5.3 Hz, 2H, 3-CH2), 3.97 (d, J = 5.6 Hz, 2H, 3-CH2), 3.83 (s, 3H, OCH3). 
13C NMR (126 MHz, DMSO-d6) δ 165.79 (C, C=O), 158.12 (C, Carom), 153.64 (CH, C2base), 151.08 (C, 
Carom), 145.07 (C, C3), 132.44 (CH, C8base), 119.40 (CH, C2), 105.37 (C, Carom), 100.87 (C, Carom), 
62.83 (CH2, 3-CH2), 57.39 (CH2, 3-CH2), 52.20 (CH3, OCH3), 41.72 (CH2, C1). 
MS (ES+) m/z 315.1 [MNa+]. 
HRMS calculated for C13H17N4O4: 293.1250; found 293.1241. 
 
 
C27H41Cl2N3O2Si2, MW 566.71 
 
1-[3,3’-Bis-(tert-butyldimethylsilyloxymethyl)-prop-2-enyl]4,6-dichloro-9H-pyrimido[4,5-b]indole 
(130). 
Compound 130 was prepared as described for 119 (procedure a) from 117 (0.23 g, 0.63 mmol) and 
97 (0.35 g, 1.46 mmol). The crude residue was purified by column chromatography on silica gel 
eluting with hexane/ethyl acetate (95:5 v/v) to give compound 130 (0.24 g, 65% yield) as an 
orange oil. 
1H NMR (500 MHz, CDCl3) δ 8.63 (s, 1H, H-2base), 8.20 (s, 1H, H-5base), 7.42 – 7.36 (m, 2H, H-7base 
and H-8base), 5.47 (t, J2,1 = 6.2 Hz, 1H, H-2), 5.10 (d, J1,2 = 6.5 Hz, 2H, H-1), 4.30 (s, 2H, 3-CH2), 3.99 
(s, 2H, 3-CH2), 0.80 (s, 9H, tBuSi), 0.66 (s, 9H, tBuSi), -0.00 (s, 6H, 2 CH3Si), -0.18 (s, 6H, 2 CH3Si). 
13C NMR (126 MHz, CDCl3) δ 155.71 (C, Carom), 154.24 (CH, C2base), 152.85 (C, Carom), 142.66 (C, 
C3), 137.54 (C, Carom), 128.35 (CH, Cbase), 127.80 (C, Carom), 122.84 (CH, C5), 119.70 (C, Carom), 
119.41 (CH, C2), 111.74 (CH, Cbase), 111.29 (C, Carom), 64.45 (CH2, 3-CH2), 59.48 (CH2, 3-CH2), 39.50 
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(CH2, C1), 25.89 (CH3, 3 CH3-tBuSi), 25.79 (CH3, 3 CH3-tBuSi), 18.32 (C, C-tBuSi), 18.28 (C, C-tBuSi), -
5.39 (CH3, 2 CH3Si), -5.44 (CH3, 2 CH3Si). 
 
 
C15H13Cl2N3O2, MW 338.19 
 
1-[3,3’-Bis-(hydroxymethyl)-prop-2-enyl]4,6-dichloro-9H-pyrimido[4,5-b]indole (131). 
Compound 131 was prepared as described for 120 from 130 (0.23 g, 0.40 mmol). The crude 
residue was purified by column chromatography on silica gel (from dichloromethane/methanol 
98:2 v/v to dichloromethane/methanol 95:5 v/v) to give compound 131 (0.10 g, 71% yield) as an 
orange oil. 
1H NMR (500 MHz, DMSO-d6) δ 8.89 (s, 1H, H-2base), 8.27 (d, J5,7 = 2.0 Hz, 1H, H-5base), 7.86 (d, J8,7 = 
8.8 Hz, 1H, H-8base), 7.73 (dd, J7,8 = 8.8 Hz, J7,5 = 2.1 Hz, 1H, H-7base), 5.53 (t, J2,1 = 6.8 Hz, 1H, H-2), 
5.28 (d, J1,2 = 6.9 Hz, 2H, H-1), 4.88 (t, J = 5.3 Hz, 1H, 3-CH2OH), 4.67 (t, J = 5.5 Hz, 1H, 3-CH2OH), 
4.28 (d, J = 5.3 Hz, 2H, 3-CH2), 3.95 (dd, JCH2,OH = 5.4 Hz, JCH2,2 = 1.2 Hz, 2H, 3-CH2). 
13C NMR (126 MHz, DMSO-d6) δ 155.63 (C, Carom), 154.97 (CH, C2base), 152.36 (C, Carom), 144.87 
(C, C3), 137.85 (C, Carom), 128.87 (CH, C7base), 127.02 (C, Carom), 122.05 (CH, C5base), 119.20 (C, 
Carom), 118.60 (CH, C2), 113.48 (CH, C8base), 110.77 (C, Carom), 62.83 (CH2, 3-CH2), 57.91 (CH2, 3-
CH2), 39.75 (CH2, C1). 
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C15H15ClN4O2, MW 318.76 
 
1-[3,3’-Bis-(hydroxymethyl)-prop-2-enyl]4-amino-6-chloro-9H-pyrimido[4,5-b]indole (132). 
Compound 131 (0.10 g, 0.28 mmol) was dissolved in a saturated (7M) solution of ammonia in 
methanol (5 mL). The reaction mixture was stirred in a screw-cap pressure glass tube at 75 °C for 
48 hours, then cooled to room temperature and concentrated to dryness. The crude residue was 
purified by flash column chromatography on silica gel (dichloromethane to dichloromethane/ 
methanol 92:8 v/v). The isolated product was further purified by flash column chromatography on 
silica gel (dichloromethane to dichloromethane/methanol 95:5 v/v) to give compound 132 (0.02 g, 
26% yield) as an off-white powder; mp: > 230 °C. 
1H NMR (500 MHz, DMSO-d6) δ 8.51 (d, J5,7 = 2.0 Hz, 1H, H-5base), 8.33 (s, 1H, H-2base), 7.63 (d, J8,7 = 
8.7 Hz, 1H, H-8base), 7.44 (dd, J7,8 = 8.7 Hz, J7,5 = 2.0 Hz, 1H, H-7base), 7.38 (br s, 2H, 4-NH2), 5.46 (t, 
J2,1 = 6.8 Hz, 1H, H-2), 5.13 (d, J1,2 = 6.8 Hz, 2H, H-1), 4.97 (t, J = 5.4 Hz, 1H, 3-CH2OH), 4.72 (t, J = 5.6 
Hz, 1H, 3-CH2OH), 4.25 (d, J = 5.4 Hz, 2H, 3-CH2), 3.93 (d, J = 5.6 Hz, 2H, 3-CH2). 
13C NMR (126 MHz, DMSO-d6) δ 158.11 (C, Carom), 155.86 (CH, C2base), 155.57 (C, Carom), 143.89 
(C, C3), 135.64 (C, Carom), 125.74 (C, Carom), 124.79 (CH, C7base), 121.37 (C, Carom), 121.18 (CH, 
C5base), 119.57 (CH, C2), 111.68 (CH, C8base), 94.83 (C, Carom), 62.78 (CH2, 3-CH2), 57.68 (CH2, 3-
CH2), 38.87 (CH2, C1). 
MS (ES+) m/z 341.1 [MNa+], 319.1 [MH+]. 
HRMS calculated for C15H16ClN4O2: 319.0962; found 319.0964. 
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C16H23N6O5P, MW 410.36 
 
1-[3,3’-Bis-(hydroxymethyl)-prop-2-enyl]adenine 3,3’-hydroxymethyl-(isopropoxy-L-alaninyl) 
phosphate (133). 
Compound 27 (0.15 g, 0.64 mmol) was suspended in anhydrous dimethylformamide under a 
nitrogen atmosphere and tert-butylmagnesium chloride 1M in tetrahydrofuran (0.64 mL, 0.64 
mmol) was added dropwise at room temperature. After stirring 10 minutes, a solution of 
compound 38 (0.26 g, 0.64 mmol) in anhydrous dimethylformamide was added slowly. The 
reaction mixture was stirred for 4 hours at room temperature, then quenched by adding water (1 
mL) slowly. The mixture was concentrated under reduced pressure by coevaporation with toluene. 
The crude residue was purified by flash column chromatography on silica gel (dichloromethane to 
dichloromethane/methanol 90:10 v/v) to isolate the titled compound. Compound 133 was further 
purified by flash column chromatography on silica gel (dichloromethane to 
dichloromethane/methanol 92:8 v/v) and obtained as a white powder (0.10 g, 39% yield). 
31P NMR (202 MHz, CDCl3) δ 5.04, 4.97. 
1H NMR (500 MHz, CDCl3) δ 8.30 (s, 1H, H-2base), 7.75, 7.75 (2 s, 1H, H-8base), 5.70 – 5.67 (m, 1H, H-
2), 5.52 (s, 2H, 6-NH2), 5.11 – 5.02 (m, 2H, 3-CH2OP), 5.01 – 4.95 (m, 1H, H-iPr), 4.86 – 4.67 (m, 3H, 
3-CHOP and H-1), 4.57 – 4.46 (m, 1H, 3-CHOP), 3.95 – 3.88 (m, 1H, CHCH3), 3.59 – 3.50 (m, 1H, 
NH), 1.35, 1.33 (2 d, J = 1.9 Hz, 3H, CHCH3), 1.21 – 1.17 (m, 6H, 2 CH3-iPr). 
13C NMR (126 MHz, CDCl3) δ 153.37, 153.36 (CH, C2base), 139.76 (CH, C8base), 122.44, 122.34 (CH, 
C2), 70.16, 70.10, 70.05, 70.00 (3-CH2OP), 69.37, 69.34 (CH, CH-iPr), 64.79, 64.73 (3-CH2OP), 50.29, 
50.27, 50.23, 50.21 (CH, CHCH3), 40.20, 40.15 (CH2, C1), 21.72, 21.66 (CH3, 2 CH3-iPr), 21.19, 21.17, 
21.15 (CH3, CHCH3). 
HPLC (system 1) tR = 16.03, 16.57 min. 
HPLC (system 2) tR = 23.41, 23.82 min. 
MS (ES+) m/z 433.1 [MNa+], 411.1 [MH+]. 
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C22H29N6O6P, MW 504.48 
 
1-[3,3’-Bis-(hydroxymethyl)-prop-2-enyl]adenine (E)-3-hydroxymethyl-[phenyl-(isopropoxy-L-
alaninyl)] phosphate (137). 
Conpound 27 (0.10 g, 0.42 mmol) was suspended in a mixture of anhydrous 
tetrahydrofuran/pyridine (1:4 v/v, 2 mL) in a 10 mL sealed microwave tube under a nitrogen 
atmosphere and 1-methylimidazole (0.21 mL, 2.68 mmol) was added dropwise at room 
temperature. After stirring 30 minutes, a solution of 36 (0.26 g, 0.85 mmol) in anhydrous 
tetrahydrofuran (1 mL) was added slowly and the reaction mixture was stirred for 5 minutes under 
MWI (100 W, 50 °C), then cooled to room temperature, diluted with dichloromethane/methanol 
and concentrated to dryness by co-evaporation with toluene. The crude residue was purified by 
flash column chromatography on silica gel (dichloromethane to dichloromethane/methanol 90:10 
v/v) to isolate the titled compound. Compound 137 was further purified by flash column 
chromatography on silica gel (dichloromethane to dichloromethane/methanol 94:6 v/v) and 
obtained as a colourless wax (0.008 g, 3% yield). 
31P NMR (202 MHz, CDCl3) δ 2.91, 2.79. 
1H NMR (500 MHz, CDCl3) δ 8.21 (s, 1H, H-2base), 7.74 (s, 1H, H-8base), 7.23 – 7.17 (m, 2H, Harom), 
7.11 – 7.03 (m, 3H, Harom), 5.93 (s, 2H, 6-NH2), 5.64 – 5.57 (m, 1H, H-2), 4.95 – 4.83 (m, 3H, H-iPr 
and H-1), 4.62 – 4.54 (m, 2H, 3-CH2OP), 4.33 – 4.23 (m, 2H, 3-CH2OH), 4.04 – 3.82 (m, 2H, CHCH3 
and NH), 1.28 – 1.23 (m, 3H, CHCH3), 1.15 – 1.11 (m, 6H, 2 CH3-iPr). 
13C NMR (126 MHz, CDCl3) δ 173.05, 173.00 (2 C, C=O), 155.67 (C, Carom), 152.62 (CH, C2base), 
150.70, 150.66, 150.65, 150.61, 149.37, 140.98, 140.94 (C, Carom and C3), 140.48 (CH, C8base), 
129.64, 129.62, 124.95 (CH, Carom), 122.80, 122.68 (CH, C2), 120.25, 120.21, 120.19, 120.16 (CH, 
Carom), 119.92 (C, Carom), 69.28 (CH, CH-iPr), 68.31, 68.27, 68.23 (CH2, 3-CH2OP), 57.31, 57.28 
4. EXPERIMENTAL PART 
267 
 
(CH2, 3-CH2OH), 50.40, 50.35 (CH, CHCH3), 40.93 (CH2, C1), 21.67, 21.61 (CH3, 2 CH3-iPr), 21.02, 
20.98, 20.94 (CH3, CHCH3). 
HPLC (system 1) tR = 21.88, 22.32 min. 
HPLC (system 2) tR = 27.39, 27.63 min. 
MS (ES+) m/z 527.2 [MNa+], 505.2 [MH+]. 
 
 
C34H45N7O10P2, MW 773.71 
 
1-[3,3’-Bis-(hydroxymethyl)-prop-2-enyl]adenine 3,3’-hydroxymethyl-bis-[phenyl-(isopropoxy-L-
alaninyl)] phosphate (140). 
Compound 140 was isolated as a side-product of the synthesis of compound 137. After the first 
chromatographical purification, compound 140 was further purified by flash column 
chromatography on silica gel (dichloromethane to dichloromethane/methanol 95:5 v/v) and 
obtained as a colourless wax (0.02 g, 6% yield). 
31P NMR (202 MHz, CDCl3) δ 3.79, 3.61, 3.27, 3.23, 2.93, 2.69, 2.55, 2.45. 
1H NMR (500 MHz, CDCl3) δ 8.25, 8.24, 8.15, 8.12 (4 s, 1H, H-2base), 7.77, 7.76 (2 s, 1H, H-8base), 7.25 
– 7.00 (m, 10H, Harom), 5.90 (s, 2H, 6-NH2), 5.84 – 5.77 (m, 1H, H-2), 5.10 – 4.83 (m, 4H, 2 H-iPr 
and H-1), 4.83 – 4.50, 4.35 – 4.30 (2 m, 5H, 2 3-CH2OP and NH), 4.17 – 4.12, 4.04 – 3.84 (2 m, 3H, 2 
CHCH3 and NH), 1.32 – 1.20 (m, 6H, 2 CHCH3), 1.16 – 1.10 (m, 12H, 4 CH3-iPr). 
13C NMR (126 MHz, CDCl3) δ 173.71, 173.65, 173.52, 173.47, 173.37, 173.30, 173.12, 173.09, 
173.05, 173.03, 173.02, 173.00, 172.98, 172.96, 172.92 (C, 4 C=O), 155.46, 155.42 (C, Carom), 
152.89, 152.82, 152.76 (CH, C2base), 150.70, 150.69, 150.65, 149.81, 149.77, 149.75 (C, Carom and 
C3), 140.51, 140.47, 140.41 (CH, C8base), 134.70, 134.65, 134.59, 134.50, 134.45, 134.40 (C, 
Carom), 129.72, 129.67, 129.66, 129.63, 129.59, 127.78, 127.68, 125.01, 124.99, 124.91, 120.36, 
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120.32, 120.31, 120.28, 120.24, 120.23, 120.21, 120.19, 120.18, 120.17, 120.16, 120.14 (CH, 
Carom and C2), 119.48, 119.46, 119.43 (C, Carom), 69.27, 69.22, 69.20, 69.17, 69.16 (CH, 2 CH-iPr), 
67.38, 67.34, 67.32, 67.30 (CH2, 3-CH2OP), 61.19, 61.15, 61.12, 61.02, 60.98, 60.95, 60.91 (CH2, 3-
CH2OP), 50.53, 50.51, 50.49, 50.45, 50.44, 50.40, 50.35, 50.34 (CH, 2 CHCH3), 40.66, 40.63, 40.56, 
40.52 (CH2, C1), 21.69, 21.67, 21.63, 21.60 (CH3, 4 CH3-iPr), 20.99, 20.98, 20.95, 20.91, 20.84, 
20.81, 20.77 (CH3, 2 CHCH3). 
HPLC (system 1) tR = 27.70 min. 
HPLC (system 2) tR = 30.84 min. 
MS (ES+) m/z 774.3 [MH+], 796.3 [MNa+]. 
 
 
C17H24N5O5P, MW 409.38 
 
1-[3,3’-Bis-(hydroxymethyl)-prop-2-enyl]7-deaza-adenine 3,3’-hydroxymethyl-(isopropoxy-L-
alaninyl) phosphate (134). 
Compound 128 (0.05 g, 0.22 mmol) was suspended in anhydrous dimethylformamide (1 mL) under 
a nitrogen atmosphere and tert-butylmagnesium chloride 1M in tetrahydrofuran (0.22 mL, 0.22 
mmol) was added dropwise at room temperature. After stirring 10 minutes, a solution of 
compound 38 (0.09 g, 0.22 mmol) in anhydrous dimethylformamide (1 mL) was added slowly. The 
reaction mixture was stirred for 4 hours at room temperature, then quenched by adding water 
(0.5 mL) slowly. The mixture was concentrated under reduced pressure by coevaporation with 
toluene. The crude residue was purified by flash column chromatography on silica gel 
(dichloromethane to dichloromethane/methanol 90:10 v/v) to isolate the titled compound. 
Compound 134 was further purified by flash column chromatography on silica gel 
(dichloromethane to dichloromethane/methanol 92:8 v/v) and obtained as a white powder (0.02 
g, 26% yield). 
31P NMR (202 MHz, CDCl3) δ 5.04, 5.00. 
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1H NMR (500 MHz, CDCl3) δ 8.35 (s, 1H, H-2base), 7.01 – 6.97 (m, 1H, H-8base), 6.44 – 6.40 (m, 1H, H-
7base), 5.78 – 5.75 (m, 1H, H-2), 5.17 (s, 2H, 6-NH2), 5.12 – 5.03 (m, 3H, 3-CH2OP and H-iPr), 4.92 – 
4.84 (m, 2H, 3-CH2OP), 4.81 – 4.75 (m, 1H, 3-CHOP), 4.65 – 4.55 (m, 1H, 3-CHOP), 4.04 – 3.95 (m, 
1H, CHCH3), 3.67 – 3.57 (m, 1H, NH), 1.44 – 1.41 (m, 3H, CHCH3), 1.31 – 1.26 (m, 6H, 2 CH3-iPr). 
13C NMR (126 MHz, CDCl3) δ 156.65 (C, Carom), 152.10 (CH, C2base), 150.25, 132.15, 132.14, 
132.09, 132.08 (C, Carom), 124.20, 124.15 (CH, C8base), 124.03, 124.01 (CH, C2), 103.14 (C, Carom), 
98.40, 98.37 (CH, C7base), 70.39, 70.34, 70.31, 70.26 (3-CH2OP), 69.31, 69.28 (CH, CH-iPr), 64.98, 
64.92, 64.86 (3-CH2OP), 50.26, 50.24, 50.21 (CH, CHCH3), 41.05, 41.00 (CH2, C1), 21.72, 21.66 (CH3, 
2 CH3-iPr), 21.18, 21.15 (CH3, CHCH3). 
HPLC (system 1) tR = 17.24, 17.73 min. 
HPLC (system 2) tR = 24.34, 24.82 min. 
MS (ES+) m/z 432.1 [MNa+], 410.1 [MH+]. 
 
 
C23H30N5O6P, MW 551.53 
 
1-[3,3’-Bis-(hydroxymethyl)-prop-2-enyl]7-deaza-adenine (E)-3-hydroxymethyl-[phenyl-
(isopropoxy-L-alaninyl)] phosphate (138). 
Compound 128 (0.07 g, 0.31 mmol) was suspended in a mixture of anhydrous 
tetrahydrofuran/pyridine (1:4 v/v, 2 mL) in a 10 mL sealed microwave tube under a nitrogen 
atmosphere and 1-methylimidazole (0.16 mL, 1.96 mmol) was added dropwise at room 
temperature. After stirring 30 minutes, a solution of 36 (0.19 g, 0.62 mmol) in anhydrous 
tetrahydrofuran (1 mL) was added slowly and the reaction mixture was stirred for 5 minutes under 
MWI (100 W, 50 °C), then cooled to room temperature, diluted with dichloromethane/methanol 
and concentrated to dryness by co-evaporation with toluene. The crude residue was purified by 
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flash column chromatography on silica gel (dichloromethane to dichloromethane/methanol 95:5 
v/v) to give compound 138 (0.01 g, 6% yield) as a colourless wax. 
31P NMR (202 MHz, CDCl3) δ 2.88, 2.76. 
1H NMR (500 MHz, CDCl3) δ 8.14 (s, 1H, H-2base), 7.22 – 7.19 (m, 2H, Harom), 7.10 – 7.04 (m, 3H, 
Harom), 6.88 (d, J8,7 = 3.4 Hz, 1H, H-8base), 6.30 (d, J7,8 = 3.4 Hz, 1H, H-7base), 5.63 – 5.56 (m, 1H, H-
2), 5.49 (s, 2H, 6-NH2), 4.94 – 4.86 (m, 1H, H-iPr), 4.85 – 4.79 (m, 2H, H-1), 4.60 – 4.51 (m, 2H, 3-
CH2OP), 4.33 – 4.21 (m, 2H, 3-CH2OH), 3.92 – 3.75 (m, 2H, CHCH3 and NH), 1.27 – 1.22 (m, 3H, 
CHCH3), 1.14, 1.13 (2 s, 6H, 2 CH3-iPr). 
13C NMR (126 MHz, CDCl3) δ 173.04, 172.98 (2 C, C=O), 156.56 (C, Carom), 150.82 (CH, C2base), 
150.69, 150.64, 150.58, 149.17, 139.28, 139.23 (C, Carom and C3), 129.67, 129.64 (CH, Carom), 
125.25, 125.24 (CH, C8base), 124.95 (CH, Carom), 124.81, 124.73 (CH, C2), 120.29, 120.25, 120.22, 
120.19 (CH, Carom), 98.00 (CH, C7base), 69.30 (CH, CH-iPr), 68.74, 68.70, 68.66 (CH2, 3-CH2OP), 
57.20, 57.17 (CH2, 3-CH2OH), 50.37, 50.32 (CH, CHCH3), 42.32 (CH2, C1), 21.69, 21.62 (CH3, 2 CH3-
iPr), 21.03, 21.00, 20.96 (CH3, CHCH3). 
HPLC (system 1) tR = 22.92, 23.27 min. 
HPLC (system 2) tR = 28.09, 28.29 min. 
MS (ES+) m/z 526.2 [MNa+], 504.2 [MH+]. 
 
 
C35H46N6O10P2, MW 772.72 
 
1-[3,3’-Bis-(hydroxymethyl)-prop-2-enyl]7-deaza-adenine 3,3’-hydroxymethyl-bis-[phenyl-
(isopropoxy-L-alaninyl)] phosphate (141). 
Compound 141 was isolated as a side-product of the synthesis of compound 138. After the first 
chromatographical purification, compound 141 was further purified by flash column 
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chromatography on silica gel (dichloromethane to dichloromethane/methanol 96:4 v/v) and 
obtained as a colourless wax (0.01 g, 4% yield). 
31P NMR (202 MHz, CDCl3) δ 3.85, 3.61, 3.18, 3.11, 3.07, 2.76, 2.61, 2.48. 
1H NMR (500 MHz, CDCl3) δ 8.16, 8.07, 8.03 (3 s, 1H, H-2base), 7.24 – 7.03 (m, 10H, Harom), 6.85 – 
6.83 (m, 1H, H-8base), 6.30 (2 s, 1H, H-7base), 5.83 – 5.75 (m, 1H, H-2), 5.69, 5.65 (2 s, 2H, 6-NH2), 
5.12 – 4.47, 4.40 – 4.30 (2 m, 9H, H-1, 2 H-iPr, 2 3-CH2OP and NH), 4.23 – 4.17, 4.02 – 3.86 (2 m, 
3H, 2 CHCH3 and NH), 1.33 – 1.20 (m, 6H, 2 CHCH3), 1.16 – 1.09 (m, 12H, 4 CH3-iPr). 
13C NMR (126 MHz, CDCl3) δ 173.82, 173.76, 173.59, 173.54, 173.48, 173.42, 173.18, 173.13, 
173.11, 173.08, 173.06, 173.02, 173.00 (C, 4 C=O), 156.31, 156.22 (C, Carom), 150.74 (CH, C2base), 
150.65, 149.62, 149.56, 133.54, 133.48, 133.42, 133.32, 133.28, 133.22 (C, Carom and C3), 129.70, 
129.64, 129.60, 124.94, 124.90 (CH, Carom and C2), 124.68, 124.59, 124.56 (CH, C8base), 120.42, 
120.38, 120.37, 120.35, 120.33, 120.32, 120.29, 120.25, 120.21, 120.17 (CH, Carom), 103.06, 
103.02 (C, Carom), 98.55, 98.52 (CH, C7base), 69.23, 69.19, 69.14, 69.12 (CH, 2 CH-iPr), 67.64, 67.60, 
67.56 (CH2, 3-CH2OP), 61.19, 61.15, 61.12, 61.01, 60.97, 60.90, 60.86 (CH2, 3-CH2OP), 50.55, 50.53, 
50.51, 50.45, 50.44, 50.41, 50.34 (CH, 2 CHCH3), 41.59, 41.48, 41.38, 41.35 (CH2, C1), 21.71, 21.68, 
21.64, 21.61 (CH3, 4 CH3-iPr), 21.01, 20.97, 20.95, 20.91, 20.85, 20.81, 20.77 (CH3, 2 CHCH3). 
HPLC (system 1) tR = 27.88 min. 
HPLC (system 2) tR = 31.12 min. 
MS (ES+) m/z 773.3 [MH+], 795.3 [MNa+]. 
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C27H30N5O6P, MW 551.53 
 
1-[3,3’-Bis-(hydroxymethyl)-prop-2-enyl]7-deaza-adenine (E)-3-hydroxymethyl-[phenyl-
(benzyloxy-L-alaninyl)] phosphate (139). 
Compound 128 (0.06 g, 0.26 mmol) was suspended in a mixture of anhydrous 
tetrahydrofuran/pyridine (1:4 v/v, 2 mL) in a 10 mL sealed microwave tube under a nitrogen 
atmosphere and 1-methylimidazole (0.13 mL, 1.66 mmol) was added dropwise at room 
temperature. After stirring 30 minutes, a solution of 35 (0.10 g, 0.39 mmol) in anhydrous 
tetrahydrofuran (1 mL) was added slowly and the reaction mixture was stirred for 30 minutes 
under MWI (100 W, 50 °C), then diluted with dichloromethane/methanol and concentrated to 
dryness by co-evaporation with toluene. The crude residue was purified by flash column 
chromatography on silica gel (dichloromethane to dichloromethane/methanol 90:10 v/v) to isolate 
the titled compound. Compound 139 was further purified by flash column chromatography on 
silica gel (dichloromethane to dichloromethane/methanol 92:8 v/v) and obtained as a colourless 
wax (0.006 g, 4% yield). 
31P NMR (202 MHz, CDCl3) δ 2.70, 2.56. 
1H NMR (500 MHz, CDCl3) δ 8.16 (s, 1H, H-2base), 7.29 – 7.16 (m, 7H, Harom), 7.09 – 7.03 (m, 3H, 
Harom), 6.88, 6.87 (2 d, J8,7 = 2.1 Hz, 1H, H-8base), 6.30 – 6.27 (m, 1H, H-7base), 5.61 – 5.54 (m, 1H, 
H-2), 5.32 (s, 2H, 6-NH2), 5.07 – 4.99 (m, 2H, CH2(C6H5)), 4.88 – 4.75 (m, 2H, H-1), 4.57 – 4.43 (m, 
2H, 3-CH2OP), 4.31 – 4.21 (m, 2H, 3-CH2OH), 4.03 – 3.91 (m, 1H, CHCH3), 3.77 – 3.63 (m, 1H, NH), 
1.29 – 1.24 (m, 3H, CHCH3). 
13C NMR (126 MHz, CDCl3) δ 173.53, 173.33 (2 C, C=O), 156.63, 156.50 (C, Carom), 151.41, 150.94 
(CH, C2base), 149.93, 149.29, 149.28, 149.24, 139.22, 135.29, 135.27, 131.94, 131.89 (C, Carom and 
C3), 129.65, 129.61, 128.65, 128.51, 128.30, 128.22 (CH, Carom), 125.25, 124.97 (CH, C8base), 
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124.35, 124.19 (CH, C2), 120.24, 120.15, 115.49, 115.47 (CH, Carom), 98.74, 97.93 (CH, C7base), 
68.83, 68.79, 68.77 (CH2, 3-CH2OP), 67.31, 67.25 (CH2, CH2(C6H5)), 57.30, 57.25 (CH2, 3-CH2OH), 
50.28, 50.21 (CH, CHCH3), 41.06, 40.99 (CH2, C1), 21.04, 20.92 (CH3, CHCH3). 
HPLC (system 1) tR = 24.44, 24.73 min. 
HPLC (system 2) tR = 29.13, 29.28 min. 
MS (ES+) m/z 552.2 [MH+], 574.2 [MNa+]. 
 
 
C43H46N6O10P2, MW 868.81 
 
1-[3,3’-Bis-(hydroxymethyl)-prop-2-enyl]7-deaza-adenine 3,3’-hydroxymethyl-bis-[phenyl-
(benzyloxy-L-alaninyl)] phosphate (142). 
Compound 142 was isolated as a side-product of the synthesis of compound 139. After the first 
chromatographical purification, compound 142 was further purified by flash column 
chromatography on silica gel (dichloromethane to dichloromethane/methanol 92:8 v/v) and 
obtained as a colourless wax (0.01 g, 5% yield). 
31P NMR (202 MHz, CDCl3) δ 3.73, 3.54, 2.96, 2.92, 2.88, 2.67, 2.40, 2.27. 
1H NMR (500 MHz, CDCl3) δ 8.19, 8.09, 8.03 (3 s, 1H, H-2base), 7.28 – 7.01 (m, 20H, Harom), 6.86 – 
6.81 (m, 1H, H-8base), 6.27 – 6.24 (m, 1H, H-7base), 5.78 – 5.69 (m, 1H, H-2), 5.28, 5.26 (2 s, 2H, 6-
NH2), 5.11 – 4.43 (m, 10H, 2 CH2(C6H5), 2 3-CH2OP and H-1), 4.37 – 4.32, 4.19 – 3.83 (2 m, 4H, 2 
CHCH3 and 2 NH), 1.34 – 1.21 (m, 6H, 2 CHCH3). 
13C NMR (126 MHz, CDCl3) δ 173.43, 173.41, 173.38, 173.34, 173.32, 173.28 (C, 4 C=O), 156.23 (C, 
Carom), 150.93, 150.88 (CH, C2base), 150.74, 150.69, 150.63, 135.34, 135.32, 135.28, 132.48 (C, 
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Carom and C3), 129.77, 129.75, 129.70, 129.65, 129.61, 128.82, 128.61, 128.46, 128.21, 128.19, 
128.18, 128.16, 128.14 (CH, Carom and C2), 124.95, 124.91, 124.89, 124.63, 124.61 (CH, C8base), 
120.41, 120.37, 120.34, 120.31, 120.30, 120.29, 120.25, 120.23, 120.21, 120.20, 120.16 (CH, 
Carom), 103.09, 103.05 (C, Carom), 98.42, 98.39 (CH, C7base), 67.68, 67.65 (CH2, 3-CH2OP), 67.20, 
67.18, 67.15 (CH2, 2 CH2(C6H5)), 61.20, 61.16, 60.99, 60.95, 60.92, 60.88 (CH2, 3-CH2OP), 50.53, 
50.52, 50.41, 50.39, 50.30 (CH, 2 CHCH3), 41.56, 41.47, 41.36, 41.34 (CH2, C1), 20.94, 20.90, 20.85, 
20.85, 20.74, 20.69 (CH3, 2 CHCH3). 
HPLC (system 1) tR = 28.93 min. 
HPLC (system 2) tR = 31.60 min. 
MS (ES+) m/z 869.3 [MH+], 891.2.2 [MNa+]. 
 
 
C19H41NO4Si2, MW 403.70 
 
N-Methoxy-N-methyl-[3,3’-bis-(tert-butyldimethylsilyloxymethyl)]-prop-2-en-1-amide (143). 
Diethyl (N-methoxy-N-methyl-carbamoylmethyl)phosphonate (0.28 ml, 1.38 mmol) was added 
dropwise to a suspension of sodium hydride 60% dispersion in mineral oil (0.06 g, 1.63 mmol) in 
anhydrous tetrahydrofuran at 0 °C under a nitrogen atmosphere. The reaction mixture was stirred 
at room temperature for 30 minutes (a clear solution was formed), before cooling to 0 °C and 
adding slowly a solution of compound 113 (0.40 g, 1.26 mmol) in anhydrous tetrahydrofuran (2 
mL). The reaction mixture was allowed to attain room temperature and stirred for 1 hours, then 
poured into water (20 mL) and extracted with ethyl acetate (3 x 20 mL), the combined organic 
layer was washed with water (50 mL) and brine (50 mL), dried over anhydrous MgSO4, filtered and 
concentrated under reduced pressure. The residue was purified by column chromatography on 
silica gel eluting with hexane/ethyl acetate (95:5 v/v) to give compound 143 (0.44 g, 87% yield) as 
a colourless oil. 
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1H NMR (500 MHz, CDCl3) δ 6.44 (br s, 1H, H-2), 4.82 (s, 2H, 3-CH2), 4.41 – 4.37 (m, 2H, 3-CH2), 3.62 
(s, 3H, OCH3), 3.13 (s, 3H, NCH3), 0.89 (s, 9H, tBuSi), 0.83 (s, 9H, tBuSi), 0.03 (s, 6H, 2 CH3Si), -0.00 
(s, 6H, 2 CH3Si). 
13C NMR (126 MHz, CDCl3) δ 167.61 (C, C=O), 158.73 (C, C3), 110.03 (CH, C2), 63.11 (CH2, 3-CH2), 
61.65 (CH2, 3-CH2), 61.27 (CH3, OCH3), 32.03, 32.02, 31.95, 31.87 (CH3, NCH3), 25.73 (CH3, 3 CH3-
tBuSi), 25.71 (CH3, 3 CH3-tBuSi), 18.16 (C, C-tBuSi), 18.04 (C, C-tBuSi), -5.60 (CH3, 2 CH3Si), -5.67 
(CH3, 2 CH3Si). 
MS (ES+) m/z 426.24 [MNa+]. 
 
 
C18H38O3Si2, MW 358.66 
 
4,4’-Bis-(tert-butyldimethylsilyloxymethyl)-but-3-en-2-one (144). 
To a solution of 1.6M methyl lithium in diethyl ether (4.63 mL, 7.41 mmol) cooled to -78 °C, a 
solution of compound 143 (0.75 g, 1.85 mmol) in diethyl ether was added dropwise under a 
nitrogen atmosphere. The reaction mixture was allowed to warm to room temperature over 2 
hours, then quenched with a 10% NH4Cl aqueous solution (10 mL) and extracted with diethyl ether 
(3 x 20 mL). The combined organic layer was washed with water (50 mL) and brine (50 mL), dried 
over anhydrous MgSO4, filtered and concentrated to dryness. The crude residue was purified by 
flash column chromatography on silica gel (from hexane/ethyl acetate 98:2 v/v to hexane/ethyl 
acetate 93:7 v/v) to give compound 144 (0.49 g, 73% yield) as a colourless oil. 
1H NMR (500 MHz, CDCl3) δ 6.31 – 6.28 (m, 1H, H-3), 4.71 (s, 2H, 4-CH2), 4.38 – 4.34 (m, 2H, 4-CH2), 
2.12 (s, 3H, H-1), 0.85 (s, 9H, tBuSi), 0.79 (s, 9H, tBuSi), -0.00 (s, 6H, 2 CH3Si), -0.05 (s, 6H, 2 CH3Si). 
13C NMR (126 MHz, CDCl3) δ 198.72 (C, C=O), 161.10 (C, C4), 118.85 (CH, C3), 62.91 (CH2, 4-CH2), 
62.60 (CH2, 4-CH2), 31.55 (CH3, C1), 25.89 (CH3, 3 CH3-tBuSi), 25.77 (CH3, 3 CH3-tBuSi), 18.40 (C, C-
tBuSi), 18.15 (C, C-tBuSi), -5.47 (CH3, 2 CH3Si), -5.62 (CH3, 2 CH3Si). 
MS (ES+) m/z 381.22 [MNa+]. 
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C18H40O3Si2, MW 360.68 
 
(R,S)-4,4’-Bis-(tert-butyldimethylsilyloxymethyl)-but-3-en-2-ol (145). 
To a solution of compound 144 (0.36 g, 0.99 mmol) in anhydrous dichloromethane, a solution of 
1M DIBALH in cyclohexane (2.1 mL, 2.08 mmol) was added slowly at -20 °C and the reaction 
mixture was stirred for 1 hour in the dry ice-acetone bath at the temperature of -20 °C to 0 °C. 
Then, methanol (2.5 mL) was added and the mixture poured into 10% Rochelle salt aqueous 
solution (20 mL) and ethyl acetate (20 mL). The two-phase solution was stirred vigorously for 1 
hour at room temperature, until the two phases were clearly separated. The organic layer was 
separated, washed with brine/water (1:1 v/v, 2 x 10 mL), dried over MgSO4, filtered and 
concentrated under reduced pressure. The residue was purified by column chromatography on 
silica gel eluting with hexane/ethyl acetate (96:4 v/v) to give compound 145 (0.21 g, 60% yield) as 
a colourless syrup. 
1H NMR (500 MHz, CDCl3) δ 5.54 (d, J3,2 = 8.0 Hz, 1H, H-3), 4.62 – 4.56 (m, 1H, H-2), 4.21 (d, Jgem = 
12.3 Hz, 1H, 4-CH), 4.10 (d, Jgem = 12.1 Hz, 1H, 4-CH), 4.06 (s, 2H, 4-CH2), 2.45 (br s, 1H, 2-OH), 1.19 
(d, J1,2 = 6.3 Hz, 3H, H-1), 0.84 (s, 9H, tBuSi), 0.83 (s, 9H, tBuSi), 0.02 (s, 6H, 2 CH3Si), -0.00 (s, 6H, 2 
CH3Si). 
13C NMR (126 MHz, CDCl3) δ 139.35 (C, C4), 131.27 (CH, C3), 64.87 (CH2, 4-CH2), 63.65 (CH, C2), 
59.27 (CH2, 4-CH2), 25.92 (CH3, 3 CH3-tBuSi), 25.84 (CH3, 3 CH3-tBuSi), 23.30 (CH3, C1), 18.36 (C, C-
tBuSi), 18.20 (C, C-tBuSi), -5.31 (CH3, 2 CH3Si), -5.43 (CH3, 2 CH3Si). 
MS (ES+) m/z 383.2 [MNa+]. 
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C18H39ClO2Si2, MW 379.13 
 
(R,S)-4,4’-Bis-(tert-butyldimethylsilyloxymethyl)-but-3-en-2-yl chloride (146). 
A solution of 145 (0.16 g, 0.44 mmol) in anhydrous pyridine was cooled to 0 °C under a nitrogen 
atmosphere before adding methanesulfonyl chloride (0.07 mL, 0.89 mmol) dropwise. The reaction 
mixture was allowed to attain room temperature and stirred for 2 hours, then the solvent was 
evaporated under reduced pressure and the crude residue was purified by column 
chromatography on silica gel eluting with hexane/ethyl acetate (95:5 v/v) to give compound 146 
(0.06 g,33% yield) as a colourless oil. 
1H NMR (500 MHz, CDCl3) δ 5.57 (d, J3,2 = 9.4 Hz, 1H, H-3), 4.97 – 4.89 (m, 1H, H-2), 4.21 (d, Jgem = 
12.6 Hz, 1H, 4-CH), 4.14 – 4.07 (m, 3H, 4-CH and 4-CH2), 1.51 (d, J1,2 = 6.5 Hz, 3H, H-1), 0.84 (s, 9H, 
3 CH3-tBuSi), 0.82 (s, 9H, 3 CH3-tBuSi), -0.00 (s, 6H, 2 CH3Si), -0.00 (s, 6H, 2 CH3Si). 
13C NMR (126 MHz, CDCl3) δ 140.02 (C, C4), 127.53 (CH, C3), 64.07 (CH2, 4-CH2), 59.12 (CH2, 4-CH2), 
52.97 (CH, C2), 26.18 (CH3, C1), 25.93 (CH3, 3 CH3-tBuSi), 25.83 (CH3, 3 CH3-tBuSi), 18.41 (C, C-
tBuSi), 18.23 (C, C-tBuSi), -5.31 (CH3, CH3Si), -5.33 (CH3, CH3Si), -5.40 (CH3, CH3Si), -5.45 (CH3, 
CH3Si). 
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C23H41ClN4O2Si2, MW 497.22 
 
2-(R,S)-[4,4’-Bis-(tert-butyldimethylsilyloxymethyl)-but-3-enyl]6-chloropurine (149). 
To a stirred solution of 0.1M 145 (0.19 g, 0.53 mmol) in anhydrous tetrahydrofuran was added 
triphenylphosphine (0.14 g, 0.53 mmol) at room temperature under a nitrogen atmosphere. The 
solution was cooled to 0 °C before adding di-isopropyl azodicarboxylate (0.1 mL, 0.53 mmol) 
dropwise. After 5 minutes, the solution was allowed to attain room temperature. 6-chloropurine 
118 (0.05 g, 0.35 mmol) was added and the reaction mixture was heated at reflux for 20 hours, 
then cooled to room temperature and concentrated to dryness under reduced pressure. The crude 
residue was purified by flash column chromatography on silica gel (hexane to hexane/ethyl 
acetate 75:25 v/v) to give compound 149 (0.06 g, 21% yield) as a colourless oil. 
1H NMR (500 MHz, CDCl3) δ 8.69 (s, 1H, H-2base), 8.13 (s, 1H, H-8base), 5.87 (d, J3,2 = 9.5 Hz, 1H, H-3), 
5.78 – 5.71 (m, 1H, H-2), 4.30 (d, Jgem = 12.7 Hz, 1H, 4-CH), 4.19 – 4.07 (m, 3H, 4-CH and 4-CH2), 
1.68 (d, J1,2 = 6.8 Hz, 3H, H-1), 0.85 (s, 9H, 3 CH3-tBuSi), 0.81 (s, 9H, 3 CH3-tBuSi), 0.01 (s, 6H, 2 
CH3Si), -0.00 (s, 6H, 2 CH3Si). 
13C NMR (126 MHz, CDCl3) δ 151.63 (CH, C2base), 151.34 (C, Carom), 150.88 (C, Carom), 143.36 (C, 
C4), 143.33 (CH, C8base), 131.77 (C, Carom), 122.94 (CH, C3), 63.92 (CH2, 4-CH2), 59.46 (CH2, 4-CH2), 
48.85 (CH, C2), 25.87 (CH3, 3 CH3-tBuSi), 25.76 (CH3, 3 CH3-tBuSi), 22.02 (CH3, C1), 18.37 (C, C-
tBuSi), 18.20 (C, C-tBuSi), -5.37 (CH3, CH3Si), -5.38 (CH3, CH3Si), -5.50 (CH3, CH3Si), -5.53 (CH3, 
CH3Si). 
MS (ES+) m/z 519.2 [MNa+]. 
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C11H13ClN4O2, MW 268.70 
 
2-(R,S)-[4,4’-Bis-(hydroxymethyl)-but-3-enyl]6-chloropurine (150). 
A 80% aqueous solution of acetic acid (0.85 mL) was added to a stirred solution of compound 149 
(0.05 g, 0.10 mmol) in tetrahydrofuran (0.15 mL). The reaction mixture was stirred for 24 hour at 
room temperature, then concentrated to dryness by co-evaporation with ethanol. The crude 
residue was purified by flash column chromatography on silica gel (dichloromethane to 
dichloromethane/methanol 96:4 v/v) to give compound 150 (0.04 g, 74% yield) as a colourless 
wax. 
1H NMR (500 MHz, CD3OD) δ 8.75 (s, 1H, H-2base), 8.70 (s, 1H, H-8base), 6.04 (d, J3,2 = 9.7 Hz, 1H, H-
3), 5.91 (dq, J2,3 = 9.7 Hz, J2,1 = 6.8 Hz, 1H, H-2), 4.36 (d, Jgem = 12.8 Hz, 1H, 4-CH), 4.27 (d, Jgem = 
12.8 Hz, 1H, 4-CH), 4.18 – 4.10 (m, 2H, 4-CH2), 1.80 (d, J1,2 = 6.8 Hz, 3H, H-1). 
13C NMR (126 MHz, CD3OD) δ 151.31 (C, Carom), 151.28 (CH, C2base), 149.76 (C, Carom), 145.18 
(CH, C8base), 143.22 (C, C4), 131.10 (C, Carom), 124.84 (CH, C3), 62.97 (CH2, 4-CH2), 57.34 (CH2, 4-
CH2), 49.38 (CH, C2), 20.15 (CH3, C1). 
MS (ES+) m/z 291.1 [MNa+], 269.1 [MH+]. 
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C11H15N5O2, MW 249.27 
 
2-(R,S)-[4,4’-Bis-(hydroxymethyl)-but-3-enyl]adenine (28). 
Compound 150 (0.05 g, 0.19 mmol) was dissolved in a 28-30% aqueous ammonia solution (0.5 mL) 
and 1,4-dioxane (0.5 mL). The reaction mixture was stirred in a screw-cap pressure glass tube at 90 
°C for 48 hours, then cooled to room temperature and concentrated to dryness by co-evaporation 
with ethanol. The crude residue was purified by flash column chromatography on silica gel 
(dichloromethane to dichloromethane/methanol 87:13 v/v) to give 28 (0.03 g, 64% yield) as a 
white powder. 
1H NMR (500 MHz, DMSO-d6) δ 8.26 (s, 1H, H-2base), 8.14 (s, 1H, H-8base), 7.19 (s, 2H, 6-NH2), 5.84 
(d, J3,2 = 9.7 Hz, 1H, H-3), 5.62 (m, 1H, H-2), 4.87 (t, J = 5.5 Hz, 1H, OH), 4.80 (t, J = 5.5 Hz, 1H, OH), 
4.16 (dd, Jgem = 12.6 Hz, JCH,OH = 5.5 Hz, 1H, 4-CH), 4.02 (dd, Jgem = 12.6 Hz, JCH,OH = 5.5 Hz, 1H, 4-CH), 
4.00 – 3.90 (m, 2H, 4-CH2), 1.63 (d, J1,2 = 6.8 Hz, 3H, H-1). 
13C NMR (126 MHz, DMSO-d6) δ 156.47 (C, Carom), 152.61 (CH, C2base), 149.28 (C, Carom), 143.06 
(C, C4), 139.44 (CH, C8base), 124.82 (CH, C3), 119.45 (C, Carom), 62.69 (CH2, 4-CH2), 57.41 (CH2, 4-
CH2), 47.97 (CH, C2), 21.90 (CH3, C1). 
HPLC (system 1) tR = 10.09 min. 
HPLC (system 2) tR = 16.49 min. 
MS (ES+) m/z 250.1 [MH+], 272.1 [MNa+]. 
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4.2.6 PROCEDURES AND SPECTRAL DATA – SECTION 2.2.5 
 
 
C22H22NO5P, MW 411.39 
 
N-(diphenoxyphosphinyl)-L-alanine benzyl ester (152). 
L-alanine benzyl ester p-tosylate salt 32 (0.50 g, 1.42 mmol) was dissolved in anhydrous 
dichloromethane under a nitrogen atmosphere and diphenylchlorophosphate 151 (0.30 mL, 1.42 
mmol) was added at room temperature. The mixture was cooled to -78 °C before adding 
triethylamine (0.40 mL, 2.85 mmol) dropwise. The reaction mixture was stirred at -78 °C for 1 
hour, then allowed to attain room temperature and stirred for additional 2 hours. The solvent was 
removed under reduced pressure. The crude residue was suspended in ethylacetate and stirred 
for 15 minutes, then filtered under vacuo. The filtrate was evaporated under reduced pressure 
and the crude residue was purified by flash column chromatography on silica gel (hexane to 
hexane/acetone 70:30 v/v) to obtain compound 152 (0.56 g, 96% yield) as a colourless oil. 
31P NMR (202 MHz, CDCl3) δ -2.79. 
1H NMR (500 MHz, CDCl3) δ 7.39 – 7.22 (m, 13H, Harom), 7.21 – 7.15 (m, 2H, Harom), 5.14 (s, 2H, 
CH2(C6H5)), 4.27 – 4.12 (m, 2H, CHCH3 and NH), 1.41 (d, J = 7.0 Hz, 3H, CHCH3). 
13C NMR (126 MHz, CDCl3) δ 173.13 (d, JC-C-N-P = 7.5 Hz, C, C=O), 150.72 (m, C, Carom), 135.29 (C, 
Carom), 129.72 (d, JC-C-O-P = 4.4 Hz, CH, Carom), 128.66 (CH, Carom), 128.50 (CH, Carom), 128.23 
(CH, Carom), 125.07 (CH, Carom), 120.30 (m, CH, Carom), 67.23 (CH2, CH2(C6H5)), 50.56 (d, JC-N-P = 
1.0 Hz, CHCH3), 20.95 (d, JC-C-N-P = 4.9 Hz, CH3, CHCH3). 
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C18H22NO5P, MW 363.34 
 
N-(diphenoxyphosphinyl)-L-alanine isopropyl ester (153). 
L-alanine isopropyl ester hydrochloride 33 (0.50 g, 2.98 mmol) was dissolved in anhydrous 
dichloromethane under a nitrogen atmosphere and diphenylchlorophosphate 151 (0.62 mL, 2.98 
mmol) was added at room temperature. The mixture was cooled to -78 °C before adding 
triethylamine (0.83 mL, 5.97 mmol) dropwise. The reaction mixture was stirred at -78 °C for 1 
hour, then allowed to attain room temperature and stirred for additional 2 hours. The solvent was 
removed under reduced pressure. The crude residue was suspended in ethylacetate and stirred 
for 15 minutes, then filtered under vacuo. The filtrate was evaporated under reduced pressure 
and the crude residue was purified by flash column chromatography on silica gel (hexane to 
hexane/acetone 70:30 v/v) to obtain compound 153 (0.90 g, 83% yield) as a colourless oil. 
31P NMR (202 MHz, CDCl3) δ -2.81. 
1H NMR (500 MHz, CDCl3) δ 7.38 – 7.32 (m, 4H, Harom), 7.29 – 7.24 (m, 4H, Harom), 7.21 – 7.17 
(m, 2H, Harom), 5.07 – 4.98 (m, 1H, H-iPr), 4.16 – 4.06 (m, 1H, CHCH3), 3.79 (m, 1H, NH), 1.39 (d, J 
= 7.0 Hz, 3H, CHCH3), 1.24 (d, J = 4.2 Hz, 6H, 2 CH3-iPr). 
13C NMR (126 MHz, CDCl3) δ 173.72 (d, JC-C-N-P = 7.4 Hz, C, C=O), 150.69 (m, C, Carom), 129.71 (d, JC-
C-O-P = 2.0 Hz, CH, Carom), 125.06 (CH, Carom), 120.26 (m, CH, Carom), 69.34 (CH, CH-iPr), 50.56 
(CH, CHCH3), 21.61 (CH3, 2 CH3-iPr), 21.10 (d, JC-C-N-P = 3.1 Hz, CH3, CHCH3). 
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C26H29N6O8P, MW 584.52 
 
Adenosine 5’-O-[phenyl-(benzyloxy-L-alaninyl)] phosphate (155). 
General procedure under MWI condition: 
Compound 154 (0.08 g, 0.28 mmol) was dissolved in anhydrous tetrahydrofuran (1.6 mL) and N-
methyl-2-pyrrolidone (0.55 mL) in a 10 mL sealed microwave tube under a nitrogen atmosphere 
and tert-butylmagnesium chloride 1M in tetrahydrofuran (0.84 mL, 0.84 mmol) was added 
dropwise at room temperature. After stirring 10 minutes, a solution of p-nitrophenolate 37 (0.26 
g, 0.56 mmol) in anhydrous tetrahydrofuran (1 mL) was added slowly. The reaction mixture was 
stirred under MWI (100 W, 65 °C) for 5 minutes, then cooled to room temperature, poured into a 
10% aqueous solution of NH4Cl (10 mL) and extracted with dichloromethane (3 x 10 mL), the 
combined organic layer was washed with water (20 mL) and brine (20 mL), dried over anhydrous 
MgSO4, filtered and concentrated under reduced pressure. The residue was purified by flash 
column chromatography on silica gel (dichloromethane to dichloromethane/methanol 92:8 v/v) to 
give compound 155 (0.06 g, 40% yield) as a colourless wax. 
General procedure by conventional heating: 
Compound 154 (0.08 g, 0.24 mmol) was dissolved in anhydrous tetrahydrofuran (1.6 mL) and N-
methyl-2-pyrrolidone (0.55 mL) under a nitrogen atmosphere and tert-butylmagnesium chloride 
1M in tetrahydrofuran (0.84 mL, 0.84 mmol) was added dropwise at room temperature. After 
stirring 10 minutes, a solution of p-nitrophenolate 37 (0.26 g, 0.56 mmol) in anhydrous 
tetrahydrofuran (1 mL) was added slowly. The reaction mixture was heated to 55 °C and stirred for 
1 hour, then cooled to room temperature, poured into a 10% aqueous solution of NH4Cl (10 mL) 
and extracted with dichloromethane (3 x 10 mL), the combined organic layer was washed with 
water (20 mL) and brine (20 mL), dried over anhydrous MgSO4, filtered and concentrated under 
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reduced pressure. The residue was purified by flash column chromatography on silica gel 
(dichloromethane to dichloromethane/methanol 92:8 v/v) to give compound 155 (0.07 g, 42% 
yield) as a colourless wax. 
Procedure for the deprotection of 157: 
Compound 157 (0.06 g, 0.09 mmol) was dissolved in a 60% aqueous solution of acetic acid (5 mL). 
The reaction mixture was stirred at room temperature for 16 hours, then evaporated by co-
evaporation with ethanol. The residue was purified by flash column chromatography on silica gel 
(dichloromethane to dichloromethane/methanol 92:8 v/v) to give compound 155 (0.02 g, 40% 
yield) as a colourless wax. 
31P NMR (202 MHz, CD3OD) δ 3.90, 3.66. 
1H NMR (500 MHz, CD3OD) δ 8.28 – 8.19 (m, 2H, H-2 and H-8), 7.35 – 7.26 (m, 7H, Harom), 7.22 – 
7.14 (m, 3H, Harom), 6.07 – 6.03 (m, 1H, H-1’), 5.15 – 5.05 (m, 2H, CH2(C6H5)), 4.67, 4.64 (2t, J = 5.1 
Hz, 1H, H-2’), 4.44 – 4.37 (m, 2H, H-3’ and H-5’a), 4.36 – 4.28 (m, 1H, H-5’b), 4.28 – 4.24 (m, 1H, H-
4’), 4.04 – 3.91 (m, 1H, CHCH3), 1.33, 1.28 (2d, J = 7.2 Hz, 1H, CHCH3). 
13C NMR (126 MHz, CD3OD) δ 173.43 (d, JC-C-N-P = 3.5 Hz, C, C=O), 173.22 (d, JC-C-N-P = 4.1 Hz, C, 
C=O), 155.90, 155.88 (C, Carom), 152.54, 152.50 (CH, C2), 150.70, 150.65, 149.28, 149.25, 135.83, 
135.76 (C, Carom), 129.37, 128.15, 127.90, 127.86, 124.78, 120.05, 120.01, 119.99, 119.95, 119.09 
(CH, Carom and C8), 88.56 (CH, C1’), 82.97 (d, JC-C-0-P = 4.0 Hz, CH, C4’), 82.91 (d, JC-C-0-P = 3.8 Hz, CH, 
C4’), 73.99 (CH, C2’), 70.18, 70.06 (CH, C3’), 66.56, 66.55 (CH2, CH2(C6H5)), 66.14 (d, JC-O-P = 4.2 Hz, 
CH2, C5’), 65.73 (d, JC-O-P = 4.1 Hz, CH2, C5’), 50.29 (d, JC-N-P = 0.4 Hz, CH, CHCH3), 50.18 (d, JC-N-P = 
0.4 Hz, CH, CHCH3), 19.01 (d, JC-C-N-P = 5.2 Hz, CH3, CHCH3), 18.84 (d, JC-C-N-P = 5.8 Hz, CH3, CHCH3). 
MS (ES+) m/z 607.2 [MNa+], 585.2 [MH+]. 
  
4. EXPERIMENTAL PART 
285 
 
 
C13H17N5O4, MW 307.31 
 
2’,3’-O,O-isopropylidene-adenosine (156).[22] 
A 70% aqueous solution of perchloric acid (0.56 mL, 6.55 mmol) was added dropwise to a stirred 
suspension of compound 154 (1.0 g, 3.74 mmol) in acetone at room temperature. The resulting 
solution was stirred for 30 minutes, then added of saturated aqueous NaHCO3 solution and 
concentrated to dryness by co-evaporation with ethanol. The crude residue was purified by flash 
column chromatography on silica gel (dichloromethane to dichloromethane/methanol 90:10 v/v) 
to give compound 156 (1.09 g, 95% yield) as a white powder; mp: 216-218 °C (lit: 220 °C). 
1H NMR (500 MHz, DMSO-d6) δ 8.35 (s, 1H, H-2), 8.16 (s, 1H, H-8), 7.35 (s, 2H, 6-NH2), 6.13 (d, J1’,2’ 
= 3.1 Hz, 1H, H-1’), 5.35 (dd, J2’,3’ = 6.1 Hz, J2’,1’ = 3.1 Hz, 1H, H-2’), 5.24 (t, J5’-OH, 5’ = 5.6 Hz, 1H, 5’-
OH), 4.97 (dd, J3’,2’ = 6.1 Hz, J3’,4’ = 2.5 Hz, 1H, H-3’), 4.22 (td, J4’,5’ = 4.8 Hz, J4’,3’ = 2.5 Hz, 1H, H-4’), 
3.55 (m, 2H, H-5’a and H-5’b), 1.56 (s, 3H, iPr-CH3), 1.34 (s, 3H, iPr-CH3). 
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C29H33N6O8P, MW 624.58 
 
2’,3’-O,O-isopropylidene-adenosine 5’-O-[phenyl-(benzyloxy-L-alaninyl)] phosphate (157). 
General procedure under MWI conditions: 
Compound 156 (0.08 g, 0.24 mmol) was dissolved in anhydrous tetrahydrofuran (1.6 mL) and N-
methyl-2-pyrrolidone (0.55 mL) in a 10 mL sealed microwave tube under a nitrogen atmosphere 
and tert-butylmagnesium chloride 1M in tetrahydrofuran (0.49 mL, 0.49 mmol) was added 
dropwise at room temperature. After stirring 10 minutes, a solution of the phosphoramidating 
reagent (2 equivalents) in anhydrous tetrahydrofuran (1 mL) was added slowly. The reaction 
mixture was stirred under MWI (100 W, 65 °C) for 2 to 60 minutes, then cooled to room 
temperature, poured into a 10% aqueous solution of NH4Cl (10 mL) and extracted with 
dichloromethane (3 x 10 mL), the combined organic layer was washed with water (20 mL) and 
brine (20 mL), dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. 
The residue was purified by flash column chromatography on silica gel (dichloromethane to 
dichloromethane/methanol 97:3 v/v) to give compound 157 as a colourless wax. 
Selected conditions: 
Compound 156 was treated with p-nitrophenolate 37 (0.22 g, 0.49 mmol) over 2 minutes to give 
compound 157 (0.06 g, 41% yield) after chromatographical purification. 
General procedure by conventional heating: 
Compound 156 (0.08 g, 0.24 mmol) was dissolved in anhydrous tetrahydrofuran (1.6 mL) and N-
methyl-2-pyrrolidone (0.55 mL) under a nitrogen atmosphere and tert-butylmagnesium chloride 
1M in tetrahydrofuran (0.49 mL, 0.49 mmol) was added dropwise at room temperature. After 
stirring 10 minutes, a solution of the phosphoramidating reagent (2 equivalents) in anhydrous 
tetrahydrofuran (1 mL) was added slowly. The reaction mixture was heated to 55 °C and stirred for 
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2 to 8 hours, then cooled to room temperature, poured into a 10% aqueous solution of NH4Cl (10 
mL) and extracted with dichloromethane (3 x 10 mL), the combined organic layer was washed with 
water (20 mL) and brine (20 mL), dried over anhydrous MgSO4, filtered and concentrated under 
reduced pressure. The residue was purified by flash column chromatography on silica gel 
(dichloromethane to dichloromethane/methanol 97:3 v/v) to give compound 157 as a colourless 
wax. 
Selected conditions: 
Compound 156 was treated with p-nitrophenolate 37 (0.22 g, 0.49 mmol) over 30 minutes to give 
compound 157 (0.07 g, 46% yield) after chromatographical purification. 
31P NMR (202 MHz, CD3OD) δ 3.72, 3.40. 
1H NMR (500 MHz, CD3OD) δ 8.24 – 8.21 (m, 2H, H-2 and H-8), 7.34 – 7.26 (m, 7H, Harom), 7.17 – 
7.08 (m, 3H, Harom), 6.21, 6.20 (2d, J1’,2’ = 2.5 Hz, 1H, H-1’), 5.37, 5.27 (2dd, J2’,3’ = 6.3 Hz, J2’,1’ = 2.5 
Hz, 1H, H-2’), 5.12 – 5.05 (m, 3H, CH2(C6H5) and H-3’), 4.49 – 4.46, 4.45 – 4.41 (2m, 1H, H-4’), 4.34 
– 4.18 (m, 2H, H-5’a and H-5’b), 3.99 – 3.91 (m, 1H, CHCH3), 1.60 (s, 3H, iPr-CH3), 1.38 (s, 3H, iPr-
CH3), 1.31 – 1.26 (m, 3H, CHCH3). 
13C NMR (126 MHz, CD3OD) δ 173.42 (d, JC-C-N-P = 4.3 Hz, C, C=O), 173.20 (d, JC-C-N-P = 4.9 Hz, C, 
C=O), 155.96 (C, Carom), 152.67 (CH, C2), 150.64, 150.62, 150.59, 150.57, 148.88, 148.83 (C, 
Carom), 140.13, 139.99 (CH, C8), 135.82, 135.77 (C, Carom), 129.35, 128.18, 127.96, 127.93, 
127.92, 127.90, 127.86, 124.79, 124.75, 119.98, 119.97, 119.94, 119.93 (CH, Carom), 119.18, 
114.23, 114.11 (C, Carom), 90.66, 90.36 (CH, C1’), 85.09 (d, JC-C-0-P = 8.5 Hz, CH, C4’), 85.03 (d, JC-C-0-
P = 6.6 Hz, CH, C4’), 84.01, 83.99 (CH, C2’), 81.31, 81.29 (CH, C3’), 66.56 (CH2, CH2(C6H5)), 66.21 (d, 
JC-O-P = 4.3 Hz, CH2, C5’), 66.20 (d, JC-O-P = 3.9 Hz, CH2, C5’), 50.28, 50.13 (CH, CHCH3), 26.09, 26.06 
(CH3, CH3-iPr), 24.20, 24.15 (CH3, CH3-iPr), 18.98 (d, JC-C-N-P = 6.7 Hz, CH3, CHCH3), 18.87 (d, JC-C-N-P = 
7.2 Hz, CH3, CHCH3). 
MS (ES+) m/z 647.3 [MNa+], 625.3 [MH+]. 
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C25H33N6O8P, MW 576.54 
 
2’,3’-O,O-isopropylidene-adenosine 5’-O-[phenyl-(isopropoxy-L-alaninyl)] phosphate (158).[7] 
General procedure under MWI conditions: 
Compound 156 (0.08 g, 0.24 mmol) was dissolved in anhydrous tetrahydrofuran (1.6 mL) and N-
methyl-2-pyrrolidone (0.55 mL) in a 10 mL sealed microwave tube under a nitrogen atmosphere 
and tert-butylmagnesium chloride 1M in tetrahydrofuran (0.49 mL, 0.49 mmol) was added 
dropwise at room temperature. After stirring 10 minutes, a solution of the phosphoramidating 
reagent (2 equivalents) in anhydrous tetrahydrofuran (1 mL) was added slowly. The reaction 
mixture was stirred under MWI (100 W, 65 °C) for 2 to 60 minutes, then cooled to room 
temperature, poured into a 10% aqueous solution of NH4Cl (10 mL) and extracted with 
dichloromethane (3 x 10 mL), the combined organic layer was washed with water (20 mL) and 
brine (20 mL), dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. 
The residue was purified by flash column chromatography on silica gel (dichloromethane to 
dichloromethane/methanol 97:3 v/v) to give compound 158 as a colourless wax. 
Selected conditions: 
Compound 156 was treated with p-nitrophenolate 38 (0.20 g, 0.49 mmol) over 2 minutes to give 
compound 158 (0.10 g, 67% yield) after chromatographical purification. 
General procedure by conventional heating: 
Compound 156 (0.08 g, 0.24 mmol) was dissolved in anhydrous tetrahydrofuran (1.6 mL) and N-
methyl-2-pyrrolidone (0.55 mL) under a nitrogen atmosphere and tert-butylmagnesium chloride 
1M in tetrahydrofuran (0.49 mL, 0.49 mmol) was added dropwise at room temperature. After 
stirring 10 minutes, a solution of the phosphoramidating reagent (2 equivalents) in anhydrous 
tetrahydrofuran (1 mL) was added slowly. The reaction mixture was heated to 55 °C and stirred for 
2 to 8 hours, then cooled to room temperature, poured into a 10% aqueous solution of NH4Cl (10 
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mL) and extracted with dichloromethane (3 x 10 mL), the combined organic layer was washed with 
water (20 mL) and brine (20 mL), dried over anhydrous MgSO4, filtered and concentrated under 
reduced pressure. The residue was purified by flash column chromatography on silica gel 
(dichloromethane to dichloromethane/methanol 97:3 v/v) to give compound 158 as a colourless 
wax. 
Selected conditions: 
Compound 156 was treated with p-nitrophenolate 38 (0.20 g, 0.49 mmol) over 30 minutes to give 
compound 158 (0.11 g, 77% yield) after chromatographical purification. 
1H NMR (500 MHz, CD3OD) δ 8.16, 8.15 (2s, 1H, H-2), 8.12, 8.11 (2s, 1H, H-8), 7.24 – 7.17 (m, 2H, 
Harom), 7.09 – 7.00 (m, 3H, Harom), 6.12, 6.11 (2d, J1’,2’ = 2.5 Hz, 1H, H-1’), 5.30, 5.20 (2dd, J2’,3’ = 
6.3 Hz, J2’,1’ = 2.5 Hz, 1H, H-2’), 5.03, 5.00 (2dd, J3’,2’ = 6.3 Hz, J3’,4’ = 3.1 Hz, 1H, H-3’), 4.85 – 4.80 (m, 
1H, CH-iPr), 4.43 – 4.39, 4.37 – 4.33 (2m, 1H, H-4’), 4.25 – 4.11 (m, 2H, H-5’a and H-5’b), 3.76 – 
3.68 (m, 1H, CHCH3), 1.50 (s, 3H, iPr-CH3), 1.29, 1.28 (2s, 3H, iPr-CH3), 1.18 – 1.14 (m, 3H, CHCH3), 
1.12 – 1.07 (m, 6H, 2 CH3-iPr). 
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APPENDIX 
Table 20. List of adenosine analogues known to be inhibitors of DENV RdRp, of which the 
phosphorylated derivatives were docked using the model of the DENV RdRp de novo initiation 
complex (see paragraph 2.1.1.2 for details), and their anti-DENV activity. 
DENV RdRp inhibitors Anti-DENV activity Reference 
2’-C-methyl-7-deazaadenosine  EC50 15 μM
a [1] 
2’-C-acetylene-7-deazaadenosine (NITD008) EC50 0.64 μM
b [2] 
2’-C-acetylene-7-deaza-7-fluoroadenosine EC50 0.42 μM
c [3] 
2’-C-acetylene-7-deaza-7-cyanoadenosine EC50 3.1 μM
c [3] 
2’-C-acetylene-7-deaza-7-carbamoyladenosine (NITD449) EC50 2 μM
c [3] 
2-amino-2’-C-methyladenosine EC50 9.5 μM
c [4] 
4-amino-9-β-D-ribofuranosyl-pyrimido[4,5-b]indole EC50 39.6 μM
a [5] 
4-amino-5-chloro-9-β-D-ribofuranosyl-pyrimido[4,5-b]indole EC50 0.85 μM
a [5] 
4-amino-5-butyl-9-β-D-ribofuranosyl-pyrimido[4,5-b]indole EC50 14.8 μM
a [5] 
4-amino-6-thiophen-3-yl-9-β-D-ribofuranosyl-pyrimido[4,5-b]indole EC50 18.8 μM
a [5] 
4-amino-6-benzofuran-2-yl-9-β-D-ribofuranosyl-pyrimido[4,5-b]indole EC50 15.4 μM
a [5] 
6-chloro-4-(furan-2-yl)-9-β-D-ribofuranosyl-pyrimido[4,5-b]indole IC50 0.238 μM
d [6] 
6-chloro-4-(thiophen-2-yl)-9-β-D-ribofuranosyl-pyrimido[4,5-b]indole IC50 0.335 μM
d [6] 
4-(benzofuran-2-yl)- 6-chloro-9-β-D-ribofuranosyl-pyrimido[4,5-
b]indole 
IC50 0.976 μM
d [6] 
Antiviral assays were performed in the following cell lines: aAfrican green monkey kidney cells (Vero cells); 
bprimary human peripheral blood mononuclear cells (PBMCs); cbaby hamster kidney cells (BHK-21); dhuman 
hepatoma cells (Huh7). DENV RdRp: Dengue virus RNA-dependent RNA polymerase. 
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